<SEC-DOCUMENT>0001047469-18-005126.txt : 20180723
<SEC-HEADER>0001047469-18-005126.hdr.sgml : 20180723
<ACCEPTANCE-DATETIME>20180723165838
ACCESSION NUMBER:		0001047469-18-005126
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20180723
DATE AS OF CHANGE:		20180723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Replimune Group, Inc.
		CENTRAL INDEX KEY:			0001737953
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				822082553
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-225846
		FILM NUMBER:		18964979

	BUSINESS ADDRESS:	
		STREET 1:		18 COMMERCE WAY
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-995-2443

	MAIL ADDRESS:	
		STREET 1:		18 COMMERCE WAY
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>a2236275z424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg76701_table_of_contents">  Table of contents</A> <BR>
<A HREF="#fa76701_index_to_consolidated_financial_statements">  Index to consolidated financial statements</A><BR></font>
</P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Filed Pursuant to Rule 424(b)(4)<BR>
Registration No.&nbsp;333-225846  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g70635.jpg" ALT="LOGO" WIDTH="331" HEIGHT="79">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=5><B><I>6,700,000&nbsp;shares  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=6><B>Replimune Group,&nbsp;Inc.<BR>  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=5><B><I>Common stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=5><B><I>$15.00 per share  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This is the initial public offering of our common stock. We are selling 6,700,000 shares of our common stock. The initial public offering price is $15.00 per
share of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to this offering, there has been no public market for our common stock. Our common stock has been approved for listing on the Nasdaq Global Select Market, or Nasdaq, under the symbol "REPL." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, and therefore have elected to comply with certain reduced public company
reporting requirements for this prospectus and future filings. See "Prospectus summary</B></FONT><FONT SIZE=2>&#151;</FONT><FONT SIZE=2><B>Implications of being an emerging growth
company."</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Investing in our common stock involves risks. See "Risk factors" beginning on page 14.</B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="67%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Per share</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Total </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2>Initial public offering price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100,500,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discount<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
1.05</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
7,035,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds to Replimune Group,&nbsp;Inc. (before expenses)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
13.95</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
93,465,000 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;See
"Underwriting" for additional information regarding total underwriting compensation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters expect to deliver the shares to purchasers on or about July&nbsp;24, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have granted the underwriters an option for a period of 30&nbsp;days to purchase up to 1,005,000 additional shares of our common stock at the initial public offering price less the underwriting
discount. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Several
of our existing stockholders (or their affiliates), including stockholders affiliated with certain of our independent directors, and one of our independent directors, have agreed to purchase
an aggregate of approximately 3.3&nbsp;million shares of our common stock in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any
shares purchased by these investors as they will on any other shares sold to the public in this offering. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <P style="font-family:arial;"><FONT SIZE=4><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="111pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>J.P.&nbsp;Morgan</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leerink&nbsp;Partners</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B> BMO&nbsp;Capital&nbsp;Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Prospectus dated July&nbsp;19, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=369142,FOLIO='blank',FILE='DISK114:[18ZBC1.18ZBC76701]BC76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_bg76701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG76701A_main_toc"></A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="bg76701_table_of_contents"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Table of contents    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG76701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Page</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ca76701_prospectus_summary"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus summary</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ca76701_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cg76701_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cg76701_risk_factors"><FONT SIZE=2>14</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cq76701_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special note regarding forward-looking statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cq76701_special_note_regarding_forward-looking_statements"><FONT SIZE=2>69</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cs76701_market_data"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market data</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cs76701_market_data"><FONT SIZE=2>71</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cs76701_use_of_proceeds"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cs76701_use_of_proceeds"><FONT SIZE=2>72</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cs76701_dividend_policy"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend policy</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cs76701_dividend_policy"><FONT SIZE=2>73</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cs76701_capitalization"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cs76701_capitalization"><FONT SIZE=2>74</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cs76701_dilution"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cs76701_dilution"><FONT SIZE=2>76</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cu76701_selected_consolidated_financial_data"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected consolidated financial data</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cu76701_selected_consolidated_financial_data"><FONT SIZE=2>78</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cu76701_management_s_discussion_and_an__man03466"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's discussion and analysis of financial condition and results of
operations</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cu76701_management_s_discussion_and_an__man03466"><FONT SIZE=2>80</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cy76701_business"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cy76701_business"><FONT SIZE=2>99</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#di76701_management"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#di76701_management"><FONT SIZE=2>143</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dk76701_executive_and_director_compensation"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive and director compensation</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dk76701_executive_and_director_compensation"><FONT SIZE=2>151</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dm76701_certain_relationships_and_related_party_transactions"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain relationships and related party transactions</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm76701_certain_relationships_and_related_party_transactions"><FONT SIZE=2>168</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#do76701_principal_stockholders"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal stockholders</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#do76701_principal_stockholders"><FONT SIZE=2>174</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#do76701_description_of_capital_stock"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of capital stock</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#do76701_description_of_capital_stock"><FONT SIZE=2>177</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dq76701_material_united_states_federal__mat03696"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material United States federal income tax consequences to non-U.S. holders of our common
stock</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq76701_material_united_states_federal__mat03696"><FONT SIZE=2>182</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dq76701_shares_eligible_for_future_sale"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares eligible for future sale</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq76701_shares_eligible_for_future_sale"><FONT SIZE=2>188</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ds76701_underwriting"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds76701_underwriting"><FONT SIZE=2>191</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ds76701_legal_matters"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal matters</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds76701_legal_matters"><FONT SIZE=2>200</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ds76701_experts"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds76701_experts"><FONT SIZE=2>200</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ds76701_where_you_can_find_more_information"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where you can find more information</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds76701_where_you_can_find_more_information"><FONT SIZE=2>200</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#fa76701_index_to_consolidated_financial_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to consolidated financial statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fa76701_index_to_consolidated_financial_statements"><FONT SIZE=2>F-1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Unless
the context otherwise requires, references in this prospectus to (i)&nbsp;"Replimune," the "Company," "we," "us" and "our" refer to Replimune Group,&nbsp;Inc. and its consolidated
subsidiaries and (ii)&nbsp;a year are references to the applicable calendar year and not our fiscal year. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
should rely only on the information contained in this prospectus or contained in any free writing prospectus prepared by or on behalf of us and filed with the Securities and Exchange Commission,
or the SEC. Neither we nor the underwriters have authorized anyone to provide you with additional information or information different from that contained in this prospectus or in any free writing
prospectus prepared by or on behalf of us and filed with the SEC. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that
others may give you. We and the underwriters are offering to sell, and seeking offers to buy, our common stock only in jurisdictions where offers and sales are permitted. The information contained in
this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of our common stock. Our business, financial conditions, results of
operations and prospects may have changed since that date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Through and including August&nbsp;13, 2018 (the 25th&nbsp;day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons who come into possession of this prospectus in jurisdictions outside of the United
States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus outside of the United States.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=633200,FOLIO='i',FILE='DISK114:[18ZBC1.18ZBC76701]BG76701A.;37',USER='CHE107312',CD='21-JUL-2018;03:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca76701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="ca76701_prospectus_summary"> </A>
<A NAME="toc_ca76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Prospectus summary    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information
that you should consider in making your investment decision. Before investing in our common stock, you should read the entire prospectus carefully, including the sections entitled "Risk factors" and
"Management's discussion and analysis of financial condition and results of operations," and our consolidated financial statements and the related notes.</I></FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ca76701_business_overview"> </A>
<A NAME="toc_ca76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Business overview    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform
the lives of cancer patients. We use our proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The
foundation of our platform consists of a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, that has been "armed" with a fusogenic therapeutic protein intended to substantially
increase anti-tumor activity. Our platform enables us to design multiple product candidates that incorporate various further genes whose expression is intended to augment the inherent properties of
HSV-1 to both directly destroy tumor cells and induce an anti-tumor immune response. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are currently conducting a Phase&nbsp;1/2 clinical trial with our lead product candidate, RP1, in approximately 150 patients with a range of solid tumors. We have entered into a collaboration
with Bristol-Myers Squibb Company, or BMS, under which it has granted us a non-exclusive, royalty-free license to, and is supplying at no cost, its anti-PD-1 therapy, nivolumab, for use in combination
with RP1 in this clinical trial. BMS has no further development-related obligations under this collaboration. The first part of this clinical trial is underway in the United Kingdom and we intend to
conduct the second part of the clinical trial, which will enroll patients with four solid tumor types, in both the United Kingdom and, pending the opening of an Investigational New Drug Application,
or IND, in the United States. We have also entered into a collaboration agreement with Regeneron Pharmaceuticals,&nbsp;Inc., or Regeneron, under which we intend to conduct clinical development of
our product candidates in combination with cemiplimab, an anti-PD-1 therapy being developed by Regeneron. For each clinical trial conducted under this collaboration, Regeneron will fund one-half of
the clinical trial costs, supply cemiplimab at no cost, and grant us a
non-exclusive, royalty-free license to cemiplimab for use in the clinical trial. The first planned clinical trial to be conducted under this collaboration is a randomized, controlled Phase&nbsp;2
clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in approximately 240 patients with cutaneous squamous cell carcinoma, or CSCC, which we intend to initiate in the first
half of 2019. If compelling clinical data are generated demonstrating the benefits of the combined treatment, we believe the data from this trial could support a filing with regulatory authorities for
marketing approval. We also intend to initiate a clinical trial with our second product candidate, RP2, in additional tumor types in the first half of 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Oncolytic
immunotherapy is an emerging class of cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent,
patient-specific, anti-tumor immune response. While clinically active alone, oncolytic immunotherapy may have synergy with certain other treatments and, in particular, with immune checkpoint blockade
therapies. Immune checkpoint blockade therapies have recently become established for the treatment of cancer, but only for patients with an ongoing anti-tumor immune response, that is, whose tumors
are immunologically "hot." Our product candidates are designed to induce a robust immune response against a patient's cancer, including to the neo-antigens that are uniquely present in tumors, with
the goal of improving responses in </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=25327,FOLIO='1',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>immunologically
"hot" tumors, turning immunologically "cold" tumors "hot," and enabling patients to respond to immune checkpoint blockade therapies to which they otherwise may not respond. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
approach combines multiple mechanisms of action into single product candidates in a practical, "off-the-shelf" format. We believe that the bundling of multiple approaches for the treatment of
cancer into single therapies will simplify the development path of our product candidates, while also improving patient outcomes at a lower cost to the healthcare system than the use of multiple
different drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
management team has worked together for more than ten&nbsp;years and successfully developed the first oncolytic immunotherapy, Imlygic, also known as talimogene laherparepvec, or T-Vec, which
was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of advanced melanoma in 2015. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ca76701_our_product_candidate_pipeline"> </A>
<A NAME="toc_ca76701_3"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our product candidate pipeline    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing a pipeline of oncolytic immunotherapy product candidates that we believe have the potential to provide meaningful and
long-lasting clinical benefits to cancer patients. The following table summarizes our current pipeline and expectations for development timelines: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g695148.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="447">
  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Two additional tumor types to be selected for Phase&nbsp;2 clinical development, with clinical trials expected to commence in H2 2019, assuming
in each case the opening of an IND or foreign equivalent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are conducting an ongoing Phase 1/2 clinical trial of RP1 in approximately 150 patients. RP1 is the first product candidate from our Immulytic platform and
is armed with two therapeutic genes that are intended to increase the natural ability of HSV-1 to kill tumor cells and induce an anti-tumor immune response. In the first part of the clinical trial,
which we are currently conducting in the United Kingdom, we are evaluating safety in approximately 30 patients with a range of solid tumor types both alone and in </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1032473,FOLIO='2',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>combination
with nivolumab. No serious adverse events have been reported to date that have been determined to be related to RP1. In the second part of the trial, which we will conduct in both the
United Kingdom and, pending the opening of an IND, in the United States, we will test RP1 in combination with nivolumab in four different tumor types in cohorts of approximately 30 patients each.
These tumor types are metastatic melanoma, metastatic bladder cancer, microsatellite instability high cancer, and non-melanoma skin cancer. In this part of the study, we intend to continue to evaluate
the safety and tolerability of RP1 in combination with nivolumab, assess efficacy endpoints under the clinical trial protocol, and then analyze each cohort's data to determine the indications that
merit progressing into further clinical development. In addition, we are preparing to initiate a randomized, controlled Phase&nbsp;2 clinical trial of RP1 in combination with cemiplimab, versus
cemiplimab alone, in approximately 240 patients with CSCC in the first half of 2019. If compelling clinical data are generated demonstrating the benefits of the combined treatment, we believe the data
from this trial could support a filing with regulatory authorities for marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are also developing additional product candidates, including RP2 and RP3, built on our Immulytic platform that are additionally engineered to further enhance anti-tumor immune responses and to
address additional tumor types. RP2 has been engineered to express an antibody-like molecule that blocks the activity of CTLA-4, a protein that inhibits immune responses to tumors. We are engineering
RP3 with the intent not only to block the activity of CTLA-4, but also to further stimulate an anti-tumor immune response through activation of the immune co-stimulatory pathways. We intend to file
INDs and foreign equivalents for both RP2 and RP3 and, subject to regulatory approval, expect that RP2 will enter clinical development in the first half of 2019, and that RP3 will enter clinical
development in the first half of 2020. As demonstrated by our planned development timelines, we believe that a particular advantage of our Immulytic platform is that it allows us to develop new
product candidates that contain additional genes encoding therapeutic proteins rapidly from conception through to the initiation of clinical trials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
administer our product candidates by direct injection into solid tumors. We believe that direct injection maximizes virus-mediated tumor cell death, provides the most efficient delivery of
virus-encoded immune activating proteins into the tumor, and limits the systemic toxicities that could be associated with intravenous administration. Activation of systemic immunity through local
administration can lead to systemic clinical benefit through the induction of responses in tumors which have not themselves been injected, which is known as an "abscopal" effect. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
products and product candidates based on the oncolytic immunotherapy approach have shown single-agent activity, we believe our product candidates will demonstrate particular synergy in
combination with immune checkpoint blockade therapies, including those that target the programmed cell death protein 1, or PD-1, a tumor cell surface receptor that plays an important role in
inhibiting, or shutting down, immune responses, or the receptor or ligand for PD-1, called PD-L1. We are designing our product candidates with additional mechanisms of action as compared to T-Vec, as
well as other oncolytic immunotherapies in development, with the goal of maximizing both direct tumor killing and the activation of the patients' immune system against their particular cancer. We
believe these additional mechanisms of action of our product candidates will increase tumor susceptibility to immune checkpoint blockade therapies and, in particular, work synergistically with
antibodies targeting PD-1 or PD-L1 to enhance response rates across a range of tumor types. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
founders and core management team, including Robert Coffin, our President and Chief Executive Officer, Philip Astley-Sparke, our Executive Chairman, and Colin Love, our Chief Operating Officer,
were the founder and senior management team of BioVex Group,&nbsp;Inc., or BioVex, where they invented and developed T-Vec. BioVex was acquired by Amgen&nbsp;Inc., or Amgen, in 2011. Our Chief
Medical Officer, Howard </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=680570,FOLIO='3',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>Kaufman,
was the principal investigator for the pivotal clinical trial upon which T-Vec was approved and previously served as President of the Society for the Immunotherapy of Cancer. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are backed by a group of leading institutional life science investors, including affiliates of Atlas Ventures, Bain Capital Life Sciences, BVF Partners, Cormorant Capital, Forbion Capital Partners,
Foresite Capital, Omega Funds and Redmile Group. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ca76701_our_strategy"> </A>
<A NAME="toc_ca76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our strategy    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to create the leading oncolytic immunotherapy company that discovers, develops and commercializes next-generation products with
multiple mechanisms of action for the treatment of a broad range of solid tumor types. Key elements of our strategy include the following: </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I>Advance the development of, and seek regulatory approval for, our lead product candidate, RP1.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the first half of 2019, we are planning
to commence a randomized, controlled Phase&nbsp;2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in approximately 240 patients with CSCC. In addition, we are
currently conducting an approximately 150 patient Phase&nbsp;1/2 clinical trial of RP1 targeting four different tumor types in the United Kingdom and, pending the opening of an IND, in the United
States. We intend to analyze data for each tumor type to determine the indications that merit further clinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Initiate the clinical development of and obtain regulatory approval for RP2, our next product candidate</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;We plan to initiate a
Phase&nbsp;1/2 clinical trial in the first half of 2019 of RP2 in combination with anti-PD-1 therapy in triple negative breast cancer and two further indications. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Leverage our Immulytic platform to build a portfolio of product candidates that target a range of immune mechanisms and progress these product candidates into the
clinic.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We plan to utilize our Immulytic platform to develop additional product candidates, including RP3, that express further combinations of proteins aimed at
activating multiple immune mechanisms for the treatment of a broad range of solid tumor types. Our current goal in the coming years is to introduce one product candidate into the clinic each year. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Apply our extensive expertise to establish, equip, and operate our own in-house manufacturing facility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to establish, equip, and operate our own
manufacturing facility in Framingham, Massachusetts for multi-product current Good Manufacturing Practice, or cGMP, manufacturing. We expect our facility to be ready to produce clinical-grade material
during the first half of 2020 and ultimately to be able to support commercial product launch. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Retain significant economic and commercial rights to our product candidates in key geographic areas.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to retain rights in the United States for our
product candidates and to develop an oncology-focused commercial organization. When economically attractive, we intend to evaluate and enter into development and marketing agreements with
pharmaceutical and biotechnology partners for geographic areas in which we are unlikely to pursue development and commercialization on our own. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=456294,FOLIO='4',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ca76701_risks_affecting_our_business"> </A>
<A NAME="toc_ca76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks affecting our business    <BR>  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>You should consider carefully the risks described under the "Risk factors" section beginning on page&nbsp;14 and elsewhere in this
prospectus. The risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our product candidates are in the early stages of development, are not approved for commercial sale and might never receive regulatory approval
or become commercially viable. We have never generated any revenue from product sales and may never be profitable. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We currently have only one product candidate, RP1, in clinical development. A failure of this product candidate in clinical development would
adversely affect our business and may require us to discontinue development of other product candidates based on the same therapeutic approach.</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We will not be able to commercialize our product candidates if our preclinical studies do not produce successful results and/or our clinical
trials do not demonstrate the safety and efficacy of our product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We anticipate that our product candidates will be used in combination with third-party drugs, some of which are still in development, and we
have limited or no control over the supply, regulatory status, or regulatory approval of these drugs. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Even if our development efforts are successful, we may not obtain regulatory approval for any of our product candidates in the United States or
other jurisdictions, which could prevent us from commercializing our product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Following submission of our IND for RP1 in February 2018, the FDA informed us that our Phase 1/2 clinical trial of RP1 may not commence at
sites in the United States until we submit the results of an additional preclinical toxicology and biodistribution study that the FDA requested at a pre-IND meeting held in October&nbsp;2017, and
the FDA clears us to proceed with the clinical trial. Until such time, the clinical trial is on clinical hold. If we are not able to obtain, or if we experience delays in obtaining, required
regulatory approvals from the FDA, we may not be able to commercialize our product candidates in the United States as expected, and our ability to generate revenue may be materially
impaired.</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Even if we obtain regulatory approval for our product candidates, any such approval may be subject to limitations, including with respect to
the approved indications or patient populations, which could impair our ability to successfully commercialize our product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays
in doing so, our business will be materially harmed. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Negative developments in the field of immuno-oncology could damage public perception of RP1 or any of our other product candidates and
negatively affect our business. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other
research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown
to be safer or more effective than ours, our commercial opportunity could be reduced or eliminated. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=530991,FOLIO='5',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We are a clinical-stage biopharmaceutical company with a very limited operating history. We have incurred net losses since our inception and
anticipate that we will continue to incur substantial and increasing net losses in the foreseeable future. We may never achieve or sustain profitability. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable
terms, or at all, could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our
intellectual property rights are inadequate, our competitive position could be harmed. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have agreements with BMS and Regeneron, and in the future may have agreements with other companies, to obtain the supply of anti-PD-1
therapies for the development of RP1 and our other product candidates. If our relationships with BMS, Regeneron or any future collaborator or supplier are not successful, we may be delayed in
completing the development of RP1 and our other product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials, and
if those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may be unable to
obtain regulatory approval for our product candidates or any product candidates that we may develop in the future. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to
limit the commercialization of any approved products and/or our product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We are highly dependent on our key personnel, including our founders, Robert Coffin, Ph.D., our President and Chief Executive Officer, Philip
Astley-Sparke, our Executive Chairman, Howard Kaufman, M.D., our Chief Medical Officer, and Colin Love, Ph.D., our Chief Operating Officer. If we are not successful in attracting, motivating and
retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material
weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our
financial condition or results of operations, which may adversely affect our business. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ca76701_company_and_other_information"> </A>
<A NAME="toc_ca76701_6"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Company and other information    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The parent company of our group is Replimune Group,&nbsp;Inc., a Delaware corporation that was formed in July 2017. Prior to the corporate
reorganization described below, the parent company of our group was Replimune Limited, a private company limited by shares incorporated in England and Wales (registered number&nbsp;09496393), which
was organized in March 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
July 2017, all of the outstanding equity securities of Replimune Limited were exchanged for equity securities of Replimune Group,&nbsp;Inc., a newly formed Delaware corporation. Following the
reorganization, Replimune Limited is a wholly owned subsidiary of Replimune Group,&nbsp;Inc. See "Management's discussion and analysis of financial condition and results of
operations&#151;Overview" for more information. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=8,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=198311,FOLIO='6',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>Our
principal executive office is located at 18&nbsp;Commerce Way, Woburn, MA&nbsp;01801 and our telephone number is (781)&nbsp;995-2443. Our website address is https://www.replimune.com. We do
not incorporate the information on or accessible through our website into this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this
prospectus. Our fiscal year end is March&nbsp;31. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
own various United Kingdom registered trademarks and United States federal trademark applications and unregistered trademarks, including our company name and the "Immulytic" platform name. All
other trademarks, service marks and trade names used in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are
referred to without the symbols &reg; and &#153;, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under
applicable law, their rights thereto. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ca76701_implications_of_being_an_emerging_growth_company"> </A>
<A NAME="toc_ca76701_7"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Implications of being an emerging growth company    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company
until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of
at least $1.07&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds
$700&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year
period. We refer to the Jumpstart Our Business Startups Act of 2012 in this prospectus as the "JOBS Act," and references in this prospectus to "emerging growth company" have the meaning ascribed to it
in the JOBS Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
emerging growth company may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but
are not limited to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present only two years of audited financial statements and only two years of related Management's discussion and analysis of
financial condition and results of operations in this prospectus; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or
Sarbanes-Oxley Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm
rotations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> exemptions from the requirement to hold a nonbinding advisory vote on executive compensation and to obtain stockholder approval of any golden
parachute payments not previously approved. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
may use these provisions until such time as we cease to be an emerging growth company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced
reporting requirements in future filings. As a result, the information that we provide to our investors may be different from the information you might receive from other public reporting companies
that are not emerging growth companies in which you hold equity interests. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=9,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=815457,FOLIO='7',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ca76701_1_8"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>The
JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies until
those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised
accounting standards as other public companies that are not emerging growth companies. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=10,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=803427,FOLIO='8',FILE='DISK114:[18ZBC1.18ZBC76701]CA76701A.;102',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc76701_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cc76701_the_offering"> </A>
<A NAME="toc_cc76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The offering    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <P style="font-family:arial;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="65%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><B>Common stock we are offering </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2> 6,700,000 shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Underwriters' option to purchase additional shares </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2> We have granted the underwriters an option for a period of 30&nbsp;days to purchase up to 1,005,000 additional shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Common stock outstanding after giving effect to this offering </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2> 30,838,587 shares (31,843,587 shares if the underwriters exercise their option to purchase additional shares in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Use of proceeds </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2> The net proceeds from the sale of 6,700,000 shares of common stock in this offering will be approximately $90.8&nbsp;million, or approximately $104.8&nbsp;million if the underwriters exercise their option to purchase
additional shares in full, at the initial public offering price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We currently expect to use the net proceeds from this offering,
together with our existing cash and cash equivalents and short-term investments, as follows:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:13pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>approximately
$20.0&nbsp;million to fund the development of RP1 through the completion of the ongoing Phase&nbsp;1/2 clinical trial in four solid tumor types;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:13pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>approximately
$15.0&nbsp;million to fund our share of the costs to fully recruit our planned Phase&nbsp;2 clinical trial with RP1 in CSCC;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:13pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>approximately
$20.0&nbsp;million to fund the completion of the preclinical development and the initial clinical trials of RP2 in approximately 100&nbsp;patients;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:13pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>approximately
$10.0&nbsp;million to fund the completion of preclinical development and a Phase&nbsp;1 clinical trial of RP3;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:13pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>approximately
$20.0&nbsp;million to fund capital expenditures associated with establishing and equipping our planned manufacturing facility in Framingham, Massachusetts; and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:13pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:arial;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>the remainder for general
corporate purposes, including working capital requirements and operating expenses.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Dividend policy </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2> We do not intend to pay dividends for the foreseeable future. Any future determination to pay dividends on our common stock will be at the discretion of our board of directors and will depend upon many factors,
including our financial position, results of operations, liquidity and legal requirements. See "Dividend policy."</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=330038,FOLIO='9',FILE='DISK114:[18ZBC1.18ZBC76701]CC76701A.;57',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_cc76701_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <P style="font-family:arial;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="65%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Risk factors </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2> See "Risk factors" beginning on page&nbsp;14 and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Nasdaq Symbol </B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2> "REPL"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Several
of our existing stockholders (or their affiliates), including stockholders affiliated with certain of our independent directors, and one of our independent directors, have agreed to purchase
an aggregate of approximately 3.3&nbsp;million in shares of our common stock in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on
any shares purchased by these investors as they will on any other shares sold to the public in this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 24,138,587 shares of our common stock outstanding as of March&nbsp;31, 2018, after giving effect to the
conversion of all outstanding shares of our preferred stock as of March&nbsp;31, 2018 into an aggregate of 19,157,360 shares of our common stock upon the completion of this offering, and
excludes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,520,247 shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2018 at a weighted average
exercise price of $2.72 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 497,344 shares of our common stock issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2018, at an exercise price of
$1.01 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,486,118 shares of our common stock reserved for future issuance under our 2018 Omnibus Incentive Compensation Plan, or our 2018 Plan, which
became effective upon the effectiveness of the registration statement of which this prospectus is a part; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 131,850 shares of our common stock reserved for future issuance as of March&nbsp;31, 2018 under our 2017 Equity Compensation Plan, as
amended, or our 2017 Plan, which became available for issuance under our 2018 Plan upon the effectiveness of our 2018 Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 348,612 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan, or our ESPP, which became effective
upon the effectiveness of the registration statement of which this prospectus is a part; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 26,258 shares of our common&nbsp;A stock outstanding as of March&nbsp;31, 2018, all of which will be repurchased by us and canceled
immediately prior to the completion of this offering. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Unless
otherwise indicated, all information in this prospectus reflects or assumes the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all outstanding shares of our preferred stock into 19,157,360 shares of our common stock upon the completion of this
offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the repurchase and cancellation of all outstanding shares of our common&nbsp;A stock immediately prior to the completion of this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a 1-for-9.94688 forward stock split of our common stock effected on July&nbsp;9, 2018, and corresponding adjustments to (i) the rate at which
shares of our preferred stock convert into shares of our common stock, (ii)&nbsp;the exercise price of all outstanding stock options and warrants and (iii)&nbsp;the number of shares of our common
stock subject to each outstanding option and warrant; </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=146330,FOLIO='10',FILE='DISK114:[18ZBC1.18ZBC76701]CC76701A.;57',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_cc76701_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no exercise by the underwriters of their option to purchase additional shares of our common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the filing of our amended and restated certificate of incorporation and adoption of our amended and restated bylaws immediately prior to the
completion of this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all outstanding warrants to purchase shares of series seed convertible preferred stock, or series seed preferred stock, into
warrants to purchase 497,344 shares of our common stock upon the completion of this offering. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=186871,FOLIO='11',FILE='DISK114:[18ZBC1.18ZBC76701]CC76701A.;57',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ce76701_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="ce76701_summary_consolidated_financial_data"> </A>
<A NAME="toc_ce76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Summary consolidated financial data    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You should read the following summary consolidated financial data together with our consolidated financial statements and the related notes
appearing at the end of this prospectus and the "Selected consolidated financial data" and "Management's discussion and analysis of financial condition and results of operations" sections of this
prospectus. We have derived the consolidated statement of operations data for the years ended March&nbsp;31, 2017 and 2018 and the consolidated balance sheet data as of March&nbsp;31, 2017 and
2018 from our audited consolidated financial statements appearing at the end of this prospectus. Our historical results are not necessarily indicative of results that should be expected in any future
period. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands, except share and per share data) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated statement of operations data</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,516</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,711</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,713 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,647</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,229 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,647</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,229</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development incentives</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,267</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>288</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(150</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(972</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>626</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,056</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense), net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,943</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(473</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3.96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,973,439</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,978,539 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro&nbsp;forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.87</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro&nbsp;forma weighted average common shares outstanding, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21,506,697 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;See
Note&nbsp;12 to&nbsp;our consolidated financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per
share attributable to common stockholders and the calculation of unaudited pro&nbsp;forma basic and diluted net loss per share attributable to common stockholders. </FONT></P>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=547539,FOLIO='12',FILE='DISK114:[18ZBC1.18ZBC76701]CE76701A.;74',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_ce76701_1_13"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>As&nbsp;of&nbsp;March&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Actual</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Pro forma<SUP>(2)</SUP></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Pro forma&nbsp;as<BR>
adjusted<SUP>(2)(3)</SUP></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated balance sheet data</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents and short-term investments</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>152,316</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,539</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,539</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150,304</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>155,916</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,642</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,858</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,216</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,216</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>86,361</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,068</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150,700 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;We
define working capital as current assets less current liabilities.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;The
pro forma consolidated balance sheet data give effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into an aggregate of 19,157,360 shares of
common stock upon the completion of this offering, (ii)&nbsp;all outstanding warrants to purchase shares of series seed preferred stock becoming warrants to purchase shares of common stock upon the
completion of this offering and (iii)&nbsp;all outstanding shares of our common A stock being repurchased by us and canceled immediately prior to the completion of this offering.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;The
pro forma as adjusted balance sheet data gives further effect to our issuance and sale of 6,700,000 shares of our common stock in this offering at the initial public offering
price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=620291,FOLIO='13',FILE='DISK114:[18ZBC1.18ZBC76701]CE76701A.;74',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cg76701_1_14"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cg76701_risk_factors"> </A>
<A NAME="toc_cg76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risk factors    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and
uncertainties described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes appearing at the end of this prospectus,
before deciding whether to purchase shares of our common stock. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and
adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. The risks and uncertainties described below are not the only ones we
face.
Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cg76701_risks_related_to_product_development"> </A>
<A NAME="toc_cg76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks related to product development    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates are in the early stages of development, are not approved for commercial sale and might
never receive regulatory approval or become commercially viable. We have never generated any revenue from product sales and may never be profitable.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All of our product candidates are in research or early development. We have not generated any revenues from the sale of products and do not expect to do so
for at least the next several years. Our lead product candidate, RP1, and any other product candidates will require extensive preclinical and/or clinical testing and regulatory approval prior to
commercial use. Our research and development efforts may not be successful. Even if our clinical development efforts result in positive data, our product candidates may not receive regulatory approval
or be successfully introduced and marketed at prices that would permit us to operate profitably. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have only one product candidate, RP1, in clinical development. A failure of this product
candidate in clinical development would adversely affect our business and may require us to discontinue development of other product candidates based on the same therapeutic approach.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>RP1 is our only clinical development-stage product candidate. Although we have other product candidates, RP2 and RP3, in preclinical development and we intend
to develop additional product candidates in the coming years, it will take additional investment and time for such product candidates to reach the same stage of development as RP1, and there can be no
assurance that they will ever do so. Since all of the product candidates in our current pipeline are based on our Immulytic platform, if RP1 fails in development as a result of any underlying problem
with our Immulytic platform, then we may be required to discontinue development of all product candidates that are based on our therapeutic approach.
If we were required to discontinue development of RP1 or our other product candidates, or if any of them were to fail to receive regulatory approval or achieve sufficient market acceptance, we could
be prevented from or significantly delayed in achieving profitability. We can provide no assurance that we would be successful at developing other product candidates based on an alternative
therapeutic approach. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will not be able to commercialize our product candidates if our preclinical studies do not produce
successful results and/or our clinical trials do not demonstrate the safety and efficacy of our product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, RP1, is in the early stages of a Phase&nbsp;1/2 clinical trial in the United Kingdom and, pending the opening of an IND, in the
United States, while our other product candidates, RP2 and RP3, are in preclinical development. We expect to file INDs and foreign equivalents for RP2 and RP3 and, subject to regulatory clearance,
expect RP2 to begin a Phase&nbsp;1/2 clinical trial in the first half of 2019 and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=946903,FOLIO='14',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>expect
RP3 to enter clinical development in the first half of 2020. Our product candidates will require preclinical and clinical trials before we can submit a marketing application to the applicable
regulatory authorities. Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the occurrence of unexpected or unacceptable adverse
events or the failure to demonstrate efficacy in clinical trials. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
results of preclinical studies, preliminary study results, and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. While we are
currently conducting an early stage Phase&nbsp;1/2 clinical trial with RP1, we do not yet have clinical results for any of our product candidates. Our product candidates may not perform as we
expect, may ultimately have a different or no impact on tumors, may have a different mechanism of action than we expect in humans, and may not ultimately prove to be safe and effective. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Preliminary
and final results from preclinical studies and early stage trials, and trials in compounds that we believe are similar to ours, may not be representative of results that are found in
larger, controlled, blinded, and longer-term studies. Product candidates may fail at any stage of preclinical or clinical
development. Product candidates may fail to show the desired safety and efficacy traits even if they have progressed through preclinical studies or initial clinical trials. Preclinical studies and
clinical trials may also reveal unfavorable product candidate characteristics, including safety concerns. A number of companies in the biopharmaceutical industry have suffered significant setbacks in
clinical trials, notwithstanding promising results in earlier preclinical studies or clinical trials or promising mechanisms of action. In some instances, there can be significant variability in
safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the
size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Moreover, should there be an issue with
the design of a clinical trial, our results may be impacted. We may not discover such a flaw until the clinical trial is at an advanced stage. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product
candidates, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial, conduct a clinical
trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical trial protocols; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with
prospective trial sites and/or clinical research organizations, or CROs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of
statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical
trials may be slower than we anticipate or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate, or may elect to participate in alternative
clinical trials sponsored by our competitors with product candidates that treat the same indications as our product candidates; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=329707,FOLIO='15',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual
obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including
noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics of the
product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain marketing
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> statutes or regulations could be amended or new ones could be adopted; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes could be adopted in the regulatory review process for submitted product applications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial
or to pay the substantial user fees required by the FDA upon the filing of a Biologics License Application, or BLA, or equivalent authorizations from comparable foreign regulatory authorities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be
insufficient or inadequate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data, or
preclinical trials, or we may abandon product development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials, and the FDA or
comparable foreign regulatory authorities may require changes to our study designs that make further study impractical or not financially prudent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulators may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that they do not
support product candidate approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting
in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or extend its duration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> there may be regulatory questions or disagreements regarding interpretations of data and results, or new information may emerge regarding our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation of data
from preclinical studies and clinical trials or find that a product candidate's benefits do not outweigh its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with our intended indications; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=18,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=582330,FOLIO='16',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or our
manufacturing facilities for clinical and future commercial supplies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign
regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future
competitive therapies in development. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process for any of our product
candidates. We may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests
or clinical trials beyond what we currently have planned will be required, will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant delays relating
to any preclinical or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to
market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or
lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of any of our product candidates. If any of these occur, our business, financial condition, results of
operations, stock price and prospects may be materially harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We anticipate that our product candidates will be used in combination with third-party drugs, some of which
are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidates are intended to be administered in combination with checkpoint blockade drugs, a class of drugs that are intended to stop tumor cells
from "switching off" an immune system attack against themselves. We have entered into an agreement with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our current
Phase&nbsp;1/2 clinical trial with RP1. We have also entered into a clinical collaboration agreement with Regeneron which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical
trials conducted under the agreement. The first planned clinical trial to be conducted under the agreement is a randomized, controlled Phase&nbsp;2 clinical trial of RP1 in combination with
cemiplimab, compared to cemiplimab alone, in approximately 240 patients with CSCC. We may enter into additional agreements for the supply of anti-PD-1 products for use in connection with the
development of one or more of our product candidates. Our ability to develop and ultimately commercialize our product candidates used in combination with nivolumab, cemiplimab or any other checkpoint
blockade therapy will depend on our ability to access such drugs on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved.
We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint blockade therapies in the market, may delay our development timelines, increase </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=19,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=78026,FOLIO='17',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>our
costs and jeopardize our ability to develop our product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results of operations, stock price
and prospects may be materially harmed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. We are
developing RP1 and our other product candidates for use in combination with anti-PD-1 or anti-PD-L1 therapies and may develop RP1 or our other product candidates for use with other therapies. The FDA
may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these
trials could show that any positive previous trial results are attributable to the combination therapy and not our product
candidates. Moreover, following product approval, the FDA may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to
the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination
as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product's safety or efficacy profile, changes to the availability of the
approved product, and changes to the standard of care. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event that BMS, Regeneron or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing
an anti-PD-1 therapy. Additionally, should the supply of products from BMS, Regeneron or any future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical
trials may be delayed. In the event we are unable to source a supply of an alternative anti-PD-1 therapy, or are unable to do so on commercially reasonable terms, our business, financial condition,
results of operations, stock price and prospects may be materially harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to develop additional product candidates, our commercial opportunity could be limited.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We expect initially to develop our lead product candidate, RP1. A key part of our strategy, however, is to pursue clinical development of additional product
candidates, including RP2 and RP3. Developing, obtaining marketing approval for, and commercializing additional product candidates will require substantial additional funding beyond the net proceeds
of this offering and will be subject to the risks of failure inherent in medical product development. We cannot assure you that we will be able to successfully advance any of these additional product
candidates through the development process. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product candidates for the treatment of solid tumors, we cannot assure you that any such
product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop
and commercialize additional product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially
harmed. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=20,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=162712,FOLIO='18',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cg76701_risks_related_to_regulatory_approval"> </A>
<A NAME="toc_cg76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks related to regulatory approval    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if our development efforts are successful, we may not obtain regulatory approval for any of our product
candidates in the United States or other jurisdictions, which would prevent us from commercializing our product candidates. Even if we obtain regulatory approval for our product candidates, any such
approval may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our ability to successfully commercialize our product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are not permitted to market or promote or sell any of our product candidates before we receive regulatory approval from the FDA or comparable foreign
regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Securing marketing approval requires the submission of extensive preclinical and clinical
data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy for that indication. Securing marketing approval also
requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities. If we do not
receive approval from the FDA and comparable foreign regulatory authorities for any of our product candidates, we will not be able to commercialize such product candidates in the United States or in
other jurisdictions. If significant delays in obtaining approval for and commercializing our product candidates occur in any jurisdictions, our business, financial condition, results of operations,
stock price and prospects will be materially harmed. Even if our product candidates are approved, they may:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or other
conditions of approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> contain significant safety warnings, including boxed warnings, contraindications, and precautions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not be approved with label statements necessary or desirable for successful commercialization; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a risk evaluation and
mitigation strategy, or REMS, to monitor the safety or efficacy of the products. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
have not previously submitted a BLA to the FDA, or a similar marketing application to comparable foreign regulatory authorities, for any product candidate, and we can provide no assurance that will
ultimately be successful in obtaining regulatory approval for claims that are necessary or desirable for successful marketing, or at all. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time
consuming and inherently unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as
expected, and our ability to generate revenue may be materially impaired.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the
commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and
amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions. For example, the FDA verbally informed
us on March&nbsp;23, 2018 and confirmed in writing on April&nbsp;18, 2018 that our Phase&nbsp;1/2 clinical trial of RP1 is on clinical hold and may not commence at U.S. sites until we submit the
results of a preclinical toxicology and biodistribution study with a longer follow-up period than </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=21,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=697297,FOLIO='19',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>was
required by the regulatory authorities in the United Kingdom and the FDA clears us to proceed with the clinical trial. We anticipate that we will be submitting the results from this study to the
FDA in the third quarter of&nbsp;2018. These regulatory requirements may require us to amend our clinical trial protocols, conduct additional preclinical studies or clinical trials that may require
regulatory or IRB approval, or otherwise cause delays in the approval or rejection of an application. Any delay in obtaining or failure to obtain required approvals could materially adversely affect
our ability to generate revenue from the particular product candidate, which may materially harm our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Regulatory
authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product
candidate. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate, the disease or condition that
the product candidate is designed to address, and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to
gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from preclinical
studies or clinical trials, any of which may cause delays or limitations in the approval or a decision not to approve an application. It is possible that our product candidates will never obtain the
appropriate regulatory approvals necessary for us to commence product sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we experience delays in obtaining approval, if we fail to obtain approval of a product candidate or if the label for a product candidate does not include the labeling claims necessary or desirable
for the successful commercialization of that product candidate, the commercial prospects for such product candidate may be harmed and our ability to generate revenues from that product candidate may
be materially impaired. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The FDA or a comparable foreign regulatory authority may determine that our product candidates have
undesirable side effects that could delay or prevent their regulatory approval or commercialization.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, the most commonly reported adverse events observed for RP1 are local erythematous and inflammatory reactions and systemic fevers and chills. However,
there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with RP1 or our other product candidates as they continue through or
enter clinical
development. Serious adverse events or undesirable side effects caused by our product candidates could cause us, IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or
halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. For example, if concerns are
raised regarding the safety of a new therapeutic as a result of undesirable side effects identified during clinical or preclinical testing, the FDA or comparable foreign regulatory authority may order
us to cease further development, decline to approve product candidate or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve
the product candidate. The FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, may also require, or we may voluntarily develop, strategies for managing adverse
events during clinical development, which could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study's design, or the monitoring of safety data by a
data monitoring committee, among other strategies. The FDA or a comparable foreign regulatory authority requests for additional data or information could also result in substantial delays in the
approval of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=22,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=798373,FOLIO='20',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Undesirable
side effects caused by any of our product candidates could also result in denial of regulatory approval by the FDA or comparable foreign regulatory authorities for any or all targeted
indications or the inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with
significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or may result in
requirements for costly post-marketing testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from commercializing
and generating revenues from the sale of our product candidates. Undesirable side effects may limit the potential market for any approved products or could result in the discontinuation of the sales
and marketing of the product, or withdrawal of product approvals. Later discovered undesirable side effects may further result in the imposition of a REMS, label revisions, post-approval study
requirements, or other testing and surveillance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
any of our product candidates is associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development or limit development
of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit
perspective. The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of
these occurrences may materially harm our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in product candidate manufacturing or formulation may result in additional costs or delay.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause
our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require
additional testing, or notification to, or approval by the FDA or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical
trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product
sales and generate revenue. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific
indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be
promoting the use of our products for unapproved or "off-label" uses, resulting in damage to our reputation and business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional
communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, Department of Health and Human
Services' Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product
candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain FDA approval for desired uses or indications for our
product candidates, we may not market or promote them for those indications and uses, referred to as off-label uses, and our business, financial condition, results of operations, stock price and
prospects </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=23,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=25942,FOLIO='21',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>will
be materially harmed. We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products to other companies' products, and must abide by the
FDA's strict requirements regarding the content of promotion and advertising. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
physicians may choose to prescribe products for uses that are not described in the product's labeling and for uses that differ from those tested in clinical trials and approved by the regulatory
authorities we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA. These off-label uses are common across medical
specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of
physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biopharmaceutical companies concerning off-label use. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
we are found to have impermissibly promoted any of our product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws
and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to
significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label
promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the United States, engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state
statutes. These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the
manner in which we promote or distribute therapeutic products and conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in
federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts. These False Claims Act lawsuits against
manufacturers of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, up to $3.0&nbsp;billion, pertaining to certain
sales practices and promoting off-label uses. In addition, False Claims Act lawsuits may expose manufacturers to follow-on claims by private payers based on fraudulent marketing practices. This growth
in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to
comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved
products, if any, we may become subject to such litigation and, if we do not successfully defend
against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the United States, the promotion of biopharmaceutical products are subject to additional FDA requirements and restrictions on promotional statements. If after one or more of our product candidates
obtains marketing approval the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional
materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests
for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in
foreign jurisdictions may prohibit companies </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=24,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=186409,FOLIO='22',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<A NAME="page_cg76701_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>from
engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and
enforcement actions our business, financial condition, results of operations, stock price and prospects will be materially harmed. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional
expense and limit how we manufacture and market our products.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and comparable
foreign regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage,
recordkeeping, export, import, advertising, marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information,
including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with cGMP requirements relating to manufacturing, quality
control, quality assurance, and corresponding maintenance of records and documents, and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA or comparable foreign regulatory authorities
become aware of
new safety information after approval of any of our product candidates, they may withdraw approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy,
impose significant restrictions on a product's indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Any such
restrictions could limit sales of the product. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs and
other FDA regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other problems with our products, manufacturers or manufacturing
processes, or failure to comply with regulatory requirements both before and after approval, may yield various negative results, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions on manufacturing, distribution, or marketing of such products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions on the labeling, including required additional warnings, such as black boxed warnings, contraindications, precautions, and
restrictions on the approved indication or use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> modifications to promotional pieces; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issuance of corrective information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requirements to conduct post-marketing studies or other clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical holds or termination of clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requirements to establish or modify a REMS or similar strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes to the way the product candidate is administered; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> liability for harm caused to patients or subjects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reputational harm; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=25,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=149322,FOLIO='23',FILE='DISK114:[18ZBC1.18ZBC76701]CG76701A.;49',USER='CHE108057',CD='19-JUL-2018;23:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ci76701_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the product becoming less competitive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> warning, untitled, or cyber letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspension of marketing or withdrawal of the products from the market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings
or other safety information about the product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal to approve pending applications or supplements to approved applications that we submit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> recalls of products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fines, restitution or disgorgement of profits or revenues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspension or withdrawal of marketing approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal to permit the import or export of our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product seizure or detention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from
federal healthcare programs, consent decrees, or corporate integrity agreements; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties, including imprisonment. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or could substantially increase the costs and expenses of
commercializing such product, which in turn could delay or prevent us from generating significant revenues from its marketing and sale. Any of these events could further have other material and
adverse effects on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
FDA's policies or those of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our
product candidates, limit the marketability of our product candidates, or impose additional regulatory obligations on us. Changes in medical practice and standard of care may also impact the
marketability of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Should
any of the above actions take place, we could be prevented from or significantly delayed in achieving profitability. Further, the cost of compliance with post-approval regulations may have a
negative effect on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=26,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=647514,FOLIO='24',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Obtaining and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining marketing approval of that product
candidate in other jurisdictions, which could prevent us from marketing our products internationally.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Obtaining and maintaining marketing approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or maintain
marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For
example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product
candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States,
including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many
jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to
charge for our products is also subject to approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Regulatory
authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining
foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our
products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our
ability to realize the full market potential of RP1 and our other product candidates will be harmed. If we obtain approval for any product candidate and ultimately commercialize that product in
foreign markets, we would be subject to additional risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and
the reduced protection of intellectual property rights in some foreign countries. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ci76701_risks_related_to_commercialization"> </A>
<A NAME="toc_ci76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to commercialization    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be
materially harmed.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we are successful in obtaining marketing approval from applicable regulatory authorities for RP1 or any of our other product candidates, our ability to
generate revenues from our product candidates will depend on our success in:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> launching commercial sales of our product candidates, whether alone or in collaboration with others; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> receiving an approved label with claims that are necessary or desirable for successful marketing, and that does not contain safety or other
limitations that would impede our ability to market the product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> creating market demand for our product candidates through marketing, sales and promotion activities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hiring, training, and deploying a sales force or contracting with third parties to commercialize product candidates in the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> manufacturing product candidates in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and
thereafter; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=27,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=857811,FOLIO='25',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> creating partnerships with, or offering licenses to, third parties to promote and sell product candidates in foreign markets where we receive
marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> achieving market acceptance of our product candidates by patients, the medical community, and third-party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> achieving appropriate reimbursement for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> effectively competing with other therapies; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintaining a continued acceptable safety profile of our product candidates following launch. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations, which may
result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than
ours, our commercial opportunity may be reduced or eliminated.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The development and commercialization of cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary rights. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or
commercialize in the future, from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. There are a number of large biopharmaceutical and
biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of solid tumors, including oncolytic immunotherapy and cancer vaccine
approaches. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and
establish collaborative arrangements for research, development, manufacturing, and commercialization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
our product candidates are intended to be used in combination with other drugs with different mechanisms of action, if and when marketed they will still compete with a number of drugs that are
currently marketed or in development that also target cancer. To compete effectively with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety
compared to these competitors when used alone or in combination with other drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are easier to
administer or are less expensive alone or in combination with other therapies than any products that we may develop alone or in combination with other therapies. Our competitors also may obtain FDA or
comparable foreign regulatory authorities' approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position
before we are able to enter the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=28,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=105904,FOLIO='26',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>market.
In addition, our ability to compete may be affected in many cases by insurers or other third-party payors coverage decisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may
result in even more resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites
and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs. If we are unable to successfully compete with these
companies our business, financial condition, results of operations, stock price and prospects may be materially harmed. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they
are approved, the revenues that we generate may be limited and we may never become profitable.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently do not have a commercial infrastructure for the marketing, sale, and distribution of our cancer immunotherapies. If and when our product
candidates receive marketing approval, we intend to commercialize our product candidates on our own in the United States and potentially with pharmaceutical or biotechnology partners in other
geographies. In order to commercialize our products, we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services. We may not be
successful in doing so. Should we decide to move forward in developing our own marketing capabilities, we may incur expenses prior to product launch or even approval in order to recruit a sales force
and develop a marketing and sales infrastructure. If a commercial launch is delayed as a result of the FDA or comparable foreign regulatory authority requirements or other reasons, we would incur
these expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure,
our sales force and marketing teams may not be successful in commercializing our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales
and marketing personnel. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product candidates in the United States, in which event, our ability
to generate product revenues may be limited. To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we may receive less revenues than if we
commercialized these products ourselves, which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties involved in our
commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a commercial infrastructure. The
establishment and development of commercial capabilities, including compliance plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and
we may not be able to successfully develop this capability. We will have to compete with other biopharmaceutical and biotechnology companies, including oncology-focused companies, to recruit, hire,
train, manage, and retain marketing and sales personnel, which is expensive and time consuming and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=29,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=106104,FOLIO='27',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>could
delay any product launch. Developing our sales capabilities may also divert resources and management attention away from product development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates in the United States or elsewhere, which could limit our ability
to generate product revenues and materially harm our business, financial condition, results of operations, stock price and prospects. Factors that may inhibit our efforts to commercialize our product
candidates include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our inability to effectively oversee a geographically dispersed sales and marketing team; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an inability to secure adequate coverage and reimbursement by government and private health plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the clinical indications for which the products are approved and the claims that we may make for the products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> limitations or warnings, including distribution or use restrictions, contained in the products' approved labeling; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of a
mandatory REMS or voluntary risk management plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with
more extensive product lines; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales
organization. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to
predict the time and cost of product candidate development.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have concentrated all of our research and development efforts on product candidates based on our Immulytic platform, and our future success depends on the
successful development of this therapeutic approach. There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or
that such development problems can be solved. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA and foreign regulatory authorities may
refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our development costs.
Moreover, even if we are able to provide the requested information or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates. We may also
experience delays in developing a sustainable, reproducible and scalable manufacturing process, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=30,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=307599,FOLIO='28',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>or
developing or qualifying and validating product release assays, other testing and manufacturing methods, and our equipment and facilities in a timely manner, which may prevent us from completing
our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate
vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The FDA and comparable foreign regulatory authorities have limited experience with
the approval of oncolytic immunotherapies. Only one oncolytic immunotherapy, T-Vec, has received FDA approval to date. Any product candidates that are approved may be subject to extensive
post-approval regulatory requirements, including requirements pertaining to manufacturing, distribution, and promotion. We may need to devote significant time and resources to compliance with these
requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales may be limited, and we may never become profitable.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for
marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval
do not gain an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical
community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients and patients
may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates
is approved but does not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our
product candidates will depend on a number of factors, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the efficacy of our product candidates in combination with marketed checkpoint blockade drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercial success of the checkpoint blockade drugs with which our products are co-administered; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prevalence and severity of adverse events associated with our product candidates or those products with which they are co-administered; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the clinical indications for which the products are approved and the approved claims that we may make for the products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> limitations or warnings contained in the product's FDA-approved labeling or those of comparable foreign regulatory authorities, including
potential limitations or warnings for our product candidates that may be more restrictive than other competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the standard of care for the targeted indications for our product candidates, which could reduce the marketing impact of any claims
that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=31,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=116204,FOLIO='29',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the relative convenience and ease of administration of our product candidates and any products with which they are co-administered; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by
government healthcare programs, including Medicare and Medicaid; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the price concessions required by third-party payors to obtain coverage; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the extent and strength of our marketing and distribution of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be
approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product candidates or to
which we agree as part of a REMS or voluntary risk management plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of market introduction of our product candidates, as well as competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to offer our product candidates for sale at competitive prices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the extent and strength of our third-party manufacturer and supplier support; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the actions of companies that market any products with which our product candidates are co-administered; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the approval of other new products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> adverse publicity about our product candidates or any products with which they are co-administered, or favorable publicity about competitive
products; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential product liability claims. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2><B><I> The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may
be smaller than our estimates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which our product
candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the market opportunity for oncolytic immunotherapies is hard to estimate given that it
is an emerging field with only one existing FDA-approved oncolytic immunotherapy, T-Vec, which has yet to enjoy broad market acceptance. Our estimates of the potential market opportunities are
predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are
reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=32,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=144840,FOLIO='30',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>independent
source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Negative developments in the field of immuno-oncology could damage public perception of RP1 or any of our other product candidates and negatively affect our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The commercial success of our product candidates will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in clinical
trials of RP1 or our other product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in the field of
immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for RP1 or our other product candidates that we may develop. These
events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer
immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential
clinical trial subjects may be discouraged from enrolling in our clinical trials. As a result, we may not be able to continue or may be delayed in conducting our development programs. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
our product candidates consist of a modified virus, adverse developments in anti-viral vaccines or clinical trials of other oncolytic immunotherapy products based on viruses may result in a
disproportionately negative effect for RP1 or our other product candidates as compared to other products in the field of immuno-oncology that are not based on viruses. Future negative developments in
the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or
approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for RP1 or our other product candidates. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ci76701_risks_related_to_our_financial__ris02844"> </A>
<A NAME="toc_ci76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to our financial position and need for additional capital    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are a clinical-stage biopharmaceutical company with a very limited operating history. We have incurred net losses since our inception and anticipate that we will continue to incur
substantial and increasing net losses in the foreseeable future. We may never achieve or sustain profitability.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company with a limited operating history, and we are early in our development efforts. We have no products approved
for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations.
Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will
fail to demonstrate adequate efficacy or an acceptable safety profile, gain marketing approval and become commercially viable. We have financed our operations to date primarily through the sale of
equity securities. Since our inception, most of our resources have been dedicated to the preclinical and clinical development of our Immulytic platform, RP1 and our other product candidates. The size
of our future net losses will depend, in part, on our future expenses and our ability to generate revenue, if any. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are not profitable and have incurred losses in each period since our inception. For the years ended March&nbsp;31, 2017 and 2018, we reported a net loss of $7.7&nbsp;million and
$19.7&nbsp;million, respectively. At March&nbsp;31, 2018, we had an accumulated deficit of $28.9&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and
we expect these losses to increase as we continue our research and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=33,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=135975,FOLIO='31',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<A NAME="page_ci76701_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>development
of, and seek marketing approvals for, RP1 and any additional product candidates we may develop. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we succeed in receiving marketing approval for and commercialize RP1, we will continue to incur substantial research and development and other expenditures to develop and market additional
potential products. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will
depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on
our stockholders' equity and working capital. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We have never generated any revenue from product sales, and our ability to generate revenue from product sales and become profitable will depend significantly on our success in
achieving a number of goals.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product
sales until after we have received marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate revenue and achieve profitability depends significantly on our
success in achieving a number of goals, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> completing research regarding, and preclinical and clinical development of RP1 and our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining marketing approvals for RP1 and our other product candidates for which we complete clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developing a sustainable and scalable manufacturing process for RP1 and our other product candidates, including establishing and maintaining
commercially viable supply and manufacturing relationships with third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> launching and commercializing RP1 and our other product candidates for which we obtain marketing approvals, either directly or with a
collaborator or distributor; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining market acceptance of RP1 and our other product candidates as viable treatment options; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> addressing any competing technological and market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> identifying, assessing, acquiring and developing new product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and
know-how; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> attracting, hiring, and retaining qualified personnel. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Even
if our product candidates or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any such
product candidate. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to change our manufacturing processes or assays, or to
perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=34,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=981278,FOLIO='32',FILE='DISK114:[18ZBC1.18ZBC76701]CI76701A.;35',USER='CHE109870',CD='21-JUL-2018;00:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ck76701_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we are successful in obtaining regulatory approvals to market RP1 or our other product candidates, our revenue will be dependent, in part, upon the size of the markets in
the territories for which we gain marketing approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If
the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, the labels for our product candidates contain
significant safety warnings, regulatory authorities impose burdensome or restrictive distribution requirements, or the reasonably accepted patient population for treatment is narrowed by competition,
physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue from the sale of any approved
products, we could be prevented from or significantly delayed in achieving profitability. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to
delay, limit, reduce or terminate our product development or commercialization efforts.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our operations have consumed substantial amounts of cash since inception. At March&nbsp;31, 2018, our cash and cash equivalents and short-term investments
were $61.6&nbsp;million. We expect to continue to spend substantial amounts to continue the clinical and preclinical development of RP1 and our other product candidates. Accordingly, we will need to
obtain substantial additional funds to achieve our business objectives. If we are able to gain marketing approval of any product candidate, we will require significant additional amounts of cash in
order to launch and commercialize such product. In addition, other unanticipated costs may arise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
future capital requirements depend on many factors, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope, progress, results and costs of researching and developing RP1 and our other product candidates, and conducting preclinical studies
and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of, and the costs involved in, obtaining marketing approvals for RP1 and our other product candidates if clinical trials are
successful; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of any collaborations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of commercialization activities for any approved product, including marketing, sales and distribution costs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and timing of establishing, equipping, and operating our planned manufacturing facility; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of manufacturing RP1 and our other product candidates for clinical trials in preparation for marketing approval and commercialization; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs
and the outcome of such litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing, receipt, and amount of sales of, or royalties on, our future products, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the emergence of competing cancer therapies and other adverse market developments. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=864307,FOLIO='33',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product revenue to finance our cash requirements, which we may
never do, we expect to finance our future cash needs through a combination of public or private equity offerings,
debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. Based on our research and development plans, we expect that the net
proceeds from this offering, together with our existing cash and cash equivalents and short-term investments, will enable us to fund our planned operating expenses and capital expenditure requirements
into the second half of 2021. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition, because
the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and
commercialization of RP1 or our other product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights
to our technologies or product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership
interest will be diluted. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are unable to raise additional funds through equity or debt financings when needed, we may be required to grant rights to develop and market one or more of our product candidates or technologies
that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ck76701_risks_related_to_intellectual_property"> </A>
<A NAME="toc_ck76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to intellectual property    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual property rights are inadequate,
our competitive position could be harmed.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and
other countries with respect to our technology, Immulytic platform, RP1 and our other product candidates. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing
and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the
United States and abroad related to our technology and product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much
litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents and any patents we own in the future are highly uncertain. The steps we have taken
to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the
United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications
issue. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our future </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=395610,FOLIO='34',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>issued
patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology or for RP1 or
our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours, and our ability
to successfully commercialize RP1 or our other product candidates and future technologies may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions
made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent
applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our
research and development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is
filed, thereby jeopardizing our ability to seek patent protection. It is also possible that we will fail to identify patentable aspects of our research and development efforts in time to obtain patent
protection. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the core technology in our Immulytic platform and each of our product candidates, patent applications are pending under the Patent Cooperation Treaty, or PCT, and are currently at the
international stage. As of July&nbsp;9, 2018, we own five PCT patent applications and four U.S. provisional applications, none of which have been issued by any patent office or examined by any
patent examining authority. Any future provisional patent applications are not eligible to become issued patents until, among other things, we file&nbsp;a non-provisional patent application within
12&nbsp;months of filing of one or more of our related provisional patent applications. If we do not timely file any non-provisional patent applications, we may lose our priority date with respect
to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. Although we intend to timely file non-provisional patent
applications relating to our provisional patent applications, we cannot predict whether any of our future patent applications will result in the issuance of patents that effectively protect our
technology or RP1 or our other product candidates, or if any of our future issued patents will effectively prevent others from commercializing competitive products. Publications of discoveries in the
scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing or
in some cases not at all until they are issued as a patent. Therefore, we cannot be certain that we were the first to make the inventions claimed in our pending patent applications, or that we were
the first to file for patent protection of such inventions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications. Because the issuance
of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties or own in the future may be challenged in the courts or
patent offices in the United States and abroad, including through opposition proceedings, derivation proceedings, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, interference
proceedings or litigation. Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could
limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection for our technology. Protecting against the unauthorized use
of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible. In some cases, it may be difficult or
impossible to detect third-party </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=837551,FOLIO='35',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>infringement
or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. If we are unable to
obtain, maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial condition, results of
operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and
proprietary information. To maintain the confidentiality of our trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and
other third parties who have access to our trade secrets. Our agreements with employees also provide that any inventions conceived by the individual in the course of rendering services to us shall be
our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of
intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring
against us, to determine the ownership of what we regard as our intellectual property. In addition, in the event of unauthorized use or disclosure of our trade secrets or proprietary information,
these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or
contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Adequate
remedies may not exist in the event of unauthorized use or disclosure of our confidential information including a breach of our confidentiality agreements. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. In addition, some courts in and outside of the United States are
less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to
prevent them from using that technology or information to compete with us. The disclosure of our trade secrets or the independent development of our trade secrets by a competitor or other third party
would impair our competitive position and may materially harm our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Third parties may in the future initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm
our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success depends on our ability and the ability of our current or future collaborators to develop, manufacture, market and sell RP1 and our
other product candidates, and to use our related proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties.
The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We may become party to, or threatened with,
adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any other future product candidates, including interference proceedings, post-grant review, </FONT> <FONT SIZE=2><I>inter
partes</I></FONT><FONT SIZE=2> review and derivation proceedings before the U.S. Patent and Trademark Office, or USPTO. Third parties may assert infringement or other
intellectual property claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party's intellectual property rights, and we are
unsuccessful in demonstrating that such </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=561374,FOLIO='36',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>intellectual
property rights are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing and commercializing RP1 and our other
product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby
giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced,
including by court order, to cease developing, manufacturing, and commercializing RP1 or our other product candidates. In addition, in any such proceeding or litigation, we could be found liable for
significant monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a patent or other intellectual property right. Any of the foregoing could have a
material adverse effect on our business, financial condition, results of operations, stock price and prospects. Any claims by third parties that we have misappropriated their confidential information
or trade secrets could have a similar material adverse effect on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we are developing RP1 in combination with nivolumab and cemiplimab, which are covered by patents or licenses held by BMS and Regeneron, respectively, to which we do not have a license
other than for use in connection with the applicable clinical trial. We also plan to develop our product candidates in combination with products developed by additional companies that are covered by
patents or licenses held by those entities to which we do not have a license. In the event that a labeling instruction is required in product packaging recommending that combination, we could be
accused of, or held liable for,
infringement of the third-party patents covering the product candidate or product recommended for administration with RP1 or our other product candidates. In such a case, we could be required to
obtain a license from the other company or institution to use the required or desired package labeling, which may not be available on commercially reasonable terms, or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We may not be able to protect our intellectual property and proprietary rights throughout the world.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Filing, prosecuting and defending patents on our technology throughout the world would be prohibitively expensive, and our intellectual property rights in
some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of some foreign countries do not protect intellectual property
rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not
obtained patent protection to develop and/or manufacture their own products, and may export otherwise infringing products to territories where we have patent protection but where enforcement is not as
strong as that in the United States. These products may compete with our products and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so
competing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the granting or enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceuticals, which
could make it difficult for us to obtain patent rights or stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights
generally in those countries. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention
from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=203698,FOLIO='37',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to protect and enforce our intellectual property and proprietary rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property we develop or license. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the laws of certain foreign countries may not protect our rights to the same extent as the laws of the United States, and those foreign laws may also be subject to change. For example,
methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries. Furthermore, biosimilar product
manufacturers or other competitors may challenge the scope, validity and enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or proceedings. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Moreover,
many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries limit the enforceability of patents against
government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a
license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payments and other similar
provisions during the patent application process and to maintain patents after they are issued. For example, periodic maintenance fees, renewal fees, annuity fees and various other government fees on
issued patents and patent applications often must be paid to the USPTO and foreign patent agencies over the lifetime of our licensed patents or any patents we own in the future. In certain
circumstances, we may rely on future licensing partners to take the necessary action to comply with these requirements with respect to licensed intellectual property. Although an unintentional lapse
can be cured for a period of time by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or
patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal
documents. If we fail to obtain and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same
as or similar to RP1 or our other product candidates, which could have a material adverse effect on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect RP1 and our other
product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and
enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws
or interpretation of the patent laws in the United States could increase the uncertainties and costs. Patent reform legislation in the United States and other countries, including the Leahy-Smith
America Invents Act, or the Leahy-Smith Act, signed into law on September&nbsp;16, 2011, could </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=963006,FOLIO='38',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>increase
those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant
changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to
challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by
USPTO administered post-grant proceedings, including post-grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, and derivation proceedings. After March 2013, under the
Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file&nbsp;a patent
application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on
our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could
change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on
the success of our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Competitors may infringe any future licensed patents or any patent we own in the future or misappropriate or otherwise violate our intellectual property
rights. We may also be required to defend against claims of infringement and our licensed patents and any patents we own in the future may become involved in priority or other intellectual property
related disputes. To counter infringement or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to
determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Also, third parties may initiate legal proceedings against us to assert that we are
infringing their intellectual property rights or to challenge the validity or scope of our owned or licensed intellectual property rights. These proceedings can be expensive and time consuming. Many
of our current and potential competitors have the ability to dedicate substantially greater resources to conduct intellectual property related litigations or proceedings than we can. We may not have
sufficient financial or other resources to conduct such litigation or proceedings adequately. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or
misappropriating our intellectual property. Litigation and other intellectual property related proceedings could result in substantial costs and diversion of management resources, which could harm our
business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other
party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or other intellectual property related proceeding
could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some of our confidential information
could be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=87225,FOLIO='39',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>compromised
by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any such
proceedings. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Any of the foregoing may
have a material adverse effect our business, financial condition, results of operations, stock price and prospects. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> We may be subject to claims by third parties asserting that our collaborators, employees or we have misappropriated their intellectual property, or claiming ownership of what we
regard as our own intellectual property.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many of our employees, including our senior management team, were previously employed at, or consulted for, universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Our collaborators' employees may currently be or previously have been employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Some of these persons, including each member of our senior management team, executed proprietary rights, non-disclosure
and non-competition agreements, or similar agreements, in connection with such previous employment or consulting agreements, that assigned ownership of intellectual property relating to work performed
under such agreements to the contracting third party. Although we try to ensure that our employees do not use, claim as theirs, or misappropriate the intellectual property, proprietary information or
know-how of others in their work for us, we may be subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual property, including trade
secrets or other proprietary information, of any such individual's current or former employer. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we
could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if we are
successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Any of the foregoing may have a material adverse effect on our business,
financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of third parties or are in breach of
non-competition or non-solicitation agreements with our competitors.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We could be subject to claims that we or our employees, including senior management, have inadvertently or otherwise used or disclosed alleged trade secrets
or other confidential information of former employers or competitors or others. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary
information, know-how or trade secrets of others in their work for us, we may be subject to claims that we caused an employee to breach the terms of their non-competition or non-solicitation
agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor or other
party. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction
to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to RP1
and our other product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers, competitors
or other parties. An inability to incorporate such technologies or features would have a material adverse effect on our business, and may </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=42,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=58436,FOLIO='40',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>prevent
us from successfully commercializing RP1 and our other product candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any
such litigation or the threat thereof may adversely affect our ability to hire employees or consultants. A loss of key personnel or their work product could hamper or prevent our ability to develop
and commercialize RP1 and our other product candidates, which could have an adverse effect on our business, financial condition, results of operations, stock price and prospects. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> If we obtain any issued patents covering our technology, such patents could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign
regulatory authority.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering any of our technology, the defendant
could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or
unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be, among other
things, an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be, among other
things, an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also
raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, </FONT><FONT SIZE=2><I>inter
partes</I></FONT><FONT SIZE=2> review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such
proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect RP1 and our other product candidates. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. For example, with respect to the validity of our licensed patents or any patents we obtain in the future, we cannot be certain that
there is no invalidating prior art of which we, our or our licensing partner's patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal
assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the
patent protection on RP1 and our other product candidates. Such a loss of patent protection could have a material adverse impact on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates for which we intend to seek approval as
biological products may face competition sooner than anticipated.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Given the amount of time required for the development, testing and regulatory review of new product candidates, such as RP1 and our other product candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984
permits a patent term extension of up to five years beyond the normal expiration of the patent, but no longer than 14 years from the product's approval date, which is limited to the approved
indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent
regulatory authorities in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited
extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and
launch their products earlier than might otherwise be the case, which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=43,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=966023,FOLIO='41',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<A NAME="page_ck76701_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, as part of the Patient Protection and Affordable Care Act, or ACA, created an abbreviated pathway for the
approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the
possible designation of a biosimilar as "interchangeable" based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA
until 12&nbsp;years after the original branded product was approved under a BLA. Certain changes, however, and supplements to an approved BLA, and subsequent applications filed by the same sponsor,
manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12-year exclusivity period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>RP1
and our other product candidates are all biological product candidates. We anticipate being awarded market exclusivity for each of our biological product candidates that is subject to its own BLA
for 12&nbsp;years in the United States, 10&nbsp;years in Europe and significant durations in other markets. However, the term of
the patents that cover such product candidates may not extend beyond the applicable market exclusivity awarded by a particular country. For example, in the United States, if all of the patents that
cover our particular biological product expire before the 12-year market exclusivity expires, a third party could submit a marketing application for a biosimilar product four years after approval of
our biological product, the FDA could immediately review the application and approve the biosimilar product for marketing 12&nbsp;years after approval of our biological product, and the biosimilar
sponsor could then immediately begin marketing. Alternatively, a third party could submit a full BLA for a similar or identical product any time after approval of our biological product, and the FDA
could immediately review and approve the similar or identical product for marketing and the third party could begin marketing the similar or identical product upon expiry of all of the patents that
cover our particular biological product. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
is also a risk that this exclusivity could be changed in the future. For example, this exclusivity could be shortened due to congressional action or through other actions, including future
proposed budgets, international trade agreements and other arrangements or proposals. Additionally, there is a risk that the FDA will not consider our product candidates to be reference products for
competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. The extent to which a biosimilar, once approved, will be substituted for any one of our
reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are
still developing. It is also possible that payers will give reimbursement preference to biosimilars over reference biologics, even absent a determination of interchangeability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that we do not receive any anticipated periods of regulatory exclusivity for our product candidates or the FDA or foreign regulatory authorities approve any biosimilar, interchangeable,
or other competing products to our product candidates, it could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=44,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=16932,FOLIO='42',FILE='DISK114:[18ZBC1.18ZBC76701]CK76701A.;47',USER='CHE109870',CD='21-JUL-2018;00:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cm76701_1_43"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cm76701_risks_related_to_manufacturing__ris02615"> </A>
<A NAME="toc_cm76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to manufacturing and our reliance on third parties    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We have agreements with BMS and Regeneron, and in the future may have agreements with other companies, to obtain the supply of anti-PD-1 therapies for the development of RP1 and our
other product candidates. If our relationships with BMS, Regeneron, or any future collaborator or supplier are not successful, we may be delayed in completing the development of RP1 and our other
product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into arrangements with BMS and Regeneron as part of our clinical development for RP1. BMS is providing nivolumab, its anti-PD-1 therapy, for
use in our ongoing Phase 1/2 clinical trial with RP1 and Regeneron is providing cemiplimab, its anti-PD-1 therapy, for use in our planned randomized, controlled Phase&nbsp;2 clinical trial with RP1
in approximately 240&nbsp;patients with CSCC and other potential clinical trials. We may also enter into agreements with additional companies for the supply of anti-PD-1 therapies for use in the
development of RP1 and our other product candidates. The outcome of these clinical trials is dependent both on the performance of our partners' products and product candidates and also on our
partners' ability to deliver sufficient quantities of adequately produced product. Should any of our partners' products or product candidates fail to produce the results that we anticipate, we may
have to rerun clinical trials for RP1 or our other product candidates or may otherwise be delayed in the commercialization of RP1 or our other product candidates. Similarly, should any partner fail to
provide us with a product or product candidate that suits our requirements we may have to rerun clinical trials for RP1 or our other product candidates or may be otherwise delayed in the
commercialization of RP1 or our other product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our collaboration agreements with any future partners may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may in the future seek collaboration arrangements with other parties for the development or commercialization of our product candidates. The success of any
collaboration arrangements may depend on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will
apply to these arrangements. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or
commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final
decision making authority. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Collaborations
with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration could adversely affect us
financially and could harm our business reputation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
future collaborations we might enter into may pose a number of risks, including the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators may not perform their obligations as expected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to
continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an
acquisition, that divert resources or create competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=45,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=921808,FOLIO='43',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<A NAME="page_cm76701_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators could fail to make timely regulatory submissions for a product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable
regulatory requirements, which could subject them or us to regulatory enforcement actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or
product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than
ours; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or
products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of such product candidate or product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of
development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product
candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to
invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>If
any collaborations we might enter into in the future do not result in the successful development and commercialization of products or if one of our collaborators subsequently terminates its
agreement with us, we may not receive any future research funding or milestone or royalty payments under such potential future collaboration. If we do not receive the funding we expect under the
agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
if any future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any product candidate
licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial
communities could be adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the
collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its
development </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=46,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=133751,FOLIO='44',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<A NAME="page_cm76701_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>program
or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and
additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary
development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be
materially and adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third parties do not perform
satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product
candidates or any other product candidates that we may develop in the future.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We rely on third-party CROs, study sites, and others to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates
and do not currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates. We expect to continue to rely on third parties, such as CROs,
clinical data management organizations, medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. Although we have agreements governing their
activities, we have limited influence over their actual performance and control only certain aspects of their activities. The failure of these third parties to successfully carry out their contractual
duties or meet expected deadlines could substantially harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our product
candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all. Moreover, these agreements might terminate for a variety of reasons,
including a failure to perform by the third parties. If we need to enter into alternative arrangements our product development activities would be delayed and our business, financial condition,
results of operations, stock price and prospects may be materially harmed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in
accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will
remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must also ensure that our preclinical trials
are conducted in accordance with the FDA's Good Laboratory Practice, or GLP, regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with
standards, commonly referred to as GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial
sites. If we or any of our third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the data generated in
our trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or
comparable foreign </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=47,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=365113,FOLIO='45',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<A NAME="page_cm76701_1_46"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>regulatory
authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials complies with the applicable regulatory requirements. In
addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials,
which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored
database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
third parties with which we work may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic development
activities that could harm our competitive position. In addition, such third parties are not our employees, and except for remedies available to us under our agreements with such third parties we
cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. If these third parties do not successfully carry out their
contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if
the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our trials may be repeated, extended,
delayed, or terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates; we may not be able to, or may be delayed in our efforts to,
successfully commercialize our product candidates; or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product
candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of
third-party service providers in the future, our business, financial condition, results of operations, stock price and prospects may be materially harmed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms. Switching or
adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result,
delays could occur, which could compromise our ability to meet our desired development timelines. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also rely on other third parties to store and distribute our products for the clinical trials that we conduct. Any performance failure on the part of our distributors could delay clinical
development,
marketing approval, or commercialization of our product candidates, which could result in additional losses and deprive us of potential product revenue. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If the manufacturers upon which we rely fail to produce our product candidates in the volumes that we require on a timely basis, or to fail comply with stringent regulations
applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our product candidates and may lose potential revenues.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Until our planned manufacturing facility is complete, we will continue to rely on third-party contract manufacturers to manufacture our clinical trial product
supplies. There can be no assurance that our clinical development will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In particular, any
replacement of our contract manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements. Any delays in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=48,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=716103,FOLIO='46',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<A NAME="page_cm76701_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>obtaining
adequate supplies of our product candidates that meet the necessary quality standards may delay our development or commercialization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our product candidates or programs. Our product candidates may compete with
other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing
and filling our viral product for us and willing to do so. If our existing third-party manufacturers, or the third parties that we engage in the future should cease to work with us, we likely would
experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers.
If for any reason we are unable to obtain adequate supplies of our product candidates or the therapeutic substances used to manufacture them, it will be more difficult for us to develop our product
candidates and compete effectively. Further, even if we do establish such collaborations or arrangements, our third-party manufacturers may breach, terminate, or not renew these agreements. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Any
problems or delays we experience in preparing for commercial-scale manufacturing of a product candidate or component may result in a delay in product development timelines and FDA or comparable
foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result
in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results of operations, stock
price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
currently have only one contract manufacturer for our product candidates for use in our clinical trials. In addition, we do not have any long-term commitments from our suppliers of clinical trial
material or guaranteed prices for our product candidates or their components. The manufacture of biopharmaceutical products requires significant expertise and capital investment, including the
development of advanced manufacturing techniques and process controls. Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up initial production. These
problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw
materials, and compliance with strictly enforced federal, state, and foreign regulations. Our contract manufacturers may not perform as agreed. If our manufacturers were to encounter these or other
difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Contract
manufacturers of our product candidates may be unable to comply with our specifications, applicable cGMP requirements or other FDA, state or foreign regulatory requirements. Poor control of
production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be
detectable in final product testing. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or
other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. Any such deviations may also require remedial measures that may be
costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure of a facility.
Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. Any delays in obtaining products or product candidates that comply with the
applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization. It may also require that we conduct additional studies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=49,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=748769,FOLIO='47',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<A NAME="page_cm76701_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
we are ultimately responsible for the manufacturing of our product candidates and therapeutic substances, other than through our contractual arrangements, we have little control over our
manufacturers' compliance with these regulations and standards. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates
or if it
withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market
our product candidates, if approved. Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take
substantial time and investment. We must also receive FDA approval for the use of any new manufacturers for commercial supply. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement actions against our manufacturers or us (including
fines and civil and criminal penalties, including imprisonment) suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical
holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal to permit the
import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act, corporate integrity agreements, consent decrees, withdrawal of
product approval, environmental or safety incidents and other liabilities. If the safety of any quantities supplied is compromised due to our manufacturers' failure to adhere to applicable laws or for
other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Any
failure or refusal to supply our product candidates or components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization
efforts. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary
technology and processes could be significant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If there are delays in completing our planned manufacturing facility, we may be delayed in scaling up manufacturing of our product candidates, may be forced to devote additional
resources and management time to completing our manufacturing facility and may face delays in our product development timelines. Additionally, the transition of our manufacturing operations to our new
facility may result in further delays or expenses, and we may not experience the anticipated operating efficiencies.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have signed a lease for an approximately 63,000&nbsp;square-foot facility in Framingham, Massachusetts at which we intend to establish and equip our own
manufacturing facility in order to secure supplies for pivotal studies and commercial launch. This facility is intended to give us control over key aspects of the supply chain for our products and
product candidates. We may face delays in the completion of the facility. In addition, we may not experience the anticipated operating efficiencies as we commence manufacturing operations at the new
facility. Any such delays may disrupt or delay the supply of our product candidates if we have not maintained a sufficient back-up supply of our product candidates through third-party manufacturers.
Moreover, changing manufacturing facilities may also require that we conduct additional studies, make notifications to the regulatory authorities, make additional filings to the
regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA's and
applicable foreign regulatory authorities' cGMP requirements for the production of our product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and
comparable foreign regulatory authority </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=50,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=6798,FOLIO='48',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<A NAME="page_cm76701_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>inspection.
These requirements include the qualification and validation of our manufacturing equipment and processes. We may not be able to develop or acquire the internal expertise and resources
necessary for compliance with these requirements. Should we fail to comply with cGMP regulations, the opening of our manufacturing facility will be delayed. If we fail to achieve the operating
efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating results. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
order to complete our planned manufacturing facility, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality,
regulatory, facilities and information technology. If we experience unanticipated employee turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations
and we may not achieve the operating efficiencies that we anticipate from the new facility, which may negatively affect our product development timeline. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
such problems could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial
condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cm76701_risks_related_to_legal_and_compliance_matters"> </A>
<A NAME="toc_cm76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to legal and compliance matters    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the commercialization of any
approved products and/or our product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to the risk of product
liability claims. We face inherent risk of product liability related to the testing of our product candidates in human clinical trials, including liability relating to the actions and negligence of
our investigators, and will face an even greater risk if we commercially sell any product candidates that we may develop. For example, we may be sued if any product candidate we develop allegedly
causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts.
Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these
claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources.
Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenue from decreased demand for our products and/or product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> impairment of our business reputation or financial stability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs of related litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> substantial monetary awards to patients or other claimants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> diversion of management attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=51,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=783734,FOLIO='49',FILE='DISK114:[18ZBC1.18ZBC76701]CM76701A.;59',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_co76701_1_50"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> significant negative media attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> decreases in our stock price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> initiation of investigations and enforcement actions by regulators; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing approval. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>We
believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or
losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient
amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA or comparable foreign regulatory approval
for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. Failure to obtain and
retain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of products we develop. On occasion, large judgments have been awarded in class
action lawsuits based on therapeutics that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if
judgments exceed our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anti-corruption laws, as well as import and export control laws, customs laws, sanctions laws
and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely
affect our business, financial condition, results of operations, stock price and prospects.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act 2010, or the Bribery Act,
and other anti-corruption laws that apply in countries where we do business. The FCPA, the Bribery Act, and these other laws generally prohibit us and our employees and intermediaries from bribing,
being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We also may participate in collaborations
and relationships with third parties whose actions, if non-compliant, could potentially subject us to liability under the FCPA, Bribery Act or local anti-corruption laws. In addition, we
cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or
interpreted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and the United Kingdom and
authorities in the European Union, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and
currency exchange regulations, collectively referred to as the trade control laws. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or other legal requirements, including trade control laws. If we
are not in compliance with applicable anti-corruption laws or trade control laws, we may be subject to criminal and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=52,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=776271,FOLIO='50',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_51"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>civil
penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price
and prospects. Likewise, any investigation of any potential violations of these anti-corruption laws or trade control laws by U.S., U.K. or other authorities could also have an adverse impact on our
reputation, our business, financial condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security laws, we could face substantial penalties
and our business, financial condition, results of operations, stock price and prospects will be materially harmed.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to many federal and state healthcare laws, including those described in "Business&#151;Regulatory matters," such as the federal
Anti-Kickback Statute, the federal civil and criminal False Claims Acts, the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans
Health Care Act of 1992, or VHCA, the federal Health Insurance Portability and Accountability Act of 1996 (as amended by the Health Information Technology for Economics and Clinical Health Act, or
HITECH), or HIPAA, the FCPA, the ACA, and similar state laws. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party
payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients' rights are and will be
applicable to our business. We would be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct
our business. In the European Union, the data privacy laws are generally stricter than those which apply in the United States and include specific requirements for the collection of personal data of
European Union persons or the transfer of personal data outside of the European Union to the United States to ensure that European Union standards of data privacy will be applied to such data. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations that apply to us, we may be subject to penalties, including
civil, criminal, and administrative penalties, damages, fines, disgorgement, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion
from participation in U.S. federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect
our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance
with applicable laws, it may be subject to criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in government healthcare programs, which could also
materially affect our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and
sustaining compliance with applicable federal, state and foreign privacy, data protection, security, reimbursement, and fraud laws may prove costly. Any action against us for violation of these laws,
even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=53,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=370078,FOLIO='51',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If the government or third-party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or if health maintenance organizations or
long-term care facilities choose to use therapies that are less expensive or considered a better value, our revenue and prospects for profitability will be limited.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and reimbursement from third-party payors.
Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage decisions may depend upon
clinical and economic standards
that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are already available or subsequently become available, even if our products are alone in a class.
If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully commercialize our product
candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our
or their investments. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Marketing approvals, pricing, and reimbursement for new therapeutic products
vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining
approvals. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing
approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might
obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may
negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our or their investment in one or more
product candidates, even if our product candidates obtain marketing approval. Our ability to commercialize our product candidates will depend in part on the extent to which coverage and reimbursement
for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Regulatory authorities and third-party
payors, such as private health insurers, and health maintenance organizations, decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused
on cost containment, both in the United States and elsewhere. Several third-party payors are requiring that companies provide them with predetermined discounts from list prices, are using preferred
drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators within classes, are challenging the prices charged for therapeutics, and are negotiating
price concessions based on performance goals. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third-party
payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no
uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, we
believe that future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement for our
products or product candidates for which we receive regulatory approval may not be available or adequate in either the United </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=54,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1040768,FOLIO='52',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>States
or international markets, which could have a negative effect on our business, financial condition, results of operations, stock price and prospects. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Assuming
coverage is approved, the resulting reimbursement payment rates might not be adequate. If payors subject our product candidates to maximum payment amounts, or impose limitations that make it
difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high copayments,
beneficiaries may seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any products to the satisfaction of hospitals, other
target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our products might not ultimately be
considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in
product development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, federal programs impose penalties on manufacturers of therapeutics in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the
Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. A few states have also passed or are considering
legislation intended to prevent significant price increases. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for
particular medications, which could affect our ability to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may
not be available to our customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us to decrease, discount, or
rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our products, if any, decrease or if
governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the indications for which the product is approved by the FDA or
comparable foreign regulatory authorities. Such delays have made it increasingly common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no
cost for a limited period in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any therapeutic will be paid for in all cases or at
a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to
cover our costs and may only be temporary. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates may
also be based on
reimbursement levels already set for lower cost products or may be incorporated into existing payments for other services. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies, benchmarking against other therapies, seeking
performance-based discounts, and challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if available, that the
reimbursement rates will be adequate. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we
obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=55,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=875307,FOLIO='53',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_54"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our
products, obtain collaborators, and raise capital.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for
which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in
additional downward pressure on the price that we may receive for any approved products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
example, legislative changes have been proposed and adopted since the ACA was enacted in 2010. These changes include, among other things, aggregate reductions to Medicare payments to providers of
up to 2% per fiscal year, which went effective on April&nbsp;1, 2013. In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Centers for Medicare and Medicaid Services, or CMS,
promulgated regulations governing manufacturers' obligations and reimbursement under the Medicaid Drug Rebate Program, and recently promulgated a regulation that limited Medicare Part&nbsp;B payment
to certain hospitals for outpatient drugs purchased under the 340B program. The current Administration's budget request for fiscal year 2018 also seeks among other health care reforms legislation that
would give states more tools to control their
Medicaid costs. Changes imposed by recent legislative actions are further described in "Business&#151;Regulatory matters." These new laws may result in additional reductions in Medicare and
other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and
operating costs, decreased net revenue from our biopharmaceutical products, decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for
any approved product. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate revenue, and we could be prevented from or significantly delayed in
achieving profitability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, there have been a number of other legislative and regulatory proposals aimed at changing the biopharmaceutical industry. For instance, the Drug Quality and Security Act imposes
obligations on manufacturers of biopharmaceutical products related to product tracking and tracing. Among the requirements of this legislation, manufacturers are required to provide certain
information regarding the product to individuals and entities to which product ownership is transferred, will be required to label products with a product identifier, and are required keep certain
records regarding the product. The transfer of information to subsequent product owners by manufacturers is also required to be done electronically. Manufacturers are also being required to verify
that purchasers of the manufacturers' products are appropriately licensed. Further, manufactures have product investigation, quarantine, disposition, and FDA, other comparable foreign regulatory
authorities, and trading partner notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences
of death to humans, as well as products that are the subject </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=56,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=698142,FOLIO='54',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_55"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Compliance
with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may
determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial
condition, results of operations, stock price and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our employees, independent contractors, consultants, commercial partners, principal investigators, CMOs, or CROs may engage in misconduct or other improper activities, including
noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial partners,
principal investigators, contract manufacturing organizations, or CMOs, or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply with
applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required by federal programs, report financial information or data accurately or
disclose unauthorized activities to us. This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in
regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter this type of misconduct, and the precautions we take to detect and prevent this activity may
not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with
such laws or regulations. Moreover, it is possible for a whistleblower to pursue a False Claims Act case against us even if the government considers the claim unmeritorious and declines to intervene,
which could require us to incur costs defending against such a claim. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, financial condition, results of operations, stock price and prospects, including the imposition of significant fines or other sanctions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect
on the success of our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage,
treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the use of hazardous and flammable materials, including chemicals and biological
and radioactive materials. Our operations also produce hazardous waste products. We would incur substantial costs as a result of violations of or liabilities under environmental requirements in
connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties
for the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting
from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or
criminal fines and penalties. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=57,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=308975,FOLIO='55',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may
not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our
storage or disposal of biological, hazardous or radioactive materials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption
of our product candidates' development programs.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite our implementation of security measures, our internal computer systems, and those of our CROs, CMOs, IT suppliers and other contractors and
consultants are vulnerable to damage from computer viruses, cyber attacks and other unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. If such an
event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss of clinical trial data from
completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any
disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur
liability and the further development of any of our product candidates could be delayed. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="co76701_risks_related_to_our_operations"> </A>
<A NAME="toc_co76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to our operations    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We will need to expand the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As of July&nbsp;9, 2018, we had 44 full-time employees, including 28 employees engaged in research and development. As our development and commercialization
plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future
growth would impose significant added responsibilities on members of management, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> identifying, recruiting, integrating, maintaining and motivating additional employees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> managing our internal development efforts effectively, including the clinical, FDA and comparable foreign regulatory review process for our
product candidates, while complying with our contractual obligations to contractors and other third parties; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> improving our operational, financial and management controls, reporting systems and procedures. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
future financial performance and our ability to commercialize RP1 and our other product candidates will depend, in part, on our ability to effectively manage any future growth, and our management
may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. The services
include substantially all aspects of clinical trial management and manufacturing, as well as support for our finance and accounting functions. We cannot assure you that the services of independent
organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively
manage our outsourced activities or if </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=58,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=490477,FOLIO='56',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing
approval of RP1 and our other product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside
contractors and consultants on economically reasonable terms, or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the
tasks necessary to further develop and commercialize RP1 and our other product candidates and, accordingly, may not achieve our research, development and commercialization goals. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are highly dependent on our key personnel, including our founders, Robert Coffin, Ph.D., our President and Chief Executive Officer, Philip Astley-Sparke, our Executive Chairman,
Howard Kaufman, M.D., our Chief Medical Officer, and Colin Love, Ph.D., our Chief Operating Officer. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly
qualified managerial, scientific and medical personnel. We are highly dependent on our management and particularly on the services of our founders, as well as our other scientific, manufacturing,
quality and medical personnel. Robert Coffin, Ph.D., our President and Chief Executive Officer, Philip Astley-Sparke, our Executive Chairman, and Colin Love, Ph.D., our Chief Operating Officer, were
the founder and senior management team of BioVex, where they invented and developed T-Vec, the only oncolytic immunotherapy to receive FDA approval. BioVex was acquired by Amgen Inc., or Amgen, in
2011. Our Chief Medical Officer, Howard Kaufman,&nbsp;M.D., was the principal investigator for the pivotal study upon which T-Vec was approved and previously served as President of the Society for
the Immunotherapy of Cancer. We believe that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult to replace. The loss of
the services of our key personnel and any of our other executive officers, key employees, and scientific and medical advisors, and our inability to find suitable replacements, could result in delays
in product development and harm our business. Furthermore, the historical results, past performance and/or acquisitions of companies with which our founders were affiliated, including BioVex, do not
necessarily predict or guarantee similar results for our company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conduct our operations at our facilities near Boston, Massachusetts and near Oxford, England, each of which are in regions that are home to many other biopharmaceutical companies and many academic
and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms
or at all. We expect that we will need to recruit talent from outside of these regions, and doing so may be costly and difficult. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants that vest over time. The value to employees of these equity
grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other
companies. Although we have employment agreements with our key employees, these employment agreements generally provide for at-will employment, which means that any of our employees could leave our
employment at any time, with or without notice. We do not maintain "key man" insurance policies on the lives of all of these individuals or the lives of any of our other employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=59,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=769723,FOLIO='57',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_58"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional
material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of
operations, which may adversely affect our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the audits of our consolidated financial statements as of and for the years ended March&nbsp;31, 2017 and 2018, we identified material
weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. If we are unable to remediate these material
weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our
financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, our stock price and ability to access the capital markets in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
material weaknesses we identified were as follows:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We did not design or maintain an effective control environment commensurate with our financial reporting requirements. We lacked a sufficient
number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally,
the limited personnel resulted in our inability to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated by, among other
things, our insufficient segregation of duties in our accounting function. This material weakness further contributed to the material weakness below. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions,
including accounting for preferred stock, stock-based compensation, warrant liabilities and leases. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Each
of these control deficiencies could result in a misstatement of our accounts or disclosures that would result in a material misstatement of our annual or interim consolidated financial statements
that would not be prevented or detected, and accordingly, we determined that these control deficiencies constitute material weaknesses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
material weaknesses also resulted in adjustments to preferred stock, stock compensation expense, warrant liability and deferred rent in our consolidated financial statements as of and for the
year ended March&nbsp;31, 2017, which were recorded prior to their issuance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to the completion of this offering, we have been a private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which to
address our internal control over financial reporting. We are in the process of implementing measures designed to improve our internal control over financial reporting and remediate the control
deficiencies that led to these material weaknesses, including hiring additional finance and accounting personnel and initiating design and implementation of our financial control environment,
including the establishment of controls to account for and disclose complex transactions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to these material weaknesses in
our internal
control over financial reporting or that they will prevent or avoid potential future material weaknesses. In addition, neither our management nor an independent registered public accounting firm has
performed an </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=60,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=840043,FOLIO='58',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>evaluation
of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required. Had we or our independent
registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses
may have been identified. If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional
material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, potentially resulting in restatements of our financial statements, we may be unable to maintain
compliance with securities law requirements regarding timely filing of periodic reports and applicable Nasdaq listing requirements, investors may lose confidence in our financial reporting, and our
share price may decline as a result. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We are required to maintain internal controls over financial reporting. Commencing with our fiscal year ending the year after this offering is completed, we
must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal
controls over financial reporting in our Form&nbsp;10-K filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. This will require that we incur substantial additional
professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. Prior to this offering, we have never been required to test our
internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. In addition, in connection with the audits of our
consolidated financial statements as of and for the years ended March&nbsp;31, 2017 and 2018, we identified material weaknesses in our internal control over financial reporting. See "Risk
factors&#151;We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional
material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of
operations, which may adversely affect our business." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, if our independent registered public accounting firm determines that we continue
to have a material weakness or significant deficiency in our internal control over financial reporting, or if we are unable to maintain proper and effective internal controls over financial reporting,
we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock
could decline and we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that any internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. Our
internal control over financial reporting will not prevent or detect all errors and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide
absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or
executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=61,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=957827,FOLIO='59',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<A NAME="page_co76701_1_60"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>related
party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the
controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, or the
Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and
communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of
the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple
error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party
transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls.
Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent
liabilities, and subject us to other risks.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights,
technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> increased operating expenses and cash requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the assumption of additional indebtedness or contingent liabilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance of our equity securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new
personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the diversion of our management's attention from our existing product programs and initiatives in pursuing such a strategic merger or
acquisition; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory
compliance status, and their existing products or product candidates and marketing approvals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or
even to offset the associated acquisition and maintenance costs. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=62,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1000138,FOLIO='60',FILE='DISK114:[18ZBC1.18ZBC76701]CO76701A.;47',USER='CHE105939',CD='23-JUL-2018;07:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cq76701_1_61"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that
could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access
to technology or products that may be important to the development of our business. Any of the foregoing may materially harm our business, financial condition, results of operations, stock price and
prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Unfavorable market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, stock price and prospects.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The most recent global
financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a
reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the
foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
March&nbsp;31, 2018, we had $61.6&nbsp;million of cash and cash equivalents and short-term investments. Although we are not aware of any downgrades, material losses, or other significant
deterioration in the fair value of our cash equivalents or short-term investments since that date, we cannot assure you that deterioration of the global credit and financial markets would not
negatively impact our current portfolio of cash equivalents or short-term investments, or our ability to meet our financing objectives. Furthermore, our stock price may decline due, in part, to the
volatility of the stock market and general economic downturns. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Exchange rate fluctuations may materially affect our results of operations and financial conditions.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the U.S. dollar and the British pound and the euro,
may adversely affect us. Although we are based in the United States, we have significant research and development operations in the United Kingdom, and source third-party manufacturing, consulting and
other services in the United Kingdom and the European Union. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a
significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cq76701_risks_related_to_our_common_stock_and_this_offering"> </A>
<A NAME="toc_cq76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks related to our common stock and this offering    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An active trading market for our common stock may not develop, and you may not be able to resell your shares
at or above the initial public offering price.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, there has been no public market for shares of our common stock. Although our common stock has been approved for listing on Nasdaq, an
active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock was determined through negotiations between us and
the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock,
investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=63,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=722445,FOLIO='61',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_62"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and fluctuate substantially, which could result in substantial
losses for purchasers of our common stock in this offering.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our stock price is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme
volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the initial
public offering price. The market price for our common stock may be influenced by many factors, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competitive products or technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> results of clinical trials of RP1 and our other product candidates or those of our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory or legal developments in the United States and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the level of expenses related to the development of RP1 and our other product candidates or clinical development programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> variations in our financial results or those of companies that are perceived to be similar to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> general economic, industry and market conditions; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the other factors described in this "Risk factors" section. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our operating results may fluctuate significantly, which makes our future operating results difficult to
predict and could cause our operating results to fall below expectations or our guidance.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results.
From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which
may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential
future license and collaboration
agreements and sales of our products, if approved. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our
operating results from one period to the next. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and
recognize the cost as an expense over the employee's requisite service period. As the variables that we use as a basis for valuing these awards change over time, including, after the completion of
this offering, our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=64,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=646808,FOLIO='62',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_63"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>underlying
stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the
following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and cost of, and level of investment in, research and development activities relating to our current and any future product
candidates, which will change from time to time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the total expenses we incur in connection with establishing, equipping, and operating our planned manufacturing facility and the actual timing
of the facility becoming operational; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to enroll patients in clinical trials and the timing of enrollment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of manufacturing our current and any future product candidates, which may vary depending on the FDA's and comparable foreign
regulatory authorities' guidelines and requirements, the quantity of production and the terms of any agreements with manufacturers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expenditures that we will or may incur to acquire or develop additional product candidates and technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and outcomes of clinical and preclinical studies for RP1 and our other product candidates or competing product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competition from existing and potential future products that compete with RP1 and our other product candidates, and changes in the competitive
landscape of our industry, including consolidation among our competitors or partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any delays in regulatory review or approval of RP1 or our other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the level of demand for RP1 and our other product candidates, if approved, which may fluctuate significantly and be difficult to predict; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential
future products that compete with RP1 and our other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to commercialize RP1 and our other product candidates, if approved, inside and outside of the United States, either independently
or working with third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of and our ability to establish and maintain collaborations, licensing or other arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to adequately support future growth; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential unforeseen business disruptions that increase our costs or expenses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> future accounting pronouncements or changes in our accounting policies; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the changing and volatile global economic environment. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>These
factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be
meaningful. Investors should not rely on our past results as an indication of our future performance. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>This
variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall
below the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=65,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=447629,FOLIO='63',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_64"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>expectations
of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price
of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in how we use the proceeds of this offering and may not use these proceeds
effectively, which could affect our results of operations and cause our stock price to decline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We will have considerable discretion in the application of the net proceeds of this offering. We intend to use the net proceeds from this offering to fund our
preclinical and clinical development programs and the establishment and equipping of our planned manufacturing facility, and the remainder for general corporate purposes, including working capital
requirements and operating expenses. See "Use of proceeds." As a result, investors will be relying upon management's judgment with only limited information about our specific intentions for the use of
the balance of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their
use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not intend to pay dividends on our common stock so any returns will be limited to the value of our
stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You should not rely on an investment in our common stock to provide dividend income. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to
the appreciation of their stock, which may never occur, as the only way to realize any return on their investment. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the
book value of your shares.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You will suffer immediate and substantial dilution in the pro forma as adjusted net tangible book value of the common stock you purchase in this offering. At
the initial public offering price of $15.00 per share, purchasers of common stock in this offering will experience immediate dilution of $10.11 per share in pro forma as adjusted net tangible book
value of the common stock. In addition, investors purchasing common stock in this offering will contribute 53.6% of the total amount invested by stockholders since inception but will only own 21.7% of
the shares of common stock outstanding. In the past, we have issued options and other securities to acquire common stock at prices significantly below the initial public offering price. To the extent
these outstanding securities are ultimately exercised, investors purchasing common stock in this offering will sustain further dilution. See "Dilution" for a more detailed description of the dilution
to new investors in the offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our executive officers, directors, and stockholders and their affiliates who beneficially own more than 5% of
our common stock will continue to exercise significant influence over our company after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change
in corporate control.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately following the completion of this offering, the existing holdings of our executive officers, directors, and stockholders and their affiliates who
beneficially own more than 5% of our common stock will represent beneficial ownership, in the aggregate, of approximately 84.3% of our outstanding common stock, assuming no exercise of the
underwriters' option to acquire additional common stock in this offering. As a result, these stockholders, if they act together, will be able to influence our management and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=66,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1023199,FOLIO='64',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_65"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>affairs
and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our
assets. These stockholders acquired their shares of common stock for substantially less than the price of the shares of
common stock being acquired in this offering, and these stockholders may have interests with respect to their common stock that are different from those of investors in this offering, and the
concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price
of our common stock by:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delaying, deferring or preventing a change of control of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> impeding a merger, consolidation, takeover or other business combination involving our company; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>See
"Principal stockholders" in this prospectus for more information regarding the ownership of our outstanding common stock by our executive officers, directors, principal stockholders and their
respective affiliates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Conflicts of interest may arise because some members of our board of directors are representatives of our
principal stockholders.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain of our principal stockholders or their affiliates are venture capital funds or other investment vehicles that could invest in entities that directly
or indirectly compete with us. As a result of these relationships, when conflicts arise between the interests of the principal stockholders or their affiliates and the interests of other stockholders,
members of our board of directors that are representatives of the principal stockholders may not be disinterested. Neither the principal stockholders nor the representatives of the principal
stockholders on our board of directors, by the terms of our amended and restated certificate of incorporation, are required to offer us any transaction opportunity of
which they become aware and could take any such opportunity for themselves or offer it their other affiliates, unless such opportunity is expressly offered to them solely in their capacity as members
of our board of directors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock in the public market could cause our stock price
to fall.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up and other
legal restrictions on resale discussed in this prospectus lapse, the market price of our common stock could decline. Based upon the number of shares of common stock, on an as-converted basis,
outstanding as of July&nbsp;9, 2018, upon the completion of this offering, we will have outstanding a total of 30,838,587 shares of common stock, assuming no exercise of the underwriters' option to
purchase an additional 1,005,000 shares. Of these shares, as of the date of this prospectus, approximately 6,700,000 shares, or 22% of our common stock, plus any shares sold upon exercise of the
underwriters' option to purchase additional shares, will be freely tradable by persons other than our "affiliates", without restriction, in the public market immediately following this offering. Under
the Securities Act, an "affiliate" of an issuer is a person who directly or indirectly controls, is controlled by or is under common control with that issuer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
lock-up agreements pertaining to this offering will expire 180&nbsp;days from the date of this prospectus. After the lock-up agreements expire, based upon the number of shares of common stock,
on an as-converted basis, outstanding as of July&nbsp;9, 2018, up to an additional approximately 24.1 million shares of common stock will be eligible for sale in the public market, approximately 21%
of which shares are held by directors, executive officers and other affiliates and will be subject to certain limitations of Rule&nbsp;144 under </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=67,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=649615,FOLIO='65',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_66"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
Securities Act. See "Shares eligible for future sale" for more information. J.P. Morgan Securities&nbsp;LLC and Leerink Partners&nbsp;LLC, however, may, in their sole discretion, permit our
officers, directors and other stockholders who are subject to these lock-up agreements to sell shares prior to the expiration of the lock-up agreements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Several
of our existing stockholders (or their affiliates), including stockholders affiliated with certain of our independent directors, and one of our independent directors, have agreed to purchase
an aggregate of
approximately 3.3&nbsp;million in shares of our common stock in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any shares
purchased by these investors as they will on any other shares sold to the public in this offering. The shares purchased by such investors in this offering will reduce the available public float of our
common shares. As a result, the purchase of common shares by such investors in this offering may reduce the liquidity of our common shares relative to what it would have been had these shares been
purchased by other investors or not subject to lock-up agreements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
completion of this offering, approximately 6.8 million shares of common stock that are either subject to outstanding options, reserved for future issuance under our equity incentive plans or
subject to outstanding warrants will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule&nbsp;144
and Rule&nbsp;701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common
stock could decline. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
the completion of this offering, the holders of approximately 19.7&nbsp;million shares of our common stock, or their permitted transferees, will be entitled to rights with respect to the
registration of their shares under the Securities Act, subject to the lock-up agreements described above. See "Certain relationships and related party transactions&#151;Stockholder
agreements&#151;Investors' rights agreement." Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities
Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur significantly increased costs as a result of operating as a public company, and our management
will be required to devote substantial time to new compliance initiatives.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the
reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial
condition. In addition, the Sarbanes-Oxley Act, and related SEC and Nasdaq rules impose significant requirements on public companies, including requiring establishment and maintenance of effective
disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was
enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas
such as "say on pay" and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this
offering. We intend to take advantage of this new legislation, but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and
thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new
regulations and disclosure obligations, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=68,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=462901,FOLIO='66',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_67"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>which
may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If
these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, results of
operations, stock price and prospects. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business. For example, we
expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain
the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it
more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities analysts do not publish research or reports about our business or if they publish negative
evaluations of our stock, the price of our stock could decline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business.
We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain
analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover
our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our
company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of our company or a
change in our management. These provisions include a classified board of directors and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because
we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which limits the ability of stockholders owning in excess of
15% of our outstanding voting stock to merge or combine with our company. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by
requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these
provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of
directors, which is responsible for appointing the members of our management. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable
to emerging growth companies will make our common stock less attractive to investors.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an emerging growth company. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting
requirements applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=69,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=960495,FOLIO='67',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_68"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>exemptions
from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an
emerging growth company for up to five years following the year in which we complete this offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth
company until
the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at
least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed
$700.0&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company" which would allow us to take advantage of many of the same exemptions from
disclosure requirements including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding
executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not
to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance
to changes in our business could significantly affect our financial position and results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America
will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or
our directors, officers, or employees.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum
for:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any derivative action or proceeding brought on our behalf; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any action asserting a breach of fiduciary duty; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and
restated bylaws; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any action asserting a claim against us that is governed by the internal-affairs doctrine. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause
of action arising under the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
exclusive-forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees,
which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of
incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=70,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=68207,FOLIO='68',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_69"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cq76701_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_cq76701_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Special note regarding forward-looking statements    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>This prospectus contains forward-looking statements concerning our business, operations and financial performance and
condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential,"
"continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such
forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from
those indicated in these statements. We believe these factors include, among other things:</I></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing, progress, and results of preclinical studies and clinical trials for RP1 or any of our other product candidates, including the
timing of initiation and completion of studies or trials and related preparatory work and the period during which the results of the trials will become available; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing, scope or likelihood of regulatory filings and approvals, including timing of our BLA filing for, and final FDA approval of, RP1 or
any of our other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing, scope, or likelihood of foreign regulatory filings and approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to develop our product candidates for use in combination with other checkpoint blockade therapies, including anti-PD-1; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to develop and advance any future product candidates into, and successfully complete, clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding the size of the patient populations for RP1 or our other product candidates if approved for commercial use; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs and timing of establishing, equipping, and operating our planned in-house manufacturing facility; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the implementation of our business model and our strategic plans for our business, RP1 and our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rate and degree of market acceptance and clinical utility of RP1 or our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential benefits of and our ability to establish or maintain future collaborations or strategic relationships; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain additional funding as necessary; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights
covering RP1 and our other product candidates, claims others may make regarding rights in our intellectual property, and any potential infringement, misappropriation or other violation of any
third-party intellectual property rights; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=71,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=59660,FOLIO='69',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<A NAME="page_cq76701_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to remediate our existing material weaknesses and to design and maintain an effective system of internal controls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our competitive position, and developments and projections relating to our competitors and our industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> negative developments in the field of immuno-oncology; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations related to the use of proceeds from this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our estimates regarding expenses and capital requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the impact of laws and regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the other risks and uncertainties described under "Risk factors." </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>The
forward-looking statements made in this prospectus relate only to events as of the date on which the statements are made. These factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included in this prospectus. Moreover, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from
time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus. We undertake no obligation
to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except to the extent required by applicable law. You should not
rely on forward-looking statements as predictions of future events. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=72,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=600487,FOLIO='70',FILE='DISK114:[18ZBC1.18ZBC76701]CQ76701A.;75',USER='HYUNG',CD='23-JUL-2018;15:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cs76701_1_71"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cs76701_market_data"> </A>
<A NAME="toc_cs76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Market data    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus includes market and industry data and forecasts concerning our business and the markets for certain cancers, including data
regarding the estimated size of those markets and the incidence and prevalence of certain medical conditions, that we have derived from independent consultant reports, publicly available information,
various industry, medical and general publications, other published industry sources, government data and our internal data and estimates. Independent consultant reports, industry publications and
other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which we operate and our management's understanding of
industry conditions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=73,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=308466,FOLIO='71',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cs76701_1_72"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cs76701_use_of_proceeds"> </A>
<A NAME="toc_cs76701_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Use of proceeds    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The net proceeds from the sale of 6,700,000 shares of common stock in this offering will be approximately $90.8&nbsp;million, or
approximately $104.8&nbsp;million if the underwriters exercise their option to purchase additional shares in full, at the initial public offering price of $15.00 per share, after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
currently expect to use the net proceeds from this offering, together with our existing cash and cash equivalents and short-term investments, as follows:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $20.0&nbsp;million to fund the development of RP1 through the completion of the ongoing Phase&nbsp;1/2 clinical trial in four
solid tumor types; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $15.0&nbsp;million to fund our share of the costs to fully recruit our planned Phase&nbsp;2 clinical trial with RP1 in CSCC; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $20.0&nbsp;million to fund the completion of the preclinical development and the initial clinical trials of RP2 in
approximately 100&nbsp;patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $10.0&nbsp;million to fund the completion of preclinical development and a Phase&nbsp;1 clinical trial of RP3; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $20.0&nbsp;million to fund capital expenditures associated with establishing and equipping our planned manufacturing facility
in Framingham, Massachusetts; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the remainder for general corporate purposes, including working capital requirements and operating expenses. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>This
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with
certainty all of the particular uses for the net proceeds from this offering or the amounts that we will actually spend on the uses set forth above. The amount and timing of our actual expenditures
depend on several factors, including the progress and results of our research and development efforts, the amount of cash used by our operations, and the other factors described under "Risk factors."
Accordingly, we will retain broad discretion in the allocation of the net proceeds from this offering. However, based on our current plans, we believe that the net proceeds from this offering,
together with our existing cash and cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2021. We
have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See "Management's discussion and analysis of financial
condition and results of operations&#151;Liquidity and capital resources." Pending application of the net proceeds, we intend to invest the net proceeds from this offering in short- and
intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=74,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=103563,FOLIO='72',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cs76701_1_73"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cs76701_dividend_policy"> </A>
<A NAME="toc_cs76701_3"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dividend policy    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the
discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, contractual restrictions, business prospects, general business conditions and
other factors that our board of directors may deem relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=75,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1037771,FOLIO='73',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cs76701_1_74"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cs76701_capitalization"> </A>
<A NAME="toc_cs76701_4"> </A></FONT> <FONT SIZE=4><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Capitalization    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our cash and cash equivalents and short-term investments and capitalization as of March&nbsp;31, 2018
on:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an actual basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a pro forma basis to give effect to: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all outstanding shares of our preferred stock into an aggregate of 19,157,360 shares of our common stock upon
the completion of this offering;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all outstanding warrants to purchase shares of series seed preferred stock becoming warrants to purchase shares of common stock
upon the completion of this offering;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all outstanding shares of our common&nbsp;A stock being repurchased by us and canceled immediately prior to the completion of
this offering; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the filing and effectiveness, as of immediately prior to the completion of this offering, of our amended and restated certificate
of incorporation and the adoption of our amended and restated bylaws. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</UL>
</DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to our issuance and sale of 6,700,000 shares of common stock in this offering at the
initial public offering price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
pro forma and pro forma as adjusted information below assumes that this offering was completed on March&nbsp;31, 2018. You should read the information in this table together with the information
contained in this prospectus, including "Use of proceeds," "Management's discussion and analysis of financial condition </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=76,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=87344,FOLIO='74',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cs76701_1_75"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>and
results of operations" and "Description of capital stock" and our consolidated financial statements and related notes appearing at the end of this prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>As of March&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Actual</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Pro&nbsp;forma</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Pro forma<BR>
as adjusted</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in&nbsp;thousands, except share<BR>
and&nbsp;per share data) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents and short-term investments</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>152,316 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,642</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock (series seed, A and B), $0.001&nbsp;par&nbsp;value; 1,975,968&nbsp;shares authorized as of March&nbsp;31, 2018;
1,925,968&nbsp;shares issued and outstanding as of March&nbsp;31, 2018; no shares issued or outstanding, pro&nbsp;forma and pro&nbsp;forma as adjusted as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>86,361</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity (deficit):</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 27,314,288&nbsp;shares authorized (inclusive of 26,258 shares of common&nbsp;A stock) as of March&nbsp;31, 2018;
5,007,485&nbsp;shares issued and outstanding (inclusive of 26,258 shares of common&nbsp;A stock) as of March&nbsp;31, 2018; 24,138,587&nbsp;shares issued and outstanding, pro&nbsp;forma as of March&nbsp;31, 2018; 30,838,587 shares issued and
outstanding, pro&nbsp;forma as adjusted as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,097</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>89,081</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>179,839</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,068</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150,700 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150,700 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
actual, pro forma and pro forma as adjusted information set forth in the table excludes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,520,247 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2018 at a weighted average
exercise price of $2.72 per share;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,486,118 shares of common stock reserved for future issuance under our 2018 Plan, which became effective upon the effectiveness of the
registration statement of which this prospectus is a part; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 348,612 shares of our common stock reserved for future issuance under our ESPP, which became effective upon the effectiveness of the
registration statement of which this prospectus is a part; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 131,850 shares of our common stock reserved for future issuance as of March&nbsp;31, 2018 under our 2017 Plan, which became available for
issuance under our 2018 Plan upon the effectiveness of our 2018 Plan; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 497,344 shares of common stock issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2018 at an exercise price of $1.01 per
share. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=77,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=635065,FOLIO='75',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cs76701_1_76"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cs76701_dilution"> </A>
<A NAME="toc_cs76701_5"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dilution    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
historical net tangible book value (deficit) as of March&nbsp;31, 2018 was $(28.1)&nbsp;million, or $(5.63) per share of our common stock. Our historical net tangible book value (deficit) is
the amount of our total tangible assets less our total liabilities and the carrying value of our preferred stock, which is not included within our stockholders' equity (deficit). Historical net
tangible book value per share represents historical net tangible book value (deficit) divided by the number of shares of our common stock issued as of March&nbsp;31, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
pro forma net tangible book value as of March&nbsp;31, 2018 was $59.9&nbsp;million, or $2.48 per share of our common stock. Pro forma net tangible book value (deficit) represents the amount of
our total tangible assets less our total liabilities, after giving effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into an aggregate of 19,157,360 shares of common
stock upon the completion of this offering and (ii)&nbsp;all outstanding warrants to purchase shares of series seed preferred stock becoming warrants to purchase shares of common stock upon the
completion of this offering, in each case assuming that this offering was completed on March&nbsp;31, 2018. Pro forma net tangible book value per share represents pro forma net tangible book value
divided by the total number of shares of our common stock issued as of March&nbsp;31, 2018, after giving effect to the conversion of all outstanding shares of our preferred stock into an aggregate
of 19,157,360 shares of our common stock upon the completion of this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
giving further effect to our sale of 6,700,000 shares of common stock in this offering at the initial public offering price of $15.00 per share, and after deducting underwriting discounts and
commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2018 would have been $150.7&nbsp;million, or $4.89 per share. This
represents an immediate increase in pro forma as adjusted net tangible book value per share of $2.41 to our existing stockholders and an immediate dilution in pro forma as adjusted net tangible book
value per share of $10.11 to new investors purchasing common stock in this offering. Dilution per share to new investors purchasing common stock in this offering is determined by subtracting pro forma
as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following table illustrates this dilution on a per share basis assuming the underwriters do not exercise their option to purchase additional shares of common stock: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial public offering price per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value (deficit) per share as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5.63</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase per share attributable to the pro forma adjustments described above</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.48</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing common stock in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.41</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.89 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors purchasing common stock in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.11 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>If
the underwriters exercise their option to purchase additional shares of common stock in this offering in full at the initial public offering price of $15.00 per share, after deducting underwriting
discounts and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=78,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=612151,FOLIO='76',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cs76701_1_77"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>commissions
and estimated offering expenses payable by us, the pro forma as adjusted net tangible book value per share after this offering would be $5.17 per share, and the decrease in dilution in pro
forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering would be $0.28 per share. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes, as of March&nbsp;31, 2018 on the same pro forma as adjusted basis as described above, the total number of shares of common stock purchased from us, the total cash
consideration paid to us and the average price per share of common stock paid by our existing investors and by new investors purchasing shares of common stock in this offering at the initial public
offering price of $15.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in
this offering will pay an average price per share substantially higher than our existing investors paid. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="77pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Shares of<BR>
common stock<BR>
purchased </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Total<BR>
consideration </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Average price<BR>
per share of<BR>
common stock</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Percent</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Amount</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Percent</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>24,138,157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>78.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>86,949,678</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>46.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,700,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>53.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15.00 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30,838,587</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>187,449,678</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
table above assumes no exercise of the underwriters' option to purchase additional shares in this offering. If the underwriters' option to purchase additional shares is exercised in full, the
number of shares of our common stock held by existing stockholders would be reduced to 75.8% of the total number of shares of our common stock outstanding after this offering, and the number of shares
of common stock held by new investors participating in the offering would be increased to 24.2% of the total number of shares outstanding after this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
table above does not include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,520,247 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2018 at a weighted average
exercise price of $2.72 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,486,118 shares of common stock reserved for future issuance under our 2018 Plan, which became effective upon the effectiveness of the
registration statement of which this prospectus is a part; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 348,612 shares of our common stock reserved for future issuance under our ESPP, which became effective upon the effectiveness of the
registration statement of which this prospectus is a part; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 131,850 shares of our common stock reserved for future issuance as of March&nbsp;31, 2018 under our 2017 Plan, which became available for
issuance under our 2018 Plan upon the effectiveness of our 2018 Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 497,344 shares of common stock issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2018 at an exercise price of $1.01 per
share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 26,258 shares of common&nbsp;A stock outstanding as of March&nbsp;31, 2018, all of which will be repurchased by us and canceled immediately
prior to the completion of this offering. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
may choose to raise additional capital through the sale of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for
our current or future operating plans. New investors will experience further dilution if any of our outstanding options are exercised, new options are issued and exercised under our equity incentive
plan or we issue additional shares of common stock, other equity securities or convertible debt securities in the future. See "Risk factors&#151;If you purchase our common stock in this
offering, you will incur immediate and substantial dilution in the book value of your shares." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=79,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1040657,FOLIO='77',FILE='DISK114:[18ZBC1.18ZBC76701]CS76701A.;107',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cu76701_1_78"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cu76701_selected_consolidated_financial_data"> </A>
<A NAME="toc_cu76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Selected consolidated financial data    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes
appearing at the end of this prospectus and the "Management's discussion and analysis of financial condition and results of operations" section of this prospectus. We have derived the consolidated
statement of operations data for the years ended March&nbsp;31, 2017 and 2018 and the consolidated balance sheet data as of March&nbsp;31, 2017 and 2018 from our audited consolidated financial
statements appearing at the end of this prospectus. Our historical results are not necessarily indicative of results that should be expected in any future period. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="87pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="87pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> Year ended March 31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands, except share and per share data) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated statement of operations data</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,516</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,711</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,713 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,647</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,229 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,647</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,229</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development incentives</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,267</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>288</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(150</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(972</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>626</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,056</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense), net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,943</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(473</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3.96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,973,439</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,978,539 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro&nbsp;forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.87</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro&nbsp;forma weighted average common shares outstanding, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21,506,697 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;See
Note&nbsp;12 to our consolidated financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per share
attributable to common stockholders and unaudited basic and diluted pro forma net loss per share attributable to common stockholders. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=80,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=4449,FOLIO='78',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_79"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> March&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> March&nbsp;31,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated balance sheet data</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents and short-term investments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20,594</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>61,551</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20,417</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>59,539</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,819</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>65,151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,642</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,725</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,858</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,609</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>86,361</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(11,515</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(28,068</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;We
define working capital as current assets less current liabilities. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=81,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=861885,FOLIO='79',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_80"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cu76701_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_cu76701_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management's discussion and analysis of financial condition and results of operations    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>You should read this discussion and analysis of our financial condition and consolidated results of operations
together with the consolidated financial statements, related notes and other financial information included in this prospectus. The following discussion and other parts of this prospectus may contain
predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under "Risk factors" and elsewhere in this prospectus. These
risks could cause our actual results to differ materially from any future performance suggested below. Accordingly, you should read "Special note regarding forward-looking statements" and "Risk
factors."</I></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cu76701_overview"> </A>
<A NAME="toc_cu76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Overview    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform
the lives of cancer patients. We use our proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. We are
conducting a Phase&nbsp;1/2 clinical trial in the United Kingdom and, pending the opening of an IND, in the United States with our lead product candidate, RP1, in approximately 150&nbsp;patients
with a range of solid tumors. In addition, in the first half of 2019, we plan to initiate a randomized, controlled Phase&nbsp;2 clinical trial of RP1 in combination with cemiplimab, versus
cemiplimab alone, in approximately 240 patients with cutaneous squamous cell carcinoma, or CSCC, which we are designing to potentially support product registration. We also intend to initiate a
clinical trial for our second product candidate, RP2, in the first half of 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Oncolytic
immunotherapy is an emerging class of cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent,
patient-specific, anti-tumor immune response. Such oncolytic, or "cancer killing," viruses have the potential to generate an immune response targeted to an individual patient's particular set of tumor
antigens, including to neo-antigens that are uniquely present in tumors. Our product candidates incorporate multiple&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mechanisms of action into single product
candidates in a practical,
"off-the-shelf" format that is intended to maximize the immune response against a patient's cancer and to offer significant advantages over personalized vaccine approaches. Our management team has
worked together for more than ten years and
successfully developed the first oncolytic immunotherapy, Imlygic, also known as T-Vec, which was approved by the FDA for the treatment of advanced melanoma in 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
foundation of our Immulytic platform consists of a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, that has been "armed" with a fusogenic therapeutic protein intended to
substantially increase anti-tumor activity. Our platform enables us to design multiple product candidates that incorporate various further genes whose expression is intended to augment the inherent
properties of HSV-1 to both directly destroy tumor cells and induce an anti-tumor immune response. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe our lead product candidate, RP1, and our other product candidates will be effective at killing tumors and inducing immunogenic, or immune-stimulating, tumor cell death and that it will be
highly synergistic with immune checkpoint blockade therapies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
began operations as Replimune Limited, an English limited company that was incorporated in 2015. On July&nbsp;5, 2017, Replimune Group,&nbsp;Inc., a Delaware corporation, was incorporated and,
on July&nbsp;10, 2017, the shareholders of Replimune Limited effected a share-for-share exchange pursuant to which they exchanged their outstanding shares in Replimune Limited for shares in
Replimune Group,&nbsp;Inc., on a one-for-one basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=82,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=416422,FOLIO='80',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_81"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the holders of warrants to purchase shares of series seed preferred stock and stock options to acquire Replimune Limited capital stock canceled their warrants and stock options in
Replimune Limited and were issued replacement warrants and stock options to acquire Replimune Group,&nbsp;Inc. capital stock on a one-for-one basis. We refer to these transactions collectively as
the reorganization. Upon completion of the reorganization, the historical consolidated financial statements of Replimune Limited became the historical consolidated financial statements of Replimune
Group,&nbsp;Inc. because the reorganization was accounted for similar to a reorganization of entities under common control due to the high degree of common ownership of Replimune Limited and
Replimune Group,&nbsp;Inc. and lack of economic substance to the transaction. We concluded that the reorganization resulted in no change in the material rights and preferences of each respective
class of equity interests and no change in the fair value of each respective class of equity interests before and after the reorganization. On December&nbsp;8, 2017, Replimune Limited transferred
all outstanding shares of its wholly owned subsidiary, Replimune,&nbsp;Inc., to Replimune Group,&nbsp;Inc., a Delaware corporation. Replimune Group,&nbsp;Inc. is the sole shareholder of
Replimune&nbsp;Limited, Replimune,&nbsp;Inc. and Replimune Securities Corporation, a Massachusetts corporation that was incorporated in November&nbsp;2017. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise indicated or the context otherwise requires, all information in this prospectus is presented giving effect to the reorganization. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cu76701_financial_overview"> </A>
<A NAME="toc_cu76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Financial overview    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since our inception, we have devoted substantially all of our resources to developing our Immulytic platform and our lead product candidate,
RP1, building our intellectual property portfolio, conducting research and development of our product candidates, business planning, raising capital and providing general and administrative support
for our operations. To date, we have financed our operations primarily with proceeds from the sale of convertible preferred stock or preferred stock. Through March&nbsp;31, 2018, we had received
gross proceeds of $86.9&nbsp;million from our sales of preferred stock. We do not have any products approved for sale and have not generated any revenue from product sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual
commercialization of one or more of our product candidates. Our net losses were $7.7&nbsp;million for the year ended March&nbsp;31, 2017 and $19.7&nbsp;million for the year ended
March&nbsp;31, 2018. As of March&nbsp;31, 2018, we had an accumulated deficit of $28.9&nbsp;million. These losses have resulted primarily from costs incurred in connection with research and
development activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next
several years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
anticipate that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical
trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company following the completion of this offering. We expect that our expenses
and capital requirements will increase substantially if and as we:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conduct our current and future clinical trials with RP1; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> progress the preclinical and clinical development of RP2 and RP3; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish, equip, and operate our own in-house manufacturing facility; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=83,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=58756,FOLIO='81',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_82"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek to identify and develop additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintain, expand and protect our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> acquire or in-license other drugs and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire and retain additional clinical, quality control, scientific and finance personnel; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> add operational, financial and management information systems and personnel, including personnel to support our research and development
programs, any future commercialization efforts and our transition to operating as a public company following the completion of this offering. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for RP1 or our other product candidates. If we obtain
regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal
commercialization capability to support product sales, marketing, and distribution. Further, upon the completion of this offering, we expect to incur additional costs associated with operating as a
public company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales,
if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. We
may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and
when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of one or more of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we
will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability
on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2018, we had cash and cash equivalents and short-term investments of $61.6&nbsp;million. We believe that the expected net proceeds from this offering, together with our
existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2021. We have based this
estimate on assumptions that
may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See "&#151;Liquidity and capital resources" and "Risk factors&#151;Risks related to our
financial position and need for additional capital." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=84,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=686033,FOLIO='82',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_83"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cu76701_components_of_our_results_of_operations"> </A>
<A NAME="toc_cu76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Components of our results of operations    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, we have not generated any revenue from product sales as we do not have any approved products and do not expect to generate any revenue from the sale
of products in the near future. If our development efforts for RP1 or any other product candidates that we may develop in the future are successful and result in regulatory approval, or if we enter
into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from those collaboration or license agreements. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our expenses since inception have consisted solely of research and development costs and general and administrative costs. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of RP1
and our other product candidates, and include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expenses incurred under agreements with third parties, including CROs that conduct research, preclinical activities and clinical trials on our
behalf as well as CMOs that manufacture our product candidates for use in our preclinical and clinical trials;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development
functions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs related to compliance with regulatory requirements in connection with the development of RP1 and our other product candidates; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other
operating costs. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us
by our service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated
financial statements as prepaid or accrued research and development expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
direct external research and development expenses are tracked on a program-by-program basis and consist of costs, such as fees paid to consultants, contractors, CMOs, and CROs in connection with
our preclinical and clinical development activities. To date, we have not allocated expenses to our earlier-stage programs for RP2 and RP3. In addition, we do not allocate employee costs, costs
associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific product development programs because these costs are deployed
across multiple product development programs and, as such, are not separately classified. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=85,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=446562,FOLIO='83',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_84"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
table below summarizes our research and development expenses by product candidate or development program for each of the periods presented: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="29pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended March&nbsp;31,</B></FONT>&nbsp;</TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 2017</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> 2018 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2><B> </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=4 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> (Amounts in thousands)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 RP1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,874</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unallocated research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,266 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,516 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages
of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the
foreseeable future as we initiate additional clinical trials of RP1, complete preclinical development and pursue initial stages of clinical development of RP2 and RP3 and continue to discover and
develop additional product candidates. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated
with product development and commercialization, including the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope, rate of progress, expense and results of our ongoing clinical trials of RP1, as well as of any future clinical trials of RP2 and RP3
or other product candidates and other research and development activities that we may conduct; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and scope of preclinical and clinical programs we decide to pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to maintain our current research and development programs and to establish new ones; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in clinical trial design and patient enrollment rates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the successful completion of clinical trials with safety, tolerability, and efficacy profiles that are satisfactory to the FDA or any
comparable foreign regulatory authority; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the receipt of regulatory approvals from applicable regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our success in establishing, equipping, and operating a manufacturing facility, or securing manufacturing supply through relationships with
third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain and maintain patents, trade secret protection, and regulatory exclusivity, both in the United States and internationally; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to protect our rights in our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercialization of our product candidates, if and when approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the acceptance of our product candidates, if approved, by patients, the medical community, and third-party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to successfully develop our product candidates for use in combination with third-party products or product candidates; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=86,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=470570,FOLIO='84',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_85"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> negative developments in the field of immuno-oncology; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competition with other products; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> significant and changing government regulation and regulatory guidance. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>A
change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that
product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical
development of a
product candidate, or if we experience significant trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the
completion of clinical development. We may never succeed in obtaining regulatory approval for any of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to use approximately $20.0&nbsp;million of the proceeds from this offering to fund the development of RP1 through the completion of the ongoing Phase 1/2 clinical trial in four solid tumor
types, approximately $15.0&nbsp;million to fund our share of the costs to fully recruit our planned Phase&nbsp;2 clinical trial with RP1 in CSCC, approximately $20.0&nbsp;million to fund the
completion of the preclinical development and the initial clinical trials of RP2 in approximately&nbsp;100 patients, approximately $10.0&nbsp;million to fund the completion of preclinical
development and a Phase&nbsp;1 clinical trial of RP3, and approximately $20.0&nbsp;million to fund capital expenditures associated with establishing and equipping our planned manufacturing
facility in Framingham, Massachusetts. However, because the design and outcome of planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts
necessary to successfully complete the development and commercialization of RP1 or our other product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive,
finance, corporate and business development and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting
services; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and
potential commercialization of our product candidates. We also expect to incur increased expenses associated with being a public company following the completion of this offering, including costs of
accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements; director and officer insurance costs; and investor and
public relations costs. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income (expense), net  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development incentives  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development incentives consists of reimbursements of research and development expenditures. We participate, through our subsidiary in the United
Kingdom, in the research and development program provided by the United Kingdom tax relief program, such that a percentage of up to 14.5% of our qualifying research and development expenditures are
reimbursed by the United Kingdom government, and such incentives are reflected as other income. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=87,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=889831,FOLIO='85',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cu76701_1_86"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in fair value of warrant liability  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the issuance of the series seed preferred stock we issued to the series seed preferred stock holders warrants to purchase shares of series
seed preferred stock. We classify the warrants as a liability on our consolidated balance sheets. We remeasure the warrant liability to fair value at each reporting date and recognize changes in the
fair value of the warrant liability as a component of other income (expense), net in our consolidated statements of operations. We will continue to recognize changes in the fair value of the warrant
liability until the warrants are exercised, expire or qualify for equity classification. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the completion of this offering, the warrants to purchase shares of series seed preferred stock will become exercisable for shares of common stock instead of shares of preferred stock, and the
warrant
liability will be reclassified to additional paid-in capital. As a result, following the completion of this offering, we will no longer recognize changes in the fair value of the warrant liability as
other income (expense), net in our consolidated statements of operations. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest income  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Interest income consists of income earned on our cash and cash equivalents and short-term investments. Our interest income has not been significant due to low
investment balances and low interest earned on those balances. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income (expense), net  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other income (expense), net consists primarily of realized and unrealized foreign currency transaction gains and losses. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since our inception and through March&nbsp;31, 2018, we have not recorded any income tax benefits for the net losses we incurred in each jurisdiction in
which we operate, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards will not be realized. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>On
December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act includes a number of changes to
existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, effective as of January&nbsp;1,
2018, as well as limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable
years beginning after December&nbsp;31, 2017 (though any
such net operating losses may be carried forward indefinitely). Under the Tax Act, our deferred tax assets and liabilities (before valuation allowance) were remeasured at the lower federal tax rate,
resulting in an increase to our income tax provision with an equal and offsetting reduction in our valuation allowance. All of our recorded income tax benefits and provisions related to the Tax Act
are provisional. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=88,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=694262,FOLIO='86',FILE='DISK114:[18ZBC1.18ZBC76701]CU76701A.;109',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cw76701_1_87"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_results_of_operations"> </A>
<A NAME="toc_cw76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Results of operations    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of the years ended March&nbsp;31, 2017 and 2018  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our results of operations for the years ended March&nbsp;31, 2017 and 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> Change</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (Amounts in thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,580</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,711</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,713</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,002 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,647</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,582 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9,647</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(19,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development incentives</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,267</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>825</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(972</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,056</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense), net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(473</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(11,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> Change</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (Amounts in thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Direct research and development expenses by program:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RP1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,874</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unallocated research and development expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel related (including stock-based compensation)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,121</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>941</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,205 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,580 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Research
and development expenses for the year ended March&nbsp;31, 2017 were $6.9&nbsp;million, compared to $13.5&nbsp;million for the year ended March&nbsp;31, 2018. The increase of
$6.6&nbsp;million was due primarily to an increase of approximately $3.4&nbsp;million in direct research costs associated with RP1 and an approximately $3.2&nbsp;million increase in our
unallocated research and development costs. The increase in RP1 costs was due primarily to an increase in clinical trial costs in the year ended March&nbsp;31, 2018 associated with our ongoing
Phase&nbsp;1/2 clinical trial, which commenced in the United Kingdom in October 2017. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
increase in unallocated research and development expenses reflected an increase of $2.0&nbsp;million in personnel-related costs, including stock-based compensation, and an increase of
$1.2&nbsp;million in other costs. The increase in personnel-related costs was primarily due to the hiring of additional personnel in our research and development functions as we began work on our
planned Phase&nbsp;2 clinical trial of RP1 in patients with CSCC. Personnel-related costs for each of the years ended March&nbsp;31, 2017 and 2018 included </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=89,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=886442,FOLIO='87',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_88"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stock-based
compensation expense of $0.2&nbsp;million and $0.8&nbsp;million, respectively. Other costs increased primarily due to purchases of supplies used across all of our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses were $2.7&nbsp;million for the year ended March&nbsp;31, 2017, compared to $5.7&nbsp;million for the year ended
March&nbsp;31, 2018. The increase of $3.0&nbsp;million primarily reflected increases of $1.1&nbsp;million in personnel related costs and $1.6&nbsp;million in professional fees. The increase in
personnel related costs was due to the hiring of additional personnel in our general and administrative functions as we expanded our operations in the United States. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income (expense), net  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other income (expense) was $1.9&nbsp;million for the year ended March&nbsp;31, 2017, compared to $(0.5) million for the year ended March&nbsp;31, 2018.
The decrease of $2.4&nbsp;million was primarily attributable to a $2.7&nbsp;million increase in the expense due to a change in foreign exchange rates and a $0.8&nbsp;million increase in the
expense due to a change in the fair value of the warrant liability, partially offset by a $0.8&nbsp;million increase in expenditure reimbursements recognized under the research and development
program provided by the United Kingdom government and a $0.3&nbsp;million increase in interest income. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_liquidity_and_capital_resources"> </A>
<A NAME="toc_cw76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Liquidity and capital resources    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash
flows from our operations. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue
from sales of any products for the foreseeable future, if at all. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sources of liquidity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, we have financed our operations primarily with proceeds from the sale of convertible preferred stock. Through March&nbsp;31, 2018, we had received
gross proceeds of $86.9&nbsp;million from our sales of preferred stock. As of March&nbsp;31, 2018, we had cash and cash equivalents and short-term investments of $61.6&nbsp;million. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash flows  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our cash flows for each of the periods presented: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (Amounts in<BR>
thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(7,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(16,014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(44,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>54,752</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate changes on cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,419</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,297 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,266</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(3,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating activities  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the year ended March&nbsp;31, 2018, net cash used in operating activities was $16.0&nbsp;million, primarily resulting from our net loss of
$19.7&nbsp;million, partially offset by net cash provided by changes in our operating assets and liabilities of $1.9&nbsp;million and non-cash charges of $1.8&nbsp;million. Net cash provided by </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=90,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=643067,FOLIO='88',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_89"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>changes
in our operating assets and liabilities for the year ended March&nbsp;31, 2018 consisted primarily of a $1.6&nbsp;million increase in accounts payable and a $1.4&nbsp;million increase in
accrued expenses and other current liabilities, partially offset by a $0.8&nbsp;million increase in the research and development incentives receivable from the United Kingdom government due to the
timing and amount of our qualifying expenditures and a $0.3&nbsp;million increase in prepaid expenses and other current assets due to CRO deposits related to the ongoing Phase&nbsp;1/2 clinical
trial for RP1. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the year ended March&nbsp;31, 2017, net cash used in operating activities was $7.1&nbsp;million, primarily resulting from our net loss of $7.7&nbsp;million, partially offset by non-cash
charges of $0.5&nbsp;million, and net cash provided by changes in our operating assets and liabilities of $0.1&nbsp;million. Net cash used by changes in our operating assets and liabilities for
the year ended March&nbsp;31, 2017 consisted primarily of a $0.2&nbsp;million increase in accounts payable and a $1.4&nbsp;million increase in accrued expenses due to accrued RP1 clinical trial
costs, accrued compensation costs and accrued audit fees, partially offset by a $1.2&nbsp;million increase in the research and development incentives receivable from the United Kingdom government
due to the timing and amount of our qualifying expenditures and a $0.3&nbsp;million increase in prepaid expenses and other current assets due to value-added tax receivables and CMO deposits for RP1
clinical trial supplies. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investing activities  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the year ended March&nbsp;31, 2018, net cash used in investing activities was $44.0&nbsp;million, consisting of $52.5&nbsp;million in purchases
of available for sale securities and $0.1&nbsp;million in purchases of property, plant and equipment, partially offset by $8.6&nbsp;million in proceeds from maturities of short-term investments. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>During
the year ended March&nbsp;31, 2017, net cash used in investing activities was $0.2&nbsp;million, consisting of purchases of property, plant and equipment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that purchases of property, plant and equipment will increase over the next several years resulting from our intended establishment of our own in-house manufacturing facility. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financing activities  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the year ended March&nbsp;31, 2018, net cash provided by financing activities was $54.8&nbsp;million, primarily consisting of net proceeds from our
issuance of series&nbsp;B convertible preferred stock, or series&nbsp;B preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the year ended March&nbsp;31, 2017, net cash provided by financing activities was $15.0&nbsp;million, primarily consisting of proceeds from our issuance of series&nbsp;A convertible
preferred stock, or series&nbsp;A preferred stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Funding requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our plan of operation is to continue implementing our business strategy, continue research and development of RP1 and our other product candidates and
continue to expand our research pipeline and our internal research and development capabilities. We expect our expenses to increase substantially in connection with our ongoing activities,
particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company
following the completion of this offering. We expect that our expenses will increase substantially if and as we:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conduct our current and future clinical trials of&nbsp;RP1; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> progress the preclinical and clinical development of&nbsp;RP2 and&nbsp;RP3; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish, equip, and operate our own in-house manufacturing facility; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=91,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=614295,FOLIO='89',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_90"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek to identify and develop additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> until our planned manufacturing facility is operational, require the manufacture by third parties of larger quantities of our product
candidates for clinical development and potentially commercialization; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintain, expand and protect our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> acquire or in-license other drugs and technologies; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> add operational, financial and management information systems and personnel, including personnel to support our research and development
programs, any future commercialization efforts and our transition to operating as a public company following the completion of this offering. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2018, we had cash and cash equivalents and short-term investments of $61.6&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our
existing cash and cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2021. We have based this
estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of the numerous risks and uncertainties associated with the development of RP1 and other product candidates and programs, and because the extent to which we may enter into collaborations with
third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the
research and development of our product candidates. Our future capital requirements will depend on many factors, including those described in this section and above under "&#151;Operating
expenses&#151;Research and development expenses." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we intend to establish, equip, and operate an in-house manufacturing facility to manufacture RP1 and our other product candidates. We expect that such a facility would require capital
expenditures of approximately $20.0&nbsp;million to commence operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Developing
novel biopharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may
never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any products for which we may obtain marketing
approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of therapies that we do not expect to be
commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Adequate
additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise additional capital
through the sale of our equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution
protections that could adversely affect your rights as a common stockholder. Additional debt or preferred equity financing, if
available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends,
which could </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=92,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=52416,FOLIO='90',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_91"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>adversely
impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute your ownership interest. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue
streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or
collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_contractual_obligations_and_commitments"> </A>
<A NAME="toc_cw76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Contractual obligations and commitments    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our contractual obligations as of March&nbsp;31, 2018 and the effects that such obligations are expected to
have on our liquidity and cash flows in future periods: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B> Payments due by period </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> Total</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> Less than<BR>
1 year</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 1 to 3<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> 4 to 5<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> More than<BR>
5 years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (Amounts in thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Manufacturing commitments<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,938</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,938</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease commitments<SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>947</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,359</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>947</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Amounts
in the table reflect commitments for costs associated with our external CMO, which we engaged to manufacture clinical trial materials. </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Amounts
in the table reflect minimum payments due under our two leases of laboratory and office space in Woburn, Massachusetts and Oxfordshire, United Kingdom, at a monthly commitment
of $7 and $31, respectively. These leases are both operating leases. Our lease in Woburn expires in March 2021, and our lease in Oxfordshire expires in April 2026 and is terminable by us in
April&nbsp;2021.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;In
June 2018, we entered into an agreement to lease approximately 63,000 square feet of office, manufacturing and laboratory space within a previously occupied building with
approximately 106,000 square feet of rentable space in Framingham, Massachusetts. Pursuant to the lease agreement, the lease term is estimated to commence in November 2018, subject to the landlord
completing certain agreed upon landlord improvements. The rent commencement date is estimated to be eight months after the commencement of the lease term. The initial lease term is ten years from the
rent commencement date and includes two optional five year extensions. As a result of the new lease agreement, our contractual obligations will increase by the following amounts over the initial ten
year lease term (which are not reflected in the table above): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 </DIV>
<DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Payments due by period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Total</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Less than<BR>
1 year</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 to 3<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 4 to 5<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> More than<BR>
5 years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (in thousands) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Operating lease commitments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,205</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">15,496 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>We
enter into contracts in the normal course of business with CROs, CMOs and other third parties for clinical trials and preclinical research studies and testing. Manufacturing and research
commitments in the preceding table include agreements that are enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased;
fixed, minimum or variable price provisions; and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts included in the preceding table are limited to the
non-cancelable portion of the agreement terms or the minimum cancellation fee. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=93,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=959055,FOLIO='91',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_92"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_collaborations"> </A>
<A NAME="toc_cw76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Collaborations    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BMS  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On February&nbsp;26, 2018, we entered into a Clinical Trial Collaboration and Supply Agreement with Bristol- Myers Squibb Company, or BMS. Pursuant to the
agreement, BMS will provide to us, at no cost, nivolumab, its anti-PD-1 therapy, for use in combination with RP1 in our ongoing Phase&nbsp;1/2 clinical trial. Under the agreement, we will sponsor,
fund and conduct the clinical trial in accordance with an agreed-upon protocol. Under the agreement, BMS granted us a non-exclusive, non-transferrable, royalty-free license (with a right to
sublicense) under its intellectual property to use nivolumab in the clinical trial and has agreed to manufacture and supply nivolumab, at its cost and for no charge to us, for use in the clinical
trial. Both parties will own the study data produced in the clinical trial, other than study data related solely to nivolumab, which will belong solely to BMS or study data related solely to RP1,
which will belong solely to us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
earlier terminated, the agreement will remain in effect until (i)&nbsp;the completion of the clinical trial, (ii)&nbsp;all related clinical trial data have been delivered to both parties
and (iii)&nbsp;the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be
terminated by either party (i)&nbsp;in the event of an uncured material breach by the other party, (ii)&nbsp;in the event the other party is insolvent or in bankruptcy proceedings or
(iii)&nbsp;for safety reasons. Upon termination, the licenses granted to us to use nivolumab in the clinical trial will terminate. The agreement contains representations, warranties, undertakings
and indemnities customary for a transaction of this nature. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regeneron  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On May&nbsp;29, 2018, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals,&nbsp;Inc., or Regeneron.
Pursuant to the agreement we agreed to undertake one or more clinical trials with Regeneron for the administration of our product candidates in combination with cemiplimab, an anti-PD-1 therapy being
developed by Regeneron, across multiple solid tumor types, the first of which is intended to be our planned Phase&nbsp;2 clinical trial of RP1 in patients with CSCC. Each clinical trial will be
conducted pursuant to an agreed study plan which, among other things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and a
schedule of clinical obligations. The first study plan related to the Phase&nbsp;2 clinical trial in CSCC has been agreed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to contribute the necessary resources needed to
fulfill their respective obligations, in each case, under the terms of agreed study plans. Development costs of a particular clinical trial will be split equally. The agreement contains
representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain covenants that restrict us from entering into a third-party
arrangement with respect to the use of our product candidates in combination with an anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use
of cemiplimab in combination with an HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed
in a future study plan, these covenants are only applicable to our planned Phase&nbsp;2 clinical trial in CSCC, and expire upon the one-year anniversary of the commencement of the applicable study
plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
agreement may be terminated by either party if (i)&nbsp;there is no active study plan for which a final study report has not been completed, (ii)&nbsp;the parties have not entered into a study
plan for an additional </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=94,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=813104,FOLIO='92',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_93"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>clinical
trial within a period of time after the delivery of the most recent final study report or (iii)&nbsp;in the event of a material breach. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_critical_accounting_policies_a__cri02744"> </A>
<A NAME="toc_cw76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Critical accounting policies and significant judgments and estimates    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management's discussion and analysis of financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us
to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial
statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our
actual results may differ from these estimates under different assumptions or conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
our significant accounting policies are described in greater detail in Note&nbsp;2 to our consolidated financial statements appearing at the end of this prospectus, we believe that the
following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrued research and development expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This
process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service
performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for
services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our
accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and
development expenses include fees paid to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> CROs in connection with performing research activities and conducting preclinical studies and clinical trials on our behalf; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> CMOs in connection with the production of preclinical and clinical trial materials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> investigative sites or other service providers in connection with clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors in connection with preclinical and clinical development activities; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors related to product manufacturing and development and distribution of preclinical and clinical supplies. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that
supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in
uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these
contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services
will be performed and the level of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=95,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=848509,FOLIO='93',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_94"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>effort
to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses
accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual
status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our
prior estimates of accrued research and development expenses. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We measure stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognizes compensation expense for
those awards over the requisite service period, which is generally the vesting period of the respective award. We have to date only issued stock-based awards with service-based vesting conditions and
record the expense for these awards using the straight-line method. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which
requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the
expected term of the option, and our expected dividend yield. See Note&nbsp;10 to our consolidated financial statements appearing at the end of this prospectus for more information. Forfeitures are
accounted for as they occur. The fair value of each stock-based award is estimated on the date of grant based on the fair value of our common stock on that same date. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>For
stock-based awards granted to consultants and non-employees, we recognize compensation expense over the period during which services are rendered by such non-employees and consultants until
completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of our common stock and
updated assumption inputs in the Black-Scholes option pricing model. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient's payroll costs are classified or in which the award
recipient's service payments are classified. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Determination of the fair value of common stock  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The estimated fair value of the common stock underlying our stock options was initially determined at each grant date by our board of directors, with input
from management. All options to purchase shares of our common stock are intended to be exercisable at a price per share not less than the per-share fair value of our common stock underlying those
options on the date of grant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the absence of a public trading market for our common stock, on each grant date, our board of directors made a reasonable determination of the fair value of our common stock based on the
information known to us on the date of grant, and upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock. Our board of directors
considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prices at which we sold preferred stock and the superior rights and preferences of the preferred stock relative to our common stock at the
time of each grant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the progress of our research and development programs, including the status of preclinical studies and planned clinical trials for our product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our stage of development and our business strategy; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=96,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=404958,FOLIO='94',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_95"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> external market conditions affecting the biotechnology industry, and trends within the biotechnology industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our financial position, including cash on hand, and our historical and forecasted performance and operating results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of an active public market for our common stock and our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the likelihood of achieving a liquidation event, such as an initial public offering, or IPO, or a sale of our company in light of prevailing
market conditions; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>We
subsequently obtained third-party valuations of our common stock as of the dates on which our board of directors had granted equity awards. See "&#151;Options granted." These third-party
valuations of common stock were prepared using the hybrid method, which used market approaches to estimate our equity value. The hybrid method is a probability-weighted expected return method, or
PWERM, where the equity value in one or more of the scenarios is allocated using an option-pricing method, or OPM. The PWERM is a scenario-based methodology that estimates the fair value of common
stock based upon an analysis of future values for the business, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment
returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation
date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then
applied to arrive at an indication of value for the common stock. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on
the value thresholds at which the allocation among the various holders of a company's securities changes. Under this method, the common stock has value only if the
funds available for distribution to stockholders exceeded the value of the preferred stock liquidation preferences at the time of the liquidation event, such as a strategic sale or a merger. These
third-party valuations were performed at various dates, which resulted in valuations of our common stock of $1.26 per share as of March&nbsp;10, 2016, $1.34 per share as of October&nbsp;12, 2016,
$1.63&nbsp;per share as of March&nbsp;10, 2017, $2.90 per share as of July&nbsp;26, 2017 and $3.83 per share as of January&nbsp;31, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
assumptions underlying these valuations represented our board of directors' best estimates at the time they were made, which involve inherent uncertainties and the application of the judgment of
our board of directors. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially
different. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once
a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board of directors to estimate the
fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the
quoted market price of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=97,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=720143,FOLIO='95',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_96"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Options granted  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth, by grant date, the number of shares subject to options granted from April&nbsp;1, 2016 through July&nbsp;9, 2018, the per
share exercise price of the options, the fair value of common stock per share on each grant date, and the per share estimated fair value of the options: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="77pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Grant Date</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Number of<BR>
shares subject<BR>
to options<BR>
granted</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Per share<BR>
exercise<BR>
price of<BR>
options</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Fair value<BR>
per common<BR>
stock on<BR>
grant date<SUP>(1)</SUP></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Per share<BR>
estimated<BR>
fair value<BR>
of&nbsp;options<BR>
on grant<BR>
date </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 April&nbsp;1, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>129,309</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>June&nbsp;1, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>39,787</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 October&nbsp;3, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>38,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>October&nbsp;12, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 November&nbsp;7, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,967</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>January&nbsp;21, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>43,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 January&nbsp;25, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>25,861</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March&nbsp;10, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>64,651</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.07</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 July&nbsp;26, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,205,543</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>August&nbsp;2, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,946</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 August&nbsp;4, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>September&nbsp;1, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>149,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 September&nbsp;4, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,973</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>September&nbsp;12, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19,893</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 September&nbsp;25, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12,433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>October&nbsp;1, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>29,840</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 January&nbsp;21, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>68,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>January&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>24,865</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 February&nbsp;16, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>49,734</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>February&nbsp;26, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,973</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 March&nbsp;5, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,946</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.58 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;For
options granted between April&nbsp;1, 2016 and March&nbsp;10, 2017, our board of directors initially determined that the fair value of our common stock was $1.75 per share as
of each respective grant date. For options granted between July&nbsp;26, 2017 and October&nbsp;1, 2017, our board of directors initially determined that the fair value of our common stock was
$3.30 per share as of each respective grant date. However, as described below, the fair value of our common stock at the date of these grants was adjusted in connection with retrospective fair value
assessments for accounting purposes.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of recording stock-based compensation for grants of options to a non-employee, we measure the fair value of the award on the service completion date (vesting date). At
the end of each reporting period prior to completion of the services, we remeasure the value of any unvested portion of the award based on the then-current fair value of the award and adjust the
expense accordingly. The amount in this column reflects only the grant-date fair value of the award to a non-employee. </FONT></P>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>In
the course of preparing for this offering, in February 2018, we performed retrospective fair value assessments for accounting purposes. We applied the fair values of our common stock from our
retrospective fair value assessments to determine the fair value of these awards and calculate stock-based compensation expense for accounting purposes. These reassessed values were based, in part,
upon third-party valuations of our common stock prepared as of each grant date on a retrospective basis. The third-party valuations were prepared using the hybrid method and used market approaches to
determine our enterprise value. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=98,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=417274,FOLIO='96',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_97"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_emerging_growth_company_status"> </A>
<A NAME="toc_cw76701_6"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Emerging growth company status    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As an "emerging growth company," the JOBS Act permits us to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to "opt out" of this provision and, as a result, we
will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_internal_control_over_financial_reporting"> </A>
<A NAME="toc_cw76701_7"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Internal control over financial reporting    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the audit of our consolidated financial statements as of and for the years ended March&nbsp;31, 2017 and 2018, we identified material
weaknesses in our internal control over financial reporting. A company's internal control over financial reporting is a process designed by, or under the supervision of, a company's principal
executive and principal financial officers, or persons performing similar functions, and effected by a company's board of directors, management and other personnel to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Under standards established by the Public
Company Accounting Oversight Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. The material weaknesses that we identified were as
follows:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We did not design or maintain an effective control environment commensurate with our financial reporting requirements. We lacked a sufficient
number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally,
the limited personnel resulted in our inability to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated by, among other
things, our insufficient segregation of duties in our accounting function. This material weakness further contributed to the material weakness below. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions,
including accounting for preferred stock, stock-based compensation, warrant liabilities and leases. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>These
material weaknesses also resulted in adjustments to preferred stock, stock compensation expense, warrant liability and deferred rent in our consolidated financial statements as of and for the
year ended March 31, 2017, which were recorded prior to their issuance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are in the process of implementing measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weaknesses, including
hiring additional finance and accounting personnel and initiating design and implementation of our financial control environment, including the establishment of formal accounting policies and
procedures, financial reporting controls and controls to account for and disclose complex transactions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We,
and our independent registered public accounting firm, were not required to perform an evaluation of our internal control over financial reporting in accordance with the provisions of the
Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we
report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section&nbsp;404 after the completion of this offering. See "Risk
factors&#151;We have identified material weaknesses in our internal </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=99,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=394253,FOLIO='97',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cw76701_1_98"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>control
over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective
system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_off-balance_sheet_arrangements"> </A>
<A NAME="toc_cw76701_8"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Off-balance sheet arrangements    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_recently_issued_accounting_pronouncements"> </A>
<A NAME="toc_cw76701_9"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Recently issued accounting pronouncements    <BR>  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note&nbsp;2 to our consolidated financial statements appearing at the end of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cw76701_quantitative_and_quali__cw702539"> </A>
<A NAME="toc_cw76701_10"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Quantitative and qualitative disclosures about market risks    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest rate sensitivity  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2018, we had cash and cash equivalents and short-term investments of $61.6&nbsp;million, which consisted of cash, commercial paper
and commercial debt securities. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest
rates would not have a material effect on the fair market value of our investment portfolio. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2018, we had no debt outstanding and are therefore not subject to interest rate risk related to debt. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign currency exchange risk  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our headquarters are located in the United States, where the majority of our general and administrative expenses are incurred in U.S. dollars. The majority of
our research and development costs are incurred by our subsidiary in Oxfordshire, United Kingdom, whose functional currency is the British Pound. We are exposed to foreign exchange rate risk. During
the years ended March&nbsp;31, 2017 and 2018, we recognized foreign currency transaction gains (losses) of $0.6&nbsp;million, and $(2.1)&nbsp;million, respectively. These gains (losses) are
primarily related to unrealized and realized foreign currency gains and losses as a result of transactions entered into by our United Kingdom subsidiary in currencies other than the British Pound,
primarily the Euro. These foreign currency transaction gains (losses) were recorded as a component of other income (expense), net in our consolidated statements of operations. We believe that a 10%
change in the exchange rate between the British Pound and the Euro would not have a material impact on our financial position or results of operations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
we continue to grow our business, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our
results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange risk. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=100,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=515557,FOLIO='98',FILE='DISK114:[18ZBC1.18ZBC76701]CW76701A.;121',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cy76701_1_99"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cy76701_business"> </A>
<A NAME="toc_cy76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Business    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cy76701_overview"> </A>
<A NAME="toc_cy76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Overview    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform
the lives of cancer patients. We use our proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against cancer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are currently conducting a Phase&nbsp;1/2 clinical trial with our lead product candidate, RP1, in approximately 150 patients with a range of solid tumors. We have entered into a collaboration
with Bristol-Myers Squibb Company, or BMS, under which it has granted us a non-exclusive, royalty-free license to, and is supplying at no cost, its anti-PD-1 therapy, nivolumab, for use in combination
with RP1 in this clinical trial. BMS has no further development-related obligations under this collaboration. The first part of this clinical trial is underway in the United Kingdom and we intend to
conduct the second part of the clinical trial, which will enroll patients with four solid tumor types, in both the United Kingdom and, pending the opening of an Investigational New Drug Application,
or IND, in the United States. We have also entered into a collaboration agreement with Regeneron Pharmaceuticals,&nbsp;Inc., or Regeneron, under which we intend to conduct clinical development of
our product candidates in combination with cemiplimab, an anti-PD-1 therapy being developed by Regeneron. For each clinical trial conducted under this collaboration, Regeneron will fund one-half of
the clinical trial costs, supply cemiplimab at no cost, and grant us a non-exclusive, royalty-free license to cemiplimab for use in the clinical trial. The first planned clinical trial to be conducted
under this collaboration is a randomized controlled Phase&nbsp;2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in approximately 240 patients with cutaneous squamous
cell carcinoma, or CSCC, which we intend to initiate in the first half of 2019. If compelling clinical data are generated demonstrating the benefits of the combined treatment, we believe the data from
this trial could support a filing with regulatory authorities for marketing approval. We also intend to initiate a clinical trial with our second product candidate, RP2, in additional tumor types in
the first half of 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Oncolytic
immunotherapy is an emerging class of cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent,
patient-specific, anti-tumor immune response. Such oncolytic, or "cancer killing," viruses have the potential to generate an immune response targeted to an individual patient's particular set of tumor
antigens, including neo-antigens that are uniquely present in tumors. Our product candidates incorporate multiple mechanisms of action into a practical, "off-the-shelf" approach, that is intended to
maximize the immune response against a patient's cancer and to offer significant advantages over personalized vaccine approaches. We believe that the bundling of multiple approaches for the treatment
of cancer into single therapies will simplify the development path of our product candidates, while also improving patient outcomes at a lower cost to the healthcare system than the use of multiple
different drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
foundation of our Immulytic platform consists of a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, that has been "armed" with a fusogenic therapeutic protein intended to
substantially increase anti-tumor activity. Our platform enables us to incorporate various genes whose expression is intended to augment the inherent properties of HSV-1 to both directly destroy tumor
cells and induce an anti-tumor immune response. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe our lead product candidate, RP1, will be effective at killing tumors and inducing immunogenic, or immune-stimulating, tumor cell death and that it will be highly synergistic with immune
checkpoint blockade therapies. In our ongoing Phase&nbsp;1/2 clinical trial of RP1, we are conducting the first part of the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=101,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=829947,FOLIO='99',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cy76701_1_100"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>trial
in the United Kingdom to evaluate safety in approximately 30 patients with a range of solid tumor types both alone and in combination with nivolumab, an anti-PD-1 therapy. No serious adverse
events have been reported to date that have been determined to be related to RP1. In the second part of the trial, we will test RP1 in combination with nivolumab in four different tumor types in
cohorts of approximately 30 patients each. These tumor types are metastatic melanoma, metastatic bladder cancer, microsatellite instability high cancer, and non-melanoma skin cancer, all of which we
have chosen because they demonstrate a level of responsiveness to single-agent anti-PD-1 therapy but for which significant unmet medical need remains. In the second part of the trial, we intend to
continue to evaluate the safety and tolerability of RP1 in combination with nivolumab. This part of the clinical trial will also evaluate efficacy under the clinical trial protocol, primarily on the
basis of the proportion of patients who have a response within each tumor type cohort. Responses are either defined as a partial response (a 30% or greater reduction in tumor size) or a complete
response (a complete eradication of the disease). We then intend to analyze each cohort's data to determine the indications that merit progressing into further clinical development. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, we are preparing to initiate in the first half of 2019 a randomized, controlled Phase&nbsp;2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in
approximately 240 patients with CSCC. If compelling clinical data are generated demonstrating the benefits of the combined treatment, we believe the data from this trial could support a filing with
regulatory authorities for marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are also developing additional product candidates, including RP2 and RP3, built on our Immulytic platform, that are further engineered to enhance anti-tumor immune responses and to address
additional tumor types. RP2 has been engineered to express an antibody-like molecule that blocks the activity of CTLA-4, a protein that inhibits the immune response to tumors. We are engineering RP3
with the intent not only to block the activity of CTLA-4, but also to further stimulate an anti-tumor response through activation of the immune co-stimulatory pathways. We intend to file INDs and
foreign equivalents and,
assuming regulatory clearance, expect that RP2 will enter clinical development in the first half of 2019, and that RP3 will enter clinical development in the first half of 2020. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
product candidates are administered by direct injection into solid tumors. We believe that direct injection maximizes virus-mediated tumor cell death, provides the most efficient delivery of
virus-encoded immune activating proteins into the tumor with the goal of activating systemic immunity, and limits the systemic toxicities that could be associated with intravenous administration.
Activation of systemic immunity through local administration can lead to systemic clinical benefit through the induction of tumor responses in tumors which have not themselves been injected, which is
known as an "abscopal" effect. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
products and product candidates based on the oncolytic immunotherapy approach have shown single-agent activity, we believe that our product candidates will demonstrate particular synergy in
combination with immune checkpoint blockade therapies, including those that target the programmed cell death protein 1, or PD-1, a tumor cell surface receptor that plays an important role in
inhibiting, or shutting down, immune responses, or the receptor or ligand for PD-1, called PD-L1. A pre-existing anti-tumor immune response and the presence of T cells within tumors are key predictors
of the effective treatment of cancer with immune checkpoint blockade therapies. Because most patients do not have an ongoing pre-existing anti-tumor immune response, only a minority of patients
respond to treatment with immune checkpoint blockade therapies alone. We believe that oncolytic immunotherapy treatments can initiate or enhance an immune response in patients with no or minimal
pre-existing anti-cancer immunity and thereby increase the effectiveness of immune checkpoint blockade therapies. We believe that this is strongly supported by the results of a randomized, controlled
Phase&nbsp;1/2 clinical trial conducted by Amgen in melanoma patients, in which the combination of T-Vec with ipilimumab anti-CTLA-4 immune checkpoint </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=102,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=453845,FOLIO='100',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cy76701_1_101"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>blockade
therapy gave a response rate (meaning the observed measurement of the reduction in tumor size per the protocol) of 38% compared to 18% for ipilimumab therapy alone. While these results
provide promising evidence of the activity of an existing oncolytic immunotherapy used in combination with checkpoint blockade therapies, we are designing our product candidates with additional
mechanisms of action compared with T-Vec and other oncolytic immunotherapies in development, with the goal of maximizing both direct tumor killing and the activation of the patient's immune system
against their particular cancer. We believe these additional mechanisms of action of our product candidates will increase tumor susceptibility to immune checkpoint blockade therapies and, in
particular, work synergistically with antibodies targeting PD-1 or PD-L1 to enhance response rates across a range of tumor types. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cy76701_our_team_and_investors"> </A>
<A NAME="toc_cy76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our team and investors    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our founders and core management team, including Robert Coffin, Ph.D., our President and Chief Executive Officer, Philip Astley-Sparke, our
Executive Chairman, and Colin Love, Ph.D., our Chief Operating Officer, were the founder and senior management team of BioVex, where they developed T-Vec, the only oncolytic immunotherapy to receive
FDA approval. BioVex was acquired by Amgen in 2011. Our Chief Medical Officer, Howard Kaufman, M.D., was the principal investigator for the pivotal study upon which T-Vec was approved and previously
served as President of the Society for the Immunotherapy of Cancer. We are backed by a group of leading institutional life science investors, including affiliates of Atlas Ventures, Bain Capital Life
Sciences, BVF Partners, Cormorant Capital, Forbion Capital Partners, Foresite Capital, Omega Funds and Redmile Group. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cy76701_our_strategy"> </A>
<A NAME="toc_cy76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our strategy    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to create the leading oncolytic immunotherapy company that discovers, develops and commercializes next-generation products with
multiple mechanisms of action for the treatment of a broad range of solid tumor types. Key elements of our strategy include the following: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Advance the development of, and seek regulatory approval for, our lead product candidate, RP1.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are advancing two clinical trials for RP1. In the first half of
2019, we are planning to commence a randomized, controlled Phase&nbsp;2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in approximately 240 patients with CSCC. We are
designing this trial to potentially support product registration. In addition, we are currently conducting a Phase&nbsp;1/2 clinical trial of RP1 targeting four different tumor types in cohorts of
approximately 30 patients each. We then intend to analyze each cohort's data to determine the indications that merit further clinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Initiate the clinical development of and obtain regulatory approval for RP2, our next product candidate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We
have engineered RP2, which is based on RP1 but additionally expresses an anti-CTLA-4 antibody-like protein, to target tumor types that do not respond to single-agent immune checkpoint blockade
therapies and patients who have not responded to or who have progressed on anti-PD-1/L1 therapy. We plan to initiate a Phase&nbsp;1/2 clinical trial in the first half of 2019 of RP2 in combination
with anti-PD-1 therapy in triple negative breast cancer and two further indications. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Leverage our Immulytic platform to build a portfolio of product candidates that target a range of immune mechanisms and progress these product candidates into the
clinic.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We plan to utilize our Immulytic platform to develop additional products, including RP3, that express further combinations of proteins aimed at activating
multiple immune mechanisms for the treatment of a broad range of solid tumor types. Our current goal in the coming years is to introduce one product candidate into the clinic each year. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=103,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=717486,FOLIO='101',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cy76701_1_102"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Apply our extensive expertise to establish, equip, and operate our own in-house manufacturing facility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to establish, equip, and operate our own
manufacturing facility in Framingham, Massachusetts for multi-product cGMP manufacturing. We expect our facility to be ready to produce clinical-grade material during the first half of 2020 and
ultimately to be able to support commercial product launch. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Retain significant economic and commercial rights to our product candidates in key geographic areas.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to retain rights in the United States for our
product candidates and to develop an oncology-focused commercial organization. When economically attractive, we intend to evaluate and enter into development and marketing agreements with
pharmaceutical and biotechnology partners for geographic areas in which we are unlikely to pursue development and commercialization on our own. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cy76701_immuno-oncology_background_and__imm02603"> </A>
<A NAME="toc_cy76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Immuno-oncology background and limitations of existing therapies    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cancer is a broad group of diseases in which normal cells are transformed into a state of rapid and uncontrolled cell division, typically
forming tumors. Cancer originates from a particular tissue in the body, such as the lung or skin, and often spreads, or metastasizes, as the disease progresses. Tumors are comprised of multiple cell
types, including cancerous cells and immune cells. The composition and the type of tumor dictate the aggressiveness of a particular cancer, its susceptibility to treatment, and ultimately the outcome
for the patient. A promising new approach to cancer treatment, which is the subject of significant ongoing drug development activity, is to activate the immune system against cancer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
immune system contains many different cells types that fall into two general categories, cells of the innate immune system and cells of the adaptive immune system. The innate immune system is a
first-line, ubiquitous, non-specific defense mechanism aimed at combating elements that the body views as foreign, particularly microbial pathogens and parasites, but also tumor cells. After the
innate immune system is activated, an adaptive immune response is triggered that is specific to particular proteins, known as antigens. The adaptive immune system is flexible and can evolve.
Importantly, it has the capacity for immune memory, or the ability to be recalled into action if the same foreign antigen is detected in the body in the future. Activation of both the innate and
adaptive components of the immune system is believed to be essential for the induction of an effective anti-cancer immune response. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immune
checkpoints are key mechanisms of the adaptive immune system that function to inhibit immune responses and, in particular, to prevent the induction of autoimmunity. In the cancer setting,
tumors can hijack these immune checkpoints such that the tumors become protected from the effects of anti-cancer immunity. This enables tumors to continue growing without or with reduced immune
interference, even if an anti-tumor immune response had been initiated. Additional immune checkpoints inhibit the initial induction of an immune response, rather than subsequently protecting the tumor
from a previously established immune response. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Checkpoint
inhibitor therapies block these negative regulators of the immune system with the intent of either rendering tumors susceptible to immune attack and/or increasing the potency of the
anti-tumor immune response that is generated. This approach to cancer therapy has the potential to result in long-lasting anti-cancer effects in certain patients with certain tumor types. To date, six
immune checkpoint blockade products have been approved in a number of cancer indications, and there are numerous other related drug candidates in preclinical and clinical development. Market
researchers forecast that immuno-oncology treatments will grow to over $25&nbsp;billion a year in sales globally by 2022. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
immune checkpoint blockade has been a transformational treatment for many patients with cancer, the majority of patients do not currently respond to treatment. This is because checkpoint
blockade </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=104,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=888016,FOLIO='102',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cy76701_1_103"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>therapies
targeting PD-1, PD-L1 or CTLA-4 require a pre-existing immune response to a patient's tumor and that the tumors be "inflamed," or "hot." Because many patients do not have an ongoing
pre-existing anti-tumor immune response, which is often referred to as a tumor being immunologically "cold," only a minority of patients respond to checkpoint blockade therapies alone. We therefore
believe that the ability to effectively convert "cold" tumors to "hot" would substantially increase the response rates and the types of tumors which are susceptible to immune checkpoint blockade. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cy76701_our_approach__#151;_oncolytic_immunotherapy"> </A>
<A NAME="toc_cy76701_6"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our approach &#151; Oncolytic immunotherapy    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidates are designed to induce a robust immune response against a patient's cancer and turn immunologically "cold" tumors
"hot." To achieve this objective, we use oncolytic immunotherapies that combine multiple mechanisms of action in a single product candidate. We believe our product candidates will initiate or enhance
an immune response in patients with no or minimal pre-existing cancer immunity, including to tumor neo-antigens, and thereby increase the effectiveness of immune checkpoint blockade therapies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Oncolytic
immunotherapy is the treatment of cancer with viruses that selectively replicate in tumors, but not in normal tissue, thereby killing the virus-infected tumor cells. In addition to this
direct oncolytic killing of cancer cells, the presence of the virus and the generation of immune-stimulating tumor cell death triggers both innate and adaptive immune responses that result in further
tumor destruction, intended to result in the establishment of lasting antitumor immunity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
product candidates are intended to act at several key points in the pathways involved in the initiation of an immune response. Following direct injection into tumors, our viruses replicate in
cancer cells and then lyse, or break them open, releasing tumor antigens, including neo-antigens specific to the patient, which could otherwise be hidden from the immune system. This process of
necrotic cell death releases intra-cellular markers of "danger," the danger associated molecular patterns, or DAMPs, while the virus
produces pathogen associated markers of danger, or PAMPs. These trigger various pathways of the innate immune system, including the STING pathway and pathways mediated through toll-like receptors, or
TLRs, each resulting in the production of interferon. Innate immune activation would be expected to itself provide anti-tumor effects, as interferon activates natural killer cells which can destroy
tumor cells. Innate immune activation also helps to trigger adaptive anti-cancer immunity, in which antigen presenting cells, or APCs, are attracted to the injected tumor. APCs internalize cancer
antigens, including neo-antigens, and traffic back to the draining lymph nodes where they present the antigens to T cells. These are then primed to proliferate and disperse systemically to seek and
destroy cancer cells with the same antigen profile throughout the body and destroy distant tumor deposits. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>To
further augment these intended effects, our oncolytic immunotherapies are intended to genetically encode and express multiple potent cell-killing and immune-stimulating proteins in the
tumor&#151;in other words, our oncolytic immunotherapies are "armed" with these therapeutic genes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=105,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=154633,FOLIO='103',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cy76701_1_104"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe our product candidates act at each of the key points needed to initiate a potent antitumor immune response, as shown in the diagram below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g846377.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="282">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that our ability to incorporate multiple mechanisms of action into a practical, "off-the-shelf" approach to initiating or enhancing an anti-tumor immune response, including to neo-antigens,
will offer significant advantages over the various approaches to immune activation that are currently in development, including personalized vaccine treatments. Tumor neo-antigens are uniquely present
in tumors as compared to normal tissue because they result from the genetic changes that occur as cancer develops. Unlike the antigens present in normal tissue, the immune system sees neo-antigens as
foreign. As a result, the immune system is able to mount an immune response to tumor neo-antigens in the same way that it would to the antigens contained in disease causing micro-organisms, which the
immune system also sees as foreign. Researchers believe immune responses to tumor neo-antigens are particularly important in providing the patient's immune system the ability to combat cancer, and as
a consequence various "personalized vaccine" approaches to generating immune responses to tumor neo-antigens are in
development. These approaches are generally both expensive and time consuming because a vaccine cannot be designed and manufactured until a tumor biopsy is taken and analyzed in the laboratory to
identify the mutated tumor antigens that will be targeted by the treatment. We believe that our approach may also offer significant advantages over other approaches to anti-cancer immune activation
that only target a single pathway of the immune system, as is the case with most of the other immune-oncology therapies currently under development. Importantly, our product candidates are intended to
act to maximally activate an immune response against cancer, the missing element needed to allow anti-PD-1 or anti-PD-L1 therapy to treat more patients and tumor types, unlike some other therapies
such as those targeting indoleamine 2,3-dioxygenase, or IDO, which are intended to act by blocking additional defense mechanisms against an anti-tumor immune response once it has been initiated. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="cy76701_our_immulytic_platform"> </A>
<A NAME="toc_cy76701_7"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our Immulytic platform    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The foundation of our oncolytic immunotherapy product candidates, which we call our Immulytic platform, consists of a proprietary strain of
HSV-1 that we have engineered to replicate selectively in tumors and to express a fusogenic glycoprotein, a protein that triggers the fusion of the membranes between cells. HSV-1 is both highly cell
lytic and inflammatory, and also has a large carrying capacity, which makes it possible to incorporate multiple genes encoding therapeutic proteins. We believe our combination of HSV-1 with the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=106,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=938934,FOLIO='104',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_cy76701_1_105"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>expression
of the fusogenic glycoprotein increases the natural ability of HSV-1 to kill tumor cells and to induce an anti-tumor immune response. The fusogenic functionality of our product candidates
is intended not only to increase the number of tumor cells that are killed, but also to cause highly immunogenic death of tumor cells. We believe that these factors will increase the potency of the
systemic anti-tumor immune response that is generated by our product candidates. With the intention of amplifying the anti-tumor response further, we have also engineered our product candidates to
express in tumors a range of additional, potent, immune activating genes encoding therapeutic proteins. Our lead product candidate, RP1, serves as the base for the development of these additional
oncolytic immunotherapies expressing further therapeutic proteins. The development process and certain advantages of our Immulytic platform are summarized below: </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selecting the virus species and the virus strain  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although a number of viral species have been developed for oncolytic use, we believe HSV-1 is the most promising for the following
reasons:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HSV-1 can infect many different tumor cell types and, following infection, can destroy tumor cells through highly lytic virus replication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HSV-1 rarely produces severe illness in humans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The deletion of the genes encoding the HSV-1 ICP34.5 protein provides both tumor-selective virus replication and a well-characterized
non-pathogenic phenotype; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HSV-1 is a highly inflammatory virus, which we believe is beneficial for triggering both innate and adaptive immune responses; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HSV-1 has a large genome, which has the packaging capacity to allow for the insertion of multiple genes expressing therapeutic proteins that
are intended to enhance tumor cell killing and immune activation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Effective anti-viral drugs are available for HSV-1, which could be used to block virus replication if needed. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, HSV-1 has a proven track record in oncolytic immunotherapy, in particular with the approval by the FDA in 2015 of T-Vec for the treatment of unresectable advanced melanoma patients with
injectable non-visceral tumors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Different
isolates, or "strains," of HSV-1 have differing properties, including with respect to the ability to infect and kill human tumor cells. Standard "laboratory" strains of HSV-1 may have
reduced potency due to long-term culture in the laboratory or because such strains were not selected for the purposes of tumor killing. We believe that "clinical" strains, which are strains taken from
individuals who suffer from cold sores, would not have become attenuated through long-term culture and, if selected on the basis of the ability to infect and kill human tumor cells, would provide
higher potency than strains that have not been selected in this way. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on this rationale, we tested 29 clinical strains of HSV-1 isolated from 183 volunteers. Through this process we expected to sample a broad spectrum of the natural variation among clinical
strains of HSV-1, including in relation to their ability to infect and kill human tumor cells. We observed a broad range of killing activity and chose the strain with the most promising overall
properties for further development. Through this process we believe we have identified a highly potent strain of HSV-1 that provides a robust foundation for the development of our Immulytic platform. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=107,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=743058,FOLIO='105',FILE='DISK114:[18ZBC1.18ZBC76701]CY76701A.;99',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da76701_1_106"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To render the replication of the virus tumor-selective, we engineered this virus strain to delete the genes encoding the HSV-1 ICP34.5 and ICP47 proteins. This combination of
deletions provides the virus with well-characterized non-pathogenic and tumor-selective properties. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>To
augment the underlying abilities of the virus both to kill tumor cells and to induce an anti-tumor immune response that may maximally activate the immune system against a patient's cancer, we have
armed all of our product candidates with genes to express between two and four therapeutic proteins. These therapeutic proteins are expressed in the tumor as the virus replicates, and, as a result,
may help to kill tumor cells and drive the initiation of an anti-tumor immune response in the tumor and draining lymph nodes. Once this anti-tumor immune response is initiated, the activated immune
cells may also attack not only the injected tumors but also tumors that are distant from the injection sites. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Maximizing direct tumor killing &#151; Expression of a fusogenic protein  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To increase the natural ability of HSV-1 to directly kill tumors and to drive the immunogenicity of tumor cell death, we engineered our viruses to express a
protein that causes cell-to-cell fusion intended to result in increased immune-stimulating cell death. Although there are various fusogenic proteins available for this purpose, we use the surface
glycoprotein, or&nbsp;GP, from another virus, gibbon ape leukemia virus, or GALV, with a specific deletion of the R-peptide. The resulting protein is known as GALV-GP R(-). We believe that the
higher levels of tumor antigens released through the expression of GALV-GP R(-), including tumor neo-antigens, combined with enhanced immunogenicity of cell death, increases both systemic
immune-mediated anti-tumor effects and local, or injected, tumor destruction. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Enhancing the systemic anti-tumor immune response  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With the aim of augmenting the potency of the anti-tumor immune response which is generated, we have also engineered our product candidates to express potent
immune-stimulating proteins within tumors as replication occurs. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expressing GM-CSF  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>RP1, our lead product candidate, expresses granulocyte-macrophage colony-stimulating factor, or GM-CSF, in addition to GALV-GP R(-). GM-CSF is a potent
cytokine that activates and causes the proliferation of APCs and is, therefore, attractive for expression in the tumor to augment the anti-tumor immune response. Due to its ability to enhance immune
responses, a number of other oncolytic immunotherapy products and product candidates in development have been designed to express GM-CSF. These include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> T-Vec, approved in the United States, the European Union and elsewhere for the treatment of advanced melanoma; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Pexa-Vec, in Phase&nbsp;3 clinical development by SillaJen,&nbsp;Inc. for the treatment of hepatocellular carcinoma, or HCC; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> CG0070, in development by Cold Genesys,&nbsp;Inc. for the treatment of bladder cancer. </FONT></DD></DL>
<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expressing additional immune-stimulating proteins  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We have designed our further product candidates, RP2 and RP3, to express additional genes encoding therapeutic immune-stimulating proteins. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>RP2
is a version of RP1 that includes a gene encoding an anti-CTLA-4 antibody-like protein. We believe that RP2 has the potential to offer advantages over current anti-CTLA-4 approaches, including
ipilimumab, an anti-CTLA-4 therapy marketed by BMS. The FDA has approved ipilimumab for intravenous administration </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=108,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=254416,FOLIO='106',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_107"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>for
the treatment of advanced melanoma and has approved nivolumab, an anti-PD-1 therapy also marketed by BMS, for use in combination with ipilimumab, for advanced melanoma and renal cell carcinoma.
Ipilimumab has also shown clinical synergy with GM-CSF. Intravenous administration of ipilimumab, however, causes significant toxicity, largely due to auto-immune side effects, particularly in
combination with nivolumab. These autoimmune side effects from the systemic administration of ipilimumab appear to result from the blocking of the immune system's ability to recognize normal tissue
and not attack it. Because the function of CTLA-4 is to inhibit the induction of immune responses, we believe that blockade of this effect should be needed only at the site where anti-tumor immune
response induction occurs, namely at the tumor and the lymph nodes draining from the tumor site. We believe that RP2 will offer advantages compared with current CTLA-4 approaches, including
ipilimumab. By expressing anti-CTLA-4
only locally in the tumor and draining lymph nodes, we believe that activity will be retained, but that toxicity will be reduced. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are designing our RP3 product candidate to express not only GALV-GP R(-) and anti-CTLA-4, but also additional proteins that are intended to stimulate the potency of the anti-cancer T cell response
through activation of the immune co-stimulatory pathways. We are studying the effects of incorporating the ligands for co-stimulatory proteins, including those known as CD40, OX40 and 4-1BB, for this
purpose, and intend to finalize the version of RP3 that we will seek to progress into clinical development during the second half of 2018. We expect to introduce RP3 into clinical development in the
first half of 2020. Currently, numerous antibodies are in clinical development by other companies that target these same pathways, but, as with CTLA-4, the site of action of these pathways is where
the anti-tumor immune response is generated, so we believe that local intratumoral expression will be an advantageous approach. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
plan to develop product candidates beyond RP3 that will express additional genes encoding therapeutic proteins targeted at particular aspects of the anti-tumor immune response. As demonstrated by
our planned development timelines, we believe that a particular advantage of our Immulytic platform is that it allows us to develop new product candidates containing genes encoding additional
therapeutic proteins rapidly from conception through to the initiation of clinical trials. Our current goal in the coming years is to bring one product candidate into the clinic each year. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Synergy with immune checkpoint blockade therapies  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While we believe our product candidates will be able to provide a clinical benefit as single agents, we believe their impact will be enhanced in combination
with immune checkpoint blockade therapies. We currently intend for our product candidates to be used in combination with immune checkpoint blockade therapies, particularly antibodies targeting PD-1 or
PD-L1. Based on a similar rationale and in support of this approach, a number of other oncolytic viruses have previously been tested in combination with immune checkpoint blockade therapies in
clinical trials with promising results. In each of the completed single arm clinical trials, so far all in melanoma, a response rate that is higher than would be expected for the immune checkpoint
blockade therapy alone has been observed, including a 62% response rate and 33% complete response rate having been seen with T-Vec combined with pembrolizumab. None of these clinical trials showed
that oncolytic immunotherapy added significant additional toxicity relative to checkpoint blockade therapy alone. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>There
has been one randomized, controlled trial to date of an oncolytic immunotherapy combined with immune checkpoint blockade therapy. In that randomized Phase 2 clinical trial, T-Vec was tested in
combination with ipilimumab compared to treatment with ipilimumab alone in 198 melanoma patients. The
primary endpoint of the study was objective response rate. The combination of T-Vec and ipilimumab gave an objective response rate (meaning the observed measurement of the reduction in tumor size per
the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=109,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=118739,FOLIO='107',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_108"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>protocol)
of 38% compared to 18% with ipilimumab alone (p=.002), which was concluded to be statistically significant. No significant increase in toxicity was observed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Later-stage
clinical development is now underway with T-Vec in combination with pembrolizumab in the following clinical trials:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> A Phase&nbsp;3 trial of T-Vec in combination with pembrolizumab, compared with pembrolizumab plus a placebo in patients with advanced
melanoma; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> A controlled Phase&nbsp;2 trial of T-Vec in combination with pembrolizumab in patients with liver metastases from a variety of tumor types. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that the early data, including randomized, controlled data described above, provides promising clinical support for oncolytic immunotherapy in combination with immune checkpoint blockade
therapy. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration by direct injection into tumors  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our product candidates are injected directly into tumors. We can inject tumors close to the body's surface either visually or with simple ultrasound guidance,
and can inject tumors found deeper in the body with imaging guidance techniques that are routinely used to take tumor biopsies. Direct
injection is intended to maximize virus-mediated tumor cell death, which is required for the optimal activation of systemic immunity. In addition, we believe that direct injection provides the most
efficient delivery of genes encoding therapeutic proteins into the tumor and thereby limits systemic exposure and related toxicities. We believe that only a limited number of injections of our product
candidates will be required to initiate an immune response, particularly when combined with immune checkpoint blockade therapies such as those targeting PD-1 or PD-L1. By contrast, we believe that the
systemic administration of oncolytic immunotherapy product candidates increases dilution in the blood, decreases tumor targeting, and increases the likelihood of an antiviral immune response, greatly
reducing the ability of the virus to reach tumors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=110,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=863444,FOLIO='108',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_109"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="da76701_our_product_candidate_pipeline"> </A>
<A NAME="toc_da76701_1"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our product candidate pipeline    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing a pipeline of oncolytic immunotherapy product candidates that we believe have the potential to provide meaningful and
long-lasting clinical benefits to cancer patients. The following table summarizes our current pipeline and expectations for development timelines: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g695148.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="447">
  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Two additional tumor types to be selected for Phase&nbsp;2 clinical development, with clinical trials expected to commence in H2 2019, assuming
in each case the opening of an IND or foreign equivalent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe that our intended step-wise development approach from RP1 through RP3 reduces clinical risk, as we will be able to study the safety profile of each
therapeutic protein prior to moving to the next
product candidate with an additional therapeutic protein that is intended to provide more potent anti-tumor immune effects. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lead product candidate: RP1  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. RP1 has the following
properties:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have deleted the ICP34.5-encoding gene, which enables tumor-selective virus replication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have deleted the ICP47-encoding gene, which is intended to prevent the inhibition of the antigen presentation pathway otherwise caused by
ICP47 binding to the transporter associated with antigen presentation. ICP47 deletion is also intended to result in the increased and earlier expression of the HSV-1 US11 gene by placing the HSV-1
US11 gene under the control of ICP47 promoter. This increases virus replication in tumors without reducing tumor-selectivity; and </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=111,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=874705,FOLIO='109',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_110"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have inserted the sequences for GALV-GP R(-) and human GM-CSF, which results in the expression of these therapeutic proteins with the
intention of increasing both the direct tumor cell killing and the potency of the anti-tumor immune response that is induced. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
are developing RP1 for use in combination with immune checkpoint blockade therapy, particularly therapies targeting PD-1 or PD-L1. We believe that the robust release of tumor antigens and the
highly immunogenic tumor cell death intended to be caused by RP1 will further increase the synergy previously seen between oncolytic viruses and immune checkpoint blockade therapy. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical results  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In one of our preclinical experiments, tumors were induced in both the left and right flanks of rats. RP1 was then injected into the tumors in only the right
flanks. As shown below, where each line represents an individual tumor and lines of the same color represent the tumors in the left and right flanks of the same rat, we observed destruction not only
of the injected tumors in the right flanks, but also of the large un-injected tumors in the left flanks of 70% of the treated rats. As reflected in the top diagram of Figure&nbsp;1 below, when
formulation buffer with no RP1 was injected into "control" rats, no impact on the growth of the injected or un-injected tumors was observed. This effect of RP1 in both injected and un-injected tumors
provides support for the potent systemic, or "abscopal," effect of RP1. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Figure&nbsp;1: RP1 has been shown to treat large injected and un-injected tumors in rats  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g139148.jpg" ALT="GRAPHIC" WIDTH="547" HEIGHT="456">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase 1/2 clinical trial in multiple tumor types  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are conducting a Phase 1/2 clinical trial of RP1 in approximately 150 patients. The first part of our Phase 1/2 clinical trial is currently being conducted
in the United Kingdom and we intend to conduct the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=112,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1014469,FOLIO='110',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_111"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>second
part of the clinical trial in both the United Kingdom and, pending the opening of an IND, in the United States. This is an open-label, multicenter study to investigate the safety, tolerability
and efficacy of RP1. We have designed this clinical trial to study RP1 in tumor types that have been shown to have some level of responsiveness to anti-PD-1 or anti-PD-L1 therapy but where we believe
there remains significant unmet medical need. In the first part of the clinical trial we are assessing the safety and tolerability of RP1, administered alone in a single tumor, in a minimum of 18
patients with advanced or metastatic solid tumors who have progressed on or cannot tolerate standard therapy. Following the dose escalation phase, up to 12 patients will be enrolled to receive RP1
administered into multiple tumors in combination with nivolumab. In the second part of the clinical trial, we will study the safety and efficacy of RP1 in combination with nivolumab in specific tumor
types in four cohorts of approximately 30 patients each. These tumor types are metastatic melanoma, metastatic bladder cancer, microsatellite instability high cancer, and non-melanoma skin cancer.
Depending on the tumor type, patients must be eligible to receive PD-1 directed therapy according to the product label or have exhausted, become intolerant to or refused currently available therapies.
We have an agreement with BMS for the supply of nivolumab for this clinical trial. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that the results from the first part of the clinical trial will help us determine the safety, tolerability and intended dose of RP1 for further development and to provide initial safety data
for RP1 in combination with nivolumab. We have also designed the first part of the trial to provide insights on the effects of RP1 on tumors, including necrosis, inflammation and erythema, the
biodistribution of RP1 in the blood, saliva and mucosa, and the impact of RP1 administration on anti-HSV-1 antibody responses. For the patients in the first part of the trial who also receive
nivolumab, we will assess certain biomarkers indicative of immune activation in tumor biopsies. These include the infiltration of T cells, expression of PD-L1, and the presence of an "inflamed gene
signature," each of which would indicate ongoing immune activation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Of
the approximately 30 patients in the first part of the clinical trial:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Approximately half will receive RP1 using direct or ultrasound guided injection to administer RP1 to tumors located on or close to the skin, or
into lymph nodes located near the skin; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Approximately half will receive RP1 using imaging guided injection to administer RP1 to tumors located deeper in the body, including in
visceral organs such as the liver. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In
the second part of the trial, we intend to continue to assess the safety and begin to assess the efficacy of RP1 in combination with nivolumab in four cohorts of approximately 30 patients, each
with one of the different cancer types described above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have chosen these tumor types because they have shown that they have some level of underlying responsiveness to treatment with immune checkpoint blockade therapies but for which we believe
considerable unmet medical need remains. We intend to expand the number of patients treated and/or add a control arm for each cohort where we see promising signs of efficacy, either as part of the
same clinical trial or as separate trials, as a means to gather more definitive data in support of the clinical benefit of the combination of RP1 and nivolumab in these respective tumor types. We
believe that the expanded clinical trials can be designed to support a filing with regulatory authorities for marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
each of the four cohorts in the second part of the trial, we plan to assess efficacy under the clinical trial protocol by examining the rate and duration of responses, including partial responses
(a 30% or greater reduction in tumor size) and complete responses (a complete eradication of the disease), as well as examining biomarkers of immune response and mechanism of action. For example, we
expect that tumors </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=113,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=414565,FOLIO='111',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_112"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>with
no or low pre-existing immune responses as evidenced by no or low T cell infiltration at baseline would not respond to anti-PD-1 therapy. Responses in these patients would therefore suggest
clinical benefit of the combination of RP1 with anti-PD-1. Likewise, an increase in post-treatment T cells infiltrating into tumors and/or an increase in inflammation as evidenced by the development
of an inflammatory gene signature would also support the activity of RP1. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical trial status  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The first part of the ongoing Phase 1/2 clinical trial of RP1 commenced in October 2017 in the United Kingdom where 16 patients have been enrolled to date,
including patients with melanoma, breast cancer, colorectal cancer, CSCC and esophageal cancer. Each of these patients has advanced, high tumor burden disease and has previously failed multiple other
therapies including in clinical trials. Approximately half of the patients have received one or more lines of immune checkpoint blockade therapy. As of July&nbsp;9, 2018, we have administered
injections into a single tumor at first doses of 1x10<SUP>4</SUP>, 1x10<SUP>5</SUP> and 1x10<SUP>6</SUP> pfu/ml by direct injection and first doses of 1x10<SUP>4</SUP> and
1x10<SUP>5</SUP> pfu/ml by imaging guided injection into deeper lesions. Subsequent doses for direct injection have been given at up to 1x10<SUP>8</SUP> pfu/ml and for deeper lesions at up to
1x10<SUP>6</SUP> pfu/ml so far. Injections have been given up to five times in each patient. During screening and in the weeks following the injections, we have taken swabs of the tumor, biopsies,
blood samples, urine samples, vital signs, photographs at various intervals and CT scans are specified at 30&nbsp;days following the final dose of RP1. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
primary objectives of the first part of the trial are to provide an initial determination of the safety of RP1 alone and in combination with nivolumab and to determine the recommended dose for the
second part of the trial. In addition, we intend to assess tumor size, erythema and inflammation in tumor biopsies for indications of biological activity. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
clinical trial is being conducted under the review of a safety review committee, which is responsible for reviewing safety data, deciding whether to move to the next dose cohort, determining the
recommended Phase&nbsp;2 dose, and identifying any safety concerns. The clinical trial is also subject to certain protocol defined safety stopping rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Preliminary
data as of July&nbsp;9, 2018 suggest that RP1 is well tolerated. We have observed the expected side effects of local inflammation and erythema combined with mild fevers and other
influenza-like symptoms for several days. These side effects are consistent with the side effects previously reported for other oncolytic viruses. Although serious adverse events, or SAEs, have been
observed in three of the 16&nbsp;patients enrolled in the first part of our ongoing Phase&nbsp;1/2 clinical trial of RP1 to date, these SAEs were determined to be related to the patients'
underlying advanced cancer and not to treatment with RP1. No SAEs have been observed which were concluded to be related to RP1. One possible dose limiting toxicity, or DLT, elevated lipase levels,
which did not meet the definition of an SAE, has been observed in one patient in the first deep visceral group cohort. At baseline, this patient was HSV seropositive and already had rising lipase
levels. The patient received prior doses of 1x10<SUP>4</SUP> pfu/ml and 1x10<SUP>5</SUP> pfu/ml with the elevated lipase levels occurring after the patient's third dose, which was at a dose
level of 1x10<SUP>6</SUP> pfu/ml. The elevated lipase levels then resolved without clinical signs or symptoms being observed and following which two
further doses of 1x10<SUP>6</SUP> pfu/ml were given with no other potential DLTs occurring. The other two patients in that cohort, who were both HSV seronegative, and the first patient in the next
dose level cohort in the deep visceral group, who was HSV seropositive and given doses of 1x10<SUP>5</SUP>, 1x10<SUP>6</SUP> and three doses of 1x10<SUP>7</SUP> pfu/ml, have not experienced
any DLTs. However, per protocol, because a potential DLT was observed in the first dose level cohort following review of laboratory values during trial monitoring, this first dose level cohort in the
deep visceral group is being expanded to include an additional three patients. As of July&nbsp;9, 2018, two of these patients have been enrolled, with the first patient having received doses of
1x10<SUP>4</SUP>, 1x10<SUP>5</SUP> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=114,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=173625,FOLIO='112',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_da76701_1_113"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
two doses of 1x10<SUP>6</SUP> pfu/ml so far, and the second patient having received a single dose of 1x10<SUP>4</SUP> pfu/ml, with no potential DLTs having been observed. While the first
part of the clinical trial is being conducted in the United Kingdom, we intend to conduct the second part of the clinical trial in both the United Kingdom and, pending an opening of an IND, the United
States. We may also consider additional countries for this clinical trial. We expect that data from the first part of our Phase&nbsp;1/2 clinical trial of RP1 will be available in the first half of
2019. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory status  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United Kingdom, prior to filing a Clinical Trial Authorization, or CTA, we participated in a pre-CTA meeting with the Medicines and Healthcare products
Regulatory Agency, or MHRA, in February 2017. We subsequently filed our CTA with the MHRA in April 2017 and received full CTA approval from the MHRA in July 2017. In June 2018, the MHRA approved an
amendment to the trial protocol to specify, among other things, that the anti-PD-1 therapy to be used is nivolumab, to specify that anti-PD-1 therapy will be included in the Phase&nbsp;1 expansion
cohort and to add nivolumab-specific information to the protocol. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, we participated in a pre-IND teleconference with the FDA in October 2017, during which the agency asked that we repeat one of the toxicology and biodistribution studies we
previously conducted but with a longer follow-up than was used in the initial study. We filed an IND on February&nbsp;23, 2018, to enable the FDA to review all other aspects of the IND, which we
will update once the additional toxicology and biodistribution data are available. The FDA verbally informed us on March&nbsp;23, 2018 and confirmed in writing on April 18, 2018 that, as expected,
the IND was on clinical hold pending submission of the additional data and review by the FDA. The in-life phase of the toxicology and biodistribution study was completed in May 2018, and no material
issues were observed. We received an unaudited toxicology
report from the CRO in July 2018, and intend to submit an amendment to the IND to the FDA in early August 2018. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Controlled Phase&nbsp;2 clinical trial in CSCC  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the first half of 2019, we intend to initiate a randomized, controlled Phase&nbsp;2 clinical trial of RP1 combined with cemiplimab, compared to
cemiplimab alone, in approximately 240 patients with CSCC. The primary objective of this controlled Phase&nbsp;2 clinical trial will be to assess the response rate of the combination therapy
compared to treatment with anti-PD-1 therapy alone, with key secondary endpoints including the rate of complete response and the duration of response. If compelling clinical data are generated
demonstrating the benefits of the combined treatment, we believe the data from the controlled Phase&nbsp;2 clinical trial could support a filing with regulatory authorities for marketing approval. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pipeline product candidate: RP2  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have designed our RP2 product candidate to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise
caused by CTLA-4. We believe that RP2 will offer advantages compared with current CTLA-4 approaches, including ipilimumab. By expressing anti-CTLA-4 only locally in the tumor and draining lymph nodes,
we believe that activity will be retained, but that toxicity will be reduced. We intend that our RP2 product candidate will be used in combination with anti-PD-1 therapy, which we believe will result
in both synergy with the oncolytic virus and the expression of the anti-CTLA-4 in the tumor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
intend to administer RP2 in combination with anti-PD-1 or anti-PD-L1 therapy in tumor types that are not responsive to anti-PD-1/L1 therapy alone, and in patients who have not responded to or who
have progressed on prior anti-PD-1/L1 therapy. We expect to include patients with triple negative breast cancer and two further indications in our initial clinical trial with RP2. We intend to file an
IND and foreign equivalents for RP2 and we expect that we will bring RP2 into clinical development in the first half of 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=115,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=555371,FOLIO='113',FILE='DISK114:[18ZBC1.18ZBC76701]DA76701A.;92',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc76701_1_114"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical results  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are currently conducting preclinical development of RP2, including toxicology and biodistribution studies, with product already manufactured to GMP
standards. Release testing is underway. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have conducted preclinical tests comparing RP1 and RP2 to determine the effect of expressing the anti-CTLA-4 antibody-like protein, and have observed an enhanced effect with RP2. In one of these
preclinical experiments, tumors were induced in both the left and right flanks of mice. Either RP1 or RP2
was then injected into the tumors in only the right flanks. As shown below in Figure&nbsp;2, where each line represents an individual tumor and lines of the same color represent the tumors in the
left and right flanks of the same mouse, we observed enhanced destruction of tumors with RP2 as compared to RP1, particularly of the un-injected tumors. In this experiment only a low dose of virus was
used such that with RP1 un-injected tumors only partially responded to the treatment. This was to allow the potential benefits of anti-CTLA-4 expression to be observed. This experiment is illustrated
in the figure below: </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Figure&nbsp;2: Expression of anti-CTLA-4 from RP2 showed an increased effect as compared to RP1 in
mice  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g904926.jpg" ALT="GRAPHIC" WIDTH="504" HEIGHT="273">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g163379.jpg" ALT="GRAPHIC" WIDTH="504" HEIGHT="280">
  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
a further experiment with RP2 in combination with anti-PD-1 therapy, we assessed the durability of response in mice in which tumors had been eradicated and whether these mice were protected against </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=116,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=588720,FOLIO='114',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_115"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>re-challenge
with tumor cells, which would demonstrate that memory immune responses had been induced. In this experiment 15 mice cured of bilateral tumors following administration of RP2 combined with
an anti-PD-1 therapy were observed until day 108 following initiation of the experiment and then re-challenged with tumor cells to assess whether the mice were protected against the formation of new
tumors. This demonstrated that anti-tumor effects were maintained throughout the experiment and that 14 out of the 15 mice were protected against re-challenge with tumor cells. This experiment is
shown in the figure below. Treatment with anti-PD-1 alone has no anti-tumor effect in this model. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;3: The treatment effect with RP2 was shown to be durable and induce memory immune responses in mice  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g251911.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="288">
  </B></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Planned Phase 1/2 clinical trial  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are currently beginning protocol development for a Phase 1/2 clinical trial of RP2 in combination with anti-PD-1 therapy and intend to initiate the
clinical trial in the first half of 2019. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pipeline product candidate: RP3  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are designing our RP3 product candidate to express immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-). These
immune activating proteins are the ligands for various immune co-stimulatory pathways responsible for T cell proliferation and/or activation, including the CD40, OX40 and 4-1BB pathways. We plan to
finalize the version of RP3 for clinical development during 2018. As with RP2, we intend to study RP3 in indications that have not so far responded to anti-PD-1 or anti-PD-L1 therapy. We expect to
bring RP3 into clinical development in the first half of 2020. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical results  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have conducted preclinical tests to assess the benefit of expressing immune co-stimulatory pathway ligands, and have observed an enhanced effect associated
with the expression of these proteins as compared to RP1. In one of these preclinical experiments, tumors were induced in both the left and right flanks of mice. Either RP1 or versions of RP1
additionally expressing the ligands which activate CD40, 4-1BB or OX40 were then injected into the tumors in only the right flanks. As shown below, where each line represents an individual tumor and
lines of the same color represent the tumors in the left and right flanks of the same mouse, we observed enhanced destruction of tumors with the co-stimulatory pathway ligand expressing viruses as
compared to RP1, particularly of the un-injected tumors. In this experiment </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=117,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=780086,FOLIO='115',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_116"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>only
a low dose of virus was used such that with RP1 un-injected tumors only partially responded to the treatment. This was to allow the potential benefits of co-stimulatory pathway ligand expression
to be observed. This experiment is illustrated in the figure below: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;4: Comparative effects of RP1 and equivalent viruses also expressing immune co-stimulatory pathway ligands in mice  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g741581.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="465">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dc76701_background_on_our_t&#97;rget_indic__bac02747"> </A>
<A NAME="toc_dc76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Background on our target indications and current treatment options    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Set forth below is a description of the target indications we currently intend to pursue with RP1 or RP2, as well as a summary of the existing
treatment options for each target indication. When we refer to "response rates" below, we mean the observed reduction in tumor size, per the criteria set forth in the applicable clinical trial
protocol; and when we refer to "complete response rate" below, we mean the observed complete eradication of disease in the patient. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bladder cancer  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According to the American Cancer Society, bladder cancer has an incidence of approximately 81,190 cases annually in the United States, with 17,240 deaths
attributable to the disease in 2018. Although 77% of bladder cancer patients survive five years from diagnosis, the five-year relative survival rate for metastatic stage&nbsp;IV bladder cancer is
just 15%. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Treatment
depends on the stage of disease and may include some combination of surgery, radiation therapy, chemotherapy and immunotherapy. Surgical options may include transurethral resection, partial
or complete removal of the bladder, or urinary diversion. Platinum-based chemotherapy is the standard of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=118,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=224060,FOLIO='116',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_117"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>care
for patients with metastatic disease. Several regimens exist, though the combined treatment of methotrexate, vinblastine, doxorubicin, and cisplatin has been the preferred one; however, patients
experience high toxicity associated with these therapies. Patients who relapsed after platinum-based therapy have median survival ranging from five to seven months and no known life-prolonging
treatments exist. Immune checkpoint blockade therapies have since shown utility in recurrent advanced bladder cancer. Specifically, pembrolizumab, atezolizumab, avelumab and durvalumab have all been
approved in various settings. Pembrolizumab received FDA accelerated approval for first-line use based on a study of 370 patients with locally advanced or metastatic urothelial carcinoma who were not
eligible for platinum-containing chemotherapy. The response rate was 29% with a 7% complete response rate. Pembrolizumab is also FDA-approved for patients who have failed platinum-containing
chemotherapy based on a 542 patient randomized, controlled clinical trial of pembrolizumab compared to chemotherapy. The response rate was 21% for pembrolizumab compared to 11% for chemotherapy, with
complete response rates of 7% and 3%, respectively, and a 27% reduction in the risk of death observed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Atezolizumab,
a PD-L1 inhibitor, has also been found to be active in bladder cancer, and was granted accelerated approval by the FDA in 2016 for patients with locally advanced or metastatic urothelial
carcinoma, who progressed on or after platinum-based chemotherapy on the basis of a 310 patient single arm study. Atezolizumab gave a response rate of 14.8% for all patients, a 9.5% response rate for
patients with low PD-L1 expression, and a 26% response rate for patients with high PD-L1 expression. Complete response rates were 5.5%, 2.4%, and 12%, respectively. Avelumab and durvalumab, additional
antibodies targeting PD-L1, were also granted accelerated approval by the FDA for the treatment of locally advanced and metastatic bladder cancer in May 2017. Avelumab is approved for patients with
advanced or metastatic bladder cancer who have disease progression on or following platinum-containing chemotherapy and for patients having disease progression within 12&nbsp;months of pre- or
post-surgery platinum-containing chemotherapy on the basis of a 242 patient single arm clinical trial. The response rate was 13.3% after 13 or more weeks of follow up and 16.1% after six&nbsp;months
or more of follow up, with complete response rates of 4% and 5.6%, respectively. There was no clear difference in response rate based on PD-L1 expression. Durvalumab is approved in the same patients
on the basis of a single arm 182 patient clinical trial which gave a 17% response rate for all patients, a 26.3% response rate for patients with high PD-L1 expression, and a 4.1% response rate for
patients with low PD-L1 expression. Complete response rates were 2.7%, 3.2%, and 1.4%, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Melanoma  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According to the American Cancer Society, melanoma has an incidence of approximately 87,000 cases annually in the United States with over 9,300 deaths
attributable to the disease in 2018. For patients with metastatic melanoma, five-year survival rates have historically been very low. While the majority of patients have clinically localized disease
at presentation, advanced melanoma spreads in an unpredictable fashion, with widespread metastasis to any organ site but often to skin, lung, brain, liver, or small bowel. Since most cases of melanoma
are diagnosed at an early stage and are curable with surgery alone, the standard treatment option for Stage&nbsp;I to resectable Stage&nbsp;III disease is surgery with or without lymph node
dissection. For more advanced stages, until recently, treatment options were limited to chemotherapy, which is of unproven benefit, and Interleukin 2, or IL-2. IL-2 was approved by the FDA in 1998 on
the basis of a 270 patient single arm study which demonstrated a 16% response rate and 6% complete response rate. While responses with IL-2 are often of long duration, toxicity is often substantial. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Since
2011, the immunotherapies ipilimumab, pembrolizumab, nivolumab, ipilimumab in combination with nivolumab, and T-Vec have received FDA approval in the United States, as have the molecular
targeted therapies vemurafenib and dabrafenib in combination with trametinib. While response rates are often high, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=119,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=193889,FOLIO='117',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_118"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>they
are also often of limited duration. The more recently approved immunotherapy products have generally been shown to give responses of longer duration. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Ipilimumab
was approved on the basis of a 676 patient randomized, controlled trial comparing ipilimumab to a peptide vaccine. The response rate for ipilimumab was 10.9% compared to 1.5% for the
peptide vaccine and the risk of death was reduced by 34%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pembrolizumab
was approved in ipilimumab na&iuml;ve patients on the basis of an 834 patient randomized, controlled Phase&nbsp;3 clinical trial testing two dose regimens (every two weeks
and every three weeks) of pembrolizumab versus ipilimumab. The response rates for pembrolizumab were 34% and 33%, respectively, and 12% for ipilimumab. The complete response rates were 5%, 6%, and 1%,
respectively. This data included patients with both previously treated and previously untreated disease. In a separate trial, the complete response rate in previously untreated melanoma with
pembrolizumab was 14% and for all patients, both previously treated and previously untreated, the complete response rate was 8%. The risk of death was reduced by 37% and 31% for pembrolizumab dosing
every two weeks and every three
weeks, respectively, as compared to treatment with ipilimumab. Pembrolizumab is also approved for ipilimumab refractory patients on the basis of a 540 patient Phase&nbsp;3 clinical trial comparing
the same two dosing regimens of pembrolizumab compared to chemotherapy. Response rates of 21% and 25% for pembrolizumab compared to 4% for chemotherapy and a 14% and 26% reduction in the risk of
death, depending on the pembrolizumab dose, were observed. The complete response rate was 2% and 3% for pembrolizumab and 0% for chemotherapy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Nivolumab
was approved in patients with previously treated melanoma on the basis of a 120 patient clinical trial in which a response rate of 32% and a complete response rate of 3.3% was observed in
patients treated with nivolumab. Nivolumab was also approved for previously untreated melanoma on the basis of a 418 patient clinical trial comparing nivolumab to chemotherapy in which response rates
of 34% for nivolumab and 9% for chemotherapy were observed, with complete response rates of 4% for nivolumab and 1% for chemotherapy and a reduction in risk of death of 58% for nivolumab. Nivolumab
was also approved in melanoma in combination with ipilimumab based on a 945 patient clinical trial in which ipilimumab na&iuml;ve patients were treated with nivolumab alone, ipilimumab
alone, or nivolumab together with ipilimumab. While toxicity in the combination arm of the trial was substantially increased as compared to the single agent treated patients, the response rate was 50%
for the combination compared to 40% for nivolumab alone and 14% for ipilimumab alone, with complete response rates of 8.9%, 8.5% and 1.9%, respectively. There was also a reduction in the risk of death
of 58% as compared to ipilimumab for the combination arm and of 43% for nivolumab compared to ipilimumab alone. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2015, T-Vec was approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery on the basis of a 436 patient
Phase&nbsp;3 clinical trial in which patients with previously treated or treatment na&iuml;ve Stage&nbsp;IIIb to Stage&nbsp;IVM1c disease were randomized, two-to-one, to receive either
T-Vec or subcutaneously administered GM-CSF. The primary endpoint was durable response rate, or DRR, the rate of responses lasting continuously for at least six&nbsp;months. The DRR was 16.3% for
T-Vec compared to 2.1% for GM-CSF, the overall response rate was 26.4% for T-Vec compared to 5.7% for GM-CSF, and the complete response rate was 16.9% for T-Vec compared to 0.7% for GM-CSF. In
combination with ipilimumab, in a 198 patient controlled Phase&nbsp;2 clinical trial, T-Vec gave a response rate of 39%, compared to 18% for ipilimumab alone. In combination with pembrolizumab,
T-VEC gave a response rate of 62% and complete response rate of 33% in a 21 patient Phase&nbsp;1b clinical trial. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=120,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=344995,FOLIO='118',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_119"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-melanoma skin cancer  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Non-melanoma skin cancer, or NMSC, is the most common cancer affecting light-skinned individuals and the incidence is increasing worldwide. Although incidence
varies by geography, about 80% of all NMSC cases are basal cell carcinoma, or BCC, while CSCC represents about 20%, and other cancer types represent only 1%. Included in that 1% are primary cutaneous
lymphoma, sarcomas of the skin, Merkel cell carcinoma, and appendageal carcinoma. NMSC is often not reported to cancer registries, hence accurate estimates of incidence are difficult to obtain. In
2013, the World Health Organization estimated there to be 2-3&nbsp;million cases per year. NMSCs, however, are most likely to be under-reported, particularly in light of a recent study that
estimated there to be 3.5&nbsp;million cases each year in the United States alone. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cutaneous squamous cell carcinoma  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>According to the American Cancer Society, CSCC has an incidence of more than 700,000 cases annually in the United States, with approximately 4,000-9,000
deaths attributable to the disease each year, and is the second deadliest skin cancer after melanoma. Although the prognosis for patients with CSCC is generally favorable, if distant metastases
occurs, the long-term prognosis is extremely poor. Most cases of CSCC can be successfully managed with a variety of simple procedures, such as cryotherapy, curettage and electro desiccation, topical
treatments, or simple surgical excision. When lesions are more advanced, micrographic surgery, more extensive surgical resection, or radiation therapy are generally sufficient to control loco-regional
disease. The five-year rate of cure in patients with large tumors is 70%, regardless of the treatment chosen. However, for those with metastatic disease, the long-term prognosis is reduced
drastically. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Stage&nbsp;IV
CSCC can be responsive to various chemotherapeutic agents. However, there are no standard or FDA-approved therapies. Targets being evaluated in clinical trials of CSCC include
epidermal growth factor receptor inhibition with drugs such as cetuximab or erlotinib, as well as PD-1 inhibition with drugs such as cemiplimab. Cemiplimab is currently under review for approval in
CSCC by the FDA based on data generated in a Phase&nbsp;2 clinical trial of 82 patients with advanced CSCC in which cemiplimab demonstrated an overall response rate of 46.3%, together with data from
a previous Phase&nbsp;1 clinical trial in 26 patients which gave a 46.2% response rate and a compete response rate of 7.7%. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basal cell cancer of the skin  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Annual rates of basal cell cancer of the skin, or BCC, in the United States have been estimated at up to 485 and up to 253 cases of BCC per 100,000 males and
females, respectively. Local treatment measures fail to control disease in 10% of patients, although metastatic disease is rare. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
most frequent site of metastatic involvement is the regional lymph node in 68% of cases. Dissemination through the blood may also occur, affecting the lungs and pleura, liver, and bones. The use
of systemic therapy is limited to patients with distant metastases or locally advanced disease that is not suitable for surgery or radiation. In the cases of locally advanced or metastatic disease,
systemic therapy with FDA-approved hedgehog pathway inhibitors is recommended. Typical outcomes with this approach include a 43% response rate, with a 7.6&nbsp;month response duration, and a 30%
response rate, with a 7.6&nbsp;month duration, for locally advanced and metastatic disease, respectively, after which there is no approved therapy. Other drugs, including those targeting PD-1 and
PI3K, are being studied in clinical trials. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Merkel cell carcinoma  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Merkel cell carcinoma, or MCC, is a rare neuroendocrine malignancy of the skin predominately affecting elderly, light-skinned individuals and may also occur
earlier and more frequently in immunosuppressed patients. The incidence of MCC is very low when compared to other cutaneous malignancies, with an </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=121,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1037014,FOLIO='119',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_120"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>estimated
1,500 cases diagnosed annually in the United States. The typical clinical course of the disease is rapid progression of the primary tumor with early and frequent metastasis to the regional
lymph nodes. In unresectable or metastatic MCC, chemotherapy achieves high remission rates. However, responses are usually short lived. In March 2017, avelumab, an anti-PD-L1 monoclonal antibody, was
approved in the United States for patients with advanced MCC based upon a single-arm, open-label, Phase&nbsp;2 clinical trial in 88 metastatic MCC patients who had failed at least one prior
chemotherapy treatment. The response rate was 33% with a complete response rate of 11.4%. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other rare non-melanoma skin cancers  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>There are many other types of rare skin malignancies that occur. As a group, these tumors are often highly aggressive and initially treated by surgical
resection with or without local radiation therapy. Once these tumors recur locally or develop metastases, outcomes are usually poor and no effective systemic therapy is available. These rare tumors
include dermatofibroma protuberans, angiosarcoma of the skin, non-HIV-related Kaposi's sarcoma, sebaceous cell carcinoma, and eccrine carcinoma. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Microsatellite instability high or mismatch repair deficient tumors  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Microsatellite instability high, or MSI-H, or mismatch repair deficient, or dMMR, tumors are characterized by defects in DNA replication, particularly in the
microsatellite regions. Typically, the nucleotide mismatches that occur during DNA replication are corrected by a proofreading system to correct these errors. Microsatellite instability describes the
predisposition for mutations in the tandem repeat sequences due to uncorrected base insertion or deletion errors. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Although
most microsatellites are located in noncoding regions of the genome, ill-placed uncorrected DNA replication errors can cause mutations within protein coding sequences, often resulting in the
expression of functionally inactive mutant proteins that interfere with normal cell regulation and help to drive cancer. The number of mutation-associated neo-antigens resulting from mismatch-repair
deficiency is more than 20 times higher than in tumors without this deficiency. The tumor microenvironment of dMMR tumors strongly expresses PD-L1, which indicates that an active response to the
neo-antigens is underway. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
presence of MSI-H and dMMR tumors has been reported in diverse cancer types, including endometrial, ovarian, gastric, pancreas, ovary, prostate, central nervous system, and non-small cell lung
cancers. The majority of the published data is based on studies of colorectal cancer patients. MSI-H tumors have been reported to be present in between 2% and 30% of primary colorectal tumors and 20%
to 77% of metastatic lesions. Stage&nbsp;II colon cancers show higher rates of MSI-H than more advanced tumors, and rectal cancers and other left-sided colon cancers are noted to have lower
frequencies of MSI-H tumors. The frequency of dMMR tumors in the other tumor types for which it has been reported is less well documented, and likely lower than seen in colorectal cancer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Due
to the high level of neo-antigens present, MSI-H tumors have been shown to respond to anti-PD-1 therapy. Pembrolizumab received accelerated approval by the FDA in 2017 for MSI-H solid tumors that
have progressed following prior treatment, as well as in colorectal cancer that has progressed following chemotherapy. In five uncontrolled, single-arm clinical trials totaling 149 patients with
diverse MSI-H tumor types, pembrolizumab gave a response rate of 39.6% and a complete response rate of 7.4%. In the 90 patient subset with MSI-H CRC, pembrolizumab gave a 36% response rate. Nivolumab
was also granted accelerated approval for MSI-H colorectal cancer that has progressed following chemotherapy. In a single arm 74 patient clinical trial with nivolumab, the response rate was 32% and
the complete response rate was 3%. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=122,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=738019,FOLIO='120',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_121"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Triple negative breast cancer  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According to the American Cancer Society, triple negative breast cancer, or TNBC, has an incidence of approximately 37,000 cases and approximately 6,000
deaths attributable to the disease annually in the United States. Globally, TNBC accounts for approximately 12% to 17% of all breast cancers, with approximately 170,000 new cases among an estimated
1&nbsp;million cases of breast cancer diagnosed annually. As a group, patients with TNBC have poor outcomes relative to other breast cancer subtypes, with reduced disease-free and overall survival
rates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>TNBC
refers to any breast cancer that does not express the genes for estrogen receptor, progesterone receptor or Her2/neu. The lack of tumor expression of these receptors precludes the use of targeted
therapies, making chemotherapy the primary systemic treatment for patients with TNBC in both the early and advanced-stages of disease. Although responses and complete responses are achieved, they are
usually short in duration. Due to the limited efficacy of systemic chemotherapy, fewer than 30% of women with metastatic TNBC survive five years after diagnosis, and virtually all women with
metastatic TNBC will ultimately die of the disease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Studies
have shown that the presence of tumor infiltrating lymphocytes, or TILs, is associated with better outcomes for TNBC. In addition, PD-L1 expression is associated with TILs and 20% to 30% of
TNBCs express PD-L1. Based upon this high incidence of expression and demonstrated responses in other tumor types, immune-based approaches are being explored using immune checkpoint blockade therapies
in TNBC. In a Phase Ib clinical trial of pembrolizumab in 32 heavily pretreated PD-L1-positive patients, the response
rate was 18.5% and the complete response rate was 3.7% for the 27 patients who were evaluable for efficacy. A Phase&nbsp;1 clinical trial of atezolizumab, a monoclonal antibody targeting PD-L1, in
27 heavily pretreated TNBC patients gave a response rate of 19% in 21 efficacy evaluable patients and a complete response rate of 9.5%. A Phase&nbsp;2 trial (KEYNOTE-082) has also tested
pembrolizumab in patients previously treated with chemotherapy for metastatic disease (Cohort A, 170 patients) and patients previously untreated with chemotherapy for metastatic disease with PD-L1
positive tumors (Cohort B, 84 patients). Cohort A gave a response rate of 4.8% for PD-L1 positive patients with a complete response rate of 1% and a response rate of 4.7% for PD-L1 negative patients
with a complete response rate of 0.6%. Cohort B gave a response rate of 23% with a complete response rate of 3.6%. Both pembrolizumab and atezolizumab are being tested in Phase&nbsp;3 trials as
single agents or in combination with other therapies. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dc76701_intellectual_property"> </A>
<A NAME="toc_dc76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Intellectual property    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe our rights under issued patents, if obtained, and patent applications will provide a competitive advantage. Our success depends in
part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent
others from infringing upon our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing United States and foreign patent applications related to
our proprietary technology, inventions and improvements that are important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to
develop and maintain our proprietary position. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the core technology in each of our product candidates, patent applications are pending under the Patent Cooperation Treaty, or PCT, and are currently at the international stage. As of
July&nbsp;9, 2018, we own five PCT applications and four U.S. provisional applications. The applications include claims to oncolytic virus compositions of matter, including RP1, pharmaceutical
compositions encompassing the oncolytic viruses, and methods of use in treating cancer, including the target indications discussed above. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=123,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=441372,FOLIO='121',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_122"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&nbsp;years from the
earliest date of filing a non-provisional patent application. In the United States, the patent term of a patent that covers an
FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration of a portion of the patent term lost during the U.S. clinical development and FDA regulatory
review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time
the drug is under clinical development in the United States and the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a
total of 14&nbsp;years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign
jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, and if and when patents grant, we expect to apply for patent
term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee
that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees,
consultants, scientific advisors and other contractors, as well as physical security of our premises and our information technology systems. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dc76701_competition"> </A>
<A NAME="toc_dc76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Competition    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary rights. We compete in the highly competitive markets that address cancer and face significant competition from many sources, including pharmaceutical, biopharmaceutical and
biotechnology companies, as well as universities and private and public research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing and drug
development resources than we do. Large biopharmaceutical companies in particular have extensive experience in clinical testing and in obtaining regulatory approvals for drugs and biologicals. These
companies also have significantly greater research capabilities than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies or universities and research institutions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
competitors fall primarily into the following groups of treatment:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> traditional cancer therapies, including chemotherapy, surgery, radiation and targeted therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approved immunotherapy antibodies and immunotherapy antibodies in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> oncolytic immunotherapies, including T-Vec, the only FDA-approved oncolytic immunotherapy for treating advanced melanoma, and other oncolytic
immunotherapies in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> therapies aimed at activating innate immunity such as those targeting STING and TLRs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cancer vaccines including personalized vaccines and those targeting tumor neo-antigens; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cell-based therapies, such as CAR-T, T cell receptor-based, and NK cell therapies. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=124,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=462272,FOLIO='122',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dc76701_1_123"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are easier to administer or are
less expensive alone or in combination with other therapies than any products that we may develop alone or in
combination with other therapies, especially if these get to market sooner than our products. These third parties also compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to
our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
oncolytic product candidates, if and when marketed, will compete with a number of drugs that are currently marketed or in development that also target cancer but that utilize a different mechanism
of action. To compete effectively with these agents, our product candidates will need to demonstrate advantages that lead to improved clinical efficacy and safety compared with these competitors. At
the same time, however, we believe that our oncolytic product candidates, if and when ultimately marketed, would likely be used principally in combination with checkpoint blockade therapies in
addition to existing cancer therapies, including surgery, chemotherapy, radiation therapy and other biological therapies such as antibodies targeting particular surface receptors. We therefore believe
that our product candidates, if and when marketed, would largely complement rather than compete directly with these existing treatment options. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
do, however, expect to face direct and increasing competition from a number of companies that are also seeking to develop cancer therapies based on oncolytic viruses and other ways to prime the
immune system, including neo-antigen vaccination. We believe that our ability to successfully compete will depend, among other things, on our ability to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expeditiously advance the development of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> design, enroll patients in and successfully complete appropriate clinical trials in a timely fashion; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> gain regulatory approval for our product candidates in their first indications as well as further indications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish collaborations and partnerships for the development and marketing of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> commercialize our product candidates successfully, including convincing physicians, insurers and third-party payors of the safety and efficacy
of our product candidates over currently approved therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> secure and protect intellectual property rights based on our innovations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> manufacture or otherwise obtain and sell commercial quantities of future products to the market. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dc76701_manufacturing_and_suppliers"> </A>
<A NAME="toc_dc76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Manufacturing and suppliers    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have established an operations leadership team with extensive experience in manufacturing biologics based on viruses, including oncolytic
products and gene therapy products, and in the construction, validation, approval and operation of facilities designed to manufacture biologics. Our team has already developed a robust and
reproducible manufacturing process for our product candidates. We are also developing our product candidates for maximum practicality of use compared with some other oncolytic immunotherapies; in
particular, our product candidates do not require refrigeration at -70<SUP>0</SUP> Celsius. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, our third-party contract manufacturer in Europe has been responsible for sourcing raw materials for use in the manufacture, in accordance with cGMP, of our product candidates for use in our
planned early clinical trials. We currently use fetal bovine sera, a commonly used growth supplement, in the initial growth of the mammalian cells used in the production of our viral product
candidates and a recombinant human protein to increase the stability of our drug formulation. We are in the process of developing our
raw material supply chain for our product candidates as part of the process of establishing our own manufacturing facility and intend to enter into commercial supply, collaboration or similar
agreements prior to conducting advanced clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=125,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=317556,FOLIO='123',FILE='DISK114:[18ZBC1.18ZBC76701]DC76701A.;106',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de76701_1_124"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have signed a lease for an approximately 63,000 square-foot facility in Framingham, Massachusetts where we plan to establish, equip, and operate our own in-house
manufacturing facility in order to secure supplies for pivotal studies and commercial launch. This facility is intended to give us control over the whole supply chain for our products and product
candidates. The facility is intended to be both multi-product and multi-use, so that we will be able to produce two different products in parallel and several different products in the same facility. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>By
establishing our own manufacturing facility, we aim to minimize or eliminate our reliance on contract manufacturing organizations, which typically have limited capacity at commercial scale and
quality. We believe that having control over the whole manufacturing process will allow us to reduce cycle times and cost of goods for commercial production and to shorten overall timelines for new
product candidates in our development pipeline, as well as help us to develop drug formulations or presentations to simplify distribution and/or administration of future oncolytic immunotherapies. We
also believe that having a dedicated manufacturing facility will allow us to optimize commercial-scale processes and to develop a suitable workforce capable of supporting market launch. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="de76701_sales_and_marketing"> </A>
<A NAME="toc_de76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Sales and marketing    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>None of our product candidates has been approved for sale. If and when our product candidates receive marketing approval, we intend to
commercialize them on our own in the United States and potentially with pharmaceutical or biotechnology partners in other geographies. We currently have no sales, marketing or commercialization
capabilities and have no experience as a company doing such activities. However, we intend to build the necessary capabilities and infrastructure over time following the advancement of our product
candidates. Clinical data, the size of the opportunity and the size of the commercial infrastructure required will influence our commercialization plans and decision making. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="de76701_collaborations"> </A>
<A NAME="toc_de76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Collaborations    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BMS  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On February&nbsp;26, 2018, we entered into a Clinical Trial Collaboration and Supply Agreement with BMS. Pursuant to the agreement, BMS will provide to us,
at no cost, nivolumab, its anti-PD-1 therapy, for use in combination with RP1 in our ongoing Phase&nbsp;1/2 clinical trial. Under the agreement, we will sponsor, fund and conduct the clinical trial
in accordance with an agreed-upon protocol. Under the agreement, BMS has granted us a non-exclusive, non-transferrable, royalty-free license (with a right to sublicense) under its intellectual
property to use nivolumab in the clinical trial and has agreed to manufacture and supply nivolumab, at its cost and for no charge to us, for use in the clinical trial. Both parties will own the study
data produced in the clinical trial, other than study data related solely to nivolumab, which will belong solely to BMS, or study data related solely to RP1, which will belong solely to us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
earlier terminated, the agreement will remain in effect until (a)&nbsp;the completion of the clinical trial, (b)&nbsp;all related clinical trial data have been delivered to both parties and
(c)&nbsp;the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be terminated
by either party (i)&nbsp;in the event of an uncured material breach by the other party, (ii)&nbsp;in the event the other party is insolvent or in bankruptcy proceedings or (iii)&nbsp;for safety
reasons. Upon termination, the licenses granted to us to use nivolumab in the clinical trial will terminate. The agreement contains representations, warranties, undertakings and indemnities customary
for a transaction of this nature. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=126,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=319187,FOLIO='124',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_125"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regeneron  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On May&nbsp;29, 2018, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals,&nbsp;Inc., or Regeneron.
Pursuant to the agreement we agreed to undertake one or more clinical trials with Regeneron for the administration of our product candidates in combination with cemiplimab, an anti-PD-1 therapy being
developed by Regeneron, across multiple solid tumor types, the first of which is intended to be our planned Phase&nbsp;2 clinical trial of RP1 in patients with CSCC. Each clinical trial will be
conducted pursuant to an agreed study plan which, among other things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and a
schedule of clinical obligations. The first study plan related to the Phase&nbsp;2 clinical trial has been agreed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to contribute the necessary resources needed to
fulfill their respective obligations, in each case, under the terms of the agreed study plans. Development costs of a particular clinical trial will be split equally. The agreement contains
representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain covenants that restrict us from entering into a third-party
arrangement with respect to the use of our product candidates in combination with an anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use
of cemiplimab in combination with an HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed
in a future study plan, these covenants are only applicable to our planned Phase&nbsp;2 clinical trial in CSCC, and expire upon the one-year anniversary of the commencement of the applicable study
plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
agreement may be terminated by either party if (i)&nbsp;there is no active study plan for which a final study report has not been completed, (ii)&nbsp;the parties have not entered into a study
plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (iii)&nbsp;in the event of a material breach. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="de76701_regulatory_matters"> </A>
<A NAME="toc_de76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Regulatory matters    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Government authorities in the United States, at the federal, state, and local level, and in other countries, extensively regulate, among other
things, the research, development, testing, approval, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of biopharmaceutical
products such as those we are developing. In addition, manufacturers of biopharmaceutical products participating in Medicaid and Medicare are required to comply with mandatory price reporting,
discount, and rebate requirements. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with compliance with applicable statutes and regulations,
require the expenditure of substantial time and financial resources. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FDA and EU regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Services Act, or PHSA, and their
implementing regulations. The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with GLP regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of an IND, which must become effective before human clinical trials may begin at United States clinical trial sites; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=127,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=758570,FOLIO='125',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_126"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval by an IRB for each clinical site, or centrally, before each trial may be initiated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> adequate and well-controlled human clinical trials to establish the safety, purity, and potency of the proposed product candidate for its
intended use, performed in accordance with GCPs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> development of manufacturing processes to ensure the product candidate's identity, strength, quality, purity, and potency; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of a BLA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory completion of an FDA advisory committee review, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the products are produced to assess
compliance with current cGMPs, and to assure that the facilities, methods, and controls are adequate to preserve the therapeutics' identity, strength, quality, purity, and potency as well as
satisfactory completion of an FDA inspection of selected clinical sites and selected clinical investigators to determine GCP compliance; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA review and approval of the BLA to permit commercial marketing for particular indications for use. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical studies and IND submission  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of the FDA's pre-market
approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Preclinical studies include
laboratory evaluation of chemistry, pharmacology, toxicity, and product formulation, as well as animal studies to assess potential safety and efficacy. Such studies must generally be conducted in
accordance with the FDA's GLPs. Prior to commencing the first clinical trial at a United States investigational site with a product candidate, an IND sponsor must submit the results of the preclinical
tests and preclinical literature, together with manufacturing information, analytical data, any available clinical data or literature, and proposed clinical study protocols among other things, to the
FDA as part of an IND. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the 30-day time period, notifies the applicant of safety concerns or questions related to one or
more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical
holds also may be imposed by the FDA at any time before or during trials due to safety concerns or non-compliance. As a result, submission of an IND may not result in FDA authorization to commence a
clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical trials  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance
with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as
well as review and approval of the study by an IRB. Investigators must also provide certain information to the clinical trial sponsors to allow the sponsors to make certain financial disclosures to
the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety, the
effectiveness criteria to be evaluated, and a statistical analysis plan. A protocol for each clinical trial, and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=128,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=45982,FOLIO='126',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_127"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>any
subsequent protocol amendments, must be submitted to the FDA as part of the IND. In addition, an IRB at each study site participating in the clinical trial or a central IRB must review and approve
the plan for any clinical trial, informed consent forms, and communications to study subjects before a study commences at that site. An IRB considers, among other things, whether the risks to
individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to
oversee the clinical trial while it is being conducted. Once an IND is in effect, each new clinical protocol and any amendments to the protocol must be submitted to the IND for FDA review, and to the
IRB for approval. If a product candidate is being investigated for multiple intended indications, separate INDs may also be required. Progress reports detailing the results of the clinical trials must
also be submitted at least annually to the FDA and the IRB and more frequently if serious adverse events or other significant safety information is found. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in
accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or
permanently, for failure to comply with the IRB's requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical
trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
about certain clinical trials, including a description of the study and study results, must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public
dissemination on their clinicaltrials.gov website. Manufacturers or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions
must also have a publicly available policy on evaluating and responding to requests for expanded access requests. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial that regularly reviews accumulated data and advises the study sponsor
regarding the continuing safety of the trial. This group may also review interim data to assess the continuing validity and scientific merit of the clinical trial. This group receives special access
to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determined there is an unacceptable safety risk for subjects or on other grounds, such as no
demonstration of efficacy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
manufacture of investigational biologics for the conduct of human clinical trials is subject to current cGMP requirements. Investigational biologics and active ingredients imported into the United
States are also subject to regulation by the FDA. Further, the export of investigational products outside of the United States is subject to regulatory requirements of the receiving country as well as
United States export requirements under the FDCA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
general, for purposes of BLA approval, human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Phase&nbsp;1&#151;Trials are initially conducted in healthy human volunteers or subjects with the target disease or condition and test
the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution, and excretion. If possible, Phase&nbsp;1 trials may
also be used to gain an initial indication of product effectiveness. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Phase&nbsp;2&#151;Controlled trials are conducted in limited subject populations with a specified disease or condition to evaluate the
effectiveness of the product candidate for a particular indication or indications, </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=129,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=881124,FOLIO='127',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_128"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>identify
optimal dosages, dosage tolerance and schedule, possible adverse effects and safety risks, and expanded evidence of safety. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Phase&nbsp;3&#151;These adequate and well-controlled clinical trials are undertaken in expanded subject populations, generally at
geographically dispersed clinical trial sites, to generate enough data to provide statistically significant evidence of clinical efficacy and safety of the product for approval, to establish the
overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Typically, two Phase&nbsp;3 trials are required by the FDA for product approval.
Under some limited circumstances, however, the FDA may approve a BLA based upon a single Phase&nbsp;3 clinical trials. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Additional
kinds of data may also help to support a BLA, such as patient experience data. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
under certain circumstances, manufacturers and sponsors of investigational biopharmaceutical product candidates can provide access to the product candidates to certain qualifying patients
outside of clinical trials. For instance, under the FDA's expanded access program, with FDA approval and subject to certain requirements, sponsors may provide access to product candidates to patients
with serious or immediately life threatening diseases or conditions for which there is no comparable or satisfactory alternative therapy, provided that the potential patient benefit justifies the
risks, the risks are not unreasonable in the context of the disease or condition to be treated, and the provision of the product candidate for the requested use will not interfere with clinical
investigations. The specific expanded access criteria and requirements depend on the number of expanded access patients. Sponsors and investigators of expanded access programs must still comply with
the FDA's clinical trial and are subject to protection regulations. Federal and state laws in the United States, referred to as right to try laws, also establish a separate mechanism through which
certain patients with life threatening diseases or conditions, who have exhausted all approved treatment options and are unable to participate in a clinical trial, may request access to
investigational product candidates that have completed a Phase&nbsp;1 clinical trial. While certain criteria must be met for a patient to be eligible for access to product candidates under right to
try laws, these laws do not require the FDA to approve the use of the product candidate and do not require compliance with the majority of the FDA's clinical trial regulations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also require, or companies may conduct, additional clinical trials for the same indication after a product is approved. These so-called Phase&nbsp;4 trials may be made a condition to be
satisfied after approval. The results of Phase&nbsp;4 trials can confirm or refute the effectiveness of a product candidate, and can provide important safety information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product
candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with current cGMP requirements. The manufacturing process must be capable of consistently
producing quality batches of the product candidate and, among other things, manufacturers must develop methods for testing the identity, strength, quality, potency, and purity of the final product.
Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its
shelf life. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
relation to the clinical trial in the United Kingdom and in so far as trials will be conducted in other countries with a view to obtaining a marketing authorization from the European Medicines
Agency, there are equivalent cGMP requirements and European Union regulatory rules that are implemented nationally. However, enforcement of such rules is conducted by the regulatory authority in which
the trial is carried out, which is the MHRA in the United Kingdom. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=130,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=288359,FOLIO='128',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_129"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BLA submission, review by the FDA, and marketing approval  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Assuming successful completion of the required clinical and preclinical testing, the results of product development, including chemistry, manufacture, and
controls, non-clinical studies, and clinical trial results, including negative or ambiguous results as well as positive findings, are all submitted to the FDA, along with the proposed labeling, as
part of a BLA requesting approval to market the product for one or more indications. In most cases, the submission of a BLA is subject to a substantial application user fee. These user fees must be
paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in certain circumstances. One basis
for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a
product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application. Product candidates
that are designated as orphan products, which are further described below, are also not subject to application user fees unless the application includes an indication other than the orphan indication. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must
contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for
each pediatric subpopulation for which the product is safe and effective. Also, under the FDA Reauthorization Act of 2017, beginning in 2020, for applications for product candidates intended for the
treatment of adult cancer which are directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, in place of the PREA
investigations, sponsors must submit, with the application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatric study data, using
appropriate formulations, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data
until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are also exempt from the PREA requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA also may require submission of a REMS to ensure that the benefits of the biologic outweigh the risks. The REMS plan could include medication guides, physician communication plans, and elements
to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. An assessment of the REMS must also be conducted at set intervals. Following product
approval, a REMS may also be required by the FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the biologic outweigh the risks. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Once
the FDA receives an application, it has 60&nbsp;days to review the BLA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing.
The FDA may request additional information rather than accept a BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also
subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of completing its review of 90% of all applications within ten
months from the 60-day filing date for its initial review of a BLA. This review goal is referred to as the PDUFA date. The PDUFA date is only a goal, thus, the FDA does not always meet its PDUFA
dates. The review process and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=131,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=389085,FOLIO='129',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_130"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
PDUFA date may also be extended if the FDA requests or the sponsor otherwise provides substantial additional information or clarification regarding the submission. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also refer certain applications to an advisory committee. Before approving a biologic for which no active ingredient, including any ester or salt of active ingredients, has previously been
approved by the FDA, the FDA must either refer that biologic to an external advisory committee or provide in an action letter, a summary of the reasons why the FDA did not refer the product candidate
to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts, which review, evaluate, and make a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
FDA reviews applications to determine, among other things, whether a product is safe, pure and potent and whether the manufacturing methods and controls are adequate to assure and preserve the
product's identity, strength, quality, potency, and purity. Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured, referred to as a
Pre-Approval Inspection. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontractors, are in
compliance with current cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA the FDA will inspect one or
more clinical trial sites to assure compliance with GCPs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
evaluating the BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites,
the FDA may issue an approval letter, or, in some cases, a Complete Response Letter, or CRL. A CRL indicates that the review cycle of the application is complete and the application is not ready for
approval and describes all of the specific deficiencies that the FDA identified in the BLA. A CRL generally contains a statement of specific conditions that must be met in order to secure final
approval of the BLA, and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. The deficiencies identified may be minor, for example, requiring
labeling changes, or major, for example, requiring additional clinical trials. If a CRL is issued, the applicant may either: resubmit the BLA, addressing all of the deficiencies identified in the
letter; withdraw the application; or request an opportunity for a hearing. The FDA has the goal of reviewing 90% of application resubmissions in either two or six months of the resubmission date,
depending on the kind of resubmission. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If
and when those conditions have been met to the FDA's satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing
information for specific indications. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling,
including a boxed warning, require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess a product's safety and efficacy after approval, require testing
and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS which can
materially affect the potential market and profitability of the product. The FDA may also not approve label statements that are necessary for successful commercialization and marketing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=132,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1048147,FOLIO='130',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_131"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and
FDA review and approval. The FDA may also withdraw the product approval if compliance with the pre- and post-marketing regulatory standards are not maintained or if problems occur after the product
reaches the marketplace. Further, should new safety information arise, additional testing, product labeling, or FDA notification may be required. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Broadly
equivalent requirements and controls similarly apply to the submission of marketing authorization applications to the European Medicines Agency in the European Union and, post-approval, to the
holding of such marketing authorizations. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biosimilars and exclusivity  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The BPCIA creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference
biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires a high similarity to the reference product notwithstanding minor differences in clinically inactive
components, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical
studies, animal studies, and at least one clinical trial, absent a waiver by the FDA. There must be no difference between the reference product and a biosimilar in mechanism of action, conditions of
use, route of administration, dosage form, and strength. A biosimilar product may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be
expected to produce the same clinical results as the reference product and,
for products administered multiple times, the biosimilar and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished
efficacy relative to exclusive use of the reference biologic. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
reference biologic is granted 12&nbsp;years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four years from the
date of licensure of the reference product. However, certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in
interest, or other related entity do not qualify for the twelve-year exclusivity period. The PHSA also includes provisions to protect reference products that have patent protection. The biosimilar
product sponsor and reference product sponsor may exchange certain patent and product information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome
of negotiations surrounding the exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The
biosimilar applicant may also be able to bring an action for declaratory judgment concerning the patent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the European Union there is a period of 10&nbsp;years (or 11&nbsp;years for significant new indications) of data exclusivity so that those seeking to market biosimilars cannot apply on an
abridged basis for a marketing authorization for eight years from when the product was first marketed in the European Union and cannot place it on the market for 10 or 11&nbsp;years from such first
marketing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
approved, biologics may also be eligible for periods of United States patent term restoration. If granted, patent term restoration extends the patent life of a single unexpired patent, that has not
previously been extended, for a maximum of five years. The total patent life with the extension also cannot exceed fourteen years from the product's approval date. Subject to the prior limitations,
the period of the extension is calculated by adding half of the time from the effective date of an IND to the initial submission of a marketing application, and all of the time between the submission
of the marketing </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=133,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=231407,FOLIO='131',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_132"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>application
and its approval. This period may also be reduced by any time that the applicant did not act with due diligence. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the European Union, a supplementary protection certificate, or SPC, can similarly extend a patent term for a maximum of five years. A six-month additional extension, however, is available if the
SPC relates to a medicinal product for which data has been submitted according to a Pediatric Investigation Plan. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-approval requirements  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements related to manufacturing, recordkeeping, and reporting, including adverse experience reporting, deviation reporting, shortage reporting, and periodic reporting, product
distribution, advertising, marketing, promotion, certain electronic records and signatures, and post-approval obligations imposed as a condition of approval, such as Phase&nbsp;4 clinical trials,
REMS, and surveillance to assess safety and effectiveness after commercialization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing annual program
user fee requirements for approved products, excluding, under certain circumstances, orphan products. In addition, manufacturers and other entities involved in the manufacture and distribution of
approved therapeutics are required to register their establishments with the FDA and certain state agencies, list their products, and are subject to periodic announced and unannounced inspections by
the FDA and these state agencies for compliance with current cGMP and other requirements, which impose certain procedural and documentation requirements upon us and third-party manufacturers.
Manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with current cGMPs. Regulatory authorities may withdraw product
approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are
subsequently discovered. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
to the manufacturing process are strictly regulated and often require prior FDA approval or notification before being implemented. FDA regulations also require investigation and correction of
any deviations from current cGMP and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use.
Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain current cGMP compliance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to safety and efficacy, purity,
and potency that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in
the product's labeling and that differ from those tested and approved by the FDA. Biopharmaceutical companies, however, are required to promote their products only for the approved indications and in
accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to
have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and False Claims Act, exclusion from
participation in federal healthcare
programs, mandatory compliance programs under corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=134,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=929203,FOLIO='132',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_133"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
the enacted Drug Quality and Security Act imposes obligations on manufacturers of biopharmaceutical products related to product tracking and tracing. Among the requirements of this
legislation, manufacturers are required to provide certain information regarding the products to individuals and entities to which product ownership is transferred, will be required to label products
with a product identifier, and are required to keep certain records regarding the product. The transfer of information to subsequent product owners by manufacturers is also required to be done
electronically. Manufacturers must also verify that purchasers of the manufacturers' products are appropriately licensed. Further, under this legislation, manufactures have product investigation,
quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences or
death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health
consequences or death. Similar requirements additionally are and will be imposed through this legislation on other companies within the biopharmaceutical product supply chain, such as distributors and
dispensers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Adverse
event reporting and submission of periodic reports, including annual reports and deviation reports, are required following FDA approval of a BLA. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant
regulatory actions. Such actions may include refusal to approve pending applications, license suspension or revocation, imposition of a clinical hold or termination of clinical trials, warning
letters, untitled letters, cyber letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for
additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of
production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing
government contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and result in
adverse publicity, among other adverse consequences. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional controls for biologics  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose
attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure
products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the
United States and between states. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests
on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together
with a release protocol showing the results of all of the manufacturer's tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products before releasing the
lots for distribution by the manufacturer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=135,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1026070,FOLIO='133',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_134"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fraud and abuse, data privacy and security, and transparency laws and regulations  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our business activities, including but not limited to, research, sales, promotion, distribution, medical education, and other activities following product
approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of
Justice, the Department of Health and Human Services and its various divisions, including the CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the
Department of Defense, and state and local governments. Our business activities must comply with numerous healthcare laws, including but not limited to, anti-kickback and false
claims laws and regulations as well as data privacy and security laws and regulations, which are described below, as well as state and federal consumer protection and unfair competition laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Anti-Kickback Statute, which regulates, among other things, marketing practices, educational programs, pricing policies, and relationships with healthcare provides or other entities,
prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or
in kind, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order, or the referral to another for the furnishing or arranging for the
furnishing of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs, in whole or in part. The term "remuneration" has been interpreted broadly to include
anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and
beneficiaries on the other, as well as free trial and starter prescriptions provided through pharmacies. There are certain statutory exceptions and regulatory safe harbors protecting some common
activities from prosecution. The exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or
recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory
safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of
all of its facts and circumstances. Several courts have interpreted the statute's intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of
federal healthcare covered business, the statute has been violated. The ACA modified the intent requirement under the Anti-Kickback Statute to a stricter standard, such that a person or entity no
longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA also provided that a violation of the federal
Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for
purposes of the federal civil False Claims Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval
by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding,
decreasing, or concealing an obligation to pay money to the federal government. A claim includes "any request or demand" for money or property presented to the U.S. government. The civil False Claims
Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper
use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off-label uses not expressly approved by the FDA in a product's label, and allegations as to
misrepresentations with respect to the services rendered. In </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=136,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=896073,FOLIO='134',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_135"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>addition,
private payers have been filing follow-on lawsuits alleging fraudulent misrepresentation, although establishing liability and damages in these cases is more difficult than under the False
Claims Act. Intent to deceive is not required to establish liability under the civil False Claims Act. Civil False Claims Act actions may be brought by the government or may be brought by private
individuals on behalf of the government, called "qui tam" actions. If the government decides to intervene in a qui tam action and prevails in the lawsuit, the individual will share in the proceeds
from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. The civil False Claims Act provides for treble damages and a civil penalty for
each false claim, such as an invoice or pharmacy claim for reimbursement, which can aggregate into millions of dollars. For these reasons, since 2004, False Claims Act lawsuits against
biopharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, as much as $3.0&nbsp;billion, regarding certain sales
practices and promoting off label uses. Civil False Claims Act liability may further be imposed for known Medicare or Medicaid overpayments, for example, overpayments caused by understated rebate
amounts, that are not refunded within 60&nbsp;days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act. In addition, conviction or civil judgment for
violating the False Claims Act may result in exclusion from federal health care programs, and suspension and debarment from government contracts, and refusal of orders under existing government
contracts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
government may further prosecute conduct constituting a false claim under the criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the
government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil False Claims Act, requires proof of intent to submit a false claim. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
civil monetary penalties statute is another potential statute under which biopharmaceutical companies may be subject to enforcement. Among other things, the civil monetary penalties statue imposes
fines against any person who is determined to have knowingly presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or
service that was not provided as claimed or is false or fraudulent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Payment
or reimbursement of prescription therapeutics by Medicaid or Medicare requires manufacturers to submit certified pricing information to CMS. The Medicaid Drug Rebate statute requires
manufacturers to calculate and report price points, which are used to determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for certain
therapeutics. For therapeutics paid under Medicare Part&nbsp;B, manufacturers must also calculate and report their Average Sales Price, which is used to determine the Medicare Part&nbsp;B payment
rate. In addition, therapeutics covered by Medicaid are subject to an additional inflation penalty which can substantially increase rebate payments. For products approved under a BLA, (including
biosimilars) or an NDA, the VHCA requires manufacturers to calculate and report to the Veterans Administration, or VA, a different price called the Non-Federal Average Manufacturing Price, which is
used to determine the maximum price that can be charged to
certain federal agencies, referred to as the Federal Ceiling Price, or FCP. Like the Medicaid rebate amount, the FCP includes an inflation penalty. A Department of Defense regulation requires
manufacturers to provide this discount on therapeutics dispensed by retail pharmacies when paid by the TRICARE Program. All of these price reporting requirements create risk of submitting false
information to the government, and potential FCA liability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
VHCA also requires manufacturers of covered therapeutics participating in the Medicaid program to enter into Federal Supply Schedule contracts with the VA through which their covered therapeutics
must be sold to certain federal agencies at FCP. This necessitates compliance with applicable federal procurement laws and regulations, including submission of commercial sales and pricing
information, and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=137,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=40212,FOLIO='135',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_136"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>subjects
us to contractual remedies as well as administrative, civil, and criminal sanctions. In addition, the VHCA requires manufacturers participating in Medicaid to agree to provide different
mandatory discounts to certain Public Health Service grantees and other safety net hospitals and clinics under the 340B program based on the manufacturer's reported Medicaid pricing information. The
340B program has its own regulatory authority to impose sanctions for non-compliance and adjudicate overcharge claims against manufacturers by the purchasing entities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
HIPAA, also created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false
or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public
or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal
investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection
with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes
under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
ACA further created new federal requirements for reporting, by applicable manufacturers of covered therapeutics, payments and other transfers of value to physicians and teaching hospitals, and
ownership and investment interests held by physicians and other healthcare providers and their immediate family members. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH, and its respective
implementing regulations imposes certain requirements on covered entities relating to the privacy, security, and transmission of certain individually identifiable health information known as protected
health information. Among other things, HITECH, through its implementing regulations, makes HIPAA's security standards and certain privacy standards directly applicable to business associates, defined
as a person or organization, other than a member of a covered entity's workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a
function or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, and individuals, and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys' fees and costs associated with pursuing federal
civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in
significant ways and may not be preempted by HIPPA, thus complicating compliance efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial
insurers. Certain state laws also regulate manufacturers' use of prescriber-identifiable data. Certain states also require implementation of commercial compliance programs and compliance with the
pharmaceutical industry's voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items
of value that may be made to healthcare providers and other potential referral sources; impose restrictions on marketing practices; or require manufacturers to track and report information related to
payments, gifts, and other </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=138,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=332754,FOLIO='136',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_de76701_1_137"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>items
of value to physicians and other healthcare providers. Recently, states have enacted or are considering legislation intended to make drug prices more transparent and deter significant price
increases. These laws may affect our future sales, marketing, and other promotional activities by imposing administrative and compliance burdens. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
our operations are found to be in violation of any of the laws or regulations described above or any other laws that apply to us, we may be subject penalties or other enforcement actions, including
criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, corporate integrity agreements,
suspension and debarment from government contracts, and refusal of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of
operations. Enforcement actions can be brought by federal or state governments, or as "qui tam" actions brought by individual whistleblowers in the name of the government under the civil False Claims
Act if the violations are alleged to have caused the government to pay a false or fraudulent claim. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing
requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.
In the European Union, the data privacy laws are generally perceived to be stricter than those which apply in the United States and include specific requirements for the transfer of personal data
outside the European Union to the United States to ensure that European Union standards of data privacy will be applied to such data. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Coverage and reimbursement generally  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The commercial success of our product candidates and our ability to commercialize any approved product candidates successfully will depend in part on the
extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, and other third-party payors provide coverage for and establish
adequate reimbursement levels for our product candidates. Government authorities, private health insurers, and other organizations generally decide which therapeutics they will pay for and establish
reimbursement levels for healthcare. Medicare is a federally funded program managed by CMS through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain
healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who
are otherwise uninsured that is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations that
govern its individual program, including supplemental rebate programs that restrict coverage to therapeutics on the state Preferred Drug List. Similarly, government laws and regulations establish the
parameters for coverage of prescription therapeutics by health plans participating in state exchanges and Tricare, the health care program for military personnel, retirees, and related beneficiaries.
Some states have also created pharmacy assistance programs for individuals who do not qualify for federal programs. In the United States, private health insurers and other third-party payors often
provide reimbursement for products and services based on the level at which the government provides reimbursement through the Medicare or Medicaid programs for such products and services. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=139,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=475027,FOLIO='137',FILE='DISK114:[18ZBC1.18ZBC76701]DE76701A.;64',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg76701_1_138"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, the European Union, and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly
attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than
they would otherwise be and sometimes at or below the provider's acquisition cost. In the United States, it is also common for government and private health plans to use coverage determinations to
leverage rebates from manufacturers in order to reduce the plans' net costs. These restrictions and limitations influence the purchase of healthcare services and products and lower the realization on
manufacturers' sales of prescription therapeutics. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs. Third-party payors may limit coverage to
specific therapeutic products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication or might impose high copayment amounts to
influence patient choice. Third-party payors also control costs by requiring prior authorization or imposing other dispensing restrictions before covering certain products and by broadening
therapeutic classes to increase competition. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in
addition to their safety and efficacy. Absent clinical differentiators, third-party payors may treat products as therapeutically equivalent and base formulary decisions on net cost. To lower the
prescription cost, manufacturers frequently rebate a portion
of the prescription price to the third-party payors. Recently, purchasers and third-party payors have begun to focus on value of new therapeutics and sought agreements in which price is based on
achievement of performance metrics. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Federal
programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and clinics and mandatory rebates on retail pharmacy
prescriptions paid by Medicaid and Tricare. These restrictions and limitations influence the purchase of healthcare services and products. Legislative proposals to reform healthcare or reduce costs
under government programs may result in lower reimbursement for our product candidates or exclusion of our product candidates from coverage. In addition, government programs like Medicaid include
substantial penalties for increasing commercial prices over the rate of inflation which can affect realization and return on investment. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Private
payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a
significant gating issue for successful introduction of a new product. In addition, many government programs as a condition of participation mandate fixed discounts or rebates from manufacturers
regardless of formulary position or utilization, and then rely on competition in the market to attain further price reductions, which can greatly reduce realization on the sale. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product
pricing, reimbursement, and utilization, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups,
competition within therapeutic classes, judicial decisions and governmental laws and regulations related to Medicare, Medicaid, and healthcare reform, biopharmaceutical coverage and reimbursement
policies, and pricing in general. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or
part of the associated healthcare costs. Sales of our product candidates will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be
paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=140,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=755647,FOLIO='138',FILE='DISK114:[18ZBC1.18ZBC76701]DG76701A.;47',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dg76701_1_139"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>administration
authorities, such as Medicare and Medicaid, private health insurers, and other third-party payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a result of the above, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs
required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective, or the rebate percentages required to secure coverage may not yield an
adequate margin over cost. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
a payor's decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us
to maintain price levels sufficient to realize an appropriate return on our investment in therapeutic development. Legislative proposals to reform healthcare or reduce costs under government insurance
programs may result in lower reimbursement for our products and product candidates or exclusion of our products and product candidates from coverage. The cost containment measures that healthcare
payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will
be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
absence in Europe of any substantive harmonization of pricing and reimbursement regimes, including health technology assessment, means that separate negotiations will need to take place with the
relevant authorities in each member state. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare reform measures  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the
healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and expanding access. In the United States, the biopharmaceutical industry has been a particular
focus of these efforts and has been significantly affected by major legislative initiatives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
example, Medicare Part&nbsp;B, which covers products administered by physicians in an outpatient setting, may be undergoing a significant change in payment rates. CMS has proposed a rule that
would compensate physicians for therapeutics they administer based on a smaller mark-up over the manufacturer's Average Sales Price and a fixed fee, which is intended to incentivize physicians to
purchase and bill Medicare for lower priced products. The proposed rule would also authorize CMS to establish methods for determining comparative cost effectiveness and seek value-based discounts </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Similarly,
the American Recovery and Reinvestment Act of 2009 established funding for the federal government to compare the effectiveness of different treatments for the same illness. The Agency for
Healthcare Research and Quality among other things, conducts patient-centered outcome research, develops evidence-based tools and resources on medication therapies, maintains databases of health care
related data and standards, and issues periodic reports on specific studies. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or
private payors, it is not clear what effect, if any, the organization's research has had or will have on the sales of any product, if any such product or the condition that it is intended to treat is
the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor's product </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=141,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1004344,FOLIO='139',FILE='DISK114:[18ZBC1.18ZBC76701]DG76701A.;47',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dg76701_1_140"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>could
adversely affect the sales of our product candidates. If third-party payors do not consider our product candidates to be cost-effective compared to other available therapies, they may not cover
our product candidates, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
the ACA broadened access to health insurance, attempts to reduce or constrain the growth of healthcare spending, enhanced remedies against fraud and abuse, added new transparency
requirements for healthcare and health insurance industries, imposed new taxes and fees on the health care industry, and imposed additional health policy reforms. The law expanded the eligibility
criteria and mandatory eligibility categories for Medicaid programs, thereby potentially increasing both the volume of sales and manufacturers' Medicaid rebate liability. The law also expanded the
340B discount program that mandates discounts to certain hospitals, community centers, and other qualifying providers, by expanding the categories of entities eligible to purchase under the program,
although, with the exception of children's hospitals, these newly eligible entities are ineligible to receive discounted 340B pricing on orphan therapeutics used to treat an orphan disease or
condition. The ACA revised the definition of "average manufacturer price, or AMP, for reporting purposes, which generally increased the amount of Medicaid rebates to states and created a separate AMP
for certain categories of therapeutics provided in non-retail outpatient settings. The law additionally extended manufacturer's Medicaid rebate liability to covered therapeutics dispensed to patients
enrolled in Medicaid managed care organizations and increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate program. The revisions to the AMP definition and
Medicaid rebate formula can have the further effect of increasing the required 340B discounts. Further, the ACA requires manufacturers of therapeutics, to pay 50% of the pharmacy charge to Medicare
Part&nbsp;D patients while they are in the coverage gap, and this percentage was increased to 70% by the Bipartisan Budget Act of 2018. Finally, the ACA imposes a significant annual fee on companies
that manufacture or import branded prescription therapeutic products. Substantial new provisions affecting compliance have also been enacted through the ACA and otherwise, including the reporting of
therapeutic sample distribution, which may require us to modify our business practices with healthcare practitioners. Although the ACA was recently amended to repeal the individual insurance mandate,
and efforts to repeal and replace portions of the law may continue, it is likely that pressure on
biopharmaceutical pricing, especially under the Medicare program, will continue, and may also increase our regulatory burdens and operating costs. Moreover, in the coming years, additional changes
could be made to governmental healthcare programs that could significantly impact the success of our product candidates. Recently, CMS issued regulations reducing Medicare Part&nbsp;B payments to
certain hospitals for outpatient therapeutics purchased under the 340B program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
cost of biopharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the biopharmaceutical industry will experience pricing pressures due to the
trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. Our results of operations could be adversely affected by current and
future healthcare reforms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some
third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse healthcare providers that use such therapies. While we cannot
predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on
our ability to obtain adequate prices for our product candidates and operate profitably. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, as amended, created the Joint Select Committee on Deficit Reduction to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=142,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=645349,FOLIO='140',FILE='DISK114:[18ZBC1.18ZBC76701]DG76701A.;47',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dg76701_1_141"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>recommend
proposals in spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013
through 2021, triggering the legislation's automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal
year. The Bipartisan Budget Act of 2018 retained the federal budget "sequestration" Medicare payment reductions of 2%, and extended it through 2027. The American Taxpayer Relief Act of 2012, further
reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. These and other healthcare reform initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our financial
operations. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for
healthcare products and services, which could further limit the prices we are able to charge, or the amounts of reimbursement available, for our product candidates once they are approved. The
Bipartisan Budget Act also extended Manufacturer responsibility for prescription costs in the Medicare Part&nbsp;D coverage gap to biosimilars, which had previously been exempt. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Foreign Corrupt Practices Act  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of
value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or
business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain
books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting
controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement,
oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
foreign anti-corruption regimes are arguably of wider application. For instance, the U.K. Bribery Act 2010 applies to dealings with any decision maker whether in the private or public sector in
a position of trust. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dg76701_facilities"> </A>
<A NAME="toc_dg76701_1"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Facilities    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our current corporate headquarters are located in Woburn, Massachusetts. We lease this facility, which consists of approximately 4,000 square
feet. Our Woburn lease expires in March 2021. We also lease an approximately 12,000 square-foot facility in Oxfordshire, United Kingdom, containing research and development, laboratory and office
space. This lease expires in April 2026 and we have the right to terminate it in April 2021. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
June&nbsp;22, 2018, we signed a lease for an approximately 63,000 square-foot facility in Framingham, Massachusetts to house our manufacturing operations and our translational science laboratory.
We expect that the facility will be ready to produce clinical-grade material during the first half of 2020 and ultimately to be able to support commercial product launch. Pursuant to the lease
agreement, the lease term is estimated to commence in November 2018 subject to the landlord completing certain agreed upon landlord improvements. The rent commencement date is estimated to be eight
months after the commencement of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=143,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=4972,FOLIO='141',FILE='DISK114:[18ZBC1.18ZBC76701]DG76701A.;47',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dg76701_1_142"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
lease term. The initial lease term is ten years from the rent commencement date and includes two optional five year extensions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe that our existing and planned facilities will be adequate to meet our planned needs and that our leases can be renewed, or suitable alternative spaces will be available in the future, on
commercially reasonable terms. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dg76701_employees"> </A>
<A NAME="toc_dg76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Employees    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of July&nbsp;9, 2018, we had 44 employees, including eight who hold Ph.D. or M.D. degrees. We had 28 employees engaged in research and
development; our remaining employees are management or administrative staff. None of our employees is subject to a collective bargaining agreement. We believe that we have good relations with our
employees. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dg76701_research_and_development"> </A>
<A NAME="toc_dg76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Research and development    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our research and development expenses were approximately $6.9&nbsp;million and $13.5&nbsp;million for the years ended March&nbsp;31,
2017 and 2018, respectively. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dg76701_legal_proceedings"> </A>
<A NAME="toc_dg76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Legal proceedings    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are not currently a party to any material legal proceedings. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=144,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=501857,FOLIO='142',FILE='DISK114:[18ZBC1.18ZBC76701]DG76701A.;47',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_di76701_1_143"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="di76701_management"> </A>
<A NAME="toc_di76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_executive_officers_and_directors"> </A>
<A NAME="toc_di76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Executive officers and directors    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth the names and positions of our executive officers and directors, and their ages as of July&nbsp;9, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="22pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="294pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Age</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Position(s) </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Executive Officers:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Robert Coffin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Philip Astley-Sparke</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Executive Chairman, Secretary, Treasurer and Director</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Colin Love, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Operating Officer</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pamela Esposito, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Howard Kaufman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Non-Management Directors:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Kapil Dhingra M.B.B.S.<SUP>(1)(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hyam Levitsky, M.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Jason Rhodes<SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Joseph Slattery<SUP>(1)(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Sander Slootweg<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Otello Stampacchia, Ph.D.<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Dieter Weinand</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Member
of the audit committee.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Member
of the compensation committee.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Member
of the nominating and corporate governance committee. </FONT></P>
 </DIV>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biographies  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Robert Coffin</I></FONT><FONT SIZE=2> is one of our co-founders and has served as our President and Chief Executive Officer
since our formation in 2015. From 2013 to 2015, Dr.&nbsp;Coffin served as a consultant for a number of biotechnology companies. From 2011 to 2013, Dr.&nbsp;Coffin served as Vice President of
Global Development at Amgen. In 1999, Dr.&nbsp;Coffin co-founded BioVex, a spin out from his research group at University College London. Dr.&nbsp;Coffin served as the Chief Technology Officer of
BioVex until it was acquired by Amgen in 2011. During his time at BioVex, Dr.&nbsp;Coffin invented all BioVex products and oversaw all research and clinical development, including bringing T-Vec
into two pivotal Phase&nbsp;3 clinical trials. Dr.&nbsp;Coffin was awarded a Ph.D. in Virology from Imperial College London prior to his move to University College London in 1991.
Dr.&nbsp;Coffin is qualified to serve on our board of directors due to his prior experience developing an oncolytic immunotherapy and his extensive knowledge of our company based on his role as
co-founder and President and Chief Executive Officer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Philip Astley-Sparke</I></FONT><FONT SIZE=2> is one of our co-founders and has served as our Executive Chairman since our formation in 2015. Since 2016,
Mr.&nbsp;Astley-Sparke has served as Chairman of uniQure N.V., a Nasdaq&#151;listed gene therapy company. From 2013 to 2015, Mr.&nbsp;Astley-Sparke served as uniQure N.V.'s President of
U.S. operations, where he established its U.S. infrastructure. Mr.&nbsp;Astley-Sparke served as Vice President and General Manager at Amgen until December 2011, following Amgen's acquisition of
BioVex in March 2011. Mr.&nbsp;Astley-Sparke was President and Chief Executive Officer of BioVex. Prior to BioVex, Mr.&nbsp;Astley-Sparke was a healthcare investment banker at Chase H&amp;Q and
qualified as a Chartered Accountant with Arthur Andersen&nbsp;LLP. Mr.&nbsp;Astley-Sparke has been a Venture Partner at Forbion Capital Partners, a venture capital fund, since May 2012 and serves
as Chairman of the Board of Oxyrane Limited, a biotechnology company. Mr.&nbsp;Astley-Sparke received a B.Sc. in Cellular and Molecular Pathology from Bristol University. Mr.&nbsp;Astley- </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=145,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=96661,FOLIO='143',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_144"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sparke
is qualified to serve on our board of directors because of his extensive knowledge of our company based on his role as co-founder and Executive Chairman and his extensive financial and
leadership experience. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Colin Love</I></FONT><FONT SIZE=2> has served as our Chief Operating Officer since October 2015 and has been a member of the board of directors of Replimune Limited
since July 2017. Following the acquisition of BioVex by Amgen in 2011, Dr.&nbsp;Love remained at Amgen as Vice President of Clinical Operations, working on T-Vec until it was approved in 2015. Since
2014, Dr.&nbsp;Love has also provided consulting support to biotechnology companies through Clove Consulting&nbsp;Ltd. From 2000 until it was acquired in 2011, Dr.&nbsp;Love served as Senior
Vice President of Product Development at BioVex. Dr.&nbsp;Love received a B.Sc. in Biochemistry and a Ph.D. in Biochemistry from Glasgow University. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Pamela Esposito</I></FONT><FONT SIZE=2> has served as our Chief Business Officer since November 2015. Previously, she was Chief Business Officer at Ra
Pharmaceuticals,&nbsp;Inc., or Ra, from 2013 to 2015. As a member of Ra's senior management team, Dr.&nbsp;Esposito played a leadership role in strategy, helping Ra transform from a discovery
platform to a clinical-stage company. Prior to Ra, from 2010 to 2011, she was Vice President of Business Development at BioVex. Dr.&nbsp;Esposito earned a Ph.D. in Pharmacology from Tufts University
School of Medicine in 2002 and a B.A. in Biochemistry/Molecular Biology from Dartmouth College. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Howard L. Kaufman</I></FONT><FONT SIZE=2> joined us as Chief Medical Officer in September 2017. He has been the Editor-In-Chief of the Journal of Targeted Therapies
in Cancer and a Senior Associate Editor at the Journal of Translational Medicine since 2007. Most recently, Dr.&nbsp;Kaufman was Associate Director for Clinical Science of the Rutgers Cancer
Institute of New Jersey from 2014 to 2017. He previously was a leading academic in the study of tumor immunotherapy and the optimization of viral vectors for the treatment of cancer from 1997 to 2017.
He was President of the Society for Immunotherapy of Cancer from 2014 to 2016. He previously was the Cancer Center Director and Associate Dean of Rush University Medical Center from 2009 to 2013.
Dr.&nbsp;Kaufman has published over 400 peer-reviewed scientific papers, books, and review articles and serves on the editorial board of the Journal for Immunotherapy of Cancer. Dr.&nbsp;Kaufman
received his Medical Degree from Loyola University in 1986, completed General Surgery residency at Boston University and fellowship training in Tumor Immunology and Surgical Oncology at the National
Cancer institute. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Kapil Dhingra</I></FONT><FONT SIZE=2> has been a member of our board of directors since July 2017. Dr.&nbsp;Dhingra currently serves as the Managing Member of
KAPital Consulting,&nbsp;LLC, a healthcare consulting firm that he founded in 2008. Dr.&nbsp;Dhingra also currently serves on the boards of directors of Median Technologies&nbsp;Inc., Five Prime
Therapeutics&nbsp;Inc., and Autolus Therapeutics plc, a Nasdaq-listed biopharmaceutical company. Dr.&nbsp;Dhingra previously served as a member of the board of directors of Micromet,&nbsp;Inc.,
until its acquisition by Amgen, and YM Biosciences&nbsp;Inc., until its acquisition by Gilead Sciences,&nbsp;Inc. From 1999 to 2008, Dr.&nbsp;Dhingra worked
at Roche where he served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. From 2000 to 2008, he held a Clinical Affiliate appointment
at Memorial Sloan Kettering Cancer Center. From 1996 to 1999, Dr.&nbsp;Dhingra worked at Eli Lilly&nbsp;&amp;&nbsp;Co., or Eli Lilly, where he served as Senior Clinical Research Physician.
Dr.&nbsp;Dhingra also served as a Clinical Associate Professor of Medicine at the Indiana University School of Medicine from 1997 to 1999. Prior to Eli Lilly, Dr.&nbsp;Dhingra was a member of the
faculty of M.D. Anderson Cancer Center from 1989 to 1996. Dr.&nbsp;Dhingra received his M.B.B.S. from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in
Internal Medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in Hematology and Oncology at Emory University School of Medicine.
Dr.&nbsp;Dhingra is qualified to serve on our board of directors due to his significant experience as a healthcare consultant and as a senior officer of Roche and Eli Lilly. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=146,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=416970,FOLIO='144',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_145"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Hyam Levitsky</I></FONT><FONT SIZE=2> has been a member of our board of directors since May 2018. Dr.&nbsp;Levitsky is currently an Adjunct Professor of Oncology,
Medicine, and Urology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD where he began as an Assistant Professor of Oncology in
1991, rose to be a Professor in 2002, and has been an Adjunct Professor since 2011. At Johns Hopkins, Dr.&nbsp;Levitsky served as Scientific Director of the George Santos Bone Marrow Transplant
Program from 2005 to 2011. He is a founding member of the Executive Council of the Cancer Immunotherapy Consortium of the Cancer Research Institute where he has served since 2005. Dr.&nbsp;Levitsky
is an active member of the American Association of Cancer Research and the American Society of Hematology, and advises the FDA on cancer immunotherapy issues. Previously, Dr.&nbsp;Levitsky served as
Executive Vice President and Chief Scientific Officer at Juno Therapeutics,&nbsp;Inc. from 2015 to 2018 and was Head of Cancer Immunotherapy Experimental Medicine at Roche from 2011 to 2015. He
served on the External Scientific Advisory Board of the Pasteur Institute's Center for Human Immunology from 2008 to 2010. Dr.&nbsp;Levitsky holds a number of honors including being named a Stohlman
Scholar by the Leukemia and Lymphoma Society in 2002, and was elected as a member of the American Society for Clinical Investigation in 2002. He was previously an Assistant Chief of Service from 1987
to 1988 and Senior Clinical Fellow from 1988 to 1991 at The Johns Hopkins Hospital and The Johns Hopkins Oncology Center, respectively. Dr.&nbsp;Levitsky received a B.S. from the University of
Pennsylvania School of Engineering and Applied Science in 1980 and an M.D. from The Johns Hopkins School of Medicine in 1984. Dr.&nbsp;Levitsky is qualified to serve on our board of directors
because of his experience in management roles at life sciences companies and extensive academic and professional background in the fields of oncology and immunology. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Mr. Jason Rhodes</I></FONT><FONT SIZE=2> has been a member of our board of directors since September 2015 and a Partner at Atlas Ventures since 2014. He has been a Founder and
Chairman of Generation Bio, Co. since 2016 and a Founder, Chairman and currently acting Chief Executive Officer of Disarm Therapeutics, Inc. since 2016. He has been a member of the board of directors
of Gemini Therapeutics, Inc. since 2016, Accent Therapeutics, Inc. since 2017, and Bicycle Therapeutics Limited since 2015. From 2010 to 2014, Mr. Rhodes was at Epizyme, Inc., where he most recently
served as President and Chief Financial Officer. He led business
development at Alnylam from 2007 to 2010. Mr.&nbsp;Rhodes obtained a B.A. from Yale University in 1991 and an M.B.A. from the Wharton School of the University of Pennsylvania in 1996.
Mr.&nbsp;Rhodes is qualified to serve on our board of directors based on his extensive leadership experience, his biotechnology company board experience and his experience investing in life science
companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Mr.&nbsp;Joseph Slattery</I></FONT><FONT SIZE=2> has been a member of our board of directors since October 2017. He has served as Executive Vice President and Chief Financial
Officer of TransEnterix,&nbsp;Inc. since 2013. From 2010 to 2013, Mr.&nbsp;Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical&nbsp;Inc. Previously, from
1996 to 2007, among other roles, he served as Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp., which was acquired by Qiagen,&nbsp;N.V.
Mr.&nbsp;Slattery has also been a member of the boards of directors of Exosome Diagnostics,&nbsp;Inc. since 2013, CVRx&nbsp;Inc. since 2008, and Micromet, Inc. from 2007 to 2012, when it was
acquired by Amgen. He earned his Bachelor's Degree in Accountancy from Bentley University in 1987 and is a certified public accountant. Mr.&nbsp;Slattery is qualified to serve on our board of
directors based on his experience in public accounting and financial expertise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Mr.&nbsp;Sander Slootweg</I></FONT><FONT SIZE=2> has been a member of our board of directors since 2015. Mr.&nbsp;Slootweg co-founded Forbion Capital Partners in 2006 and
has served as one of its Managing Partners since that time. Mr.&nbsp;Slootweg has served on the boards of Forbion's portfolio companies, NorthSea Therapeutics,&nbsp;Inc., since 2017, Oxyrane
Limited since 2011 and Xention Discovery&nbsp;Ltd. and Ario Pharma&nbsp;Ltd. since 2006. Mr.&nbsp;Slootweg served on the boards of uniQure N.V. from 2012 to 2014, Fovea Pharmaceutics&nbsp;S.A.
from </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=147,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=142027,FOLIO='145',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_146"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>2007
until its sale to Sanofi&nbsp;S.A. in 2009, Argenta Discovery&nbsp;Ltd. from 2001 until its sale to Galapagos&nbsp;N.V. in 2010, BioVex from 2003 until its sale to Amgen in 2011, Alantos
Pharmaceuticals,&nbsp;Inc. from 2005 to until its sale to Amgen in 2007, Impella Cardiosystems AG from 2001 to 2003 until its sale to Abiomed,&nbsp;Inc. in 2005, and Glycart AG from 2003 until its
sale to F. Hoffmann-La Roche&nbsp;&amp; Co., or Roche, in 2005. Mr.&nbsp;Slootweg has also acted as the Chairman of the Board of AMT&nbsp;N.V., Belgium from 2006 to 2012 and as the Chairman of the
Board of Dezima Pharma B.V. from 2012 until its sale to Amgen in 2015. Before co-founding Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences from 1999 to 2006.
Mr.&nbsp;Slootweg holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands. Mr.&nbsp;Slootweg
is qualified to serve on our board of directors because of his extensive leadership experience, his biotechnology company board experience and his experience investing in life science companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Dr.&nbsp;Otello Stampacchia</I></FONT><FONT SIZE=2> has been a member of our board of directors since May 2015. Since 2006, Dr.&nbsp;Stampacchia has been a managing member
at Omega Fund Management. Previously, Dr.&nbsp;Stampacchia was in charge of life sciences direct investments at AlpInvest Partners&nbsp;B.V. from 2001 to 2003. Before AlpInvest
Partners&nbsp;B.V., from 2000 to 2001, Dr.&nbsp;Stampacchia was the portfolio manager of the Lombard
Odier Immunology Fund. Previously, Dr.&nbsp;Stampacchia was a member of the healthcare corporate finance and mergers and acquisitions team at Goldman Sachs Group,&nbsp;Inc. from 1997 to 2000.
Before joining Goldman Sachs Group,&nbsp;Inc., Dr.&nbsp;Stampacchia helped co-found the healthcare investment activities at Index Securities, now Index Ventures,&nbsp;Inc. Dr.&nbsp;Stampacchia
is currently a member of the boards of directors of Median Technologies&nbsp;S.A., Trevi Therapeutics,&nbsp;Inc., and Gossamer Bio,&nbsp;Inc. and has served in such roles since 2014, 2017, and
2018, respectively. Dr.&nbsp;Stampacchia received a Ph.D. in Molecular Biology from the University of Geneva, Switzerland in 1997, and a Ph.D. in Biotechnology in 1998. Mr.&nbsp;Stampacchia is
qualified to serve on our board of directors because of his extensive leadership experience, his biotechnology company board experience and his experience investing in life science companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Mr.&nbsp;Dieter Weinand</I></FONT><FONT SIZE=2> has been a member of our board of directors since June 2018. Since 2014, Mr.&nbsp;Weinand has been President, Pharmaceutical
Division at Bayer AG. From 2013 to 2014 Mr.&nbsp;Weinand was President, Global Commercialization at Otsuka Pharmaceutical&nbsp;Co.,&nbsp;Ltd. and from 2010 to 2013 Mr.&nbsp;Weinand was
President, Primary Care and Asia-Pacific Region at Pfizer&nbsp;Inc. From 2001 to 2010, Mr.&nbsp;Weinand served as President, Senior Vice President, and Vice President of BMS. Prior to joining BMS,
Mr.&nbsp;Weinand was Senior Vice President at F.H. Faulding,&nbsp;Inc. from 2000 to 2001, Managing Director, Director, Vice President, and Senior Director at Warner-Lambert Company, which was
acquired by Pfizer&nbsp;Inc. in 2000, during the period from 1994 to 2000, Vice President at Pharmos Corporation during 1994, and Director, Area Business Operations Coordinator, and International
Product Manager at Lederle International during the period from 1990 to 1994. Mr.&nbsp;Weinand has been a member the board of directors of Bayer AG since 2013 and was previously a member of the
board of directors of HealthPrize Technologies&nbsp;LLC from 2014 to 2018. Mr.&nbsp;Weinand received a M.S. in Pharmacology and Toxicology from Long Island University in 1987 and a B.A. from
Concordia College in 1982. Mr.&nbsp;Weinand is qualified to serve on our board of directors because of his extensive leadership experience, his biotechnology company board experience and his
experience in management roles at life sciences companies. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_composition_of_our_board_of_directors"> </A>
<A NAME="toc_di76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Composition of our board of directors    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors currently consists of nine directors, each of whom serves pursuant to the board composition provisions of our amended
and restated voting agreement which is described under "Certain relationships and related party transactions." These board composition provisions will terminate upon the completion of this offering.
Upon the termination of these provisions, there will be no further contractual </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=148,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=5463,FOLIO='146',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_147"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>obligations
regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the
qualifications and background of nominees, which may include diversity, which is not only limited to race, gender or national origin. We have no formal policy regarding board diversity. Our nominating
and corporate governance committee's and our board of directors' priority in selecting board members is identification of persons who will further the interests of our stockholders through their
established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive
landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier
of their resignation or removal. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors consists of nine members. Our board of directors has determined that Mr.&nbsp;Rhodes, Mr.&nbsp;Slootweg, Dr.&nbsp;Stampacchia, Dr.&nbsp;Dhingra, Mr.&nbsp;Slattery,
Mr.&nbsp;Weinand and Dr.&nbsp;Levitsky are independent, including for purposes of the rules of Nasdaq and relevant federal securities laws and regulations. Nasdaq independence definition includes
a series of objective tests, including that a director is not, and has not been for at least three years, one of our employees and that neither a director nor any of his family members has engaged in
various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships
exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations,
our board of directors reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us
and our management. There are no family relationships among any of our directors or executive officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated certificate of incorporation and amended and restated bylaws that will become effective immediately prior to the completion of this offering will provide that our board of
directors will be divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, with members of each class serving staggered three-year terms. Upon the completion of this offering,
the members of the classes will be divided as follows </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our Class&nbsp;I directors will be Mr.&nbsp;Astley-Sparke, Dr.&nbsp;Dhingra, and Mr.&nbsp;Slattery, and their terms will expire at the
annual meeting of stockholders to be held in 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our Class&nbsp;II directors will be Mr.&nbsp;Rhodes, Mr.&nbsp;Slootweg, and Dr.&nbsp;Stampacchia, and their terms will expire at the
annual meeting of stockholders to be held in 2020; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our Class&nbsp;III directors will be Dr.&nbsp;Coffin, Dr.&nbsp;Levitsky and Mr.&nbsp;Weinand, and their terms will expire at the annual
meeting of stockholders to be held in 2021. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which
their term expires. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_board_committees"> </A>
<A NAME="toc_di76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Board committees    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each
of which will operate pursuant to a charter adopted by our board of directors that became effective upon the effectiveness of the registration statement of which this prospectus is a part. The
composition and functioning of all of our committees is in compliance with all applicable requirements of the Sarbanes-Oxley Act, Nasdaq and the SEC rules and regulations. The initial </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=149,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=267908,FOLIO='147',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_148"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>composition
and responsibilities of each committee are described below. Members will serve on these committees until their resignation or until otherwise determined. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our audit committee provides oversight of our accounting and financial reporting process, the audit of our financial statements and our internal control
function. Among other matters, the audit committee is responsible for the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assisting the board of directors in oversight of the independent auditors' qualifications, independence and performance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the engagement, retention and compensation of the independent auditors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing the scope of the annual audit and reviewing and discussing with management and the independent auditors the results of the annual
audit and the review of our quarterly financial statements, including the disclosures in our annual and quarterly reports filed with the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing our risk assessment and risk management processes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing policies and procedures with respect to our related party transactions policy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conducting an annual self-evaluation process; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing procedures for receiving, retaining and investigating complaints received by us regarding accounting, internal accounting controls
or audit matters; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approving audit and permissible non-audit services provided by our independent auditor. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
members of our audit committee are Kapil Dhingra, Sander Slootweg and Joseph Slattery, who serves as the chair of the committee. All members of our audit committee meet the requirements for
financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Joseph Slattery is an audit committee financial expert as defined under
the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. Dr.&nbsp;Dhingra and Mr.&nbsp;Slattery, members of
our audit committee, are independent directors as defined under the applicable rules and regulations of the SEC and Nasdaq. Within twelve months of the completion of this offering, we expect
Mr.&nbsp;Weinand to replace Mr.&nbsp;Slootweg as a member of the audit committee, at which time all of the members of our audit committee will be independent directors as defined under the
applicable rules and regulations of the SEC and Nasdaq. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our compensation committee has adopted and currently administers the compensation policies, plans and benefit programs for our executive officers and all
other members of our executive team. Our compensation committee is also responsible for making recommendations regarding non-employee director compensation to the full board of directors. In addition,
among other things, our compensation committee will evaluate annually, in consultation with the board of directors, the performance of our chief executive officer, review and approve corporate goals
and objectives relevant to compensation of our chief executive officer and other executives and evaluate the performance of these executives in light of those goals and objectives. Our compensation
committee has adopted and currently administers our equity compensation plans. Jason Rhodes, Joseph Slattery and Kapil Dhingra serve on the compensation committee, which is </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=150,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=565883,FOLIO='148',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_149"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>chaired
by Kapil Dhingra. All of the members of our compensation committee are independent under the applicable rules and regulations of the SEC and Nasdaq. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and corporate governance committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our nominating and corporate governance committee is responsible for, among other things, making recommendations regarding corporate governance, the
composition of our board of directors, the identification, evaluation and nomination of director candidates and the structure and composition of committees of our board of directors. In addition, our
nominating and corporate governance committee oversees our corporate governance guidelines, approves our committee charters, oversees compliance with our code of business conduct and ethics and
contributes to succession planning. Jason Rhodes, Otello Stampacchia and Hyam Levitsky serve on the nominating and corporate governance committee, which is chaired by Jason Rhodes. All of the members
of our nominating and corporate governance committee are independent under the applicable rules and regulations of Nasdaq. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_compensation_committee__di702486"> </A>
<A NAME="toc_di76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Compensation committee interlocks and insider participation    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>None of the members of our compensation committee is or has at any time during the past year been one of our officers or employees. None of
our executive officers currently serves or in the past year has served as a member of our board of directors or compensation committee of any entity that has one or more executive officers serving on
our board of directors or compensation committee. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_board_observer_rights"> </A>
<A NAME="toc_di76701_6"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Board observer rights    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a party to an amended and restated investors' rights agreement with certain of our investors. Under this agreement, Bain Capital Life
Science Fund,&nbsp;L.P. has the right to appoint one person to attend board and committee meetings from time to time in a nonvoting observer capacity. Certain provisions of the amended and restated
investors' rights agreement, including the board observer right described above, will terminate immediately prior to the completion of the offering. See "Certain relationships and related party
transactions" for further information concerning the amended and restated investors' rights agreement. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_role_of_the_board_in_risk_oversight"> </A>
<A NAME="toc_di76701_7"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Role of the board in risk oversight    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks,
including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property, in each case as more fully discussed under
"Risk factors" in this prospectus. Management is responsible for the day-to-day management of the risks we face, while our board of directors, as a whole and through committees, has responsibility for
the oversight of risk management. Our board of directors performs this oversight role by using several different levels of review. In connection with its reviews of the operations and corporate
functions of our company, our board of directors addresses the primary risks associated with those operations and corporate functions. In addition, our board of directors reviews the risks associated
with our company's business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Astley-Sparke
serves as executive chairman of our board of directors. The role of the board of directors in overseeing the management of our risks is conducted primarily through committees
of the board of directors, as disclosed in the descriptions of each of the committees above and in the charters of each such committee. The full board of directors (or the appropriate board committee
in the case of risks </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=151,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=127190,FOLIO='149',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<A NAME="page_di76701_1_150"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>that
are under the purview of a particular committee) discusses with management our major risk exposures, the potential impact on us, and the steps we take to manage them. When a board committee is
responsible for evaluating and overseeing the management of a particular risk or risks, the chairperson of the relevant committee reports on the discussion to the full board of directors during the
committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="di76701_code_of_business_conduct_and_ethics"> </A>
<A NAME="toc_di76701_8"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Code of business conduct and ethics    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the Corporate Governance
section of our website, which is located at https://ir.replimune.com/corporate-governance/governance-documents. If we make any substantive amendments to, or grant any waivers from, the code of
business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K. We do not incorporate the
information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=152,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=66202,FOLIO='150',FILE='DISK114:[18ZBC1.18ZBC76701]DI76701A.;73',USER='CHE109864',CD='23-JUL-2018;07:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dk76701_1_151"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dk76701_executive_and_director_compensation"> </A>
<A NAME="toc_dk76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive and director compensation    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The compensation of our chief executive officer and our other executive officers identified in the summary compensation table below, who we
refer to as the named executive officers, has consisted of a combination of base salary, bonuses and long-term incentive compensation in the form of stock options. In preparing to become a public
company, we have begun a thorough review of all elements of the compensation of our executives, including our compensation philosophy and the function and design of our long-term incentive
compensation programs. We have begun and expect to continue to evaluate the existing executive compensation program to ensure our program is competitive with the companies with which we compete for
executive talent and is appropriate for a public company. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dk76701_summary_compensation_table"> </A>
<A NAME="toc_dk76701_2"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Summary compensation table    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table presents compensation awarded, paid to or accrued for our named executive officers for services rendered during our fiscal
year 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name&nbsp;&amp; Principal Position</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Year</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Salary<BR>
($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Bonus<BR>
($)<SUP>(1)</SUP></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Option<BR>
awards<BR>
($)<SUP>(2)</SUP></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>All Other<BR>
compensation ($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total<BR>
($) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Robert Coffin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>389,478</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>146,817</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>592,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,128,295</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President, Chief Executive Officer and Director</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Colin Love, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>311,834</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>101,784</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>277,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>691,118</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Operating Officer</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pamela Esposito, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>264,633</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>86,815</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>249,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>601,198</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Business Officer</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Philip Astley-Sparke</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>254,687</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>83,765</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>166,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>504,952</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Executive Chairman, Secretary,</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Treasurer and Director</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The
amounts reported in this column represent bonuses based upon the achievement of company and individual performance objectives for the year ended March&nbsp;31, 2018, which we
paid in April 2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;The
amounts reported in this column reflect the full grant date fair value for awards granted during fiscal year 2018. The grant date fair value was computed in accordance with
Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation. The assumptions we used in valuing options are described in Note&nbsp;10 to our audited consolidated
financial statements appearing at the end of this prospectus.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Amounts
presented for Dr.&nbsp;Love are based on an assumed conversion ratio of British pounds to dollars of 1.4015, which was the exchange rate in effect as of March&nbsp;31,
2018. </FONT></P>
 </DIV>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dk76701_narrative_disclosure_to_summary_compensation_table"> </A>
<A NAME="toc_dk76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Narrative disclosure to summary compensation table    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment arrangements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Set forth below are descriptions of the employment agreements that we have entered into with each of our named executive officers, including descriptions of
our named executive officers' base salary, target annual bonus opportunity and standard benefit plan participation. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Robert Coffin  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Effective as of October&nbsp;1, 2015, Replimune,&nbsp;Inc. entered into an employment agreement with Dr.&nbsp;Coffin for the position of Chief Executive
Officer of Replimune. Dr.&nbsp;Coffin currently receives an annual base salary of approximately $500,000. In addition, pursuant to his employment agreement, Dr.&nbsp;Coffin is eligible for annual
performance bonuses. Dr.&nbsp;Coffin's annual target bonus is currently up to 50% of his annual base </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=153,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=903524,FOLIO='151',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_152"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>salary.
Dr.&nbsp;Coffin is eligible to participate in our employee benefit plans, practices and programs on a basis which is no less favorable than is provided to our other similarly situated
executives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Coffin's
employment agreement further provides that in the event his employment is terminated without "cause," as defined in his employment agreement, or he terminates his employment for
"good reason," as defined in his employment agreement, and subject to customary conditions, including his execution of an acceptable release, Dr.&nbsp;Coffin is entitled to receive 12&nbsp;months
of base salary and monthly cash payments equal to the costs of COBRA health continuation for the earlier of six months or until Dr.&nbsp;Coffin becomes eligible under another employer's group
coverage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, in the event of a change in control of our business, if, within 24&nbsp;months following such change of control, Dr.&nbsp;Coffin is terminated without "cause" or he has terminated his
employment for "good reason," Dr.&nbsp;Coffin will be entitled to receive any accrued but unpaid compensation, together with a lump sum payment equal to the sum of Dr.&nbsp;Coffin's then current
base salary or, if greater, the base salary for the year immediately preceding, subject to customary conditions, including his execution of an acceptable release. If an excise tax under
Section&nbsp;4999 of the Code is imposed on the payments and benefits payable to Dr.&nbsp;Coffin in connection with a change in control, Dr.&nbsp;Coffin will be entitled to a tax gross-up
payment for such excise taxes. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Colin Love  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Effective as of September&nbsp;16, 2015, Replimune Limited entered into an employment agreement with Dr.&nbsp;Love for the position of Chief Operating
Officer of Replimune. Dr.&nbsp;Love currently receives an annual base salary of approximately $335,000. In addition, pursuant to his employment agreement, Dr.&nbsp;Love is eligible for annual
performance bonuses. Dr.&nbsp;Love's annual target bonus is currently up to 35% of his annual base salary. Dr.&nbsp;Love is eligible to participate in our employee benefit plans, practices and
programs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Love's
employment agreement further provides that in the event he is terminated, Dr.&nbsp;Love may be entitled to receive payment in lieu of receiving six months' notice of termination in
an amount equal to his basic annual salary, as at the date of termination, which he would have been entitled to receive during the six month notice period less income tax and National Insurance
contributions, and subject to customary conditions, the "payment in lieu". </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Love's
employment agreement further provides that in the event his employment is terminated without "cause," as defined in his employment agreement, or he terminates his employment for
"good reason," as defined in his employment agreement, Dr.&nbsp;Love is entitled to be paid a sum equal to twelve months of his "fixed annual salary," as defined in his employment agreement, less
any "payment in lieu," payable in twelve equal monthly installments following his termination. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, in the event of a change in control of our business, if, within twenty-four months following such change in control, Dr.&nbsp;Love is terminated without "cause" or he has terminated his
employment for "good reason," Dr.&nbsp;Love will be entitled to receive a sum equal to twelve months of his "fixed annual salary," less any "payment in lieu," payable within thirty days following
his termination. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pamela Esposito  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Effective as of November&nbsp;1, 2015, Replimune,&nbsp;Inc. entered into an employment agreement with Dr.&nbsp;Esposito for the position of Chief
Business Officer of Replimune. Dr.&nbsp;Esposito currently receives an annual base salary of approximately $350,000. In addition, pursuant to her employment agreement, Dr.&nbsp;Esposito is
eligible for annual performance bonuses. Dr.&nbsp;Esposito's annual target bonus is currently up to 35% of her </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=154,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=29545,FOLIO='152',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_153"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>annual
base salary. Dr.&nbsp;Esposito is eligible to participate in our employee benefit plans, practices and programs on a basis which is no less favorable than is provided to our other similarly
situated executives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Esposito's
employment agreement further provides that in the event her employment is terminated without "cause," as defined in her employment agreement, or she terminates her employment for
"good reason," as defined in her employment agreement, and subject to customary conditions, including her execution of an acceptable release, Dr.&nbsp;Esposito is entitled to receive six months of
base salary and monthly cash payments equal to the costs of COBRA health continuation for the earlier of six months or until Dr.&nbsp;Esposito becomes eligible under another employer's group
coverage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, in the event of a change in control of our business, if, within twenty-four months following such change of control, Dr.&nbsp;Esposito is terminated without "cause" or she has
terminated her employment for "good reason," Dr.&nbsp;Esposito will be entitled to receive any accrued but unpaid compensation, together with a lump sum payment equal to the sum of the
Dr.&nbsp;Esposito's then current base salary or, if greater, the base salary for the year immediately preceding, and one hundred percent of her annual bonus, subject to customary conditions,
including her execution of an acceptable release. If an excise tax under Section&nbsp;4999 of the Code is imposed on the payments and benefits payable to Dr.&nbsp;Esposito in connection with a
change in control, Dr.&nbsp;Esposito will be entitled to a tax gross-up payment for such excise taxes. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Philip Astley-Sparke  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Effective as of October&nbsp;1, 2015, Replimune,&nbsp;Inc. entered into an employment agreement with Mr.&nbsp;Astley-Sparke for the position of
Executive Chairman of Replimune. Mr.&nbsp;Astley-Sparke currently spends 80% of his time working for Replimune and receives an annual base salary of approximately $400,000. In addition, pursuant to
his employment agreement, Mr.&nbsp;Astley-Sparke is eligible for annual performance bonuses. Mr.&nbsp;Astley-Sparke's annual target bonus is currently up to 50% of his annual base salary.
Mr.&nbsp;Astley-Sparke is eligible to participate in our employee benefit plans, practices and programs on a basis which is no less favorable than is provided to our other similarly situated
executives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Astley-Sparke's
employment agreement further provides that in the event his employment is terminated without "cause," as defined in his employment agreement, or he terminates his employment
for "good reason," as defined in his employment agreement, and subject to customary conditions, including his execution of an acceptable release, Mr.&nbsp;Astley-Sparke is entitled to receive
12&nbsp;months of base salary and monthly cash payments equal to the costs of COBRA health continuation for the earlier of six months or until Mr.&nbsp;Astley-Sparke becomes eligible under another
employer's group coverage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, in the event of a change in control of our business, if, within 24&nbsp;months following such change of control, Mr.&nbsp;Astley-Sparke is terminated without "cause" or he has
terminated his employment for "good reason," Mr.&nbsp;Astley-Sparke will be entitled to receive any accrued but unpaid compensation, together with a lump sum payment equal to the sum of
Mr.&nbsp;Astley-Sparke's then current base salary or, if greater, the base salary for the year immediately preceding, subject to customary conditions, including his execution of an acceptable
release. If an excise tax under Section&nbsp;4999 of the Code is imposed on the payments and benefits payable to Mr.&nbsp;Astley-Sparke in connection with a change in control, Mr. Astley-Sparke
will be entitled to a tax gross-up payment for such excise taxes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to their employment agreements, our named executive officers are subject to standard covenants of confidentiality and nondisclosure, assignment of intellectual property work product and
post-termination noncompetition and non-solicitation of employees, consultants and customers. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=155,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=267687,FOLIO='153',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_154"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bonuses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash incentives, which are designed to motivate
our executives to achieve defined annual corporate goals and to reward our executives for their contributions towards the achievement of these goals. The annual performance-based incentive each named
executive officer was eligible to receive in fiscal year 2018 was generally based on the extent to which the officer achieved the corporate goals and individual objectives that our board of directors
established at the beginning of fiscal year 2018. After the end of fiscal year 2018, our board of directors reviewed performance against each goal and objective and determined the extent to which each
goal and objective was achieved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
our fiscal year 2018, Dr.&nbsp;Coffin was eligible to receive a target bonus of up to 40% of his base salary, while each of Dr.&nbsp;Love, Dr.&nbsp;Esposito and Mr.&nbsp;Astley-Sparke was
eligible to receive a target bonus of up to 35% of their respective base salary. Our board of directors reviewed the fiscal year 2018 corporate goals and the individual objectives of each named
executive officer and determined that on an overall basis, significant progress had been made towards achieving all of those goals. In recognition of these achievements and the efforts of each
executive, the committee awarded each of our named executive officers eligible for performance bonuses a portion of their target bonus opportunity for fiscal year 2018. For fiscal year 2018,
Dr.&nbsp;Coffin, Dr.&nbsp;Love, Dr.&nbsp;Esposito and Mr.&nbsp;Astley-Sparke were paid bonuses of $146,817, $101,784, $86,815 and $83,756, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pension benefits  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan during fiscal year 2017, other
than pursuant to the plans described under "&#151;Employee benefit and stock plans&#151;401(k) plan" or "&#151;Employee benefit and stock plans&#151;U.K. pension
contribution plan." </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-qualified deferred compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our named executive officers did not participate in, or earn any benefits under, a non-qualified deferred compensation plan during fiscal year 2017. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding equity awards at fiscal year end  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth information regarding outstanding equity awards held by our named executive officers as of March&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="106pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=10 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Option awards </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Stock awards </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options (#)<BR>
exercisable</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options (#)<BR>
unexercisable</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Option<BR>
exercise<BR>
price<BR>
($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Option<BR>
expiration<BR>
date</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
securities<BR>
that have<BR>
not vested</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Market<BR>
value of<BR>
securities<BR>
that have<BR>
not<BR>
vested</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Coffin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>318,299</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>July&nbsp;26, 2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Colin Love, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>149,203</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>July&nbsp;26, 2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pamela Esposito, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>124,332</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24,871</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.01</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>November&nbsp;1, 2025</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>102,168</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93,994</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.75</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>March&nbsp;1, 2026</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>134,281</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>July&nbsp;26, 2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Philip Astley-Sparke</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>89,521</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>July&nbsp;26, 2027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font>&nbsp;&nbsp;25%
of the shares underlying this stock option vest on July&nbsp;26, 2018 and the remainder of the shares underlying this stock option vest in 36 equal monthly
installments thereafter. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=156,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=631361,FOLIO='154',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_155"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font>&nbsp;&nbsp;The
shares underlying this stock option vest in two equal installments of 12,433 on June&nbsp;30, 2018 and September&nbsp;30, 2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font>&nbsp;&nbsp;The
shares underlying this stock option were granted under the Replimune Limited 2015 Enterprise Management Incentive Share Option Plan, or the 2015 Plan, which was
terminated in July 2017. Upon termination of the 2015 Plan, all awards issued thereunder were cancelled and replaced with awards issued under our 2017 Plan.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font>&nbsp;&nbsp;The
shares underlying this stock option vest in 23 equal monthly installments. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dk76701_employee_benefit_and_stock_plans"> </A>
<A NAME="toc_dk76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Employee benefit and stock plans    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Omnibus Incentive Compensation Plan  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose and types of grants  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The purpose of our 2018 Plan is to attract and retain employees, non-employee directors and consultants, and advisors. Our 2018 Plan provides for the issuance
of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Our 2018 Plan is intended to provide an incentive to
participants to contribute to our economic success by aligning the economic interests of participants with those of our stockholders. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our 2018 Plan will be administered by our compensation committee, and our compensation committee will determine all of the terms and conditions applicable to
grants under our 2018 Plan. Our compensation committee will also determine who will receive grants under our 2018 Plan and the number of shares of common stock that will be subject to grants. Our
compensation committee may delegate authority under the 2018 Plan to one or more subcommittees as it deems appropriate. Subject to compliance with applicable law and the applicable stock exchange
rules, our board of directors, in its discretion, may perform any action of our compensation committee under the 2018 Plan. Subject to compliance with applicable law and applicable stock exchange
requirements, the compensation committee
(or our board of directors or a subcommittee, as applicable) may delegate all or part of its authority to our chief executive officer, as it deems appropriate, with respect to grants to employees or
key advisors who are not executive officers or directors under Section&nbsp;16 of the Exchange Act. Our compensation committee, our board of directors, any subcommittee or the chief executive
officer, as applicable, that has authority with respect to a specific grant will be referred to as "the committee" in this description of the 2018 Plan. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shares subject to the plan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to adjustment as described below, the maximum aggregate number of shares of common stock that may be issued or transferred under the 2018 Plan is
3,617,968 shares, which is equal to the sum of (i)&nbsp;3,486,118 shares of our common stock, plus (ii)&nbsp;the number of shares of our common stock reserved for issuance under the 2017 Plan that
remain available as of the effective date of the 2018 Plan (not to exceed 131,850 shares of our common stock). If any options or stock appreciation rights, including outstanding options and stock
appreciation rights granted under our 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock
awards, stock units or other stock-based awards, including outstanding awards granted under our 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the
shares of our common stock subject to such grants will again be available for purposes of our 2018 Plan. In addition, as of the first trading day of each fiscal year during the term of the 2018 Plan
(excluding any extensions), an additional number of shares of our common stock equal to 4% of the total number of shares outstanding on the last trading day in the immediately preceding fiscal year
(or such lesser amount as determined by our board of directors) will be added to the number of shares authorized under the 2018 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=157,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=84960,FOLIO='155',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_156"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject
to adjustment as described below, the aggregate number of shares of common stock that may be issued or transferred under the 2018 Plan pursuant to incentive stock options will not exceed the
lesser of the maximum aggregate number of shares of common stock that may be issued or transferred under the Plan and 16,000,000 shares. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Shares
of our common stock that are surrendered in payment of the exercise price of an option or stock appreciation right will not be available for issuance under the 2018 Plan. Shares of our common
stock that are withheld in satisfaction of the withholding taxes, or surrendered for the payment of taxes, will not be available for issuance under the 2018 Plan. When stock appreciation rights are
granted, the full number of
shares subject to the stock appreciation rights will be considered issued under the 2018 Plan regardless of the number of shares issued upon exercise of the stock appreciation rights. If any grants
are paid in cash, and not in shares of our common stock, any shares of our common stock subject to such grants will also be available for future grants. If we repurchase shares of our common stock on
the open market with the proceeds from the exercise price we receive from options, the repurchased shares will not be available for issuance under the 2018 Plan. In addition, shares of our common
stock issued under grants made pursuant to assumption, substitution, or exchange of previously granted awards of a company that we acquire will not reduce the number of shares of our common stock
available under the 2018 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
maximum number of shares of our common stock that may be subject to options, stock appreciation rights, stock units and other stock-based awards made to employees, consultants and advisors under
the 2018 Plan in any calendar year will not exceed 1,562,352 shares of our common stock in the aggregate. The maximum aggregate grant date value of shares of common stock subject to grants made to any
non-employee member of our board of directors during any calendar year for services rendered as a non-employee member of our board, including any cash fees earned for services rendered as a
non-employee member of our board of directors during the calendar year, will not exceed $750,000 in total value. For grants that are made to any non-employee member of our board of directors for
services rendered as a non-employee member of our board of directors during the calendar year in which the non-employee member of the board of directors is first appointed to our board of directors,
such grants taken together with any cash fees earned for services rendered as a non-employee member of our board of directors will not exceed $1,000,000 in total value. In determining these dollar
limits, the value of grants will be calculated based on the grant date fair value of the grants for financial reporting purposes. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustments  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with stock splits, stock dividends, recapitalizations, and certain other events affecting our common stock, the committee will make adjustments
as it deems appropriate in the maximum number of shares of common stock reserved for issuance as grants; the maximum number and kind of shares for which any individual may receive grants in any year;
the number and kind of shares covered by outstanding grants; the number and kind of shares that may be issued or transferred under our 2018 Plan; the price per share or market value of any outstanding
grants; the exercise price of options; the base amount of stock appreciation rights; and the performance goals or other terms; and conditions as the committee deems appropriate. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All of our employees are eligible to receive grants under our 2018 Plan. In addition, our non-employee directors and key advisors who perform services for us
are also eligible to receive grants under our 2018 Plan. The committee selects the employees, non-employee directors and key advisors who will receive grants. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=158,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=408507,FOLIO='156',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_157"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vesting  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The committee determines the vesting and exercisability terms of awards granted under our 2018 Plan. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Options  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018 Plan, the committee will determine the exercise price of the options granted and may grant options to purchase shares of common stock in such
amounts as it determines. The committee may grant options that are intended to qualify as incentive stock options under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, or the
Code, or non-qualified stock options, which are not intended to so qualify. Incentive stock options may only be granted to our employees. Anyone eligible to participate in our 2018 Plan may receive a
grant of non-qualified stock options. The exercise price of a stock option granted under our 2018 Plan cannot be less than the fair market value of a share of our common stock on the date the option
is granted. If an incentive stock option is granted to a 10% stockholder, the exercise price cannot be less than 110% of the fair market value of a share of our common stock on the date the option is
granted. The aggregate number of shares of common stock that may be issued or transferred under the 2018 Plan pursuant to incentive stock options under Section&nbsp;422 of the Code may not exceed
3,617,968 shares of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
exercise price for any option is generally payable in cash or check. In certain circumstances as permitted by the committee, the exercise price may be paid by the surrender of shares of our common
stock with an aggregate fair market value on the date the option is exercised equal to the exercise price; by payment through a broker in accordance with procedures established by the Federal Reserve
Board; by withholding shares of common stock subject to the exercisable option which have a fair market value on the date of exercise equal to the aggregate exercise price; or by such other method as
the committee approves. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
term of an option cannot exceed ten years from the date of grant, except that if an incentive stock option is granted to a 10% stockholder, the term cannot exceed five years from the date of
grant. In the event that on the last day of the term of a non-qualified stock option, the exercise is prohibited by applicable law, including a prohibition on purchases or sales of our common stock
under our insider trading policy, the term of the non-qualified option will be extended for a period of 30&nbsp;days following the end of the legal prohibition, unless the committee determines
otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as provided in the grant instrument, an option may only be exercised while a participant is employed by or providing service to us. The committee will determine in the grant instrument under
what circumstances and during what time periods a participant may exercise an option after termination of employment. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock appreciation rights  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018 Plan, the committee may grant stock appreciation rights, which may be granted separately or in tandem with any option. Stock appreciation
rights granted with a non-qualified stock option may be granted either at the time the non-qualified stock option is granted or any time thereafter while the option remains outstanding. Stock
appreciation rights granted with an incentive stock option may be granted only at the time the grant of the incentive stock option is made. The committee will establish the base amount of the stock
appreciation right at the time the stock appreciation right is granted, which will be equal to or greater than the fair market value of a share of our common stock as of the date of grant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a stock appreciation right is granted in tandem with an option, the number of stock appreciation rights that are exercisable during a specified period will not exceed the number of shares of our
common stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=159,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=940042,FOLIO='157',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_158"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>that
the participant may purchase upon exercising the related option during such period. Upon exercising the related option, the related stock appreciation rights will terminate, and upon the exercise
of a stock appreciation right, the related option will terminate to the extent of an equal number of shares of our common stock. Generally, stock appreciation rights may only be exercised while the
participant is employed by, or providing services to, us. When a participant exercises a stock appreciation right, the participant will receive the excess of the fair market value of the underlying
common stock over the base amount of the stock appreciation right. The appreciation of a stock appreciation right will be paid in shares of our common stock, cash or both. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
term of a stock appreciation right cannot exceed ten years from the date of grant. In the event that on the last day of the term of a stock appreciation right, the exercise is prohibited by
applicable law, including a prohibition on purchases or sales of our common&nbsp;A stock under our insider trading policy, the term of the stock appreciation right will be extended for a period of
30&nbsp;days following the end of the legal prohibition, unless the committee determines otherwise. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock awards  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018 Plan, the committee may grant stock awards. A stock award is an award of our common stock that may be subject to restrictions as the committee
determines. The restrictions, if any, may lapse over a specified period of employment or based on the satisfaction of pre-established criteria, in installments or otherwise, as the committee may
determine. Except to the extent restricted under the grant instrument relating to the stock award, a participant will have all of the rights of a stockholder as to those shares, including the right to
vote and the right to receive dividends or distributions on the shares. Dividends with respect to stock awards that vest based on performance shall vest if and to the extent that the underlying stock
award vests, as determined by the committee. All unvested stock awards are forfeited if the participant's employment or service is terminated for any reason, unless the committee determines otherwise. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock units  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018 Plan, the committee may grant restricted stock units to anyone eligible to participate in our 2018 Plan. Restricted stock units are phantom
units that represent shares of our common stock. Stock units become payable on terms and conditions determined by the committee and will be payable in cash or shares of our stock as determined by the
committee. All unvested restricted stock units are forfeited if the participant's employment or service is terminated for any reason, unless the committee determines otherwise. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other stock-based awards  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018 Plan, the committee may grant other types of awards that are based on, measured by, or payable to, anyone eligible to participate in our 2018
Plan in shares of our common stock. The committee will determine the terms and conditions of such awards. Other stock-based awards may be payable in cash, shares of our common stock, or a combination
of the two. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividend equivalents  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our 2018 Plan, the committee may grant dividend equivalents in connection with grants of stock units or other stock-based awards made under our 2018
Plan. Dividend equivalents entitle the participant to receive amounts equal to ordinary dividends that are paid on the shares underlying a grant while the grant is outstanding. The committee will
determine whether dividend equivalents will be paid currently or accrued as contingent cash obligations. Dividend equivalents may be paid in cash, in shares of common </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=160,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=504109,FOLIO='158',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dk76701_1_159"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stock,
or in a combination of the two. The committee will determine the terms and conditions of the dividend equivalent grants, including whether the grants are payable upon the achievement of
specific performance goals. Dividend equivalents with respect to stock units or other stock-based awards that vest based on performance shall vest and be paid only if and to the extent that the
underlying stock units or other stock-based awards vest and are paid as determined by the committee. No dividends or dividend equivalents will be granted in connection with stock options or stock
appreciation rights. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change of control  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we experience a change of control where we are not the surviving corporation (or survive only as a subsidiary of another corporation), all outstanding
grants that are not exercised or paid at the time of the change of control will be assumed by, or replaced with grants that have comparable terms by, the surviving corporation (or a parent or
subsidiary of the surviving corporation). If the surviving corporation does not assume or replace the outstanding grants with grants that have comparable terms, outstanding stock options and stock
appreciation rights will automatically accelerate and become fully exercisable and the restrictions and conditions on outstanding stock awards, stock units, other stock-based awards and dividend
equivalents will immediately lapse. However, if the vesting of such grants is based on performance (in whole or in part), the vesting terms applicable to such grants will be determined under the
applicable grant instrument. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the outstanding grants are assumed, or replaced with grants that have comparable terms by, the surviving corporation (or parent or subsidiary of the surviving corporation) and if the participant's
employment or service is terminated without cause or by the participant for good reason (if applicable) upon or within 12&nbsp;months following the change of control, the participant's outstanding
grants shall become fully vested as of the date of such termination; provided that if the vesting of any such grants is based on performance (in whole or in part), the vesting terms applicable to such
grants will be determined under the applicable grant instrument. The committee may provide for more beneficial vesting terms upon a termination of employment or service in connection with the change
of control, as set forth in the applicable grant instrument or otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
there is a change of control and all outstanding grants are not assumed by, or replaced with grants that have comparable terms by, the surviving corporation, the committee may take any of the
following action without the consent of any participant:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pay participants, in an amount and form determined by the committee, in settlement of outstanding stock units, other stock based awards, cash
awards, or dividend equivalents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require that participants surrender their outstanding stock options, stock appreciation rights or any other exercisable grant, in exchange for
a payment by us, in cash or shares of our common stock, equal to the difference between the exercise price and the fair market value of the underlying shares of common stock; provided, however, if the
per share fair market value of the common stock does not exceed the per share stock option exercise price or stock appreciation right base amount, as applicable, we will not be required to make any
payment to the participant upon surrender of the stock option or stock appreciation right; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> after giving participants an opportunity to exercise all of their outstanding stock options and stock appreciation rights, terminate any
unexercised stock options and stock appreciation rights on the date determined by our compensation committee. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=161,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=595381,FOLIO='159',FILE='DISK114:[18ZBC1.18ZBC76701]DK76701A.;90',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dm76701_1_160"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general terms, a change of control under our 2018 Plan occurs if:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a person, entity or affiliated group, with certain exceptions, acquires more than 50% of our then outstanding voting securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we merge into another entity unless the holders of our voting shares immediately prior to the merger have at least 50% of the combined voting
power of the securities in the merged entity or its parent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we merge into another entity and the members of the board of directors prior to the merger would not constitute a majority of the board of the
merged entity or its parent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we sell or dispose of all or substantially all of our assets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our complete liquidation or dissolution; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a majority of the members of our board of directors is replaced during any 12-month period by directors whose appointment or election is not
endorsed by a majority of the incumbent directors. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferrals  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The committee may permit or require participants to defer receipt of the payment of cash or the delivery of shares of common stock that would otherwise be due
to the participant in connection with a grant under our 2018 Plan. The committee will establish the rules and procedures applicable to any such deferrals, consistent with the requirements of
Section&nbsp;409A of the Code. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Withholding  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All grants under the 2018 Plan are subject to applicable U.S. federal, including Federal Insurance Contributions Act, or FICA, state and local, foreign, or
other tax withholding requirements. We may require participants or other persons receiving grants or exercising grants to pay an amount sufficient to satisfy such tax withholding requirements with
respect to such grants, or we may deduct from other wages and compensation paid by us the amount of any withholding taxes due with respect to such grant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
committee may permit or require that our tax withholding obligation with respect to grants paid in our common stock to be paid by having shares withheld up to an amount that does not exceed the
participant's minimum applicable withholding tax rate for United States federal, including FICA, state and local tax liabilities, or as otherwise determined by the committee. In addition, the
committee may, in its discretion, and subject to such rules as the committee may adopt, allow participants to elect to have such share withholding applied to all or a portion of the tax withholding
obligation arising in connection with any particular grant. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transferability  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except as permitted by the committee with respect to non-qualified stock options, only a participant may exercise rights under a grant during the
participant's lifetime. Upon death, the personal representative or other person entitled to succeed to the rights of the participant may exercise such rights. A participant cannot transfer those
rights except by will or by the laws of descent and distribution or, with respect to grants other than incentive stock options, pursuant to a domestic relations order. The committee may provide in a
grant instrument that a participant may transfer non-qualified stock options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with
applicable securities laws. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=162,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=760687,FOLIO='160',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_161"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment; termination  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors may amend or terminate our 2018 Plan at any time, except that our stockholders must approve an amendment if such approval is required
in order to comply with the Code, applicable laws, or applicable stock exchange requirements. Unless terminated sooner by our board of directors or extended with stockholder approval, our 2018 Plan
will terminate on the day immediately preceding the tenth anniversary of the effective date of the 2018 Plan. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Establishment of sub-plans  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors may, from time to time, establish one or more sub-plans under the 2018 Plan to satisfy applicable blue sky, securities, or tax laws of
various jurisdictions. Our board of directors may establish such sub-plans by adopting supplements to the 2018 Plan setting forth limitations on the committee's discretion and such additional terms
and conditions not otherwise inconsistent with the 2018 Plan as our board of directors will deem necessary or desirable. All such supplements will be deemed part of the 2018 Plan, but each supplement
will only apply to participants within the affected jurisdiction. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to applicable law, the committee may provide in any grant instrument that if a participant breaches any restrictive covenant agreement between the
participant and us, or otherwise engages in activities that constitute cause (as defined in our 2018 Plan) either while employed by, or providing services to, us or within a specified period of time
thereafter, all grants held by the participant will terminate, and we may rescind any exercise of an option or stock appreciation right and the vesting of any other grant and delivery of shares upon
such exercise or vesting, as applicable on such terms as the committee will determine, including the right to require that in the event of any rescission:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the participant must return the shares received upon the exercise of any option or stock appreciation right or the vesting and payment of any
other grants; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if the participant no longer owns the shares, the participant must pay to us the amount of any gain realized or payment received as a result of
any sale or other disposition of the shares (if the participant transferred the shares by gift or without consideration, then the fair market value of the shares on the date of the breach of the
restrictive covenant agreement or activity constituting cause), net of the price originally paid by the participant for the shares. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>The
committee may also provide for clawbacks pursuant to a clawback policy, which our board of directors may in the future adopt and amend from time to time. Payment by the participant will be made in
such manner and on such terms and conditions as may be required by the committee. We will be entitled to set off against the amount of any such payment any amounts that we otherwise owe to the
participant. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Equity Compensation Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our 2017 Plan, was adopted by our board of directors in July 2017, approved by our stockholders in July 2017 and became effective at that time. Our 2017 Plan
will be replaced by our 2018 Plan as our board of directors has determined not to make additional awards under the 2017 Plan following the completion of our initial public offering. However,
outstanding grants under our 2017 Plan will continue in effect according to their terms, consistent with our 2017 Plan. Our 2017 Plan allows our board of directors or the compensation committee
consisting of members thereof to: (i)&nbsp;determine the individuals to whom grants will be made under the 2017 Plan, (ii)&nbsp;determine the type, size and terms of the grants to be made to each
such individual, (iii)&nbsp;determine the time when the grants will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the
acceleration of exercisability, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=163,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=646622,FOLIO='161',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_162"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(iv)&nbsp;amend
the terms of any grant previously made under the 2017 Plan and (v)&nbsp;deal with any other matters arising under the 2017 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
had reserved 2,659,885 shares of our common stock for the issuance of awards under our 2017 Plan, 2,502,530 shares of which are subject to outstanding equity awards as of July&nbsp;9, 2018. Upon
the adoption of our 2018 Plan, any reserved shares that are not subject to outstanding equity awards under the 2017 Plan will be added to the shares of common stock available for issuance under our
2018 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to
determine the specific terms and conditions of each award, subject to the provisions of our 2017 Plan. Persons eligible to participate in our 2017 Plan will be those full or part-time officers,
employees, non-employee directors, and other key persons, including consultants, as selected from time to time by the committee in its discretion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
2017 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The
option exercise price of each option will be determined by the committee but may not be less than 100% of the fair market value of our common stock on the date of grant. The term of each option will
be fixed by the committee and may not exceed ten years from the date of grant. The committee will determine at what time or times each option may be exercised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
committee may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock equal to
the value of the appreciation in our stock price over the exercise price. The exercise price may not be less than 100% of the fair market value of our common stock on the date of grant. The term of
each stock appreciation right will be fixed by the committee and may not exceed ten years from the date of grant. The committee will determine at what time or times each stock appreciation right may
be exercised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
committee may award other equity-based awards of common stock to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the
achievement of certain performance goals and/or other conditions. In the case of equity-based awards other than stock awards, awards may be payable in cash, our capital stock or any combination of the
foregoing, as the committee may determine. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
2017 Plan provides that in the event of a "Change in Control," as defined in our 2017 Plan, the committee may provide that (i)&nbsp;(x) all outstanding options and SARs will accelerate and
become fully exercisable and (y)&nbsp;all outstanding stock awards, stock units and other equity awards will become fully vested and will be payable on terms determined by the committee,
(ii)&nbsp;determine that all outstanding options and SARs that are not exercised will be assumed by, or replaced with comparable options by the surviving corporation, or a parent or subsidiary of
the surviving corporation, and other outstanding grants that remain in effect after the Change of Control will be converted to similar grants of the surviving
corporation, or a parent or subsidiary of the surviving corporation, (iii)&nbsp;require that grantees surrender their outstanding options and SARs, in whole or in part, in exchange for one or more
payments, in cash or our capital stock as determined by the committee, in an amount, if any, equal to the amount by which the then fair market value of the shares of our capital stock subject to the
grantee's unexercised options and SARs exceeds the exercise price or base amount of the options and SARs, on such terms as the committee determines or (iv)&nbsp;after giving grantees an opportunity
to exercise their outstanding options and SARs, in whole or in part, terminate any or all unexercised options and SARs at such time as the committee deems appropriate. Such assumption, surrender or
termination will take place as of the date of the Change of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=164,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=724315,FOLIO='162',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_163"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Control
or such other date as the committee may specify. Without limiting the foregoing, if the per share fair market value of our capital stock equals or is less than the per share exercise price or
base amount, as applicable, we would not be required to make any payment to the grantee upon surrender of the option or SAR. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
"Change of Control" under the 2017 Plan is defined as the occurrence of any of the following: (1)&nbsp;any person becoming a beneficial owner of our securities representing more than fifty percent
of the voting power of our existing voting securities, subject to certain carve-outs, including a qualified initial public offering, or (2)&nbsp;the consummation of a merger or consolidation of the
Company with another corporation, a sale of all or substantially all of our assets, or our liquidation or dissolution. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose and types of grants  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The purpose of our ESPP is to enable eligible employees to purchase shares of our common stock at a discount following the completion of this offering. Our
ESPP is intended to qualify as an employee stock purchase plan under Section&nbsp;423 of the Code. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A committee comprised of two or more members of our board of directors (referred to as "the plan administrator" in this description of our ESPP) will
administer our ESPP and have authority to authorize offerings under our ESPP that are intended to comply with foreign law, as applicable. We expect to appoint the compensation committee of our board
of directors as the plan administrator for our ESPP. The plan administrator has the authority to interpret and construe the provisions of our ESPP, and adopt rules and regulations for administering
our ESPP in compliance with Section&nbsp;423 of the Code, and its decisions are final and binding on all parties having an interest under our ESPP. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shares subject to our ESPP  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to adjustment as described below, the maximum aggregate number of shares of common stock that may be issued or transferred under our ESPP will
initially be limited to 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of our ESPP (excluding any extensions), an additional number of shares of our
common stock equal to 1% of the total number of shares outstanding on the last trading day in the immediately preceding fiscal year or 697,224 shares, whichever is less (or such lesser amount as
determined by our board of directors) will be added to the number of shares authorized under our ESPP. If the total number of shares of common stock to be purchased pursuant to outstanding purchase
rights on any particular date exceed the number of shares then available for issuance under our ESPP, then the plan administrator will allocate the available shares pro-rata and refund any excess
payroll deductions or other contributions to participants. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustments  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with stock splits, stock dividends, recapitalizations, and certain other events affecting our common stock, the plan administrator will make
adjustments as it deems appropriate in the maximum number and kind of shares of our common stock available for issuance under our ESPP, the maximum number of shares of our common stock available for
the annual increase in shares available for issuance under our ESPP, the maximum number and kind of shares of common stock purchasable per participant on a purchase date during an offering period, the
number and kind of shares in effect under each outstanding purchase right, and the price per share in effect under each outstanding purchase right. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=165,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=577492,FOLIO='163',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_164"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our employees (and those of participating affiliates) who are regularly expected to work more than 20&nbsp;hours per week for more than five&nbsp;months
per calendar year are eligible to participate in our ESPP, unless otherwise mandated by local law. However, the plan administrator may waive one or both of these service requirements prior to the
start of the applicable offering period. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payroll deductions  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under our ESPP, eligible employees will be able to acquire shares of our common stock by accumulating funds through payroll deductions or other contributions,
as determined by the plan administrator. Eligible employees will be able to select a rate of payroll deduction between 1% and 15% of their eligible compensation, unless the plan administrator
establishes a different maximum percentage prior to the start date of the applicable offering period. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Offering periods  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ESPP is implemented through a series of offering periods under which participating employees will automatically be granted a nontransferable purchase
right to purchase shares of our common stock in that offering period using their accumulated payroll deductions, or other contributions, if permitted by the plan administrator. Each offering period
will consist of one or more periods at the end of which shares will be purchased (each, a purchase interval). Each individual who is an eligible employee on the start date of an offering period under
our ESPP may enter that offering period on such start date or on the start date of any purchase interval within that offering period, provided he or she remains an eligible employee. Each individual
who first becomes an eligible employee after the start date of an offering period may enter that offering period on the start date of any purchase interval within that offering period on which he or
she is an eligible employee. We have not yet determined when or how long the first offering period will be. Purchase intervals will be successive six&nbsp;month periods within an offering period,
unless determined otherwise by the plan administrator prior to the start of the applicable offering period. In no event may an offering period exceed 27&nbsp;months. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination and suspension of participation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A participant may irrevocably and prospectively withdraw from an offering period prior to the next scheduled purchase date in that offering period, and may
elect to have any payroll deductions or other contributions collected during the purchase interval refunded or held for the purchase of shares on the next purchase date. To resume participation in any
subsequent offering period, such individual must re-enroll in the ESPP. A participant's payroll deductions and other contributions will automatically be suspended while on an approved unpaid leave of
absence and will terminate if the leave exceeds the longer of three months or the period that the participant has continued re-employment rights under law or contract. A participant's payroll
deductions and other contributions will automatically be suspended when any limitations described below are reached. A participant's participation in an offering period automatically ends when he or
she ceases to be an eligible employee, including due to termination of employment for any reason. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on purchase  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to the start date of the applicable offering period, and subject to the limitations described below and the adjustments described above, the plan
administrator will determine the maximum number of shares of our common stock that a participant can purchase, each purchase date within that offering period and the maximum number of shares of our
common stock that each participant can purchase for that offering period. Each purchase right will be automatically exercised in installments on each successive purchase </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=166,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=433520,FOLIO='164',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_165"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>date
within the offering period to purchase shares of common stock on behalf of each participant, other than participants whose payroll deductions have previously been refunded pursuant to the
termination of purchase right provisions described above, on each such purchase date. Under no circumstances will purchase rights be granted under our ESPP to any eligible employee who would,
immediately after the grant, own or hold outstanding options or other rights to purchase stock possessing 5% or more of the total combined voting power or value of all classes of our stock or that of
any parent corporation or subsidiary corporation within the meaning of Section&nbsp;424 of the Code. Prior to the start of any offering period and subject to any adjustments described above, the
plan administrator will determine the maximum number of shares purchasable in total by all participants on a purchase date within an offering period and the maximum number of shares purchasable in
total by all participants for that offering period. The foregoing limitations shall apply for each subsequent offering period, unless otherwise determined by the plan administrator prior to the start
of any offering period. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrual limitations  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No participant will have the right to purchase shares of our common stock in an amount that, when aggregated with the shares subject to purchase rights under
all our employee stock purchase plans that are also in effect in the same calendar year, have a fair market value of more than $25,000, determined as of the first day of the applicable offering
period. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purchase price  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The purchase price for shares of our common stock purchased under our ESPP will be established by the plan administrator prior to the start of the offering
period, but will not be less than 85% of the lower of the fair market value of our common stock on (i)&nbsp;the date the eligible employee enters an offering period and (ii)&nbsp;the purchase
date. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change of control  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we experience a change of control, each outstanding purchase right will automatically be exercised, immediately prior to the effective date of the change
of control. However, the applicable limitation on the number of shares of common stock purchasable per participant will continue to apply to any such purchase, but not the limitation applicable to the
maximum number of shares of common stock purchasable in total by all participants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
general terms, a change of control under our ESPP occurs if:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any person, entity or affiliated group, with certain exceptions, acquires more than 50% of our then outstanding voting securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we merge into another entity unless the holders of our voting shares immediately prior to the merger have at least 50% of the combined voting
power of the securities in the merged entity or its parent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we merge into another entity and the members of the board of directors prior to the merger would not constitute a majority of the board of the
merged entity or its parent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we sell or dispose of all or substantially all of our assets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our complete liquidation or dissolution; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a majority of the members of our board of directors is replaced during any 12-month period by directors whose appointment or election is not
endorsed by a majority of the incumbent directors. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=167,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=16277,FOLIO='165',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_166"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment; termination  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors may amend, effective as of the start date of the next offering period, our ESPP at any time, except that our stockholders must approve
an amendment if such approval is required to comply with Section&nbsp;423 of the Code or other applicable law. Our board of directors may terminate our ESPP, effective following the close of the
purchase interval, at any time. Unless terminated sooner by our board of directors, our ESPP will terminate on the earliest of: (1)&nbsp;the day immediately preceding the tenth anniversary of the
effective date of our ESPP; (2)&nbsp;the date on which all shares available for issuance under our ESPP have been sold under our ESPP; or (3)&nbsp;the date on which all purchase rights under our
ESPP are exercised in connection with a change of control. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We participate in a tax-qualified retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis.
Eligible employees are able to defer eligible compensation up to certain Code limits, which are updated annually. We provide matching contributions up to 50% of actual dollars contributed, not to
exceed a maximum of 6% of gross wages. Employee contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the
participants' directions. Employees are immediately and fully vested in their own contributions, but any contributions we make vest equally over the first five years of service. After five years of
service, contributions we make vest 100%. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code, with the related trust intended to be tax exempt under
Section&nbsp;501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are not taxable
to the employees until withdrawn or distributed from the 401(k) plan. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.K. pension contribution plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We provide a pension contribution plan for our employees in the United Kingdom, pursuant to which we match our employees' contributions each year in amounts
up to 8% of their annual base salary. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on liability and indemnification matters  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;145 of the DGCL authorizes a corporation's board of directors to grant, and authorizes a court to award, indemnity to officers, directors and
other corporate agents. As permitted by Delaware law, our amended and restated certificate of incorporation as currently in effect provides that, to the fullest extent permitted by Delaware law, no
director will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Pursuant to Delaware law, such protection would be not available for
liability:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for any breach of a duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for any transaction from which the director derived an improper benefit; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for an act or omission for which the liability of a director is expressly provided by an applicable statute, including unlawful payments of
dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the DGCL. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated certificate of incorporation as currently in effect also provides that if Delaware law is amended after the approval by our stockholders of the amended and restated
certificate of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=168,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=979652,FOLIO='166',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_167"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>incorporation
to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent
permitted by Delaware law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated bylaws as currently in effect further provide that we must indemnify our directors and officers to the fullest extent permitted by Delaware law. Our amended and restated
bylaws as currently in effect also authorize us to indemnify any of our employees or agents and permit us to
secure insurance on behalf of any officer, director, employee or agent for any liability arising out of their action in that capacity, whether or not Delaware law would otherwise permit
indemnification. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our amended and restated bylaws as currently in effect provide that we are required to advance expenses to our directors and officers as incurred in connection with legal proceedings
against them for which they may be indemnified and that the rights conferred in the amended and restated bylaws are not exclusive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, would require us to indemnify each director and officer to the
fullest extent permitted by Delaware law, the amended and restated certificate of incorporation and amended and restated bylaws, for expenses such as, among other things, attorneys' fees, judgments,
fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action by or in our right, arising out of the person's services as our director or
executive officer or as the director or executive officer of any subsidiary of ours or any other company or enterprise to which the person provides services at our request. Upon the completion of the
offering, we intend to obtain and maintain directors' and officers' liability insurance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
SEC has taken the position that personal liability of directors for violation of the federal securities laws cannot be limited and that indemnification by us for any such violation is
unenforceable. The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws, each as currently in effect, may
discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our
directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs
of settlement and damage awards against directors and officers as required by these indemnification provisions. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee director compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other than with respect to the $36,000 of fees paid to Dr.&nbsp;Dhingra, and the $164,237 and $55,590 worth of non-qualified stock options granted to
Dr.&nbsp;Dhingra and Mr.&nbsp;Slattery, respectively, no compensation was paid to or earned by our non-employee directors during our fiscal year ended March&nbsp;31, 2018. Following the
completion of this offering, we intend to consider and adopt a compensation policy for non-employee directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=169,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=378719,FOLIO='167',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_168"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dm76701_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_dm76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Certain relationships and related party transactions    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other than compensation arrangements, we describe below transactions and series of similar transactions, during our last three fiscal years,
to which we were a party or will be a party, in which:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the amounts involved exceeded or will exceed $120,000; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any of the directors, executive officers or holders of more than 5% of the common stock of Replimune, or any member of the immediate family of
the foregoing persons, or person sharing the household with any of these individuals, had or will have a direct or indirect material interest. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Compensation
arrangements for our directors and named executive officers are described elsewhere in this prospectus. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dm76701_financings"> </A>
<A NAME="toc_dm76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Financings    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series seed financing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On May&nbsp;8, 2015, Replimune Limited entered into an initial share subscription agreement, which provided for the issue and sale by Replimune Limited of
(i)&nbsp;an aggregate of 200,000 shares of series seed preferred stock and (ii)&nbsp;warrants to purchase an aggregate of 50,000 shares of series seed preferred stock to an affiliate of Omega
Funds and an affiliate of Forbion Capital Partners for aggregate consideration of $2.0&nbsp;million. The following table sets forth the numbers of shares of our series seed preferred stock and
warrants to purchase shares of series seed preferred stock that were purchased by our directors, executive officers and holders of more than 5% of our capital stock and their respective affiliates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="86pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="108pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Purchaser</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares of series<BR>
seed preferred<BR>
stock purchased</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
warrants</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Aggregate purchase<BR>
price ($) </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forbion Capital Fund III Co&ouml;peratief U.A.<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,000,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Omega Fund IV,&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,000,000 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Forbion
Capital Fund III Co&ouml;peratief U.A. is a holder of more than 5% of our capital stock and is affiliated with Sander Slootweg, a current member of our board of
directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Omega
Fund IV,&nbsp;L.P. is a holder of more than 5% of our capital stock and is affiliated with Otello Stampacchia, a current member of our board of directors. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A financing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On September&nbsp;16, 2015, Replimune Limited entered into a subscription agreement, pursuant to which it sold to affiliates of Omega Funds, Forbion Capital
Partners and Atlas Ventures an aggregate of 432,276 shares of its series&nbsp;A preferred stock at a price of $34.70 per share for aggregate consideration of approximately $15.0&nbsp;million. At a
subsequent closing on March&nbsp;10, 2017, Replimune Limited sold to the same group of investors an additional 432,277 shares of its series&nbsp;A preferred stock at a price of $34.70 per share
for aggregate consideration of approximately $15.0&nbsp;million. The following table sets forth the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=170,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=612859,FOLIO='168',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_169"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>numbers
of shares of our series&nbsp;A preferred stock that were purchased by our directors, executive officers and holders of more than 5% of our capital stock and their respective affiliates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="83pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Purchaser</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares of<BR>
series A<BR>
preferred stock<BR>
purchased</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Aggregate purchase<BR>
price ($) </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forbion Capital Fund III Co&ouml;peratief U.A.<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>259,366</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,000,007.80</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Omega Fund IV,&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>259,366</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,000,007.80</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Atlas Venture Fund X,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>345,821</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,999,996.30 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Forbion
Capital Fund III Co&ouml;peratief U.A. is a holder of more than 5% of our capital stock and is affiliated with Sander Slootweg, a current member of our board of
directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Omega
Fund IV,&nbsp;L.P. is a holder of more than 5% of our capital stock and is affiliated with Otello Stampacchia, a current member of our board of directors.  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Atlas
Venture Fund X,&nbsp;L.P. is a holder of more than 5% of our capital stock and is affiliated with Jason Rhodes, a current member of our board of directors. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate reorganization  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On July&nbsp;10, 2017, we completed a corporate reorganization, or the reorganization, in which all the shareholders of Replimune Limited exchanged all of
the shares in Replimune Limited for shares of capital stock of Replimune Group. Following the reorganization, Replimune Limited is a wholly owned subsidiary of Replimune Group,&nbsp;Inc., a Delaware
corporation. In order to give effect to the reorganization, we issued shares of our common stock, series seed preferred stock, series&nbsp;A preferred stock, and warrants to purchase shares of
series seed preferred stock to each of the then existing shareholders of Replimune Limited in the same amount and classes of shares, or in the same form with respect to the warrants, as each such
shareholder then held in Replimune Limited in exchange for each such shareholder's holdings in Replimune Limited, all pursuant to an exchange and contribution agreement among us, Replimune Limited and
the then existing shareholders of Replimune Limited. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the reorganization, each option issued by Replimune Limited to acquire ordinary shares granted under Replimune Limited's then existing equity compensation plan was terminated and an
equivalent number of options to acquire our common stock was granted, pursuant to an option rollover agreement, in the case of options granted in compliance with the requirements of the U.K.
government's enterprise management incentive scheme, or pursuant to an option award, in the case of other outstanding options. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B financing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We entered into a series&nbsp;B preferred stock purchase agreement pursuant to which we sold an aggregate of 861,415 shares of our series&nbsp;B preferred
stock to certain investors at an initial closing on July&nbsp;21, 2017 and a subsequent closing on September&nbsp;15, 2017, in each case at a price of $63.79 per share, for aggregate consideration
of approximately $55.0&nbsp;million. The following table sets forth the numbers of shares of our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=171,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=725295,FOLIO='169',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_170"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>series&nbsp;B
preferred stock that were purchased by our directors, executive officers and holders of more than 5% of our capital stock and their respective affiliates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="83pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="103pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Purchaser</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares of<BR>
series&nbsp;B<BR>
preferred stock<BR>
purchased</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Aggregate purchase<BR>
price ($) </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forbion Capital Fund III Co&ouml;peratief U.A.<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>101,896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,499,945.84</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Omega Fund IV,&nbsp;LP<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>101,896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,499,945.84</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Atlas Venture Fund X,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>101,896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,499,945.84</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Foresite Capital<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>156,764</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,999,975.66</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Bain Capital Life Sciences<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>235,146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,999,963.34</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Redmile Group, LLC<SUP>(6)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>78,382</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,999,987.78 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Forbion
Capital Fund III Co&ouml;peratief U.A. is a holder of more than 5% of our capital stock and is affiliated with Sander Slootweg, a current member of our board of
directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Omega
Fund IV,&nbsp;L.P. is a holder of more than 5% of our capital stock and is affiliated with Otello Stampacchia, a current member of our board of directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Atlas
Venture Fund X,&nbsp;L.P. is a holder of more than 5% of our capital stock and is affiliated with Jason Rhodes, a current member of our board of directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;Entities
affiliated with Foresite Capital are collectively the holders of more than 5% of our capital stock.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Entities
affiliated with Bain Capital Life Sciences are collectively the holders of more than 5% of our capital stock.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)&nbsp;&nbsp;&nbsp;Entities
affiliated with Redmile Group, LLC will collectively become the holders of more than 5% of our capital stock upon the completion of this offering. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common&nbsp;A stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2017, we issued 26,258 shares of common&nbsp;A stock to Colin Love, our Chief Operating Officer, for nominal consideration. Our common&nbsp;A
stock carries voting rights, but only nominal economic rights. All such common&nbsp;A stock will be repurchased by us for nominal consideration and cancelled immediately prior to the completion of
this offering. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dm76701_stockholder_agreements"> </A>
<A NAME="toc_dm76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Stockholder agreements    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investors' rights agreement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the completion of this offering, the holders of approximately 19.7&nbsp;million shares of our common stock, or their permitted transferees, will
be entitled to the registration rights set forth below with respect to registration of the resale of such shares under the Securities Act, pursuant to the amended and restated investors' rights
agreement by and among us and certain of our stockholders. Additionally, each of Dr.&nbsp;Coffin, Mr.&nbsp;Astley-Sparke and Dr.&nbsp;Love will be entitled to the registration rights set forth
below with respect to the shares of our common stock he holds on the effective date of the registration statement of which this prospectus is a part only after such time as he no longer provides
services to us as an employee, consultant, officer or director. The provisions of the amended and restated investors' rights agreement, other than those relating to registration rights and certain
transfer restrictions and lock-up obligations on the holders party thereto, will terminate immediately prior to the completion of this offering. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand registration rights  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At any time after 180&nbsp;days after the effective date of this initial public offering as set forth on the cover page of this prospectus, upon the written
request of the holders holding at least 30% of the registrable securities then outstanding that we file&nbsp;a registration statement under the Securities Act covering the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=172,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=275680,FOLIO='170',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_171"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>registration
of registrable securities owned by such holder(s) having an anticipated aggregate offering price, net of selling expenses, of at least $30.0&nbsp;million, we will be obligated to notify
all holders of registrable securities of such request within 10&nbsp;days of receipt of such notice. As soon as practicable thereafter, and in any event within 60&nbsp;days after the date such
request is received, we will be required to register the sale on a registration statement on Form&nbsp;S-1 of all registrable securities that holders may request to be registered, subject to
specified exceptions, conditions and limitations. We may postpone the filing of a registration statement for up to 120&nbsp;days once in any 12-month period if in the good faith judgment of our
board of directors such registration would be materially detrimental to us, and we are not required to effect the filing of a registration statement during the period starting with the date that is
60&nbsp;days prior to our good faith estimate of the date of filing of a registration statement initiated by us and ending on a date 180&nbsp;days after the effective date of a registration
statement initiated by us. The underwriters of any underwritten offering will have the right to limit the number of shares having registration rights to be included in the registration statement. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Piggyback" registration rights  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we register any securities for public sale, holders of registration rights will have the right to include their shares in the registration statement. The
underwriters of any underwritten offering will have the right to limit the number of registrable securities to be included in the registration statement, but such number may not be below 30% of the
total number of shares included in such registration statement. While the holders of such registrable securities will be entitled to notice of this offering and, at their option, to include their
registrable securities in the registration statement of which this prospectus forms a part, we anticipate that all registration rights in respect of this offering will be waived and accordingly, no
such registrable securities will need to be registered. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form&nbsp;S-3 registration rights  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, holders of at least 30% of our registrable securities then outstanding have the
right to request that we file&nbsp;a registration statement on Form&nbsp;S-3, so long as the aggregate price to the public of the securities to be sold under the registration statement on
Form&nbsp;S-3 is at least $3&nbsp;million or consists of all the remaining registrable securities, and subject to specified exceptions, conditions and limitations. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses of registration  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are generally required to bear all expenses, including the fees and expenses of one counsel, not to exceed $50,000, representing the selling holders,
incurred in connection with the demand, piggyback and Form&nbsp;S-3 registrations described above. We are not required to bear selling expenses, which include all underwriting discounts, selling
commissions, stock transfer taxes applicable to the sale of registrable securities and fees and disbursements of any additional counsel for any selling holder. We are not required to pay registration
expenses if the registration request is withdrawn at the request of the holders of a majority of the registrable securities unless (i)&nbsp;the holders of a majority of the registrable securities
then outstanding agree to forfeit their right to one registration or (ii)&nbsp;the withdrawal is due to the discovery of a material adverse change in the conduct of our business. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination of registration rights  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The demand, piggyback and Form&nbsp;S-3 registration rights discussed above will terminate as to a given holder of registrable securities upon the earlier
of (i)&nbsp;the closing of a liquidity event as defined in our certificate of incorporation, (ii)&nbsp;five years following the completion of this offering, and (iii)&nbsp;such time as
Rule&nbsp;144 or another similar exemption under the Securities Act is available for the sale of all shares held </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=173,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=787699,FOLIO='171',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_172"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>by
the holder during a three-month period without registration and without the requirement for us to be in compliance with the current public information required under Rule&nbsp;144(c)(1). </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Agreements with our stockholders  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to the amended and restated investors' rights agreement, we have also entered into an amended and restated voting agreement and an amended and
restated right of first refusal and co-sale agreement with holders of our preferred stock. The amended and restated voting agreement, among other things, provides for the voting of shares with respect
to the composition of our board of directors and the voting of shares in favor of specified transactions approved by our board of directors and the holders of a requisite percentage of our preferred
stock. The amended and restated right of first refusal and co-sale agreement, among other things, provides first refusal and tag-along sale rights for holders of our preferred stock with respect to
transfers by certain stockholders. The provisions each of the amended and restated voting agreement and the amended and restated right of first refusal and co-sale agreement will terminate immediately
prior to the completion of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dm76701_other_transactions_with_related_persons"> </A>
<A NAME="toc_dm76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Other transactions with related persons    <BR>  </B></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director relationships  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain of our directors serve on our board of directors as representatives of entities which beneficially own 5% or more of our common stock, as indicated in
the table below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Director</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Principal stockholders </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Sander Slootweg</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>Forbion Capital Fund III Co&ouml;peratief U.A.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Otello Stampacchia</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>Omega Fund IV,&nbsp;L.P.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Jason Rhodes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>Atlas Venture Fund X,&nbsp;L.P. </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>In
addition, Mr.&nbsp;Astley-Sparke serves as a venture partner at Forbion Capital Partners, pursuant to which he is paid an annual retainer of $25,000. Mr.&nbsp;Astley-Sparke does not serve as a
representative of Forbion Capital Partners on our board of directors. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related party employment relationships  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our executive officers have employment agreements with us for their services. For information about the employment agreements with our named executive
officers, refer to "Executive and director compensation&#151;Employment arrangements." </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related party transactions policy  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their
affiliates, each a related party. Prior to this offering, the material facts as to the related party's relationship or interest in the transaction are disclosed to our board of directors prior to
their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approve
the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party's relationship or interest in the transaction are
disclosed to the stockholders, who must approve the transaction in good faith. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=174,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=123068,FOLIO='172',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<A NAME="page_dm76701_1_173"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the completion of this offering, we intend to adopt and maintain a written related party transactions policy that such transactions are subject to review and approval or
ratification by our audit committee. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification of directors and officers  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See "Executive and director compensation&#151;Limitation on liability and indemnification matters." </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indications of interest  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Several of our existing stockholders (or their affiliates), including stockholders affiliated with certain of our independent directors, and one of our
independent directors, have agreed to purchase an aggregate of approximately 3.3&nbsp;million shares of our common stock in this offering at the initial public offering price. The underwriters will
receive the same underwriting discount on any shares purchased by these investors as they will on any other shares sold to the public in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=175,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=994209,FOLIO='173',FILE='DISK114:[18ZBC1.18ZBC76701]DM76701A.;78',USER='HYUNG',CD='23-JUL-2018;14:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_do76701_1_174"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="do76701_principal_stockholders"> </A>
<A NAME="toc_do76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Principal stockholders    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth information regarding the beneficial ownership of our common stock as of July&nbsp;9, 2018
by:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our directors and named executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all of our directors and executive officers as a group; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Beneficial
ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or
investment power of that security, including options and warrants that are currently exercisable or exercisable within 60&nbsp;days after July&nbsp;9, 2018. Shares of our common stock issuable
pursuant to stock options and warrants are deemed outstanding for computing the percentage of the person holding such options or warrants and the percentage of any group of which the person is a
member but are not deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the
persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community property laws where applicable.
The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Section&nbsp;13(d) and 13(g) of the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
calculation of the percentage of beneficial ownership prior to this offering is based on 24,138,587 shares of common stock outstanding as of July&nbsp;9, 2018, after giving effect to
(i)&nbsp;the conversion of all outstanding shares of our preferred stock into an aggregate of 19,157,360 shares of common stock upon the completion of this offering and (ii)&nbsp;all outstanding
warrants to purchase shares of preferred stock becoming warrants to purchase shares of common stock upon the completion of this offering, in each case assuming that this offering was completed on
July&nbsp;9, 2018. Our calculation of the percentage of beneficial ownership after this offering is based on 30,838,587 shares of common stock outstanding immediately after the completion of this
offering (assuming no exercise of the underwriters' over-allotment option to purchase additional shares of our common stock). In addition, several of our existing stockholders (or their affiliates),
including stockholders affiliated with certain of our independent directors, and one of our independent directors, have agreed to purchase an aggregate of approximately 3.3&nbsp;million shares of
our common stock in this offering at the initial public offering price. The columns in the beneficial ownership table entitled "After this offering" give effect to such purchases. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=176,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=997376,FOLIO='174',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_175"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Prior to this offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>After this offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Beneficial owner</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Percent</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Percent</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Greater than 5% stockholders:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Atlas Venture Fund X,&nbsp;L.P.<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,453,386</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,453,386</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bain Capital Life Sciences Fund,&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,338,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.7%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,838,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.2%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forbion Capital Fund III Co&ouml;peratief U.A.<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,836,788</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,970,121</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16.0%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Foresite Capital<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,559,312</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.5%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,009,312</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.5%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Omega Fund IV,&nbsp;L.P.<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,836,788</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,103,455</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Redmile Group, LLC<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>779,655</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.2%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,979,655</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Named Executive Officers:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Philip Astley-Sparke<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,466,542</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.1%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,466,542</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Coffin<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,498,324</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.3%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,498,324</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.1%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pamela Esposito<SUP>(9)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>295,737</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.2%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>295,737</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Colin Love<SUP>(10)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,159,433</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,159,433</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jason Rhodes<SUP>(11)</SUP><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,453,386</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,453,386</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sander Slootweg<SUP>(12)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,836,788</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,970,121</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16.0%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Otello Stampacchia<SUP>(13)</SUP><SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,836,788</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,103,455</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kapil Dhingra</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>155,210</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>155,210</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hyam Levitsky</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joseph Slattery<SUP>(14)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,667</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Dieter Weinand</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors and executive officers as a group (12&nbsp;persons)<SUP>(7)(8)(9)(10)(11)(12)</SUP><SUP>(13)</SUP><SUP>(14)</SUP><SUP>(15)
</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,702,208</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>78.1%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,108,875</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>63.0% </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
beneficial ownership of less than one percent of our outstanding common stock.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;3,439,839 shares of common stock issuable upon conversion of shares of our series&nbsp;A preferred stock and (ii)&nbsp;1,013,547 shares of common stock
issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Atlas Venture Fund X,&nbsp;L.P. Atlas Venture Associates X,&nbsp;L.P. is the general partner of Atlas
Venture Fund X,&nbsp;L.P., and Atlas Venture Associates X,&nbsp;LLC is the general partner of Atlas Venture Fund X,&nbsp;L.P. Jason Rhodes, Peter Barrett, Bruce Booth, Jean-Francois Formela,
Jeff Fagnan, Chris Lynch and Ryan Moore are the members of Atlas Venture Associated X,&nbsp;LLC and collectively make investment decisions on behalf of Atlas Venture Fund X,&nbsp;LLC. The address
for Atlas Venture Fund X, is 25 First Street, Suite&nbsp;303, Cambridge, Massachusetts 02140.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;2,121,788 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Bain Capital Life Sciences
Fund,&nbsp;L.P., or BCLS and (ii)&nbsp;217,180 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by BCIP Life Sciences
Associates,&nbsp;L.P., or BCIP. The governance, investment strategy and decision-making process with respect to investments held by BCLS and BCIP are directed by Bain Capital Life Sciences
Investors,&nbsp;LLC, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, each of Bain Capital Life Sciences Investors,&nbsp;LLC, Mr.&nbsp;Schwartz and Dr.&nbsp;Koppel may be
deemed to share voting and dispositive power over the shares held by BCLS and BCIP. The address of BCLS is c/o Bain Capital Life Sciences,&nbsp;L.P., 200 Clarendon Street, Boston, Massachusetts
02116. Entities affiliated with Bain Capital have agreed to purchase 500,000 shares of our common stock in this offering.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock, (ii)&nbsp;994,688 shares of common stock issuable upon
conversion of shares of our series seed preferred stock, (iii)&nbsp;2,579,881 shares of common stock issuable upon conversion of shares of our series&nbsp;A preferred stock, and
(iv)&nbsp;1,013,547 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Forbion Capital Fund III Co&ouml;peratief U.A. The
address for Forbion Capital Fund III Co&ouml;peratief U.A. is Gooimeer 2-35, 1411 DC Naarden, the Netherlands. Forbion Capital Fund&nbsp;III Co&ouml;peratief U.A. has agreed to
purchase 133,333 shares of our common stock in this offering.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;779,656 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Foresite Capital Fund III, or FCF III,
and (ii)&nbsp;779,656 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Foresite Capital Fund IV,&nbsp;L.P., or FCF IV. Foresite
Capital Management III,&nbsp;LLC, or FCM III is the general partner of FCF III and Foresite Capital Management IV,&nbsp;LLC, or FCM IV, is the general partner of FCF IV. The managing director of
FCM III and FCM IV, James Tananbaum, may be deemed to have voting and investment power with respect to such shares. Each of FCM III and its members, FCM IV and its members and Mr.&nbsp;Tananbaum
disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and this footnote is not an admission that FCM III and its members, FCM IV or
Mr.&nbsp;Tananbaum is the beneficial owner of these shares for purposes of Section&nbsp;16 or any other purpose. The address of FCF III and FCF IV is c/o Foresite Capital Management,&nbsp;LLC,
600 Montgomery Street, Suite&nbsp;4500, San Francisco, California 94111. Entities affiliated with Foresite Capital have agreed to purchase 450,000 shares of our common stock in this offering. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=177,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=755113,FOLIO='175',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_176"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock, (ii)&nbsp;994,688 shares of common stock issuable upon
conversion of shares of our series seed preferred stock, (iii)&nbsp;2,579,881 shares of common stock issuable upon conversion of shares of our series&nbsp;A preferred stock, and
(iv)&nbsp;1,013,547 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Omega Fund IV,&nbsp;L.P., or Omega IV. Omega Fund
IV&nbsp;GP,&nbsp;L.P. is the general partner of Omega IV. Omega Fund IV&nbsp;GP Manager,&nbsp;Ltd., or Omega IV&nbsp;GP&nbsp;Ltd, is the general partner of Omega Fund
IV&nbsp;GP,&nbsp;L.P. Otello Stampacchia, Richard Lim, and Anne-Mari Paster are all the shareholders and all the directors of Omega IV&nbsp;GP&nbsp;Ltd. Together they have shared voting and
investment power over the shares held by Omega IV. The address of Omega IV, Omega IV GP LP and Omega IV GP Ltd and the above named individuals is c/o&nbsp;Omega Fund Management
LLC,&nbsp;185&nbsp;Dartmouth Street, Suite&nbsp;502, Boston, Massachusetts 02116. Omega Fund&nbsp;IV, L.P. has agreed to purchase 266,667 shares of our common stock in this offering. </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;535,818 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Redmile Biopharma
Investments&nbsp;I, L.P. and (ii)&nbsp;243,837 shares of common stock issuable upon conversion of shares of our series&nbsp;B preferred stock held directly by Redmile Capital Offshore
Fund&nbsp;II, Ltd. Redmile Group, LLC is the investment manager of each of Redmile Biopharma Investments&nbsp;I, L.P. and Redmile Capital Offshore Fund&nbsp;II, Ltd. (the "Redmile Funds").
Redmile Group, LLC may be deemed to beneficially own the securities held by the Redmile Funds. Jeremy&nbsp;C. Green serves as the managing member of Redmile Group, LLC and as such shares voting and
dispositive power over the shares held by the Redmile Funds. Redmile Group, LLC and Mr.&nbsp;Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary
interest in such shares, if any. The address of Redmile Group, LLC is One Letterman Drive, Building&nbsp;D, Suite D3-300, San Francisco, CA 94129. Entities affiliated with Redmile Group, LLC have
agreed to purchase 1,200,000 shares of our common stock in this offering.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(7)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;1,442,297 shares of our common stock and (ii)&nbsp;24,245 shares of common stock underlying options that are exercisable within 60 days of July&nbsp;9,
2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(8)&nbsp;&nbsp;&nbsp;Consists
of (i)&nbsp;2,412,118 shares of our common stock and (ii)&nbsp;86,206 shares of common stock underlying options that are exercisable within 60 days of July&nbsp;9,
2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9)&nbsp;&nbsp;&nbsp;Consists
of 295,737 shares of common stock underlying options that are exercisable within 60&nbsp;days of July&nbsp;9, 2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(10)&nbsp;&nbsp;Consists
of (i)&nbsp;1,119,024 shares of our common stock and&nbsp;(ii)&nbsp;40,409 shares of common stock underlying options that are exercisable within 60 days of
July&nbsp;9, 2018. Does not include 26,258 shares of common&nbsp;A stock held by Dr.&nbsp;Love, which will be repurchased by us and cancelled immediately prior to the completion of this
offering.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(11)&nbsp;&nbsp;Mr.&nbsp;Rhodes
is a partner at Atlas Ventures. Mr.&nbsp;Rhodes disclaims beneficial ownership of all shares held of record by affiliates of Atlas Ventures.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(12)&nbsp;&nbsp;Mr.&nbsp;Slootweg
is a managing partner of Forbion Capital Partners. Mr.&nbsp;Slootweg disclaims beneficial ownership of all shares held of record by affiliates of Forbion
Capital Partners.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(13)&nbsp;&nbsp;Dr.&nbsp;Stampacchia
is a managing member of Omega Fund Management. Dr.&nbsp;Stampacchia disclaims beneficial ownership of all shares held of record by affiliates of Omega Fund
Management.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(14)&nbsp;&nbsp;Mr.&nbsp;Slattery
has agreed to purchase 6,667 shares of our common stock in this offering.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(15)&nbsp;&nbsp;Dr.&nbsp;Howard
Kaufman does not own any shares of our common stock. </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=178,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=884275,FOLIO='176',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_177"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="do76701_description_of_capital_stock"> </A>
<A NAME="toc_do76701_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Description of capital stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>The following description of our capital stock and provisions of our amended and restated certificate of incorporation
and bylaws as they will be in effect immediately prior to the completion of this offering are summaries and are qualified in their entirety by reference to our amended and restated certificate of
incorporation and bylaws that will be in effect immediately prior to the completion of this offering, the forms of which have been filed as exhibits to the registration statement of which this
prospectus forms&nbsp;a part, and by applicable law, including the DGCL. </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the completion of this offering, our authorized capital stock will consist of 150&nbsp;million shares of common stock, par value $0.001 per share, and 10&nbsp;million shares of preferred
stock, par value $0.001 per share, all of which shares will be undesignated. Unless our board of directors determines otherwise, we will issue all shares of our capital stock in uncertificated form. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
connection with this offering, we effected a 1-for-9.94688 forward stock split of our common stock on July&nbsp;9, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of July&nbsp;9, 2018, we had approximately 23 stockholders of record and 5,007,485 shares of our common stock were outstanding, including 26,258 shares of our common A stock which we will
repurchase at a nominal value and cancel immediately prior to the completion of this offering. Upon completion of the conversion of our preferred stock into shares of our common stock and the
repurchase and cancelation of all outstanding shares of our common A stock, 24,138,587 shares of our common stock will be outstanding. In addition, as of July&nbsp;9, 2018, we had outstanding
options to purchase 2,502,530 shares of our common stock under our 2017 Plan at a weighted average exercise price of $2.72 per share, 660,368 of which were exercisable as of that date. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_common_stock"> </A>
<A NAME="toc_do76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Common stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The
holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally
available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or
redemption or sinking fund provisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and
any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and non-assessable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to our amended and restated certificate of incorporation as currently in effect, 26,258 shares of our common stock is designated as common A stock. Effective as of immediately prior to the
completion of this offering, we will repurchase all outstanding shares of our common A stock at a nominal purchase price and cancel such shares immediately thereafter. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_preferred_stock"> </A>
<A NAME="toc_do76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Preferred stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately prior to the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our
common stock. Upon the completion of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10&nbsp;million shares of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=179,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=989003,FOLIO='177',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_178"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>preferred
stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion
rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater
than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend
payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other
corporate action. Immediately after the completion of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock following this
offering. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_options"> </A>
<A NAME="toc_do76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Options    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon completion of the offering, we will have options to purchase 2,502,530 shares of our common stock outstanding. Effective upon the
completion of this offering, we expect to grant to certain of our employees and directors options to purchase approximately 1,147,500 shares of our common stock under our 2018 Plan at an exercise
price equal to the initial public offering price listed on the cover page of this prospectus. See "Executive and director compensation&#151;Employee benefit and stock plans" for a discussion of
the terms of the 2018 Plan and the 2017 Plan. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_warrants"> </A>
<A NAME="toc_do76701_6"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Warrants    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately prior to the completion of this offering, all warrants to purchase shares of series seed preferred stock will become warrants to
purchase shares of common stock on a one-for-one basis. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="do76701_anti-takeover_effects_of_provi__ant05584"> </A>
<A NAME="toc_do76701_7"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-takeover effects of provisions of Delaware law and our amended and restated certificate of incorporation  and amended and restated bylaws    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Requirements for advance notification of stockholder meetings, nominations and proposals  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated certificate of incorporation provides that special meetings of the stockholders may be called only by or at the direction of our
board of directors. Our amended and restated bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the
effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of our company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or
at the direction of our board of directors or a committee of our board of directors. In order for any matter to be "properly brought" before a meeting, a stockholder will have to comply with advance
notice requirements and provide us with certain information. Additionally, vacancies and newly created directorships may be filled only by a vote of a majority of the directors then in office, even
though less than a quorum, and not by the stockholders. Our amended and restated bylaws allow the presiding officer at a meeting of the stockholders to adopt rules and regulations for the conduct of
meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a
potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise attempting to obtain control of our company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=180,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=251987,FOLIO='178',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_179"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated certificate of incorporation provides that our board of directors is expressly authorized to adopt, amend or repeal our amended and restated bylaws. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No cumulative voting  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The DGCL provides that stockholders are not entitled to cumulate votes in the election of directors unless our amended and restated certificate of
incorporation provides otherwise. Our amended and restated certificate of incorporation does not expressly provide for cumulative voting. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendments to certificate of incorporation and bylaws  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The DGCL provides that, unless a corporation's certificate of incorporation provides otherwise, the affirmative vote of holders of shares constituting a
majority of the votes of all shares entitled to vote may approve amendments to the certificate of incorporation. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
amended and rested certificate of incorporation and amended and restated bylaws will provide that the affirmative vote of holders of at least 75% of the outstanding shares of capital stock, voting
together as a single class, and entitled to vote in the election of directors will be required to amend, alter, change or repeal the amended and restated certificate of incorporation and the amended
and restated bylaws. This requirement of a supermajority vote to approve amendments to our amended and restated certificate of incorporation and amended and restated bylaws could enable a minority of
our stockholders to exercise veto power over such amendments. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Forum selection clause  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court of
Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or
proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers or other employees to us or our stockholders;
(iii)&nbsp;any action asserting a claim against us or any director or officer or other employee of ours arising pursuant to any provision of the DGCL or our amended and restated certificate of
incorporation or amended and restated bylaws; or (iv)&nbsp;any action asserting a claim against us or any director or officer or other employee of ours governed by the internal affairs doctrine. Our
amended and restated certificate of incorporation will further provide that any person or entity that acquires any interest in shares of our capital stock shall be deemed to have notice of and to have
consented to the provisions described above. Moreover, our amended and restated certificate of incorporation will provide that the federal district courts of the United States will be the exclusive
forum for resolving any complaint asserting a cause of action arising under the Securities Act. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Staggered board  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated certificate of incorporation will provide that our board of directors will be divided into three classes of directors, with the
number of directors in each class to be as nearly equal as possible. See "Management&#151;Composition of our board of directors." </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder action by written consent  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to Section&nbsp;228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a
meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum
number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=181,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=25261,FOLIO='179',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_180"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>corporation's
certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation will prohibit the taking of any action of our stockholders by written consent
without a meeting. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware anti-takeover statute  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have not opted out of, and therefore are subject to, Section&nbsp;203 of the DGCL. Section&nbsp;203 provides that, subject to certain exceptions
specified in the law, a publicly-held Delaware corporation shall not engage in certain "business combinations" with any "interested stockholder" for a three-year period after the date of the
transaction in which the person became an interested stockholder unless:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
that resulted in the stockholder becoming an interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least 85% of
the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are
directors and also officers and (2)&nbsp;shares owned under employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the outstanding voting stock which is not owned by the interested stockholder. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>Generally,
a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person
who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation's outstanding voting stock.
Since Section&nbsp;203 will apply to us,
we expect that it would have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. In such event, we would also anticipate that Section&nbsp;203
could discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
certain circumstances, Section&nbsp;203 makes it more difficult for a person who would be an "interested stockholder" to effect various business combinations with a corporation for a
three-year period. The provisions of Section&nbsp;203 may encourage companies interested in acquiring our company to negotiate in advance with our board of directors because the stockholder approval
requirement would be avoided if our board of directors approves either the business combination or the transaction that results in the stockholder becoming an interested stockholder. These provisions
also may make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized but unissued capital stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The DGCL does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of Nasdaq, which apply so long as our
common stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common
stock. These additional shares may be used for a variety </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=182,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=471237,FOLIO='180',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<A NAME="page_do76701_1_181"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>One
of the effects of the existence of unissued and unreserved common stock or preferred stock may be to enable our board of directors to issue shares to persons friendly to current management, which
issuance could render more difficult or discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our
management and possibly deprive our investors of opportunities to sell their shares of common stock at prices higher than prevailing market prices. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_registration_rights"> </A>
<A NAME="toc_do76701_8"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Registration rights    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the completion of this offering, the holders of approximately 19.7&nbsp;million shares of our common stock, or their transferees,
will be entitled to the registration rights with respect to registration of the resale of such shares under the Securities Act pursuant to the amended and restated investors' rights agreement, by and
among us and certain of our investors. See "Certain relationships and related party transactions&#151;Stockholder agreements&#151;Investors' rights agreement" for more information. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_limitations_of_liability_and_indemnification"> </A>
<A NAME="toc_do76701_9"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Limitations of liability and indemnification    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See "Executive and director compensation&#151;Limitation on liability and indemnification matters." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_market_listing"> </A>
<A NAME="toc_do76701_10"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Market listing    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock has been approved for listing on Nasdaq under the symbol "REPL." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="do76701_transfer_agent_and_registrar"> </A>
<A NAME="toc_do76701_11"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Transfer agent and registrar    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the completion of this offering, the transfer agent and registrar for our common stock will be Computershare. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=183,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=781493,FOLIO='181',FILE='DISK114:[18ZBC1.18ZBC76701]DO76701A.;90',USER='HYUNG',CD='23-JUL-2018;15:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq76701_1_182"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dq76701_material_united_states_federal__mat03696"> </A>
<A NAME="toc_dq76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Material United States federal income tax consequences to non-U.S. holders of our common stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following is a discussion of the material U.S. federal income tax consequences of the acquisition, ownership, and disposition of our
common stock to a non-U.S. holder that purchases shares of our common stock for cash in this offering. For purposes of this discussion, a "non-U.S. holder" means a beneficial owner (other than a
partnership or other pass-through entity) of our common stock that is not, for U.S. federal income tax purposes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an individual who is a citizen or resident alien of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes, created or organized in the United
States or under the laws of the United States or of any state thereof or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust if (i)&nbsp;the trust is subject to the primary supervision of a U.S. court and all substantial decisions of the trust are controlled
by one or more U.S. persons or (ii)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion does not address the tax treatment of partnerships (or other entities that are treated as partnerships, grantor trusts, or other pass-through entities for U.S. federal income tax
purposes) or persons that hold their common stock through partnerships, grantor trusts or such other pass-through entities. The tax treatment of a partner in a partnership or a holder of an interest
in another pass-through entity that will hold our common stock generally will depend upon the status of the partner or interest holder and the activities of the partner or interest holder and the
partnership or other pass-through entity, as applicable. Such a partner or interest holder should consult his, her, or its own tax advisor regarding the tax consequences of the acquisition, ownership
and disposition of our common stock through a partnership or other pass-through entity, as applicable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion is based upon the provisions of the Code, the U.S. Treasury regulations promulgated thereunder, judicial decisions, and published rulings, administrative procedures and other guidance
of the Internal Revenue Service, which we refer to as the IRS, all as in effect as of the date hereof. These authorities are subject to change and to differing interpretations, possibly with
retroactive effect, which could result in U.S. federal income tax consequences different from those summarized below. No ruling has been or will be sought from the IRS with respect to the matters
summarized below, and there can be no assurance that the IRS will not take a contrary position regarding the U.S. federal income tax consequences
of the acquisition, ownership, or disposition of our common stock, or that any such contrary position would not be sustained by a court. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion is not a complete analysis of all of the potential U.S. federal income tax consequences relating to the acquisition, ownership, and disposition of our common stock by non-U.S. holders,
nor does it address any U.S. federal estate or gift tax or generation-skipping transfer tax consequences, any tax consequences arising under any state, local, or non-U.S. tax laws, the impact of any
applicable income tax treaty, any consequences under the Medicare contribution tax on net investment income, the alternative minimum tax, or any consequences under other U.S. federal tax laws. In
addition, this discussion does not </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=184,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=578350,FOLIO='182',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_183"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>address
tax consequences resulting from a non-U.S. holder's particular circumstances or to non-U.S. holders that may be subject to special tax rules, including, without
limitation:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> non-U.S. governments, agencies or instrumentalities thereof, or entities they control; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> "controlled foreign corporations" and their shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> "passive foreign investment companies" and their shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> partnerships, grantor trusts or other entities that are treated as pass-through entities for U.S. federal income tax purposes, and their
owners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> corporations that accumulate earnings to avoid U.S. federal income tax; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> former citizens or former long-term residents of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> banks, insurance companies or other financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> tax-exempt pension funds or other tax-exempt organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons who acquired our common stock pursuant to the exercise of employee stock options or otherwise as compensation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> tax-qualified retirement plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> traders, brokers or dealers in securities, commodities or currencies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons who hold our common stock as a position in a hedging transaction, wash sale, "straddle," "conversion transaction" or other risk
reduction transaction or synthetic security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment
purposes); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons who own or have owned, or are deemed to own or to have owned, more than 5% of our common stock (except to the extent specifically set
forth below); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> accrual method taxpayers who are required to recognize income for U.S. federal income tax purposes no later than when such income is taken into
account for financial accounting purposes; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons deemed to sell our common stock under the constructive sale provisions of the Code. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Prospective
investors should consult their tax advisors regarding the particular U.S. federal income, estate, gift, and generation-skipping transfer tax consequences to them of acquiring, owning and
disposing of our common stock, as well as any tax consequences arising under any state, local or non-U.S. tax laws and any other U.S. federal tax laws. Prospective investors should also consult their
tax advisors regarding the potential impact of any applicable income or estate tax treaty between the United States and such prospective investor's country of residence and of the rules described
below under the heading "Foreign Account Tax Compliance Act." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_distributions_on_common_stock"> </A>
<A NAME="toc_dq76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Distributions on common stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As described in the section entitled "Dividend policy," we currently intend to retain all available funds and any future earnings for use in
the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. The disclosure in this section addresses the consequences </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=185,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=934261,FOLIO='183',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_184"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>should
our board of directors, in the future, determine to make a distribution of cash or property with respect to our common stock (other than certain distributions of stock which may be made free of
tax), or to effect a redemption that is treated for tax purposes as a distribution under U.S. federal income tax principles. Any such distribution will generally constitute a dividend for U.S. federal
tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent such a distribution exceeds both our current
and our accumulated earnings and profits, such excess will be allocated ratably among the shares of common stock with respect to which the distribution is made, will constitute a return of capital,
and will first be applied against and reduce the non-U.S. holder's adjusted tax basis in those shares of common stock, but not below zero. Distributions in excess of our current and accumulated
earnings and profits and in excess of a non-U.S. holder's tax basis in that non-U.S. holder's shares of common stock then will be treated as gain from the sale of that common stock, subject to the tax
treatment described below under "Gain on disposition of common stock." A non-U.S. holder's adjusted tax basis in a share of common stock is generally the purchase price of the share, reduced by the
amount of any distributions constituting a return of capital with respect to that share. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
dividend paid to a non-U.S. holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividend, or such lower rate as may be
specified by an applicable income tax treaty between the United States and such non-U.S. holder's country of residence. If a non-U.S. holder is eligible for benefits under an income tax treaty and
wishes to claim a reduced rate of withholding, the non-U.S. holder generally will be required to provide us or our paying agent with a properly completed IRS Form&nbsp;W-8BEN, Form&nbsp;W-8BEN-E,
or other applicable form, certifying under penalties of perjury the non-U.S. holder's qualification for the reduced rate. This certification must be provided to us or our paying agent prior to the
payment of the dividend and may be required to be updated periodically. Special certification requirements apply to non-U.S. holders that hold common stock through certain foreign intermediaries.
Non-U.S. holders that do not timely provide the required
certifications, but that qualify for a reduced income tax treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. If we are not
able to determine whether or not a distribution will exceed current and accumulated earnings and profits at the time the distribution is made, we may withhold tax on the entire amount of any
distribution at the same rate as we would withhold on a dividend. However, a non-U.S. holder may obtain a refund of amounts that we withhold to the extent attributable to the portion of the
distribution in excess of our current and accumulated earnings and profits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a non-U.S. holder holds our common stock in connection with the conduct of a trade or business in the United States, and dividends paid on the common stock are effectively connected with the
non-U.S. holder's U.S. trade or business (and, if required by an applicable income tax treaty between the United States and such non-U.S. holder's country of residence, are attributable to a permanent
establishment or fixed base maintained by the non-U.S. holder in the United States, as defined under the applicable income tax treaty), the non-U.S. holder will be exempt from U.S. federal withholding
tax on the dividends. To claim the exemption, the non-U.S. holder must furnish a properly executed IRS Form&nbsp;W-8ECI (or other applicable form) prior to the payment of the dividends. Any
dividends paid on our common stock that are effectively connected with a non-U.S. holder's U.S. trade or business (and satisfy any other applicable income tax treaty requirements) generally will be
subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates generally applicable to U.S. persons (as defined in the Code). A non-U.S. holder that is
treated as a corporation for U.S. federal income tax purposes also may be subject to an additional branch profits tax equal to 30% (or such lower rate as is specified by an applicable income tax
treaty between the United States and such non-U.S. holder's country of residence) of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=186,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=6230,FOLIO='184',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_185"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>a
portion of its earnings and profits for the taxable year that are effectively connected with a U.S. trade or business, as adjusted for certain items. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_gain_on_disposition_of_common_stock"> </A>
<A NAME="toc_dq76701_3"> </A></FONT> <FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Gain on disposition of common stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the discussion below regarding backup withholding and foreign accounts, a non-U.S. holder generally will not be subject to U.S.
federal income tax on any gain realized upon the sale, exchange, or other taxable disposition of our common stock unless:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a U.S. trade or business (and, if required by an applicable income tax
treaty between the United States and such non-U.S. holder's country of residence, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United
States), in which case the non-U.S. holder will generally be required to pay tax on the gain derived from the sale, exchange, or other taxable disposition (net of certain deductions or credits) under
regular graduated U.S. federal income tax rates generally applicable to U.S. persons, and in the case of a non-U.S. holder that is treated as a corporation for U.S. federal income tax purposes, such
non-U.S. holder may be subject to a branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such non-U.S. holder's
country of residence; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the non-U.S. holder is an individual who is present in the United States for a period or periods aggregating 183&nbsp;days or more during the
taxable year in which the sale, exchange, or other taxable disposition occurs and certain other conditions are met, in which case the non-U.S. holder will be subject to U.S. federal income tax at a
flat 30% rate (or such lower rate as is specified by an applicable income tax treaty between the United States and such non-U.S. holder's country of residence) on the net gain derived from the sale,
exchange, or other taxable disposition, which gain may be offset by U.S. source capital losses (even though the non-U.S. holder is not considered a resident of the United States) provided that the
non-U.S. holder has timely filed U.S. federal income tax returns reporting those losses; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our common stock is a "United States real property interest" by reason of our status as a "United States real property holding corporation," or
USRPHC, for U.S. federal income tax purposes during the five-year period preceding such sale, exchange or other taxable disposition (or the non-U.S. holder's holding period, if shorter). Generally, a
corporation is a USRPHC only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its
other assets used or held for use in a trade or business. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe we are not now and we do not anticipate becoming a USRPHC. However, there can be no assurance that we are not now a USRPHC or will not become one in the future. Even if we are or become a
USRPHC, for so long as our common stock is "regularly traded," as defined by applicable U.S. Treasury regulations, on an established securities market, sales of our common stock generally will not be
subject to tax for non-U.S. holders that have not held more than 5% of our common stock, actually or constructively, during the five-year period preceding such non-U.S. holder's sale, exchange or
other taxable disposition of our common stock (or the non-U.S. holder's holding period, if shorter). If we are determined to be a USRPHC and the foregoing exception does not apply, then the non-U.S.
holder generally will be taxed on its
net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=187,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=664870,FOLIO='185',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_186"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_information_reporting_and_backup_withholding"> </A>
<A NAME="toc_dq76701_4"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Information reporting and backup withholding    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Generally, we or certain financial middlemen must report annually to the IRS and to each non-U.S. holder the gross amount of dividends and
other distributions on our common stock paid to the non-U.S. holder and the amount of tax withheld, if any, with respect to those distributions. Pursuant to applicable income tax treaties or other
agreements, the IRS may make these reports available to tax authorities in the non-U.S. holder's country of residence or incorporation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
non-U.S. holder may be subject to backup withholding with respect to dividends paid on shares of our common stock, unless, generally, the non-U.S. holder certifies under penalties of perjury
(usually on IRS Form&nbsp;W-8BEN or W-8BEN-E) that the non-U.S. holder is not a U.S. person or otherwise establishes an exemption. The backup withholding rate is currently 24%. Dividends that are
paid to non-U.S. holders subject to the withholding of U.S. federal income tax, as described above under the heading "Distributions on common stock" generally will be exempt from U.S. backup
withholding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additional
rules relating to information reporting requirements and backup withholding with respect to payments of the proceeds from the disposition of shares of our common stock are as
follows:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If the proceeds are paid to or through the U.S. office of a broker, the proceeds generally will be subject to backup withholding and
information reporting, unless the non-U.S. holder certifies under penalties of perjury (usually on IRS Form&nbsp;W-8BEN or W-8BEN-E) that the non-U.S. holder is not a U.S. person and satisfies
certain other requirements or otherwise establishes an exemption. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If the proceeds are paid to or through a non-U.S. office of a broker that is not a U.S. person and is not a foreign person with certain
specified U.S. connections, which we refer to below as a "U.S.-related person," information reporting and backup withholding generally will not apply. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If the proceeds are paid to or through a non-U.S. office of a broker that is a U.S. person or a U.S.-related person, the proceeds generally
will be subject to information reporting (but not to backup withholding), unless the non-U.S. holder certifies under penalties of perjury (usually on IRS Form&nbsp;W-8BEN or W-8BEN-E) that the
non-U.S. holder is not a U.S. person. A "U.S.-related person" includes (i)&nbsp;an entity classified as a "controlled foreign corporation" for U.S. federal income tax purposes, (ii)&nbsp;a foreign
person, 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business, or (iii)&nbsp;a foreign partnership if at any time during its tax year
(a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or (b)&nbsp;the foreign partnership is engaged
in a U.S. trade or business. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Backup
withholding is not an additional tax. Any amounts withheld from a non-U.S. holder under the backup withholding rules may be allowed as a refund or a credit against the non-U.S. holder's U.S.
federal income tax liability, if any, provided that the non-U.S. holder timely furnishes the required information to the IRS. Non-U.S. holders should consult their own tax advisors regarding the
application of the information reporting and backup withholding rules to them. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_foreign_account_tax_compliance_act"> </A>
<A NAME="toc_dq76701_5"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Foreign Account Tax Compliance Act    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sections&nbsp;1471 to 1474 of the Code (commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) generally impose
withholding tax on certain types of payments made to "foreign financial institutions" (as defined in the Code) and other non-U.S. entities unless those institutions and entities meet additional
certification, information reporting and other requirements. FATCA generally imposes a 30% withholding tax on dividends on, or gross proceeds from the sale or other disposition of, our common </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>186</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=188,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=490640,FOLIO='186',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_187"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stock
paid to a foreign financial institution unless the foreign financial institution enters into an agreement with the U.S. Treasury to, among other things, (i)&nbsp;undertake to identify accounts
held by certain U.S. persons (including certain equity and debt holders of such institution) or by U.S.-owned foreign entities, (ii)&nbsp;annually report certain information about such accounts, and
(iii)&nbsp;withhold 30% on payments to account holders whose actions prevent it from complying with these reporting and other requirements. In addition, subject to certain exceptions, FATCA imposes
a 30% withholding tax on the same types of payments to a "non-financial foreign entity" (as defined in the Code) unless the entity certifies that it does not have any substantial U.S. owners (which
generally include any U.S. persons who directly or indirectly own more than 10% of the entity) or furnishes identifying information regarding each such substantial U.S. owner or agrees to report that
information to the IRS. These withholding taxes will be imposed on dividends paid on our common stock, and, after December&nbsp;31, 2018, on gross proceeds from sales or other dispositions of our
common stock. Withholding under FATCA generally will not be reduced or limited by bilateral income tax treaties. However, intergovernmental agreements between the United States and other countries
with respect to the implementation of FATCA and non-U.S. laws, regulations and other authorities enacted or issued with respect to those intergovernmental agreements may modify the FATCA requirements
described above. Non-U.S. holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in our common stock and the entities through which they hold
our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>187</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=189,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=20611,FOLIO='187',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_188"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dq76701_shares_eligible_for_future_sale"> </A>
<A NAME="toc_dq76701_6"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Shares eligible for future sale    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, there has been no public market for shares of our common stock and a liquid trading market for our common stock may
not develop or be sustained after this offering. We cannot predict the effect, if any, that future sales of shares of common stock, or the availability for future sale of shares of common stock, will
have on the market price of shares of our common stock prevailing from time to time. The sale of substantial amounts of shares of our common stock in the public market, or
the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of July&nbsp;9, 2018, 5,007,485 shares of our common stock were outstanding, including 26,258 shares of our common A stock, which we will repurchase at a nominal value and cancel immediately
prior to the completion of this offering. Upon completion of the conversion of our preferred stock into shares of our common stock and the repurchase and cancellation of all outstanding shares of our
common A stock, 24,138,587 shares of our common stock will be outstanding. In addition, as of July&nbsp;9, 2018, we had outstanding options to purchase 2,502,530 shares of our common stock under our
2017 Plan at a weighted average exercise price of $2.72 per share, 660,368 of which were exercisable as of that date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the completion of this offering, we will have a total of 30,838,587 shares of our common stock outstanding, or 31,843,587 shares of common stock if the underwriters exercise in full their option
to purchase additional shares of common stock, at the initial public offering price of $15.00 per share. All of these shares of common stock will have been sold in this offering and will be freely
tradable without restriction or further registration under the Securities Act by persons other than our "affiliates." Under the Securities Act, an "affiliate" of an issuer is a person who directly or
indirectly controls, is controlled by or is under common control with that issuer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of July&nbsp;9, 2018, 660,368&nbsp;shares of common stock were issuable upon the exercise of outstanding stock options. In addition, 3,617,968 shares of common stock may be granted under our
2018 Plan and 348,612 shares of common stock may be purchased under our ESPP. In addition, effective upon the completion of this offering, we expect to grant to certain of our employees and directors
options to purchase approximately 1,147,500&nbsp;shares of our common stock under our 2018 Plan at an exercise price equal to the initial public offering price listed on the cover page of this
prospectus. See "Executive and director compensation&#151;Employee benefit and stock plans&#151;2018 Omnibus Incentive Compensation Plan" and "Executive and director
compensation&#151;Employee benefit and stock Plans&#151;Employee stock purchase plan." We intend to file one or more registration statements on Form&nbsp;S-8 under the Securities Act
to register shares of common stock or securities convertible into or exchangeable for shares of common stock issued under or covered by our 2017 Plan, 2018 Plan, and ESPP. Any such Form&nbsp;S-8
registration statements will automatically become effective upon filing, subject to vesting restrictions, the lock-up agreements described herein and Rule&nbsp;144 limitations applicable to
affiliates. Accordingly, shares of common stock registered under such registration statements will be available for sale in the open market. We expect that the initial registration statement on
Form&nbsp;S-8 will cover all shares of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
certificate of incorporation authorizes us to issue additional shares of common stock and options, rights, warrants and appreciation rights relating to common stock for the consideration and on
the terms and conditions established by our board of directors in its sole discretion. In accordance with the DGCL and the provisions of our certificate of incorporation, we may also issue preferred
stock that has designations, preferences, rights, powers and duties that are different from, and may be senior to, those applicable to shares of common stock. See "Description of capital stock." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>188</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=190,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1026286,FOLIO='188',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_189"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_registration_rights"> </A>
<A NAME="toc_dq76701_7"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Registration rights    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the completion of this offering, the holders of approximately 19.7&nbsp;million shares of our common stock, or their transferees,
will be entitled to registration rights with respect to registration of the resale of such shares under the Securities Act pursuant to the amended and restated investors' rights agreement, by and
among us and certain of our investors. See "Certain relationships and related party transactions&#151;Stockholder agreements&#151;Investors' rights agreement" for more information. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_lock-up_agreements"> </A>
<A NAME="toc_dq76701_8"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Lock-Up agreements    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, each of our directors and officers and holders of substantially all of our fully diluted outstanding capital stock have agreed to certain
restrictions on our and their ability to sell additional shares of our common stock for a period of 180&nbsp;days after the date of this prospectus. We and they have agreed not to directly or
indirectly offer for sale, sell, contract to sell, grant any option for the sale of, or otherwise issue or dispose of, any shares of our common stock, options or warrants to purchase shares of our
common stock, or any related security or instrument without the prior written consent of each of J.P. Morgan Securities&nbsp;LLC and Leerink Partners&nbsp;LLC. The agreements provide exceptions
for (a)&nbsp;sales to the underwriters in connection with this offering, (b)&nbsp;our sales in connection with existing incentive plans and (c)&nbsp;certain other exceptions. J.P. Morgan
Securities&nbsp;LLC and Leerink Partners&nbsp;LLC in their sole discretion may release any of the securities subject to these lock-up agreements at any time. If the restrictions under the lock-up
agreements are waived, shares of our common stock may become available for resale into the market, subject to applicable law, which could reduce the market price for our common stock. See
"Underwriting." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_rule_144"> </A>
<A NAME="toc_dq76701_9"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Rule&nbsp;144    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, under Rule&nbsp;144 a person (or persons whose shares are aggregated) who may be deemed our affiliate is entitled to sell within
any three-month period a number of restricted securities that does not exceed the greater of 1% of the then outstanding shares of common stock and the average weekly trading volume during the four
calendar weeks preceding each such sale, provided that at least six months has elapsed since such shares of common stock were acquired from us or any affiliate of ours and certain manner of sale,
notice requirements and requirements as to availability of current public information about us are satisfied. Any person who is deemed to be our affiliate must also comply with such provisions of
Rule&nbsp;144 (other than the six-month holding period requirement) in order to sell shares of common stock which are not restricted securities (such as shares of common stock acquired by affiliates
through purchases in the open market following this offering). A person who is not our affiliate, and who has not been our affiliate at any time during the 90&nbsp;days preceding any sale, is
entitled to sell shares of common stock (i)&nbsp;subject only to the requirements as to availability of current public information about us, provided that a period of at least six months has elapsed
since the shares of common stock were acquired from us or any affiliate of ours, and (ii)&nbsp;without regard to the requirements as to availability of current public information about us or any
other requirement of Rule&nbsp;144, provided that at least one year has elapsed since the shares of common stock were acquired from us or any affiliate of ours. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_stock_options_and_restricted_stock"> </A>
<A NAME="toc_dq76701_10"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Stock options and restricted stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See "Shares eligible for future sale." For a more complete discussion of our stock plans, see "Executive and director
compensation&#151;Employee benefit and stock plans." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>189</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=191,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=713907,FOLIO='189',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<A NAME="page_dq76701_1_190"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="dq76701_rule_701"> </A>
<A NAME="toc_dq76701_11"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Rule&nbsp;701    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon
Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers or directors who purchased
shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until
90&nbsp;days after the date of this prospectus before selling their shares. However, substantially all Rule&nbsp;701 shares are subject to lock-up agreements as described below and under
"Underwriting" included elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>190</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=192,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=352588,FOLIO='190',FILE='DISK114:[18ZBC1.18ZBC76701]DQ76701A.;43',USER='CHE107312',CD='21-JUL-2018;03:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ds76701_1_191"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="ds76701_underwriting"> </A>
<A NAME="toc_ds76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Underwriting    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities&nbsp;LLC
and Leerink Partners&nbsp;LLC are acting as book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the representatives.
Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the initial public offering
price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="87%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
shares </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 J.P. Morgan Securities&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,182,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leerink Partners&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,010,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 BMO Capital Markets Corp.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,507,500 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,700,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:arial;"><FONT SIZE=2>The
underwriters are committed to purchase all the common shares offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase
commitments of non-defaulting underwriters may also be increased or the offering may be terminated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters propose to offer the common shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less
a concession not in excess of $0.63 per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $0.21 per share from the initial public offering price.
After the initial offering of the shares to the public, the offering price and other selling terms may be changed by the underwriters. Sales of shares made outside of the United States may be made by
affiliates of the underwriters. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters' right to reject any order in whole or in part. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Several
of our existing stockholders (or their affiliates), including stockholders affiliated with certain of our independent directors, and one of our independent directors, have agreed to purchase
an aggregate of approximately 3.3&nbsp;million shares of our common stock in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any
shares purchased by these investors as they will on any other shares sold to the public in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have an option to buy up to 1,005,000 additional shares of common stock from us to cover sales of shares by the underwriters that exceed the number of shares specified in the table
above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional
shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the
additional shares on the same terms as those on which the shares are being offered. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $1.05 per share.
The following table shows the per share and total underwriting discounts and commissions to be paid to the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>191</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=193,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=730955,FOLIO='191',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_192"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>underwriters
assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="74%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Without<BR>
option to<BR>
purchase<BR>
additional<BR>
shares<BR>
exercise</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>With full<BR>
option to<BR>
purchase<BR>
additional<BR>
shares<BR>
exercise </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,035,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,090,250 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:arial;"><FONT SIZE=2>We
estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and
commissions, will be approximately $2.7&nbsp;million. We have agreed to reimburse the underwriters for certain expenses related to clearance of this offering with the Financial Industry Regulatory
Authority, or FINRA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The underwriters may
agree
to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have agreed that we will not (i)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the SEC a registration statement under the Securities Act relating to, any shares of our
common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or
filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such
other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the
prior written consent of J.P. Morgan Securities&nbsp;LLC and Leerink Partners&nbsp;LLC for a period of 180&nbsp;days after the date of this prospectus, subject to certain limited exceptions set
forth in the underwriting agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
directors, executive officers and holders of substantially all of our fully diluted outstanding capital stock have entered into lock-up agreements with the underwriters prior to the commencement
of this offering pursuant to which each of these persons or entities, with certain limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior
written consent of J.P. Morgan Securities&nbsp;LLC and Leerink Partners&nbsp;LLC, (i)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any
securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by
such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or
(ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>192</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=194,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=808723,FOLIO='192',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_193"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>transaction
described in clause&nbsp;(i) or (ii)&nbsp;above is to be settled by delivery of common stock or such other securities, in cash or otherwise, or (iii)&nbsp;make any demand for or
exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
common stock has been approved for listing on Nasdaq under the symbol "REPL." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the
purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common
stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open
market to cover positions created by short sales. Short sales may be "covered" shorts, which are short positions in an amount not greater than the underwriters' option to purchase additional shares
referred to above, or may be "naked" shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase
additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for
purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if
the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the
common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover
short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>These
activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the
price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The
underwriters may carry out these transactions on Nasdaq, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to this offering, there has been no public market for our common stock. The initial public offering price was determined by negotiations between us and the representatives of the underwriters.
In determining the initial public offering price, we and the representatives of the underwriters considered a number of factors, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the information set forth in this prospectus and otherwise available to the representatives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our prospects and the history and prospects for the industry in which we compete; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an assessment of our management; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>193</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=195,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=846298,FOLIO='193',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_194"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our prospects for future earnings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the general condition of the securities market at the time of this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other factors deemed relevant by the underwriters and us. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor the underwriters can assure investors that an active trading market will develop for our common stock, or that the shares will trade in the public market at or above the initial public
offering price. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action
for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the
distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such
an offer or a solicitation is unlawful. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ds76701_selling_restrictions"> </A>
<A NAME="toc_ds76701_2"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Selling restrictions    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, or a Relevant Member State, an offer to the
public of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our common stock may be made
at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010&nbsp;PD Amending Directive, 150,
natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the
representatives for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such offer of shares of our common
stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this provision, the expression an "offer to the public" in relation to any shares of our common stock in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares of our common stock, as the same
may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto,
including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>194</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=196,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=827910,FOLIO='194',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_195"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>relevant
implementing measure in the Relevant Member State, and the expression "2010 PD Amending Directive" means Directive 2010/73/EU. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each underwriter has represented and agreed that:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to
engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or FSMA, received by it in connection with the issue or sale of the shares of our
common stock in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our
common stock in, from or otherwise involving the United Kingdom. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares of our common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
"professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in
the document being a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within
the meaning of that Ordinance. No advertisement, invitation or document relating to the shares of our common stock has been or may be issued or has been or may be in the possession of any person for
the purposes of issuance, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so
under the securities laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional
investors" as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of our common stock may not be circulated or distributed, nor may the shares of our common
stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person
pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
any other applicable provision of the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Where
the shares of our common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust (where the trustee is not an accredited investor) the sole purpose of which is to hold investments and each beneficiary of the trust is
an individual who is an accredited investor, </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>195</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=197,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=447487,FOLIO='195',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_196"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that
corporation or that trust has acquired the shares of our common stock pursuant to an offer made under Section&nbsp;275 of the SFA except:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer
referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where no consideration is or will be given for the transfer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where the transfer is by operation of law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> as specified in Section&nbsp;276(7) of the SFA; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> as specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of
Singapore. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>No registration pursuant to Article&nbsp;4, paragraph&nbsp;1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accordingly,
the shares of our common stock have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any
resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale,
directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and
the other applicable laws and regulations of Japan. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


For Qualified Institutional Investors, or QII  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph&nbsp;2, Article&nbsp;4 of the FIEL) in relation
to the shares of our common stock constitutes either a "QII only private placement" or a "QII only secondary distribution" (each as described in Paragraph&nbsp;1, Article&nbsp;23-13 of the FIEL).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the shares of our common stock. The shares
of our common stock may only be transferred to QIIs. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


For Non-QII Investors  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph&nbsp;2, Article&nbsp;4 of the FIEL) in relation
to the shares of our common stock constitutes either a "small number private placement" or a "small number private secondary distribution" (each as is described in Paragraph&nbsp;4,
Article&nbsp;23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the
shares of our common stock. The shares of our common stock may only be transferred en bloc without subdivision to a single investor. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>196</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=198,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=154008,FOLIO='196',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_197"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Australia  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments
Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the
Corporations Act, and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
offer in Australia of the shares may only be made to persons, or the Exempt Investors, who are "sophisticated investors" (within the meaning of section&nbsp;708(8) of the Corporations Act),
"professional investors" (within the meaning of section&nbsp;708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section&nbsp;708 of the Corporations Act
so that it is lawful to offer the shares without disclosure to investors under Chapter&nbsp;6D of the Corporations Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12&nbsp;months after the date of allotment under the offering, except in
circumstances where disclosure to investors under Chapter&nbsp;6D of the Corporations Act would not be required pursuant to an exemption under section&nbsp;708 of the Corporations Act or otherwise
or where the offer is pursuant to a disclosure document which complies with Chapter&nbsp;6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>This
prospectus contains general information only and does not take into account the investment objectives, financial situation or particular needs of any particular person. It does not contain any
securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate for their needs,
objectives and circumstances, and, if necessary, seek expert advice on those matters. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dubai International Financial Centre  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA. This prospectus
is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in
connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which
this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not
understand the contents of this prospectus you should consult an authorized financial advisor. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Switzerland  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares of our common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document nor any other offering or marketing material relating to the offering, us or the shares have been or will be filed with or approved by any Swiss regulatory authority. In </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>197</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=199,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=53095,FOLIO='197',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_198"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>particular,
this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of shares has not
been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined
in National Instrument&nbsp;45-106 </FONT><FONT SIZE=2><I>Prospectus Exemptions</I></FONT><FONT SIZE=2> or subsection&nbsp;73.3(1) of the </FONT><FONT SIZE=2><I>Securities
Act</I></FONT><FONT SIZE=2> (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103 </FONT><FONT SIZE=2><I>Registration Requirements, Exemptions and Ongoing Registrant
Obligations</I></FONT><FONT SIZE=2>. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of
applicable securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal
advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to section&nbsp;3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National Instrument&nbsp;33-105 </FONT> <FONT SIZE=2><I>Underwriting Conflicts</I></FONT><FONT SIZE=2>
(NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements of NI&nbsp;33-105 regarding
underwriter conflicts of interest in connection with this offering. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Israel  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law,
5728-1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law,
5728-1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the "Addressed Investors"); or (ii)&nbsp;the
offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law,&nbsp;5728-1968, subject to certain conditions (the "Qualified
Investors"). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The
company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law,&nbsp;5728-1968. We have not and will not
distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed
Investors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728-1968. In particular, we may request, as a
condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within
one of the categories listed in the First Addendum to the Israeli Securities Law,&nbsp;5728-1968; (ii)&nbsp;which of the categories listed in the First Addendum to the Israeli Securities
Law,&nbsp;5728-1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>198</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=200,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=935277,FOLIO='198',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_199"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>it
will abide by all provisions set forth in the Israeli Securities Law,&nbsp;5728-1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock;
(iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law,&nbsp;5728-1968: (a)&nbsp;for its own account;
(b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities
Law,&nbsp;5728-1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their
identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor's name, address and passport number or Israeli identification number. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=2><A
NAME="ds76701_other_relationships"> </A>
<A NAME="toc_ds76701_3"> </A></FONT> <FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Other relationships    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the
underwriters and their respective affiliates may in the future perform various financial advisory and investment banking services for us, for which they may receive customary fees and expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, in the ordinary course of business, the underwriters and their respective affiliates may make or hold a broad array of investments including serving as counterparties to certain
derivative and hedging arrangements and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the
accounts of their customers, and such investment and securities activities may involve our securities and/or instruments. The underwriters and
their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or
recommend to clients that they acquire, long and/or short positions in such securities and instruments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
a series of related transactions in August and September 2017, entities affiliated with Leerink Partners&nbsp;LLC purchased an aggregate of 7,054 shares of our series&nbsp;B preferred stock on
the same terms as the other investors in the series&nbsp;B financing. These shares will convert into 70,164 shares of our common stock upon the completion of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>199</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=201,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=807748,FOLIO='199',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<A NAME="page_ds76701_1_200"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="ds76701_legal_matters"> </A>
<A NAME="toc_ds76701_4"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal matters    <BR>  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The validity of the shares of common stock offered hereby will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP. Certain
legal matters in connection with this offering will be passed upon for the underwriters by Cravath, Swaine&nbsp;&amp; Moore&nbsp;LLP. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="ds76701_experts"> </A>
<A NAME="toc_ds76701_5"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Experts    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements as of March&nbsp;31, 2018 and 2017 and for the years then ended included in this prospectus have been so included
in reliance on the report (which contains an explanatory paragraph relating to the Company's requirement of additional financing to fund future operations as described in Note&nbsp;1 to the
consolidated financial statements) of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="ds76701_where_you_can_find_more_information"> </A>
<A NAME="toc_ds76701_6"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Where you can find more information    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-1 (including exhibits, schedules, and amendments) under the Securities
Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of that registration statement, does not contain all the information set forth in
the registration statement or the exhibits and schedules that are part of the registration statement. Some items included in the registration statement are omitted from the prospectus in accordance
with the rules and regulations of the SEC. For further information about us and the shares of common stock to be sold in this offering, you should refer to the registration statement and the
accompanying exhibits and schedules filed therewith. Statements contained in this prospectus relating to the contents of any contract, agreement or other document that is filed as an exhibit to the
registration statement are not necessarily complete and are qualified in all respects by the complete text of the applicable contract, agreement or other document, a copy of which has been filed as an
exhibit to the registration statement. Whenever this prospectus refers to any contract, agreement, or other document, you should refer to the exhibits that are a part of the registration statement for
a copy of the contract, agreement, or document. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
may read and copy all or any portion of the registration statement and the accompanying exhibits or any other information we file at the SEC's public reference room at 100&nbsp;F Street, N.E.,
Room&nbsp;1580, Washington, D.C. 20549. You can request copies of these documents, upon payment of a duplicating fee, by writing to the SEC. Please call the SEC at 1-800-SEC-0330 for further
information about the operation of the public reference rooms. Our SEC filings, including the registration statement, are also available to you on the SEC's Website
(</FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act. Under the Exchange Act, we will file annual, quarterly and
current reports, as well as proxy statements and other periodic information with the SEC. These periodic reports, proxy statements, and other information will be available for inspection and copying
at the SEC's Public Reference Room and the website of the SEC referred to above. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>200</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=202,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=383446,FOLIO='200',FILE='DISK114:[18ZBC1.18ZBC76701]DS76701A.;50',USER='CHE109871',CD='23-JUL-2018;01:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fa76701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="fa76701_index_to_consolidated_financial_statements"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Index to consolidated financial statements    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="FA76701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Page</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fc76701_report_of_independent___fc702285"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of independent registered public accounting firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fc76701_report_of_independent___fc702285"><FONT SIZE=2>F-2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fe76701_replimune_group,_inc._consolidated_balance_sheets"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated balance sheets</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fe76701_replimune_group,_inc._consolidated_balance_sheets"><FONT SIZE=2><BR>
F-3</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fg76701_replimune_group,_inc.___fg702388"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated statements of operations</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fg76701_replimune_group,_inc.___fg702388"><FONT SIZE=2><BR>
F-4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fi76701_replimune_group,_inc._consolid__rep02679"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated statements of comprehensive loss</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fi76701_replimune_group,_inc._consolid__rep02679"><FONT SIZE=2><BR>
F-5</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fk76701_replimune_group,_inc._consolid__rep04054"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated statements of convertible preferred stock and
stockholders' deficit</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fk76701_replimune_group,_inc._consolid__rep04054"><FONT SIZE=2><BR>
F-6</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fm76701_replimune_group,_inc.___fm702367"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated statements of cash flows</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fm76701_replimune_group,_inc.___fm702367"><FONT SIZE=2><BR>
F-7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#notes"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to consolidated financial statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#notes"><FONT SIZE=2><BR>
F-8</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=203,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=807251,FOLIO='F-1',FILE='DISK114:[18ZBC1.18ZBC76701]FA76701A.;7',USER='CHE108057',CD='19-JUL-2018;23:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fc76701_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="fc76701_report_of_independent___fc702285"> </A>
<A NAME="toc_fc76701_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Report of Independent Registered Public Accounting Firm  <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the Board of Directors and Stockholders of<BR>
Replimune Group,&nbsp;Inc. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have audited the accompanying consolidated balance sheets of Replimune Group,&nbsp;Inc. and its subsidiaries as of March&nbsp;31, 2018 and 2017, and
the related consolidated statements of operations, of comprehensive loss, of convertible preferred stock and stockholders' deficit and of cash flows for the years then ended, including the related
notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company as of March&nbsp;31, 2018 and 2017, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the
United States of America. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a
reasonable basis for our opinion. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Emphasis of Matter  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As discussed in Note&nbsp;1 to the consolidated financial statements, the Company will require additional financing to fund future operations. Management's
plans in regard to this matter are described in Note&nbsp;1. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP<BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Boston,
Massachusetts<BR>
June&nbsp;11, 2018, except for the effects of the forward stock split discussed in Note&nbsp;16<BR>
to the consolidated financial statements, as to which the date is July&nbsp;10, 2018 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have served as the Company's auditor since 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=204,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=754955,FOLIO='F-2',FILE='DISK114:[18ZBC1.18ZBC76701]FC76701A.;22',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fe76701_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fe76701_replimune_group,_inc._consolidated_balance_sheets"> </A>
<A NAME="toc_fe76701_1"> </A></FONT> <FONT SIZE=4><B><BR>  Replimune Group,&nbsp;Inc.    <BR>    <BR>    Consolidated balance sheets    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31,<BR> </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Pro forma<BR>
March&nbsp;31,<BR>
2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ROWSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,583</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,583</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term investments</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>43,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>43,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development incentives receivable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,389</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,389</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>401</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>763</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>763 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,402</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>64,703</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>64,703</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>342</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>370</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>370</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>75</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>78</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>78 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,819</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,151 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>323</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,993</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,993</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses and other current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,662</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,171</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,171 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,985</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,164</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,164</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent, net of current portion</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>70</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>670</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,642</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,725</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,858</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,216 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies (Note&nbsp;13)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock (series seed, A and B), $0.001 par value; 1,114,553 shares authorized as of March&nbsp;31, 2017 and 1,975,968 shares authorized
as of March&nbsp;31, 2018; 1,064,553 shares issued and outstanding as of March&nbsp;31, 2017 and 1,925,968 shares issued and outstanding as of March&nbsp;31, 2018; no shares issued or outstanding, pro forma (unaudited) as of March&nbsp;31,
2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31,609</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>86,361</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' Equity (Deficit):</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 27,314,288 shares authorized as of March&nbsp;31, 2017 and 27,314,288 shares authorized (inclusive of 26,258 shares of
common&nbsp;A stock) as of March&nbsp;31, 2018; 4,973,439 shares issued and outstanding as of March&nbsp;31, 2017 and 5,007,485 issued and outstanding (inclusive of 26,258 shares of common&nbsp;A stock) as of March&nbsp;31, 2018; 24,138,587 shares
issued and outstanding, pro forma (unaudited) as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>259</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,097</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>89,081</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,230</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,932</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,549</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(11,515</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28,068</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,935 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,819</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,151</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,151 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these consolidated financial
statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=205,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=510267,FOLIO='F-3',FILE='DISK114:[18ZBC1.18ZBC76701]FE76701A.;46',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fg76701_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fg76701_replimune_group,_inc.___fg702388"> </A>
<A NAME="toc_fg76701_1"> </A></FONT> <FONT SIZE=4><B><BR>  Replimune Group,&nbsp;Inc.    <BR>    <BR>    Consolidated statements of operations    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,516</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,711</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,713 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,647</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,229 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,647</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,229</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Research and development incentives</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,267</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>288</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Change in fair value of warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(150</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(972</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>626</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,056</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total other income (expense), net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,943</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(473</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3.96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,973,439</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,978,539 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.87</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pro forma weighted average common shares outstanding, basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21,506,697 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these consolidated financial
statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=206,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=15664,FOLIO='F-4',FILE='DISK114:[18ZBC1.18ZBC76701]FG76701A.;33',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fi76701_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fi76701_replimune_group,_inc._consolid__rep02679"> </A>
<A NAME="toc_fi76701_1"> </A></FONT> <FONT SIZE=4><B><BR>  Replimune Group,&nbsp;Inc.    <BR>    <BR>    Consolidated statements of comprehensive loss    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income (loss):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Foreign currency translation gain (loss)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,437</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net unrealized loss on short-term investments, net of tax</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9,141</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,391</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these consolidated financial
statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=207,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=704853,FOLIO='F-5',FILE='DISK114:[18ZBC1.18ZBC76701]FI76701A.;25',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fk76701_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fk76701_replimune_group,_inc._consolid__rep04054"> </A>
<A NAME="toc_fk76701_1"> </A></FONT> <FONT SIZE=4><B><BR>  Replimune Group,&nbsp;Inc.    <BR>    <BR>    Consolidated statements of convertible preferred stock and<BR>  stockholders' deficit    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Convertible<BR>
preferred stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Common stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Additional<BR>
paid-in<BR>
capital</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Accumulated<BR>
other<BR>
comprehensive<BR>
Loss</B></FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Total<BR>
stockholders'<BR>
deficit</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ROWSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(Amounts in thousands,<BR>
except share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Accumulated<BR>
deficit</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Amount</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Amount</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Balances as of March&nbsp;31, 2016</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">632,276</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">16,609</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,973,439</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">51</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,526</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,112</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,582</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">432,277</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">15,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Foreign currency translation adjustment</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,437</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,437</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">208</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">208</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Balances as of March&nbsp;31, 2017</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,064,553</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">31,609</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,973,439</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">259</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9,230</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,549</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(11,515</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of series&nbsp;B convertible preferred stock, net of $198 issuance costs</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">861,415</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">54,752</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of common&nbsp;A stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">26,258</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Foreign currency translation adjustment</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,376</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,376</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Unrealized loss on short-term investments, net of tax</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(65</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(65</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock options in exchange for consulting services</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,788</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">26</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">26</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">812</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">812</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Balances as of March&nbsp;31, 2018</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,925,968</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">86,361</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,007,485</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,097</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(28,932</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(238</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(28,068</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these consolidated financial
statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=208,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=958638,FOLIO='F-6',FILE='DISK114:[18ZBC1.18ZBC76701]FK76701A.;38',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fm76701_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fm76701_replimune_group,_inc.___fm702367"> </A>
<A NAME="toc_fm76701_1"> </A></FONT> <FONT SIZE=4><B><BR>  Replimune Group,&nbsp;Inc.    <BR>    <BR>    Consolidated statements of cash flows    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(Amounts in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>208</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>812</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>122</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>109</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>972</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock options in exchange for consulting services</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net amortization of premiums and discounts on short-term investments</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(123</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development incentives receivable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,210</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(767</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(325</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(305</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>203</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,596</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses and other current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,406</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,393</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,077</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property, plant and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(136</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of short-term investments</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(52,463</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from maturities of short-term investments</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,553 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(238</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(44,046</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of series&nbsp;B convertible preferred stock, net of issuance costs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>54,752 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>54,752 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Effect of exchange rate changes on cash and cash equivalents</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,419</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,297</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase (decrease) in cash and cash equivalents</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,011</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at beginning of year</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,328</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,594 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at end of year</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,583 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these consolidated financial
statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=209,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=439850,FOLIO='F-7',FILE='DISK114:[18ZBC1.18ZBC76701]FM76701A.;29',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fo76701_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="notes"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fo76701_replimune_group,_inc._notes_to__rep04765"> </A>
<A NAME="toc_fo76701_1"> </A></FONT> <FONT SIZE=4><B><BR>  Replimune Group,&nbsp;Inc.    <BR>    <BR>    Notes to consolidated financial statements    <BR>    <BR>    </B></FONT><FONT SIZE=3><B>(Amounts in thousands, except share and per share
amounts)    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nature of the business  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Replimune Group,&nbsp;Inc. (the "Company") is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Replimune
Limited ("Replimune UK") was incorporated in 2015 under the laws of England, and was the sole shareholder of Replimune,&nbsp;Inc. ("Replimune US"), a Delaware corporation. On
July&nbsp;5, 2017, Replimune Group,&nbsp;Inc., a Delaware corporation, was incorporated and on July&nbsp;10, 2017 the shareholders of Replimune UK effected a share-for-share exchange pursuant to
which they exchanged their outstanding shares in Replimune UK for shares in Replimune Group,&nbsp;Inc., on a one-for-one basis. In addition, the holders of warrants and stock options to purchase
Replimune UK capital stock canceled their warrants to purchase shares of series seed preferred stock and stock options in Replimune UK and were issued replacement warrants to purchase shares of series
seed preferred stock and stock options to acquire Replimune Group,&nbsp;Inc. capital stock on a one-for-one basis. These transactions are collectively referred to as the reorganization. Upon
completion of the reorganization, the historical consolidated financial statements of Replimune UK became the historical consolidated financial statements of Replimune Group,&nbsp;Inc. because the
reorganization was accounted for similar to a reorganization of entities under common control due to the high degree of common ownership of Replimune UK and Replimune Group, Inc. and lack of economic
substance to the transaction. The Company concluded that the reorganization resulted in no change in the material rights and preferences of each respective class of equity interests and no change in
the fair value of each respective class of equity interests before and after the reorganization. On December&nbsp;8, 2017, Replimune UK transferred all outstanding shares of its wholly owned
subsidiary, Replimune US to Replimune Group,&nbsp;Inc. Replimune Group.&nbsp;Inc., a Delaware corporation, is the sole shareholder of Replimune UK, Replimune US and Replimune Securities
Corporation, a Massachusetts corporation that was incorporated in November 2017. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product
candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to
commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company's
product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the
ordinary course of business. Through March&nbsp;31, 2018, the Company has funded its operations primarily with proceeds from the sale of convertible preferred stock. The Company has incurred
recurring losses since its inception, including net losses of $7,704 for the year ended March&nbsp;31, 2017 and $19,702 for the year ended March&nbsp;31,
2018. In addition, as of March&nbsp;31, 2018, the Company had an accumulated deficit of $28,932. The Company expects to continue to generate operating losses for the foreseeable future. As of
June&nbsp;11, 2018, the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=210,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=46466,FOLIO='F-8',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<A NAME="page_fo76701_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>issuance
date of the consolidated financial statements for the year ended March&nbsp;31, 2018, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to
fund its operating expenses and capital expenditure requirements through at least 12&nbsp;months from the issuance of the consolidated financial statements. The future viability of the Company
beyond that point is dependent on its ability to raise additional capital to finance its operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is seeking to complete an initial public offering ("IPO") of its common stock. Upon the completion of a qualified public offering on specified terms, the Company's outstanding convertible
preferred stock will convert into shares of common stock (see Note&nbsp;7). In the event the Company does not complete an IPO, the Company will seek additional funding through private equity
financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain funding on acceptable terms,
or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the Company is unable to obtain funding it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization
efforts, which could adversely affect its business prospects, or it may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company
will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of significant accounting policies  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principles of consolidation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of
America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Replimune UK, Replimune US and Replimune Securities Corporation, after elimination of all intercompany
accounts and transactions. The consolidated financial statements reflect the capital as if Replimune Group,&nbsp;Inc. had been in existence for all periods presented. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of estimates  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting
periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation
of common stock and stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable
under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become
known. Actual results could differ from those estimates or assumptions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=211,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=410931,FOLIO='F-9',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<A NAME="page_fo76701_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited pro forma information  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The accompanying unaudited pro forma consolidated balance sheet as of March&nbsp;31, 2018 has been prepared to give effect, upon the completion of the
proposed IPO, to (i)&nbsp;the conversion of all outstanding shares of convertible preferred stock into 19,157,360 shares of common stock and (ii)&nbsp;all outstanding warrants to purchase shares
of series seed preferred stock becoming warrants to purchase shares of common stock, as if the proposed IPO had occurred on March&nbsp;31, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the accompanying consolidated statement of operations, the unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the year ended March&nbsp;31, 2018 has
been prepared to give effect, upon the completion of the proposed IPO, to (i)&nbsp;the conversion of all outstanding shares of convertible preferred stock into shares of common stock and
(ii)&nbsp;all outstanding warrants to purchase shares of series seed preferred stock becoming warrants to purchase shares of common stock as if the proposed IPO had occurred on the later of
April&nbsp;1, 2017 or the issuance date of the convertible preferred stock or the warrants. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign currency and currency translation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The functional currency for the Company's wholly owned foreign subsidiary, Replimune UK, is the British Pound. Assets and liabilities of Replimune UK are
translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period.
Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of convertible preferred stock and stockholders' deficit
as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other
income (expense), net in the consolidated statements of operations as incurred. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentrations of credit risk and of significant suppliers  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as
short-term investments. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits, and has not experienced any losses on such accounts and does not
believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by
a significant interruption in these manufacturing services or the availability of raw materials. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash and cash equivalents  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company considers all highly liquid investments with original maturities of three months or less at date of purchase to be cash equivalents. Cash
equivalents consisted of money market funds at March&nbsp;31, 2018. As of March&nbsp;31, 2017 and 2018, cash equivalents consisted of $0 and $4,130, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=212,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=14595,FOLIO='F-10',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<A NAME="page_fo76701_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted cash  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company maintains certain minimum balances in segregated bank accounts in connection with its corporate credit cards. As of March&nbsp;31, 2017 and
2018, restricted cash consisted of $75
and $78, respectively. These amounts have been classified as non-current assets on the Company's consolidated balance sheets. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Short-term investments  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company's short-term investments are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a
component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Realized gains and losses and declines in value determined to be other than temporary are based on the
specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company evaluates its short-term investments with unrealized losses for other-than-temporary impairment. When assessing short-term investments for other-than-temporary declines in value, the
Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its
original cost, the Company's ability and intent to retain the short-term investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in
general. If any adjustment to fair value reflects a decline in the value of the short-term investment that the Company considers to be "other than temporary," the Company reduces the short-term
investment to fair value through a charge to the consolidated statements of operations. No such adjustments were necessary during the periods presented. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's short-term investments as of March&nbsp;31, 2017 and 2018 had original maturities of less than one year. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred offering costs  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as
deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders' equity (deficit) as a reduction of proceeds
generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a
charge to operating expenses in the consolidated statements of operations. The Company did not record any deferred offering costs as of March&nbsp;31, 2017 or 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=213,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=122126,FOLIO='F-11',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<A NAME="page_fo76701_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property, plant and equipment  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using
the straight-line method over the estimated useful lives of the respective assets as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="177pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Estimated useful life </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Office equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Computer equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>3&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Plant and laboratory equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Lesser of lease term or 10&nbsp;years </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Costs
for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or
sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs
and maintenance are charged to expense as incurred. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of long-lived assets  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Long-lived assets consist of property, plant and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in
business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in
deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes
or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows
expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows
expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair
value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred rent  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company recognizes rent expense on a straight-line basis over the respective lease terms and has recorded deferred rent for rent expense incurred but not
yet paid. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair value measurements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an
asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=214,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=764681,FOLIO='F-12',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<A NAME="page_fo76701_1_13"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered
unobservable:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market
data. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair
value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>The
Company's short-term investments, cash equivalents and warrant liability are carried at fair value, determined according to the fair value hierarchy described above (see Note&nbsp;3). The
carrying values of research and development incentives receivable, other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the
short-term nature of these assets and liabilities. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrant liability  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company classifies warrants to purchase shares of series seed preferred stock (see Note&nbsp;8) as a liability on its consolidated balance sheets as
these warrants to purchase shares of series seed preferred stock are free-standing financial instruments that may require the Company to transfer assets upon exercise. The warrant liability was
initially recorded at fair value upon the date of the warrants' issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liability are
recognized as a component of other income (expense), net in the consolidated statements of operations. Changes in the fair value of the warrant liability will continue to be recognized until the
warrants to purchase shares of series seed preferred stock are exercised, expire or qualify for equity classification. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company utilizes the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant liability. The Company assesses these assumptions and estimates on a
quarterly basis as additional information impacting assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the expected stock price volatility, the expected
term of the warrant, the risk-free interest rate for a period that approximates the expected term of the warrant, and the Company's expected dividend yield (see Note&nbsp;3). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment information  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company's
current focus is on developing oncolytic immunotherapies for the treatment of cancer. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=215,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=828843,FOLIO='F-13',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<A NAME="page_fo76701_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development costs  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development
activities, including salaries, stock-based compensation and benefits, facilities costs and laboratory supplies, depreciation and external costs of outside vendors engaged to conduct preclinical
development, clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no
longer expected that the goods will be delivered or the services rendered. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research contract costs and accruals  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company has entered into various research and development-related contracts with companies both inside and outside of the United States. These agreements
are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the
adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant
judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual
estimates have not been materially different from the actual costs. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent costs  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation
expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant
using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the
risk-free interest rate for a period that approximates the expected term of the option, and the Company's expected dividend yield (see Note&nbsp;10). Forfeitures are accounted for as they occur. To
date, the Company has issued stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
stock-based awards granted to consultants and non-employees, compensation expense is recognized over the shorter of the vesting period or the period during which services are rendered by such
consultants and non-employees until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current
fair value of the Company's common stock and updated assumption inputs in the Black-Scholes option-pricing model. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=216,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=254089,FOLIO='F-14',FILE='DISK114:[18ZBC1.18ZBC76701]FO76701A.;50',USER='CHE109570',CD='21-JUL-2018;00:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fq76701_1_15"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued)  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient's payroll costs are classified or in which the
award recipient's service payments are classified. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development incentives and receivable  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company, through its subsidiary in the United Kingdom, receives reimbursements of certain research and development expenditures as part of a United
Kingdom government's research and development tax reliefs program. Under the program, a percentage of qualifying research and development expenses incurred by the Company's subsidiary in the United
Kingdom are reimbursed up to 14.5%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Management
has assessed the Company's research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development
incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable
assurance that the reimbursement will be received. The Company records these research and development incentives as other income. The research and development incentives receivable represents an
amount due in connection with the above program. The Company recorded other income from research and development incentives of $1,442 and $2,267 during the years ended March&nbsp;31, 2017 and 2018,
respectively, in the consolidated statements of operations and a research and development incentives receivable of $1,407 and $2,389 as of March&nbsp;31, 2017 and 2018, respectively, on the
consolidated balance sheets. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive loss  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than
those with stockholders. For the year ended March&nbsp;31, 2017, comprehensive loss included $(1,437) of foreign currency translation adjustments. For the year ended March&nbsp;31, 2018,
comprehensive loss included $2,376 of foreign currency translation adjustments and $(65), respectively, of unrealized losses on short-term investments, net of tax. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Deferred tax assets and liabilities are determined on the
basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to
reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=217,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=904967,FOLIO='F-15',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>a
valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and
considering prudent and feasible tax planning strategies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First,
the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be
sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest
amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax
benefits, that are considered appropriate as well as the related net interest and penalties. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net income (loss) per share  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating
securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in
undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Basic
net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of
common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate
undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income
(loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect
of common stock equivalents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Common
A shares are excluded when computing net income (loss) per share as they have nominal economic rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's convertible preferred stock contractually entitles the holders of such shares to participate in dividends but contractually do not require the holders of such shares to participate in
losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net
loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive
common shares are not assumed to have been issued if their effect is anti-dilutive. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=218,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=579841,FOLIO='F-16',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently adopted accounting pronouncements  </I></B></FONT></P>

</UL>


<P style="font-family:arial;"><FONT SIZE=2>In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&nbsp;2016-09, </FONT> <FONT SIZE=2><I>Compensation&#151;Stock Compensation (Topic&nbsp;718): Improvements to Employee
Share-Based Payment Accounting</I></FONT><FONT SIZE=2> ("ASU&nbsp;2016-09").
ASU&nbsp;2016-09 addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an
option to recognize gross share compensation expense with actual forfeitures recognized as they occur, and classification on the consolidated statements of cash flows. Certain of these changes are
required to be applied retrospectively, while other changes are required to be applied prospectively. The Company adopted ASU&nbsp;2016-09 as of the required effective date of April&nbsp;1, 2017
and elected prospectively to account for forfeitures as they occur rather than apply an estimated forfeiture rate to share-based compensation expense. The adoption of ASU&nbsp;2016-09 did not have a
material impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2015, the FASB issued ASU No.&nbsp;2015-17, </FONT><FONT SIZE=2><I>Income Taxes (Topic&nbsp;740): Balance Sheet Classification of Deferred Taxes</I></FONT><FONT SIZE=2>
("ASU&nbsp;2015-17"). ASU&nbsp;2015-17 requires deferred tax liabilities and assets to be classified as non-current in the consolidated balance sheet. The amendment may be applied either
prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company adopted ASU 2015-17 retrospectively to all periods presented as of March&nbsp;31,
2017, and its adoption had no impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2014, the FASB issued ASU No.&nbsp;2014-16, </FONT><FONT SIZE=2><I>Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to
Debt or to Equity</I></FONT><FONT SIZE=2> ("ASU&nbsp;2014-16"). The guidance requires an entity to determine the nature of the host contract by considering all stated and implied substantive terms
and features of the hybrid financial instrument, weighing each term and feature on the basis of the relevant facts and circumstances (commonly referred to as the whole-instrument approach). The
Company adopted ASU&nbsp;2014-16 as of the required effective date of April&nbsp;1, 2016 and reflected the adoption on a modified retrospective basis, and its adoption had no impact on the
Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued ASU No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</I></FONT><FONT SIZE=2>
(Subtopic&nbsp;205-40) ("ASU&nbsp;2014-15"). The amendments in this update explicitly require a company's management to assess an entity's ability to continue as a going concern and to provide
related footnote disclosures in certain circumstances. The Company adopted ASU&nbsp;2014-15 as of the required effective date of March&nbsp;31, 2017. This guidance relates to footnote disclosure
only, and its adoption had no impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In July 2017, the FASB issued ASU&nbsp;No.&nbsp;2017-11, </FONT><FONT SIZE=2><I>Earnings Per Share (Topic&nbsp;260), Distinguishing Liabilities from
Equity (Topic&nbsp;480), Derivatives and Hedging (Topic&nbsp;815)&nbsp;I. Accounting for Certain Financial Instruments with Down Round Features&nbsp;II. Replacement of the Indefinite Deferral
for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I></FONT><FONT SIZE=2>
("ASU&nbsp;2017-11"). Part&nbsp;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=219,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=70926,FOLIO='F-17',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>down-round
features. Part&nbsp;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities
contained within Accounting Standards Codification ("ASC") Topic&nbsp;480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU&nbsp;2017-11
is required to be adopted for annual periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the
adoption of ASU&nbsp;2017-11 will have on its consolidated financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2017, the FASB issued ASU No.&nbsp;2017-09, </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation (Topic&nbsp;718): Scope of Modification Accounting</I></FONT><FONT SIZE=2>
("ASU&nbsp;2017-09"), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is
required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective
for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company will apply ASU&nbsp;2017-09 to any changes
to the terms or conditions of share-based payment awards after the adoption date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2016, the FASB issued ASU No.&nbsp;2016-18, </FONT><FONT SIZE=2><I>Statement of Cash Flows (Topic&nbsp;230): Restricted Cash</I></FONT><FONT SIZE=2> ("ASU&nbsp;2016-18"), which
requires restricted cash to be presented with cash and cash equivalents on the consolidated statements of cash flows and disclosure of how the consolidated statements of cash flows reconciles to the
balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The standard is effective for annual periods beginning after December&nbsp;15, 2017,
including interim periods within those fiscal years. Early adoption is permitted. Upon adoption on April&nbsp;1, 2018, the amount of cash and cash equivalents previously presented on the
consolidated statements of cash flows for the years ended March&nbsp;31, 2017 and 2018 will increase by $75 and $78, respectively, to reflect the inclusion
of restricted cash. Additionally, transfers between restricted and unrestricted cash will no longer be presented as a component of the Company's investing activities. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
October 2016, the FASB issued ASU No.&nbsp;2016-16, </FONT><FONT SIZE=2><I>Income Taxes (Topic&nbsp;740): Intra-Entity Transfer of Assets Other than Inventory</I></FONT><FONT SIZE=2>
("ASU&nbsp;2016-16"), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective
for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU&nbsp;2016-16
will have on its consolidated financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2016, the FASB issued ASU No.&nbsp;2016-15, </FONT><FONT SIZE=2><I>Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</I></FONT><FONT SIZE=2>
("ASU&nbsp;2016-15"), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the consolidated statements of cash flows. The standard is
effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of
ASU&nbsp;2016-15 will have on its consolidated financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2016, the FASB issued ASU No.&nbsp;2016-02</FONT><FONT SIZE=2><I>, Leases (Topic&nbsp;842)</I></FONT><FONT SIZE=2> ("ASU&nbsp;2016-02"), which sets out the principles for the
recognition, measurement, presentation and disclosure of leases for both parties to a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=220,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=756963,FOLIO='F-18',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>contract
(i.e.,&nbsp;lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or
not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their
classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU&nbsp;2016-02 supersedes the previous leases standard,
ASC&nbsp;840, Leases. The standard is effective for public entities for annual periods beginning after December&nbsp;15, 2018 including interim periods within those fiscal years. Early adoption is
permitted. The Company is currently evaluating the impact that the adoption of ASU&nbsp;2016-02 will have on its consolidated financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2014, the FASB issued ASU No.&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers</I></FONT><FONT SIZE=2> (Topic&nbsp;606) ("ASU&nbsp;2014-09"), which supersedes
existing revenue recognition guidance under GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this
principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying
performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance
obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued
ASU No.&nbsp;2015-14, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers</I></FONT><FONT SIZE=2> (Topic&nbsp;606): Deferral of the Effective Date, which delays the effective date of
ASU&nbsp;2014-09 such that the standard is effective for public entities for annual periods beginning after December&nbsp;15, 2017 and for interim periods within those fiscal years. Early adoption
of the standard is permitted for annual periods beginning after December&nbsp;15, 2016. The adoption of ASU&nbsp;2014-09 is not expected to have an impact on the Company's consolidated financial
statements as the Company does not currently have any revenue-generating arrangements. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of financial assets and liabilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Fair value measurements<BR>
as of March&nbsp;31, 2017 using: </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;1</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;2</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;3</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>670 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>670 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=221,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=102555,FOLIO='F-19',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Fair value measurements<BR>
as of March&nbsp;31, 2018 using: </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;1</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;2</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;3</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,130</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,130</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commercial paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,970</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,970 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>48,098</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>48,098 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,642</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,642 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,642</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,642 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>During
the years ended March&nbsp;31, 2017 and 2018, there were no transfers between levels. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of cash equivalents and short-term investments  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Money market funds, commercial paper and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities,
which represent a Level&nbsp;2 measurement within the fair value hierarchy. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of warrant liability  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The warrant liability is related to the warrants to purchase shares of series seed preferred stock (see Note&nbsp;8). The fair value of the warrant
liability was determined based on significant
inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company used the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant liability. Key estimates and assumptions impacting the fair value
measurement include (i)&nbsp;the expected term of the warrants, (ii)&nbsp;the risk-free interest rate, (iii)&nbsp;the expected dividend yield and (iv)&nbsp;expected volatility of the price of
the underlying series&nbsp;seed preferred stock. The Company estimated the fair value per share of the underlying series&nbsp;seed preferred stock based, in part, on the results of third-party
valuations and additional factors deemed relevant. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining
contractual term of the warrants. The Company estimated a 0% expected dividend yield based on the fact that the Company has never paid or declared dividends and does not intend to do so in the
foreseeable future. As the Company is a private company and lacks company-specific historical and implied volatility information of its stock, the expected stock volatility was based on the historical
volatility of publicly traded peer companies for a term equal to the remaining expected term of the warrants. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=222,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=950042,FOLIO='F-20',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_21"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table presents the unobservable inputs of the warrant liability: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.33%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.69%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>65.8% </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
following table presents a roll forward of the warrant liability: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Warrant<BR>
liability </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at March&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>150 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at March&nbsp;31, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>972 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at March&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,642 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=3><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Short-term investments by investment type consisted of the following as of March&nbsp;31, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="88pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="88pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Amortized<BR>
cost</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Gross unrealized<BR>
gains</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Gross unrealized<BR>
losses</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Fair<BR>
value </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commercial paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>28,028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16,005</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,970 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>44,033</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>43,968 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
Company did not have any short-term investments as of March&nbsp;31, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=223,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=626727,FOLIO='F-21',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Property, plant and equipment, net consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Office equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plant and laboratory equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>336 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: Accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(147</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>370 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Depreciation
and amortization expense was $122 and $109 for the years ended March&nbsp;31, 2017 and 2018, respectively. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accrued expenses and other current liabilities consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31,<BR> </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued research and development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>649</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued compensation and benefits costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>514</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,094</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>153 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,662</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,171 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=3><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible preferred stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2017, the Company's certificate of incorporation, as then in effect, authorized the Company to issue&nbsp;1,114,553 shares of par value
$0.001 per share convertible preferred stock. As of March&nbsp;31, 2018, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue&nbsp;1,975,968 shares
of par value $0.001 per share convertible preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company has issued series&nbsp;seed convertible preferred stock (the "series seed preferred stock"), series&nbsp;A convertible preferred stock (the "series&nbsp;A preferred stock") and
series&nbsp;B convertible preferred stock (the "series&nbsp;B preferred stock"). The series seed preferred stock, series&nbsp;A preferred stock and series&nbsp;B preferred stock are
collectively referred to as the "preferred stock." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=224,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=913567,FOLIO='F-22',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2015, the Company issued and sold 200,000 shares of series seed preferred stock at a price of $10.00 per share for cash proceeds of $2,000. In connection with the series seed preferred stock
issuance, the Company issued 50,000 warrants to purchase shares of series seed preferred stock (See Note&nbsp;8). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
September 2015, the Company entered into a subscription agreement (the "Subscription Agreement") for the sale of series&nbsp;A preferred stock in two investment closings of (i)&nbsp;first
tranche shares of series&nbsp;A preferred stock and (ii)&nbsp;second tranche shares of series&nbsp;A preferred stock. In September 2015, the Company issued and sold 432,276 first tranche shares
of series&nbsp;A preferred stock at a price of $34.70 per share for cash proceeds of $15,000. Under the Subscription Agreement, the issuance and sale of second tranche shares of series&nbsp;A
preferred stock was subject to a Milestone, defined as the filing of an Investigational New Drug application by the Company (or a subsidiary thereof) with the U.S. Food and Drug Administration in
respect of the Company's first clinical trial becoming effective. In March 2017, Replimune UK's board of directors, including the required number of investor directors, waived the Milestone required
by the Subscription Agreement and the Company issued and sold 432,277 second tranche shares of series&nbsp;A preferred stock at a price of $34.70 per share for cash proceeds of $15,000. The Company
determined that the future tranche obligation of the Subscription Agreement did not meet the definition of a freestanding financial instrument because, while separately exercisable, it was not legally
detachable. Further, the Company determined that, while embedded, the future tranche obligation of the Subscription Agreement did not require bifurcation for accounting purposes as it was clearly and
closely related to the economic characteristics and risks of the series&nbsp;A preferred stock and would not meet the definition of a derivative on a standalone basis. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
July 2017, the Company issued and sold 861,415 shares of series&nbsp;B preferred stock at a price of $63.79 per share for cash proceeds of $54,950, net of issuance costs of $198. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of each balance sheet date, preferred stock consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
shares<BR>
authorized</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
shares<BR>
issued and<BR>
outstanding</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Carrying<BR>
value</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Liquidation<BR>
preference</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Common stock<BR>
issuable upon<BR>
conversion</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series seed preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,609</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,989,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>864,553</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>864,553</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,599,601 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,114,553</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,064,553</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,609</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,588,977 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=225,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=576673,FOLIO='F-23',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
shares<BR>
authorized</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
shares<BR>
issued and<BR>
outstanding</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Carrying<BR>
value</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Liquidation<BR>
preference</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Common stock<BR>
issuable upon<BR>
conversion</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series seed preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,609</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,989,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>864,553</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>864,553</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,599,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>861,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>861,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>54,752</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>54,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,586,383 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,975,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,925,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>86,361</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>86,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19,157,360 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
holders of the preferred stock have the following rights and preferences: </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The holders of the preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to the stockholders for a vote
and are entitled to the number of votes equal to the number of whole shares of common stock into which such holders of preferred stock could convert on the record date of for determination of
stockholders entitled to vote. The holders of preferred stock and common stock, voting as a single class, are entitled to elect two directors of the Company. Additionally, the holders of the series
seed preferred stock are entitled to elect two directors of the Company, the holders of the series&nbsp;A preferred stock are entitled to elect one director of the Company and the holders of at
least 55% of the outstanding series&nbsp;B preferred stock are entitled to elect two directors of the Company. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Each share of preferred stock is convertible into common stock, at any time, at the option of the holder, and without the payment of additional consideration,
at the applicable conversion ratio then in effect for each series of preferred stock and subject to adjustment in accordance with anti-dilution provisions. In addition, each share of preferred stock
will be converted into common stock at the applicable conversion ratio then in effect for each series of preferred stock upon the earlier of (i)&nbsp;the closing of a firm commitment underwritten
public offering of the Company's common stock with gross proceeds to the Company of at least $30,000 and at a price per share of not less than $9.62, subject to appropriate adjustment in the event of
any stock split, stock dividend, combination or other similar recapitalization, or (ii)&nbsp;a date specified by vote or written consent of the holders of 75% of the outstanding preferred stock
(voting together as a single class on an as-converted basis). For any events of deemed liquidation (as&nbsp;defined below) in which series&nbsp;B preferred stock investors would receive less than
their full liquidation preference, a further approval of holders of 55% of the outstanding series&nbsp;B preferred stock is required. As of March&nbsp;31, 2017 and 2018, each share of preferred
stock was convertible into one share of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
conversion ratio for each series of preferred stock is determined by dividing the original issue price of each series of preferred stock by the conversion price of each series (as defined below).
As of March&nbsp;31, 2017 and 2018, the series seed preferred stock original issue price and series seed preferred stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=226,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=112900,FOLIO='F-24',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fq76701_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>conversion
price were $10.00 per share and $1.01&nbsp;per share, respectively. As of March&nbsp;31, 2017 and 2018, the series&nbsp;A preferred stock original issue price and Series&nbsp;A
preferred stock conversion price were $34.70 per share and $3.49&nbsp;per share, respectively. As of March&nbsp;31, 2017 and 2018, the series&nbsp;B preferred stock original issue price and
series&nbsp;B preferred stock conversion price were $63.79 per share and $6.41&nbsp;per share, respectively. Such series seed preferred stock original issue price, series&nbsp;A preferred stock
original issue price and series&nbsp;B preferred stock original issue price and series seed preferred stock conversion price, series&nbsp;A preferred stock conversion price and series&nbsp;B
preferred stock conversion price, and the rate at which each series of preferred stock may be converted into common stock, are subject to appropriate adjustment from time to time in the event of any
stock dividend, stock split, combination or other similar recapitalization with respect to the preferred stock. The series seed preferred stock conversion price, series&nbsp;A preferred stock
conversion price and series&nbsp;B preferred stock conversion price are also subject to adjustments based on weighted-average anti-dilution provisions set forth in the Company's certificate of
incorporation, as amended and restated, in the event that additional securities are issued at a purchase price less than the series seed preferred stock conversion price, series&nbsp;A preferred
stock conversion price or series&nbsp;B preferred stock conversion price then in effect. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The holders of the preferred stock are entitled to be paid noncumulative dividends if and when declared by the Company's board of directors. The Company may
not pay any dividends on shares of common stock of the Company unless the holders of preferred stock then outstanding simultaneously receive dividends at the same rate and same time as dividends paid
with respect to common stock. Dividends shall accrue on a daily basis assuming a 365-day year, and shall be paid in cash. Through March&nbsp;31, 2017 and 2018, no dividends have been declared or
paid. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation preference  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In the event of any voluntary or involuntary liquidation event, dissolution, winding up of the Company or an event of deemed liquidation, each holder of the
then outstanding series&nbsp;B preferred stock will be entitled to receive, prior and in preference to any distributions to the holders of series&nbsp;A preferred stock, series seed preferred
stock and common stock, an amount equal to the greater of (i)&nbsp;the applicable original issue price, plus any declared but unpaid dividends thereon, or (ii)&nbsp;the amount such
holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
the payment of all preferential amounts to the holders of series&nbsp;B preferred stock, each holder of the then outstanding series&nbsp;A preferred stock will be entitled to receive, prior
and in preference to any distributions to the holders of series seed preferred stock and common stock, an amount equal to the greater of (i)&nbsp;the applicable original issue price, plus any
declared but unpaid dividends thereon, or (ii)&nbsp;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=227,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=386535,FOLIO='F-25',FILE='DISK114:[18ZBC1.18ZBC76701]FQ76701A.;66',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fs76701_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued)  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After the payment of all preferential amounts to the holders of series&nbsp;A preferred stock, each holder of the then outstanding series seed preferred stock will be
entitled to receive, prior and in preference to any
distributions to the holders of common stock, an amount equal to the greater of (i)&nbsp;the applicable original issue price, plus any declared but unpaid dividends thereon or (ii)&nbsp;the amount
such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
payments have been made in full to the holders of preferred stock, then, to the extent available, the remaining amounts will be distributed among the holders of the shares of common stock, the
holders of series&nbsp;B preferred stock and the holders of series&nbsp;A preferred stock, pro rata based on the number of shares held by each holder, assuming full conversion of all such
preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
holders of series&nbsp;B preferred stock and series&nbsp;A preferred stock are subject to a participation cap (as defined below) for remaining amounts that will be distributed, which is
$127.58 per share for the series&nbsp;B preferred stock and $69.40 per share for the series&nbsp;A preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent available, the remaining amounts greater than the total of the participation caps will be distributed among the holders of the shares of common stock, pro rata based on the number of
shares held by each holder. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
a majority of the holders of the then outstanding preferred stock, on an as-if-converted basis voting together as a single class, elect otherwise, an event of deemed liquidation shall include a
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation), sale, transfer or
exclusive license of substantially all of the assets of the Company. The preferred stock is conditionally redeemable upon an event of deemed liquidation, which is defined as any (i)&nbsp;merger,
consolidation or acquisition, involving the Company or its Subsidiary Undertaking, in which the Company or its subsidiary undertaking is not the surviving entity, (ii)&nbsp;an asset sale,
(iii)&nbsp;a share sale, (iv)&nbsp;an initial public offering, (v)&nbsp;the occurrence of a change of control in respect of the Company, (vi)&nbsp;a winding up (vii)&nbsp;or any other a
return of capital to stockholders (other than a conversion, redemption or repurchase of shares made in accordance with the applicable governing documents). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company's certificate of incorporation, as amended and restated, does not provide redemption rights to the holders of preferred stock. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
holders of shares of convertible preferred stock have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company.
Therefore, convertible preferred stock is classified outside of stockholders' deficit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
issuance of each class of preferred stock, the Company assessed the embedded conversion and liquidation features of the securities. The Company determined that each class of preferred stock did
not require the Company to separately account for the liquidation features. The Company also concluded that no beneficial conversion feature existed upon the issuance date of the series&nbsp;A
preferred stock or series&nbsp;B </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=228,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=329159,FOLIO='F-26',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>preferred
stock as of March&nbsp;31, 2017 or 2018. However, the Company did conclude that a beneficial conversion feature existed upon the issuance date of the series seed preferred stock. As the
series seed preferred stock is convertible into common stock, at any time, at the option of the holder, and without the payment of additional consideration, at the applicable conversion ratio then in
effect, the Company recognized the accretion of the beneficial conversion feature as a deemed dividend immediately upon the issuance of the series seed preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock warrants  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the issuance of the series seed preferred stock, the Company issued to the holders of the series seed preferred stock warrants for the
purchase of 50,000 shares of series seed preferred stock, which became fully vested and exercisable in the year of issuance. The warrants to purchase shares of series seed preferred stock were issued
at an exercise price of $10.00 per share and expire on the earlier of September&nbsp;16, 2025 or a qualified change of control event. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
issuance date fair value of the warrants to purchase shares of series seed preferred stock was $391 and was recorded as a liability with a corresponding reduction in the carrying value of the
series seed preferred stock. As of March&nbsp;31, 2017 and 2018, the fair value of the warrant liability was $670 and $1,642, respectively. The Company recognized a loss of $150 and $972 within
other income (expense), net in the consolidated statements of operations for the years ended March&nbsp;31, 2017 and 2018, respectively, related to the change in fair value of the warrant liability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2017 and 2018, the Company was authorized to issue 27,314,288 shares and 27,314,288&nbsp;shares, respectively, of par value $0.001 per
share common stock (including 26,258 authorized shares of common&nbsp;A stock). In July 2017, the Company issued and sold 26,258 shares of par value $0.001 per share common&nbsp;A stock for
nominal cash proceeds. The voting, dividend and liquidation rights of the holders of the Company's common stock is subject to and qualified by the rights, powers and preferences of the holders of the
preferred stock as set forth above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2017 and 2018, the Company had reserved 13,746,206&nbsp;shares and 22,306,801&nbsp;shares, respectively, of common stock for the conversion of outstanding shares of
preferred stock (see&nbsp;Note&nbsp;7), the exercise of outstanding stock options, the number of shares remaining available for grant under the Company's 2017 Equity Compensation Plan
(see&nbsp;Note&nbsp;10) and&nbsp;the exercise of the outstanding warrants to purchase shares of series seed preferred stock (see&nbsp;Note&nbsp;8), assuming all warrants to purchase shares
of series seed preferred stock became warrants to purchase shares of common stock at the applicable conversion ratio. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Each share of common stock, including common A stock, entitles the holder to one vote, together with the holders of preferred stock, on all matters submitted
to the stockholders for a vote. The holders of common </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=229,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=345084,FOLIO='F-27',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_28"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stock,
together with the holders of preferred stock and voting as a single class, are entitled to elect two directors of the Company by vote of a majority of such&nbsp;shares. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Common stockholders are entitled to receive dividends, as may be declared by the Company's board of directors, if any, subject to the preferential dividend
rights of the preferred stock. Through March&nbsp;31, 2017 and 2018, no cash dividends have been declared or&nbsp;paid. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
share of common&nbsp;A stock is entitled to receive dividends, as may be declared by the Company's board of directors, if any, equal to a maximum of 100% of each share's par value. Upon an
event of deemed liquidation, common&nbsp;A stock is entitled to receive dividends equal to a maximum of 300% of each share's par value. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>10.&nbsp;&nbsp;&nbsp;Stock-based compensation  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Enterprise Management Incentive Share Option Plan  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the "2015 Plan") provided for Replimune UK to grant incentive stock options,
non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options are granted only to the Company's employees, including officers
and directors who are also employees. Non-statutory stock options are granted to employees, members of the board of directors, outside advisors and consultants of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
maximum number of common shares that could be issued under the 2015 Plan was 2,659,885 as of March&nbsp;31, 2017, of which 1,729,858 remained available for future grants as of March&nbsp;31,
2017. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Equity Compensation Plan  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In July 2017, in conjunction with the Reorganization, the 2015 Plan was terminated and all awards were cancelled with replacement awards issued under the 2017
Equity Compensation Plan (the "2017 Plan"). Subsequent to the Reorganization, no additional grants will be made under the 2015 Plan and any outstanding awards under the 2015 Plan will continue with
their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a modification with no change in the material rights and
preferences and therefore no recorded change in the fair value of each respective award. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's 2017 Plan provides for the Company to grant incentive stock options or non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards.
Incentive stock options may be granted only to the Company's employees, including officers and directors who are also employees. Restricted stock awards and non-statutory stock options may be granted
to employees, officers, members of the board of directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under the 2017 Plan was 2,659,885 as of
March&nbsp;31, 2018, of which 131,850 remained available for future grants as of March&nbsp;31, 2018. Shares with respect to which awards have expired, terminated, surrendered or cancelled under
the 2017 Plan without having been fully </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=230,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=906327,FOLIO='F-28',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>exercised
will be available for future awards under the 2017 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of
shares of common stock available for the grant of awards. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
2017 Plan is and the 2015 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. However, the board of directors
shall administer and approve all grants made to non-employee directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, except that the
exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant (or 110% of fair value in the case of an award granted
to employees who hold more than 10% of the total combined voting power of all classes of stock at the time of grant) and the term of stock options may not be greater than five years for an incentive
stock option granted to a 10% stockholder and greater than ten years for all other options granted. Stock options awarded under both plans expire ten years after the grant date, unless the board of
directors sets a shorter term. Vesting periods for both plans are determined at the discretion of the board of directors. Incentive stock options
granted to employees and non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock option valuation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks
company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and
expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected
term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The expected term of stock options granted to
non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award
for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash
dividends in the foreseeable future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="14pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.67%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.01%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0% </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=231,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=87027,FOLIO='F-29',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_30"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following table presents the assumptions that the Company used to determine the grant-date fair value of stock options granted to a non-employee: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Year ended<BR>
March&nbsp;31, 2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.29%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0% </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
Company did not grant stock options to non-employees during the year ended March&nbsp;31, 2017. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock options  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes the Company's stock option activity since March&nbsp;31, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="94pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="129pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="77pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Weighted average<BR>
exercise price</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Weighted average<BR>
contractual term (years)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Aggregate<BR>
intrinsic value </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of March&nbsp;31, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>930,027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.63</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.08</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,598,008</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.35</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.39</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,788</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,520,247</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,808</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options exercisable as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>592,412</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.84</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,184</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options vested and expected to vest as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,520,247</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,808 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company's common stock for those stock options
that had exercise prices lower than the fair value of the Company's common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
weighted average grant-date fair value per share of stock options granted during the years ended March&nbsp;31, 2017 and 2018 was $0.82 and $1.92, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
total fair value of options vested during the years ended March&nbsp;31, 2017 and 2018 was $168 and $398, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2017 and 2018 there were no outstanding unvested service-based stock options held by non-employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=232,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=1031942,FOLIO='F-30',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Stock-based compensation expense was classified in the consolidated statements of operations as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>477 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total share based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>812 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2018, total unrecognized compensation cost related to the unvested stock-based awards was $2,765, which is expected to be recognized over a weighted average period of
2.66&nbsp;years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>11.&nbsp;&nbsp;&nbsp;Income taxes  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 U.S. tax reform  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>On December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Reform
Act"), which significantly reforms the Internal Revenue Code of 1986, as amended (the "Code"). The Tax Reform Act, among other things, contains significant changes to corporate taxation, including
reduction of the corporate tax rate from the existing top marginal rate of 35% to a flat rate of 21%, effective as of January&nbsp;1, 2018; limitation of the deduction for net operating losses to
80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any such tax losses
may be carried forward indefinitely); and modifying or repealing many business deductions and credits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No.&nbsp;118 ("SAB&nbsp;118") to address the application of U.S.&nbsp;GAAP in situations when a registrant
does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act.
In connection with the initial analysis of the impact of the Tax Reform Act, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse
in the future, which is generally 21%. The remeasurement of the Company's deferred tax assets and liabilities was offset by a corresponding change in the Company's valuation allowance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is still in the process of analyzing the impact of the Tax Reform Act. Where the Company has been able to make reasonable estimates of the effects for which its analysis is not yet
complete, the Company has recorded provisional amounts. The ultimate impact to the Company's consolidated financial statements of the Tax Reform Act may differ from the provisional amounts due to,
among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a
result of the Tax Reform Act. The accounting is expected to be complete when the Company's 2017 U.S. corporate income tax return is filed in 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=233,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=10403,FOLIO='F-31',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the years ended March&nbsp;31, 2017 and 2018, the Company recorded no income tax benefits for the net operating losses incurred and capitalized
start-up costs generated during the years then ended, due to its uncertainty of realizing a benefit from those items. The Company's net loss before income taxes were generated in the United States and
the United Kingdom. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net
loss before income taxes for the years ended March&nbsp;31, 2017 and 2018 were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year Ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>United States</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(3,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(8,992</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign (United Kingdom)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4,254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(10,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>A
reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate for the years ended March&nbsp;31, 2017 and 2018 is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Federal statutory income tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (21.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State taxes, net of federal benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (2.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remeasurement of deferred taxes as a result of tax reform</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign tax rate differential</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>19.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.0 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective income tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00% </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=234,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=966919,FOLIO='F-32',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_33"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Components
of the Company's deferred tax assets as of March&nbsp;31, 2017 and 2018 were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>247</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,405</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalized start-up costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,340</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,909</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,761 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,887</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4,724</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2017 and 2018, the Company had foreign net operating loss carryforwards of approximately $1,451 and $8,265 respectively, which can be carried forward indefinitely. As of
March&nbsp;31, 2018, the Company had state net operating loss carryforwards of $235 which will expire in 2038. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Changes
in the valuation allowance for deferred tax assets during the years ended March&nbsp;31, 2017 and 2018 related primarily to the increase in net operating loss carryforwards and capitalized
start-up costs in 2018, and were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance as of beginning of year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,887</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increases recorded to income tax provision</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,471</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remeasurement of deferred taxes as a result of tax reform</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance as of end of year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,887</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,724 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2017 and 2018, the Company had not recorded any amounts for unrecognized tax benefits. The Company's policy is to record interest and penalties related to income taxes as part
of its income tax provision. As of March&nbsp;31, 2017 and 2018, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the
Company's consolidated statements of operations and comprehensive loss. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company files income tax returns in the United States, Massachusetts and the United Kingdom as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of
business, the Company is subject to examination by U.S. federal, state and foreign jurisdictions, where applicable. There </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=235,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=283754,FOLIO='F-33',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>are
currently no pending tax examinations. The Company is open to future tax examination in the U.S. under statute from 2016 to the present and in the United Kingdom from 2015 to the present. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>12.&nbsp;&nbsp;&nbsp;Net loss per share and unaudited pro forma net loss per share  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net loss per share  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,704</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,973,439</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,978,539 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3.96</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
Company's potentially dilutive securities, which include stock options, preferred stock and warrants to purchase shares of series seed preferred stock, have been excluded from the computation of
diluted net loss per share as the effect would be to reduce the net loss per share. Common&nbsp;A stock has been excluded from the computation of diluted net loss per share because the shares have
nominal economic participation rights. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common
stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share
attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="88pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Year ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>930,027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,520,247</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock (as converted to common stock)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,588,977</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,157,360</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants to purchase shares of series seed preferred stock (as converted to common stock)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>497,344</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>497,344 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,016,348</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,174,951 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited pro forma net loss per share attributable to common stockholders  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the year ended March&nbsp;31, 2018 has been prepared to
give effect to adjustments arising upon the completion of the proposed IPO. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited pro forma basic
and diluted net loss per share attributable to common stockholders does not include the effects of the warrant liability because the calculation gives effect, upon </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=236,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=348669,FOLIO='F-34',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_35"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
proposed IPO, to (i)&nbsp;the conversion of shares of preferred stock into shares of common stock and (ii)&nbsp;the warrants to purchase shares of series seed preferred stock becoming warrants
to purchase shares of common stock as if the proposed IPO had occurred on the later of April&nbsp;1, 2017 or the issuance date of the preferred stock and the warrants to purchase shares of series
seed preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unaudited
pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="88pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Year ended<BR>
March&nbsp;31, 2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(19,702</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>972 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(18,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,978,539</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma adjustment to reflect assumed conversion of preferred stock to common stock upon the completion of the proposed initial public
offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,528,159 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21,506,697 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.87</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=3><B>13.&nbsp;&nbsp;&nbsp;Commitments and contingencies  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lease agreements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In December 2015, the Company entered into a lease agreement for office space in Woburn, Massachusetts, which expires on March&nbsp;30, 2021. The Company
has the option to extend the lease agreement for successive periods of five years. Monthly lease payments, inclusive of base rent and ancillary charges, total $7. Monthly base rent is subject to
increase each year in proportion to the Consumer Price Index. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
April 2016, the Company entered into a lease agreement for office and laboratory space in Abingdon, England, which expires on April&nbsp;3, 2026. The Company has the right to terminate the lease
as of April&nbsp;4, 2021 upon at least nine months' prior written notice. Monthly lease payments are inclusive of base rent, ancillary charges, non-rent shared tenant occupancy costs and the
respective value added tax to be paid. Monthly lease payments include base rent of approximately $23 through December&nbsp;3, 2016 and $31 thereafter. Monthly base rent is subject to increase after
April 2021 in proportion to the Retail Price Index. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
April 2016, the Company subleased a portion of the leased premises for monthly base rent of approximately $23. The Company recognized $205 and $0 under the sublease as a reduction to rent expense
recorded within research and development expenses in the consolidated statements of operations during the years ended March&nbsp;31, 2017 and 2018, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=237,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=570528,FOLIO='F-35',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company recorded rent expense of $282 and $430 during the years ended March&nbsp;31, 2017 and 2018, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes the future minimum lease payments due under the Company's operating leases as of March&nbsp;31, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>431</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>431</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>431 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,293 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing commitments  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of March&nbsp;31, 2017 and 2018,
the Company had committed
to minimum payments under these arrangements totaling $2,004 and $2,938, respectively, through March&nbsp;31, 2019. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification agreements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other
parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In
addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain
liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these
indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under
indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&nbsp;31, 2017 or 2018. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal proceedings  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Agreement with Bristol-Myers Squibb Company  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In February&nbsp;2018, the Company entered into an agreement with Bristol-Myers Squibb Company ("BMS"). Pursuant to the agreement, BMS will provide to the
Company, at no cost, a compound for use in the Company's ongoing clinical trial. Under the agreement, the Company will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon
protocol. BMS granted the Company a non-exclusive, non-transferrable, royalty-free license (with a right to sublicense) under its intellectual property to its compound in the clinical trial and agreed
to manufacture and supply its compound, at its
cost and for no charge to the Company, for use in the clinical trial. Both parties will own the study data produced in the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=238,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=287186,FOLIO='F-36',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_37"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>clinical
trial, other than study data related solely to BMS's compound, which will belong solely to BMS, or study data related solely to the Company's compound, which will belong solely to the
Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
earlier terminated, the agreement will remain in effect until (i)&nbsp;the completion of the clinical trial, (ii)&nbsp;all related clinical trial data have been delivered to both parties
and (iii)&nbsp;the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be
terminated by either party (i)&nbsp;in the event of an uncured material breach by the other party, (ii)&nbsp;in the event the other party is insolvent or in bankruptcy proceedings or
(iii)&nbsp;for safety reasons. Upon termination, the licenses granted to the Company to use BMS's compound in the clinical trial will terminate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>14.&nbsp;&nbsp;&nbsp;Benefit plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company established a defined-contribution savings plan under Section&nbsp;401(k) of the Code (the "401(k) Plan"). The 401(k) Plan covers substantially
all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the 401(k) Plan may be
made at the discretion of the Company's board of directors. During the years ended March&nbsp;31, 2017 and 2018, the Company made contributions totaling $8 and $49, respectively, to the 401(k) Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
provide a pension contribution plan for our employees in the United Kingdom, pursuant to which we match our employees' contributions each year in amounts up to 8% of their annual base salary. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>15.&nbsp;&nbsp;&nbsp;Geographic information  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company's
long-lived assets held in different geographic regions is presented in the tables below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>United States</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>United Kingdom</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>312</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>350 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>370 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=3><B>16.&nbsp;&nbsp;&nbsp;Subsequent events  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For its consolidated financial statements as of March&nbsp;31, 2018 and for the year then ended, the Company evaluated subsequent events through
June&nbsp;11, 2018, the date on which those financial statements were issued. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=239,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=546827,FOLIO='F-37',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Agreement with Regeneron Pharmaceuticals,&nbsp;Inc.  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In May 2018, the Company entered into an agreement with Regeneron Pharmaceuticals,&nbsp;Inc., ("Regeneron"). The Company and Regeneron are each
independently developing compounds for the treatment of certain tumor types. Pursuant to the agreement, the Company and Regeneron will undertake one or more clinical trials using a combination of the
compounds being developed by each entity. Under the agreement, each study will be conducted under terms set out in a separately agreed upon study plan that will identify the name of the sponsor and
which party will manage the particular clinical trial, and include the protocol, the budget and a schedule of clinical obligations. The Company and Regeneron have not yet agreed to any study plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the terms of the agreement, each party granted the other party a non-exclusive license under its respective intellectual property and agreed to contribute the necessary resources needed to
fulfill its respective obligations, in each case, under the terms of the to-be agreed upon study plans. Development costs of a particular clinical trial will be split equally between the Company and
Regeneron. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
agreement may be terminated by either party if (i)&nbsp;there is no active study plan for which a final study report has not been completed, (ii)&nbsp;the parties have not entered into a study
plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (iii)&nbsp;in the event of a material breach. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Events assessed for recognition subsequent to the original issuance of the consolidated financial
statements  </I></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Forward stock split  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>On July&nbsp;9, 2018, the Company effected a 1-for-9.94688 forward stock split of its issued and outstanding shares of common stock and a proportional
adjustment to the existing conversion ratios
for each series of the Company's Preferred Stock (see Note&nbsp;7). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and
notes thereto have been adjusted retroactively, where applicable, to reflect this forward stock split and adjustment of the preferred stock conversion ratios. Further, on July&nbsp;9, 2018, the
Company's authorized shares of common stock were increased to 27,314,288. Accordingly, the authorized shares of common stock presented in the accompanying consolidated financial statements and notes
thereto have been adjusted retroactively, where applicable, to reflect the newly authorized shares of common stock. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Events assessed for disclosure subsequent to the original issuance of the consolidated financial
statements (unaudited)  </I></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lease agreement  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In June 2018, the Company entered into an agreement to lease approximately 63,000 square feet of office, manufacturing and laboratory space within a
previously occupied building with approximately 106,000&nbsp;square feet of rentable space in Framingham, Massachusetts. Pursuant to the lease agreement, the lease term is estimated to commence in
November&nbsp;2018, subject to the landlord completing certain agreed upon landlord improvements. The rent commencement date is estimated to be eight months after the commencement of the lease term.
The initial lease term is ten years from the rent commencement </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=240,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=527452,FOLIO='F-38',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<A NAME="page_fs76701_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=4><B><BR>
Replimune Group,&nbsp;Inc. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=4><B> Notes to consolidated financial statements (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>(Amounts in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>date
and includes two optional five year extensions. Annual lease payments during the first year are $2,373 with increases of 3.0% each year. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Study plan for agreement with Regeneron  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In June 2018, under the terms of the agreement between the Company and Regeneron, the parties agreed to the first study plan. The Company and Regeneron have
agreed to the protocol, budget, sample testing and clinical obligations schedule under the study plan. Development and supply costs associated with the study plan will be split equally between the
Company and Regeneron. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Omnibus Incentive Compensation Plan  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>On July&nbsp;9, 2018, the Company's board of directors adopted and the Company's stockholders approved the 2018 Omnibus Incentive Compensation Plan (the
"2018 Plan"), which will become effective immediately prior to the effectiveness of the registration statement for the Company's initial public offering. The 2018 Plan provides for the issuance of
incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. The number of shares initially reserved for issuance under the
2018 Plan is 3,617,968 shares, which is equal to the sum of (i)&nbsp;3,486,118 shares of the Company's common stock, plus (ii)&nbsp;the number of shares of the Company's common stock reserved for
issuance under the 2017 Plan that remain available as of the effective date of the 2018 Plan (not to exceed 131,850 shares of the Company's common stock). If any options or stock appreciation rights,
including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without
having been exercised, or if any stock awards, stock units or other stock-based awards, including outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in
full in shares of common stock, the shares of the Company's common stock subject to such grants will be available for purposes of our 2018 Plan. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee Stock Purchase Plan  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>On July&nbsp;9, 2018, the Company's board of directors adopted and the Company's stockholders approved the Employee Stock Purchase Plan (the "ESPP"), which
will become effective immediately prior to the effectiveness of the registration statement for the Company's initial public offering. The total shares of common stock initially reserved for issuance
under the ESPP will be limited to 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of the ESPP
(excluding any extensions), an additional number of shares of the Company's common stock equal to 1% of the total number of shares outstanding on the last trading day in the immediately preceding
fiscal year or 697,224 shares, whichever is less (or such lesser amount as determined by the Company's board of directors) will be added to the number of shares authorized under the ESPP. If the total
number of shares of common stock to be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the ESPP, then the plan
administrator will allocate the available shares pro-rata and refund any excess payroll deductions or other contributions to participants. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=241,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=109065,FOLIO='F-39',FILE='DISK114:[18ZBC1.18ZBC76701]FS76701A.;121',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B><I>6,700,000 shares  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>Replimune Group,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B><I>Common stock  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>
<IMG SRC="g70635.jpg" ALT="LOGO" WIDTH="331" HEIGHT="79">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>July&nbsp;19, 2018 </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <P style="font-family:arial;"><FONT SIZE=4><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="111pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="195pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=4><B>J.P. Morgan</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Leerink Partners</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=4><B> BMO Capital Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2><B>Until August&nbsp;13, 2018 (25&nbsp;days after the date of this prospectus), all dealers that effect buy, sell or trade shares of our Common Stock, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriter and with respect to their
unsold allotments or subscriptions.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=242,EFW="2236275",CP="REPLIMUNE GROUP, INC.",DN="1",CHK=105006,FOLIO='blank',FILE='DISK114:[18ZBC1.18ZBC76701]HO76701A.;22',USER='CHE108057',CD='19-JUL-2018;23:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g70635.jpg
<DESCRIPTION>G70635.JPG
<TEXT>
begin 644 g70635.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@ S35),3%]'4D%02$E#4SI;4D503$E-
M54Y%75)%4$Q)355%7TY%5U\T0U],3T=/+D504__; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $\!2P,!(@ "
M$0$#$0'_Q  >  $  P # 0 #            " D*!08'! $" __$ %00   &
M 0,"! ($!! *"@,   $" P0%!@< "!$)$A,4(3$5018B46$C<8&A%Q@D)S(V
M.#E"=WB1L;7!\!DH0U9V@H.VT>$E)BDS-5>%EJ;"M];Q_\0 '0$  0,% 0
M              ,$!0$"!@<("?_$ #X1  (" 0,# @0$! ,$"P    $" P01
M  42!A,A(C$'%$%1"!4R82-"<8$D-5(V8G)T0T9U@H2QLK/!PO#_V@ , P$
M A$#$0 _ -_&FFOP/L/' #Q[CZ@'W\![\?9R'/MR'OHT:_.FJQWG4TQWCJ_7
M/%6=*5;*=;J/9']>>S%5:$M]4ED6YRK1\TS3!=A9(]M+Q;AE)I,EXI\9J5SX
M'G7(IBJ;[;3U5]J\+#.WU??W6YRZ1# R@8VF3$,H\7$/P9592R(Q<8R;B;CQ
M7!UEE4R=PIM5U.U,TV.G-]8QA-KMR+,J/%)%&98720*R.)XRT01E93R+@ ')
MQ@XU\?BM\.D2R9^K]EJ2TI)X;=.[:%/<*\]9VBGKOM]D173-'*CQ]M('9W7$
M8?*YLKU':TY8^#[EL68F*;A.TX]R!-.BF.4"B];.X=:#$0$!,)_*U^S%( "4
M!*J;]D( &JZ]M&_W-FY_<[3Z(TK]5H6-2,K98+%%1S5Q8Y][#Q$*Y%DA(V63
M\!%MW33J((8\1"QIC=QDO&.0X@/&YLRL6/Z@=7GB.#&CZ)9*%1USF-V@5J];
M@VL)2\&$H%(I;GW(CP!CH?7* !K3OQSZ@M_"_;NE'NS1UIMWZTZ1IV5BE61X
M]KDW-KNYJ[*"N6H[;8CD$;.!'.OJR^ MT_U]LG5^UON_3[VI=OBWM=I^:LUV
MJ"RT*5K-B6M%*1.:_:G$8:>*"0N)!V^*AFNOTU5!OEWBYKVI9DHB578U>SXY
MM]%5>*UZRQ3ANH6P0L\Y9S*D=98I=L_;*JQSV%,"#I*3;(F,*I68 H(&_O2N
MKEM\F(9LM=ZWD.DV#P@%_'-(-*W1(+@)2F"-F(IT@Y<H&$1,0S^'C%@* @=(
M#<=VYDZ9WF:E6OUJC6ZUI2R-582NA#,C+)",2J596!8(R>/U^VF$WQ<Z$I;]
MNO3>[[RFQ[KM$ZPSQ[NAIUY@\4,T<U:Z2]22.2*>-T1YH[!5LF 8.+6--5;R
M'5.Q/8YFO4C#%(O=_O=QG8>LUU":C4*?7"2L\^;QS162>N73^:,U:*.0<NTV
M$(LH=!!0"+H@(K)VBI^("9 5$IE *4%#$(*9#'   YB$,=4Q"&, F(4RAS%*
M( )S" F&/N[9?VX1?/5I*K3AS%', LK*A4,QCSS1<L I=5#$-QSQ;&3[!U;T
MYU2UT=/;K6W>/;V@2W8I%Y:D<MA7>.);87Y>:7A&7D2"21HE:,RA!+'S_?33
M33#61Z::::-&FFFFC1IIIIHT:::::-&FFFFC1IIIIHT:::::-&FFFFC1IIII
MHT:::::-&FFFFC1IIIIHT:::::-&FFFFC1IIIIHT::::ZM=KI6,=U.?N]RF&
MD#6*S&KRLS*O52I(-&B  'IS]95RX5,FU9-4@.X>O5F[1LFHNLF0URJSLJ(K
M.[L%1%!9F9B JJHR2S$@  9).!I.::*O%+//+'#!!&\TTTKK'%%%&I>2621R
M%2.-%+.[$*J@L2 "=9F^IZBS2WAW8S3M!5>I8\7D@+Z!\1&O D(F] #N&.1C
M3"/)N[D![A'D K\_FX]Q$1X   .1$1]N ^?/  'KKUS/65'F;LQY#RH\27;!
M<;&Z?1K%R("O&P#5-*,KL:MP8Q2KLH-DP2<E3,*?FP<&((@;D9X=-?:!%9NL
MDCEW)$6E)XVH<JG'0T ]3[V%QNB*23Y1.11$G8ZK]9078NGC(Y@0E)5TS9.2
M+,6D@V7Z&2U%T[T[4DOD@T:%6%T7!=YUB2,01C/EC)Z ?95!=L(K$>8-C:+?
MQ0^*&\5>FHU=>H.HMWNUYY0RP5]N>Y/.^X6B%Y1Q)6(F< &1Y'6"-6FD1#[G
MTD,+W"!F\@YLL]9DX.L3%+BJY29J8:^1;V%J^F33$_)0Y''8Z<QC=*&B4RRA
M42L'8K&*R<.027%.&&2+<XN&1KS>$C'*O8;E8;&S,(_72*YF7+N+ IBB(!X+
M<C0I!+Z%[ [?0 '6CS/=H0Q]@_)MC2+Y<(6CS:4<5N4B94GSM@>)ATTR%$A"
M$*_>-"$(0"@0H 5,H<%+K,60OA@0@>OAE(3[>>PH%^?O[?EUY._CEZQFWK>N
MCML/&!A#N.]35HV+=M#\KMNV/EL$L!6W++@ ,[R$*H(4=R[-TE4Z"Z8V7I2E
M9DNK3^;M6;DR)%)9M6Y^Y)/V4Y"- S/%#'SD:.%(T>65U,CVH]1O'ENW ;<\
M'9;H-8D[8[KY"V>:90+;XC)L:M<J<V>RL@#)OR[>-XR5BXT'J;%!PNB0QW'@
M> BNHGGU 0, &*(&*(<@8H@("'V@(<@/Y-:S]B=J^E&VJCHG'N<556;I[@W>
M)O2$E%Q8?8*8_"GC  +R(@4"B!N!#5='4]V<PL!'N=R>,XAO%-_/MD,L0$<@
M5!B924=$:,;XT:ID*BU74D5VT=:$T/#1='=LYKP0<EE5W/H'\%/B#%OG2'2)
MM\0N][+MFX5[() %O<*D5F>K,I& 3:EE1'7&)?X;+Y##3?Q\^%%K=X[7Q+V2
M9K$RT*D^_P"UE!GY6G4B@;<:<B ,QK5XD-R"16/9B>Q'*.V86@KT]F3!_O'P
MDE(]@I(2UE?MP4[0*,BPHUF<QW;W\AW@Y3(=,H!WB<I1)]8.0UA!P   >P '
M'XM8E*=;)ZA6RM7:KOE(VQU.<CI^&>$.8G@OXUR1RD17M'N.U<E(=H]1$!(N
MR7<-U"F35,4=?VWO.U/W$XO@<DU!<")OT@9ST(HJ11_5[,U21-+UV2*0?JKL
ME52J-5A*1.0C5V4DW 4'9!UDGQ'HV/FJ6Y %JIKBFQ )$4R2RRKS/L!,LAX?
M<Q,#],N?PK]1;9^5;_TL[I#NZ[D=[A1RJM<I35*5*3L@^7:E+44S+[A;D3*"
M!(5]NTTTUK+77&H@[LMZ.,=G;*C/LE05YFTK^]GV$.6E1D+(J-EJZUC7CTTB
M$Q/0944U4I- &PMS.3'.18%"I 4ACPO_ ,-MM:_S#SM_[8I7_P"_:\7ZZ_[7
MML_^DF4?ZCJ&N'Z>?3]VQ;A-L55R;E"G3DQ<)2R7N.>OV-YM\&W5:0=H?1<:
MF6.B)5JQ2%%FW33.HF@518X&56.H<W(3<-6@FWQ6[2S$N[(>TP]^<@7P2  %
M3R02<_3SK$[5_>9=YL[;M\E5%ABCF7YA#^GMURXYJ'))>7(RH 'C/C4CH[K6
M[3W;M-N]JV;XANH(%-(.J=7'K= 1,4.]5O$7-](&( ")C"W:+' "B $,82@-
MD6&,\XDW!U4+GB&[Q%SA"+$:OC,#K(24,_,D5?X;/0SY)M+0DB"1O$!I),VZ
MBB?X9#QD>%!KOR5T<=JUAJ$M'XZ;6['5S%NJI7[)],[#9X]&2 GZE1FX2Q.9
M-L^B%E@(F](S%C))HG.JR?(K$*!J5^GQDZX;=MZE%K3Q=S'-K7>%\'Y+@"+&
M59NU7\J\K3(')"")5UJW=4V+V.>% %4&X/R$,#=^[16J*=&W!-)2:9)8%+&.
M7B>0P2/;/N%8 AO!\,OD'5/S3>-MN5(=V2K+7N2"))JW(=MB57SRX^%+J65D
M&5)*.2I76Q;37\E5DD$CKKJ$2223.HJHH<I$TR)E$RASJ'$I")IE*8QU#F*0
MA0$QC 4!'43;!ORV<5>4<PTSN/Q.C(-#F3<HM+2UEB(J$,)#I*.H@C]F"I#
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M,^22?EF(7SQ1B1@>.H=1>VE@-OXP15NQ>ZW"O0HD P$[F,8HM97QCB(^J?\
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MF')7!/I54&7:0L 8Q&#(' *88 CRRZ/J=3W.I=LBZ,2\>H4L"7;WHMVYX"@
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M1J8>*;%0X_#)**FX!$ 'S K&3#_O YED&^_JN^P8FGP !$ #]*[<  H!P':
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MYCKID0*FFMW)W,(="UV2L'.?<>F2X P.=NQ;8U*C4@E/"Y0:+.3VD\V$>+@
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M]*3_ +MWG\_W_+48G^=_^,?_ -3??60R_P"R@_[)B_\ 937#=$DH%VNY X
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MC-,IEEVAVP)Q]E:-OU0K'(M)!LBX<Q1&SKN_5GGF4ONBC(MH8#N*QBJJQLF
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M:[N?P%+RG:1BWRG5VZZA^T"(FE7)X5NN<3_5*1!W)-UC&]R@GR4>X"ZV$%]
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ME^B[+!9.?5>.DJ=96\6F2(;U:M2I$5XR2B)B,<*B[EG0F<G:@N)!23!0I$P
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-HTTTTT:-----&C7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g695148.jpg
<DESCRIPTION>G695148.JPG
<TEXT>
begin 644 g695148.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$Q-#I;,3A:0D,Q+C$X6D)#
M-S8W,#$N3U544%5473DV-C=?,5]#04Y$241?4$E015\T0U]40DPN15!3_]L
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M^OJ^*[M9;=?7T:8K*UN[6TK7T:4\:U[=J4\:UIR,?'5\M/K6G/\ QT_/B?\
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M*:8CRFUO'VW'''+%1QQQP'''' <<<<!QQQP'''' <<<<!QQQP-GFK_U+3O\
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MROV4-R9&1P=\.10SHU-%&;,Y*LF*Y/U;_P!2.>(N%7X[D0/B@D;#C3 ,VVB
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MFC=Y1Q^N5_/;.V6:=LVW^7TSM_<G''' <<<<!QQQP'''' <<<<!QQQP''''
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M/#1HMX^&E;QG^Y=]GB;=.8F=LZ4_MOZ?ZQP1:8M<M?\ "9KY&QPE%5A^Z$R
MT7FM 4>J4*"]KSYE3>4>_5R*JU,0)52C.KL=D>5,LR+,N18HRYE5U<W/IRUT
MU_>&(L&'2$(E7#IV08BTT9,T?#%&TJ*\'K'JY0^IL3;CM7$B?UM71.^WUHZX
M**E5,*NRBG/3)*3]QV./R=_ZT=_^_<?<=CC\G?\ K1W_ ._<:SA9^Y5G>_NT
MYWVW][Q\=[GL\3]4^'C.5K6_KP^6+>"/<0#A*/QQJ#P48'PT48\%4S.-"[0A
M8V-LP7Y+\V2Q$VMV' EPUS9\F10HRTQUS*5&3(H4Y<V?)DR7>DYO)]QV./R=
M_P"M'?\ []Q]QV./R=_ZT=_^_<[K6'&RFO\ JGJ<]C7.V8SV_2_K/]<6-=2O
MQJ/W_(?L#_V3$O-8,'_F,'_[C#__  K.2SZPQ0!8)K%46!CKAP$: P$7;T7)
MTK?F8B<-?6QX2XLERVMR?*H1Y+L=BK#6Q0GNK[I@OLOI2[F_UG32U'MLLMH#
M$':VRVVE/NA&_A2VVE*4_P#LU\E*4Y"?\O#BJ9F*[333$91?*:KW][COG9/"
M]M/^-B5X=,1-.554S>9\8HW1.Z;JS_'+,7WM/4C\AB#ZPC;^M<?>T]2/R&(/
MK"-OZUSNNX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(/K"-OZUQ][
M3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(/K"
M-OZUQ][3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2
M/R&(/K"-OZUQ][3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<
MLQ?>T]2/R&(/K"-OZUQ][3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=
MIX7K.\<LQ?>T]2/R&(/K"-OZUQ][3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM
M^'S5=/=IX7K.\<LQ?>T]2/R&(/K"-OZUQ][3U(_(8@^L(V_K7&NX.[$Y:>KN
MT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(/K"-OZUQ][3U(_(8@^L(V_K7&NX.
M[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(/K"-OZUQ][3U(_(8@^L(V
M_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(/K"-OZUQ][3U(_
M(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(/K"-OZU
MQ][3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7K.\<LQ?>T]2/R&(
M/K"-OZUQ][3U(_(8@^L(V_K7&NX.[$Y:>KNT\+M2QM^'S5=/=IX7@[:O_4M.
M_P#XIHX_[(C7FL/+2&'0O6G !N,;8Q!ZH).I@UG2U#4U++E&0C9F1>/(%=KA
M5UJNQX<36YJ\-R+'FM29<E]N?+BNS8[+[?(_>T]2/R&(/K"-OZUR%/\ F84:
M5XKSJF?AC9:(_5Z7_M.K_$Q9BB(FC*+3G._Y>[*SO'+,7WM/4C\AB#ZPC;^M
M<?>T]2/R&(/K"-OZUR>NX.[$Y:>KNT\+PU+&WX?-5T]VGA>L[QRS%][3U(_(
M8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%
M][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA
M>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?
M-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3P
MNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3
MEIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M
M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB
M#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'W
MM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L
M(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U
M(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[Q
MRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]
MVGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&
MWX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN
M[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@
M[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC
M;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C
M\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K
M7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%][3U(_(8
M@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>L[QRS%]
M[3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-5T]VGA>
ML[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PNU+&WX?-
M5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3EIZN[3PN
MU+&WX?-5T]VGA>L[QRS%][3U(_(8@^L(V_K7'WM/4C\AB#ZPC;^M<:[@[L3E
MIZN[3PNU+&WX?-5T]VGA>L_9_MV_\*W^=.3!1#^*:+_^3L)_TTV<W?ITU-2*
M5I6@,0=Z5[T_^^$;>=/_ /-<S>R:MPT/,S0P-; Y86QC;$#.W8<A&^*,F)"V
M),2))COSYEU^;-?C3X,=MV7+?=DR74K?DNNNNK6M6+_E8=<1$17E/C$;OF6X
M7^)B43,S-&RV4SXVG]*%WCCCF<.... XXXX#CCC@....!G;67\>T<?YLX?Z=
M>N38V^5/HI_+D)VLOX]HX_S9P_TZ]<FQM\J?13^7*J]L>7WEJP/@GYI](<\<
M5K2E*UKX4I3O6OLI3F+V2:XD)'&5FAAD8.=G2#'BQ@F% A?D&=5&CUD%6\XL
M;33#;E](?5WB#JW$EN-?3%W9UF%=2ON-U;J07,H<<Q+&4\0U,R=L5Q3)@9(*
M9ZCH%EQISB;ZC><+C&4G*B=%'QTCR);[[<XP8JPLK3CSM96J9RS#[M9@NNJC
MR]LL5NMIV\?/Q^7R]M:_)3V5KVI7Y*\#ZXYY$G/0P+6"" L)V4=6GQ8F! I,
M\+\"',4F2QF?2%*,,5F>ZVKD]YV,9(';&WIO347(&9Q4TM]S2Y*T]9Z=OAX^
M=._>E*UI2E?&E:UI3M;2OR5K6G?Y.!]<<\H0'(>*.P6Q$A*S,;S(I(I#P1L<
MU^%&M+2A&+D1JK8!]/ENMO='5,)"1,19T::E^7&T,3JNNI3"CS5M]36ZVE._
M?OY>5*W5KW\NU*4K6OAX^'?P\?+@?7'/GTK?"O?PK[*5K^BM:]J>%*?^U6OA
M;\O;G/I6]ZT[^7G[/;V[^7>E/&M._>E/'MV\>!SQSYK?;2VMU:]J4I6M>]*T
MKVIW\>W;O6GA6M.U*]Z4K6G?GDA(_"3SX3? PI8B?X&%SV!%?O(XIW#X/&@W
M5+1^%W?W"Z[U)\:*K4E'!NS>BH2U48:9+:>Z6]P]?QSY].WMW\?/MV]&[TN_
M_![>EY>/EY>/EX\Q8_SC$ J88@ CD@.937,LCIOQ"SB^(TS[>MEUP-FF,4UK
M=??ZQ[L=N4<'B$7LK;3WW5")!A2^G<V**6AE7CGDU1V&HC-ACQ83,J8Y*!LG
M,!T3SK\&-^>A8,<1=I*R!M;;KJ*%;0/.1J)(79=BMNP(E)$SXLMU+EV'TNY;
MWIH=LKGA:W1N<LS(Y9&9XQ(%R59D:G?$E2+LK6Y6)LN6Y XXT2]"KR(5=,*J
MQ*M2*+L5,*G!?D#L^.?-;J4\^]/U5[4I\M:U[>%*?+6O:E/E\Z<>G;V[^/GV
M[>C=Z7?_ (/;TJ^WR\O'RX'UQSCTJ>'CY^5:4K6G[:>'_P#/M3SK3BE:5IWI
MW_72M*T^FE:4K3V^-/+M7RKP.>... XXXX#CCC@:-]26=3G6K2:>YLC=X1#Q
MF"CC$L9W]>/8BQ.R5=CH3''!W^#6>S+B?,[:TO3@L1M=V!3ZVLPI\5$JFZZB
M?)& 2;X;71H6$^".B0PVQB-++6AX4QG)'KLUP&6N4BSML_?%,G:[BJ@V1Q(!
MFRUQBF]I-L!SB1M"&)W5=5*5DZO(_L34V3>[ P6%;*1(60O(>5\P"!G:QVN^
M4<<,#6\VT'R=D+4'J:Y2A<<."M71@0VJ*WH\WNB2N?#;[G?DMS8_J9(-"YR:
M0AF,\KWB2 ,PQ/-S'<R.&%#FO,H;.6N01'$OO4(E]JADR/S2EL=V_%8GS+4%
M<R; M1Y+Z*+ CG(NJXG%X0S221Z_N@69"DL31"TL"DESI!L<@<='\%8$BPA8
M?NUD1)C%2USD!*YM=(8:QYGRN1FL5J4Y(F D[*^+F_F,.KU&<T3/"D8QM%10
MY-<PQEKA*>!01R#$P7*C>(;.QA9+ F9L,$/Y7@-9&C2.!U8V(9PD$)7.*$#(
M,KRUM+685#R[,SY4,^F'#A(=H9,'9&EZ/#=-)6QLD9WX;SQ<]*[\^U..,[9<
M9&FL@1:9VB-BC+$85G$3 /M9))"[DSK@932Q$^.:3/X /Z1D4"ML L3A/NR)
M[&6N:_7]Z (HD1WB,L&&\@UF2LB&+W5B?UT0?='CA/G2B8961AN)#8!%)37C
M61X-V1T=363%9J'Z=.^K7!^XDN-$8";%</8))!3&4(*?;Y,B0V<CX& 7,=;B
M/*<@("7OYM!)8I2%3&7"X=)C6C7OX6K4K+U;84L).',>8E&P^PJ+J/">L;_&
MT=#NNA7K--DLA,B(C=R*)+D$QC$SUG'5Z=X$+AA@:8O'AJLPOK?AP6$,@+CG
M+ZB\54A^%JN:G/LM;-#@S64A%UHO+LX%H5&((01E"<3FA*+Y(_B,&(WII=5+
M,U8!4,%2,^5,R$?81 -(9A(9#(0@(:K1T7<FZCN2K7O8YYA<0?)PC_8!;E>:
M'4;1G*D4#V' NP8V"\8E\DBDI*\CBW7(KU"IUQN<."5K0LQ+TV)$ER/&',E5
MWK<.5&&L\W;N*XWF9]A2,-?Y2V*)XPCH!F.>$\7+1&QUC>-I.,"4.!;F(<?W
M="[R;(!+G!CXC;X^&<:97<)!#TKN>*$;H%"I9'_'?52+QD;J82DTFTL/=C07
MH4$4Q,  +3E*7@BZKI+H-$BQE*B<X'\J9YQ85H6D?F1X1-C!>U)G8NSON-[O
MJR5D0G#14-F:57F7&N7)RA-_D"/@>)9M3P@6,(72;(SC@Q?C8)&"I_4B3R:B
M2Y@6EYRR)#>)BB/3^@H<D;#4FI91A5,7AVWI>:UM.1IR)%LF6^\JUB7(;+BE
MLOLMR#V\N#J"-V/)2@S2Z_#2=4^)#FM]*E^2/Z5':9+7'N0T#6XEZLXV#O65
MUF 2D&(5<06;?A\S0VV-H!)MI+)$'V:KY@=J").2DP[>K5'--EXX;XY3XQYJ
M1/[Z>K&N0\X)C#JN"W-<@]0L]B:.W!_E;5 JB0S:9%J!N&"6YLA2.8/]4SQ]
M@D9H*6W9(B?< 0^('W'GK&C<S,[*K)<4RH704=6IM$D5LAJ._E#I8ZOR^\RF
M^&OW1%BN6W6;G\@QI"M$APM9%.@WKDP/1 ,7XA^JMF>0Y9JQ$99':ZBI3D'2
MUM<G-71Y2KL3<DZI[Z9@^4%PA*A=M%LZ6S@(GI2:(I=(ET).[DG1F$>",8NP
MD+QVNA-3"L7M&(;"&-:V/L4QH%'"$MO?2S*5JW,H(?? .=(=XUVY,A2,4BJ1
M7@A-ZU0T8V,AT>>F=M:3=MMV79)Z>B%K*UB1Q7(<SE94!'&^Q/A7JFMM5)UV
M9$XK$2VBBNN<&]5J5I4'(F&"/58P:Y:E-LW+.")Q"B>.W*/(7A75#81=!+])
M!4L?C2Y>_OMB]>.I6H&'<;FM-2A&]WHKV 3NL<T&]VH.C$5Z8M=[;'A/)!9E
MOBF&X6HYR(],;RX6@$"KI-SQDAOS,8P-V*W5J0RF^-+N0+\:MU(T[>T.#SGS
MO='1S=/+P[T[X>AQX=GAJ,)1)<RD4VEC]D2DSN)U2BD?;:S6W3](0DS^\ 6Q
M*EZ9AD)"IRA+T1JGPB;6=T7-#XZD-N%MS-X:JLW5O%1*NEXT>!SVZXMEF72L
M<0GS\8PH 2"9&>WS.#HQ,P"];T9R^%Y$ L1:9L[7,! -K[6B.'5P<$8QB/F@
M8>W5%EZ%]ZWULZ<8;M_,[$Z'QL\N>432AL:,S4@>SV0R_8MS@2)@@7;5[BB9
MD+@4E+D&C][DYN21H;/6UA \*DS<E5Y+/-8.C["+,L;+@N9)]"&1L>]/S&QB
M8U4-9[W YT@88=&8/(GHJ>X9<SMW:DS1!4>7DT;*BBD6/+ZWKR9.&-CVZ+%.
M39Y3HI#.74S'IVE<#YMCIM7)GX6*$!*G3R0&&C++'W< LZ&R6QH]1P$X%*&!
MK*!G(O8W!JNRLR!O?FI\;,C@D7!I81[\SR<;$:BZ_C45D,,%:O= ZA#< >SN
MT7G"I@9@75);M (H0LM=LV-K(X]E<-?!DK5F8\.-IVVLX^4A:1L%S>F&MW]]
MH]H)+'-RI4A;%L)*,&Q_'FI\'3 S5B330DVI=78HD0]V882YP*<PM%DG+&)"
MT-,2B=P\QYJ,%SYGSOE&_*X9;,_J&UT9: QD '8W+CX?2O*$R-,Z&^Q)%)YT
M[B6-[/9'-8"NUDI\)&8/"A43;Q,0AG&VB@.(AK$+-+%5H2NN>UR=5KZK=]D6
M>%@]DG _V 197JIU)$:15%)#AS+L%[!8,0^2RL5">1N;K45BA,Z97.8BRUW5
MY5ZG$M28VC#A2H[D6;*L"OT!]1G8*5T>OF:5MB,&L*B0>F;"6U2G-"FMN+:!
M(727),ARR-+'>QI'AN3W%M8U(P'!KXWQVU.J=QPO1"ZB*8B='1LR9\.] SMW
MO&F(^E*Q2UK[&T;M&VS<A9]FWIQ+GK%( 1,OQ7)XF1?%@G#>1E4V#+;B=HP9
M7IR+B"3GYT8,2I='*@/5.5F<N3[2ZPZ(0UJ>J%UL<.\A.JD0U_"]:F?*9D38
M[ULC./Y%D>2A;!GM;!YCMR/*!WDY]:ZN-E,6'*/H61#5#:I1J5RW/$C0N'R>
M7P<:DF1YQO&OTF.DK@EC6MPI$.4G=HIDF'%6-_P942J]P:J"4J$V3"C3YV_-
M8\8VM;55?A1Y4:H,![J[CI=/! <*5H*C*$K_ 'D^3.]E4M1A"$?,.(49<;WD
M:78^DYY1(\AJ94R49XU#FAJ=%94]X5MKDN&6-M<'Y-HK&757(Y'-W++'D9$4
MKML_)=*%.G,54M&H\)KL.Q>HAAM@9N,N&;BM>&L59 X!$'5\(7&Q,2YVY>F0
MB@\W/SD]H*7[^[*:9!VR1[$4G.$@R+&YQ#;)* F.OP#BCE8H4",QXPNP\:J6
M23'L@X!IZ5Y(_%\[)((-B%I$&+DJW R$Z9"[.*11KF%])J&XT%([;H[F&?1*
M0XBK WW,)F2O4;.9Z'V:\0B7:V!:?&WO48.("0H'R"C9]CT^;BL.?$1:GO1D
MBC$D,&](_8@QP4=8%J2"=A #ZJS:8N0OKE..S<T,"\@C ,SP^':NS,2P5L&&
MNR]X)E*0HE 5.PHQ1!K$,>M#$@X1Q8N3F; V9DB_-ZG)U@8"KM"W:^IF;+F'
M54P@^N2R1<LC12D?TDZ2*,BI*,L>"!%!9;-KE'=N<U&@A\EA$+7,#/(+CE;J
MH%8DU/1NW97%>F#KD(@I0"(W25'!&;ZO3'JL:/;T:)70E*178"0S269AD!V<
M\X_Z%\K',D2$7ESB_IDB<?3.#QD3M@FC;4Z5%A[@=Z>D?B4IXSL8EV=6 )S2
MN-SP_0<T$XHVQN4S(,!(V$)3%Z=T 0EE:C6\8Q 8*RZ-VR2&Z+S Y9\1$0""
MVU>]-[H'C=_NI6&]/])B(9"CM:]!+4#K)(*B53)T41\K7C[6]>]3L)PX*')(
M@))MF!L0XU)2KCD<0M&&P:QI;Z%-7]X9!]PZ>WJ>,":978-?X,D(7A<>V<E+
M4-\V$?",$L'\$Q1=#1#.[DN0 J!W7&2^,,P0)$C>I-\N)$X-9DWVLEPHM:[E
M)$B];METUHHVY,I"+RJ39AC]3+>N==7)021OGC5-D*(J3NQV^-B!N*32,C0T
M '%,XR266O&>.2<42FK:N3-!LA?D3<@LP>[0Z"PGZ@V(GUR.2W(DV@)MN7E0
M0N _7&62R:Q:4Q$88G]K;A5N9LH20BYD07K!5L0-R;$O66^J+,#=AL;N!J[K
M?U$Y1V2VNUR!<D%ET)PQ/&D$W;>@JHW<0$F=9$"DDE:U,$-D%5H>_.:H"*;!
M*3'Q^-(S<\2RQN0F@57X3.;TW$#4P?P<^I43"9G(49A\.R=LG(":3-X\K0W(
M;8KA\;"@#3'/ UINU.Q2[EKO1UHJ^[>PML<OF9HM=S$ASWH"MN"6C#>1)LX:
MR=->.M9), Y-;IMV(E15#L $&J\&B\LE($ZBT0:_/Q( $]D>CV(3C4-?B;,T
M*HS#FUN.9'?S205#"S(VA[)G? D278,C,&AD(C<BE,G-ZLZN)"^[:RYUQJ2!
M!E;+:[BN<*.TL^J);6+'EPT3*H$!Z"'IJ<WO+BS/MBWWXN<$]Z /RG^\@0.P
M'K9- 2&ED@O&XKE$PYK9&&+.Q"Q,:E,Q@#A*@^VD#J\N&4?#6X:C=C*#<]>%
M2MUHRL8J]86- 4/^1E8W?70ZZH[L#MC^J6Z<[ V/$*0N_P"PVVXLZK0-D>H'
MB(;D60XYR/X]>H>U#3."\MI$<FR3&C:"N:-*<1&)7%&!W;2%^&PQUV;+]'HP
M)(%UT@QF)Y!![M2E42O&O$I#CD.*9*CLGAH(4QL-$=F4F%GX*(E3Q'[H1AIF
MUDH6Y#Q(/E1 DRM"3*H1*4&OQ5TH8P+6%W9'+83:KW63(O)H6V:?\DD#3F2[
M3Q>6R,8R>\",I.SV NEPHBPODCR2P#>:#<,3* J.3X@C<.O8Q5..(V .@=>J
M,\KI1LCN,=3Y*D-L?-E9&T^ SFZ18L%&(LG< B%=.E^>Y"ZNRIY:(>7QXRD&
M7-(]R-Q?6\C9\C#ACEVM5)7')J<S]:D\N*I2E##JS*YWK*!:F:U[52IG'GF%
MV<JU9CXH>MH1><WHQM?3YO6S$\#S[!JM2UB<:X7&U8+"!"_-+O>M<FA@=961
MW1J%!<I&2UIRF&%P$MJ9"V_94GOPVV-2>49*B0NA5\;/4<#'AI:#H0HT=<;&
M/X<F%4WN&!N4WNZE.EO1Y]2'?HS:_*FY_%AV:-FP<!D6&A/7B<H^%S:/K!Z=
M8.$3^5Y$31V=+7>*78J94CJZS5(3*^$<9D8&8+ Y_6B^!^1H%BR]2'FUW5(=
M!.AXRB<029LL0L"K?B55"QIR11$H^*PAIC.C)&Y8B]]W,P=\)$Z941:S)8G4
MVI,#A)ER>Y<94CJR]P6MWO)&ZLD:1]*D"!:J.7F\1V!(M:!(&(G:2(E&C\F=
MML,H\@C)Y X,="JZ1#< ''TN&AR6S9/C9TP*[+UUS:VE[<.$:YMSRT].^ 65
MU/W9!G/,6:1P;;:/'U/:0-EB%(.;G2@R2U+.%E38A['1OSMQ*/MR0%NK<HP#
MK%9>W*T[SDK8KQX0=NDA#>8CSO@S,D\ R)26:G2&J8AK+#&3&ND/3%HB%@A8
MC="5]AIY.75F2MD'Q]D(HT7%.6+'A[;UQ-C#D#VZ+E68-;HLZMIHK$AR3)MB
MHM'B%V MDL;-KY&3.%%MQX;!'4#C;26'D3-(2P]N5-!:4&QXQ!*EH7)Z!%ZE
MP)#US(&)C9F1O6[%9^IH4_"U@@E!J1)+EM>Z2_)<).\.89%C5,(#)1'L$"6R
M:0K<IB7+$S6KBXUB@X&E8R4M@DI(+"IPO$'D*;'-"X9$O>7])C7Y2P$#"X'D
MVK**J3-:".V(J%&AZB.LO;6A.ZJ%4!N#(#-V10ZQ-L0 L!E%[P:VER],CLSC
MQKD-6B_$GPY5BC0&+HWE%CF]WD&5Y2G%MDN2Y>)I*/7D0L=CHRE.)@N#%.0C
M8@X*%!9L'1**XX$1  &0YD%V5@3-&==GP.SPYO3@O#[1;\QTNU>UEVSQA9PG
MC38\KUX%JVK?@VD<XIKL45,X"//4B7Y'NK3B9!D\(6,:*5["Y.^+!<XXW5NN
M7-6/*IMT<3]::'9IBD4)(?9Y;#7@H=W5<X*W0)"7YW!1P+W7USU>;,1.,O9B
MSH<=NPF*<FHAC1?A<LRA''&5].*I\KNPMS&Z[^O&A4%OVCJOI_.5YKF@Q5$M
M(>Q+[")-@D-N8T];,[2_MA1@:,:1(8C[I@1/C&]6L=V%$\-Z)5<WYK,5V')B
M-FZ36HXXZSB\#[6;LRF?L6G:8OQH25%1(S(](EP4XQ$C"TN9@S8AQ*\*X^&,
M\D8L=%7PR4H?7;[FY?=:JQAIBR=4C;IQ,07/74):1V*T_572DD1ADA12@<,K
M9HKM-$</C9SGD,P,,+6V7(1QY.!5X8D5%MQK)65K<VU / 6?"^M$BDH[VB05
MKQK9L&%QG(DIHML2G7T0AP(8KA4?*5;ILHTX7@!4E&<G?T;".M+2C4X5IPMH
MZ..1A;<#DL0I7O(BL2*^ +I_Q4"F)(9T-91)53PNW2O8VI_=!"QI"F/?&4@F
M:9P%Q^UB"F9Q6M6&2@OX0A*PI<2%^'\1&_,ZMV>&BUC1LF0+M.XFOB?5R&[E
M)?\ !'45_@\DBO)1Z1^_"APU_&KA0%M+%OO1[B\ILS9=6Y^Q(T;3<XJ^V9/D
M06?[EP-"+^JXRLQ )E$@ADA C,UL4OB<V15A;@$K21J8Q-O-"^FL@2.LE1"2
M(E3X&1T0R)C)LF%A&O5B"+'%U,EUC&4#%H>IR$7=4M%4ID$-A?6F79L?HO<=
MDW@KQ-3T!"*-9$^II<PQ=+D@AZXC>JXB1T<)H6&,21@!9J,[N<%,62&O7.8H
M,MC:].N9\_3<UO6JI04.N T>$\O!&W@ 9-CD0(<K?F8-UI99)FF#WOLPL6!0
M@<$9BP-]09PL4WYAENLNQ7^^BZF%QPX^<NE9"B./HM 8PE">86OCK7HRU8?3
M@ *A!;(,N0G([@A()"9I-(#T!-,*PT+#-,O/\TL"S:*R4RFI*6O8X1M521P3
MW!T^N'4/:Y:G\AC;/163"$NS?F9-:2-F9D;0D;8L;>GMJ%N%>K-Z+U:9X4.#
M_FG]SN:[K&[*M1UR8VARPI,+9CS9<6%766%6T 9)4#M89J/@1/K=KOM5(J]N
M((N974.C'9*79%A<+96=K?"E.G,Y,2$\;O+JX"^)T8!^HO2]?A-??6Q*R.&?
MWCI@PPD<!U^AN1)GUU)PZ0K3D.(8G>@90H%&W-JK%6FSA'S,VR7'L@LE@:MA
M6&(^3X,R]L7F3(7,MI8Q%C<MS94]WVQ]++6E@AY?"*)QE/('..N6N&KRE0M,
M6Y6_W1OJ[(I_*$;JJNV0:_W4K5$LD$-"Q\4)LUCZ@M08K$#>KPJ%JL/ D74Y
M<A %D9Q,=><X)(,3[#OFO4@LTA[ 0B!1.+/*&'@B=AE_<YY)WA -VH9$!9%$
MF<(9$XZI)5TBK5XRY-K4PLKH:)].@_K<OSF22W,J77>4I!TP%H$TEVA)Y$9E
M$2"SWK3"&S45DQ,[OY\.OYXE*93(&-^8%[J1C,<(GJ@Z',SBZM;P]*E#.QN\
MB\F]-R)9 EJLYM$@2M'4HWS,6S3<3#&6,WVB9[/(-AK7XK:F9GDN,SQD8$ZP
M&@B/U303M#>FD(5(\#TO'#!O;"!U9%&N#!T1H!'1E;'Z"?=JKHP,8TA.$YKC
M5291=F&IZAC7E<^9XNC>1G#[CUI@B;D;6_N(N7DD>E .;R*+JUS0;$KOC<E]
M^<)G,=]N2RV^RZVZV^E+K;K;J76W6UIWMNMNMK6EUMUM:76W4_VK:TK\O/OG
MS2EN.WM3M;;;Y4\J4IY4I2GR4IX6VVT\J=K:4[=J<77TM[=Z7>/C3M9?=^WT
M;:]OHKVKP/KCGSZ5/2]'Q[_\&[T?H]+MZ/?]'?O^CGUP*Z_'''-#SSCCC@..
M.. XXXX#CCC@9VUE_'M''^;.'^G7KDV-OE3Z*?RY"=K+^/:./\V</].O7)L;
M?*GT4_ERJO;'E]Y:L#X)^:?2'SDI6N.^E*=ZULNI2E/.M>U?#E6:08!V=:MM
M-O&B/XLF/!'G4MV[<M7)P,F47>4[&&Q(* .JQ:BV%6.>5+CP)1!U@91N) ;:
M:X,MC:JDM9&@SC<+U>&]-BM.<<@N578I#MTXWU4CN/8G"=CH_E5BTCZ8XMJR
M'IV21!R,@?:5GFW=G(6M,U-MR/"-L\+,$;IP1'MHVDB6U9?$UX6W(4M\CJX?
MMIBZ6;MP%ML?9,A3NH!O;7JO$:K7J\K#=P#:9<^Z:R5)N1;-YW!GB0U#81+Y
M/32#4"2MXEL,NIK6LUW5,ZZ,LC/ MY>YXK>7:G\O^CR_^?;VK\E.<5MMKV\/
M+P[4K6E.WLK2E>U:>->U*]Z4^2G JLAPY*97N+JI@D]BV^(-O SJJ[ G^S%,
MXYLPOU28=7DD<;8C.LY>(+WI(KUU9XS:PD@A5GC)2*.="9"5$\@)2R[*6.IG
MGR^]ZK)UL.GV)*\D5L.PPP]PX+ZH'<>E8=\;(SRDS(DF:K[-N:#HY@@31P@W
MHVT"P/PWL:23R4G[P[C=S SM\<MC2E&;C"S5Z-._?Q[_ $U[>/GVIW[4K7Y:
MTIWK\O.*VTKXU[_MK3]?:E:4[T^2[SI\E:<"I.S17)T[;*ZU@IHMWF9-J,FW
M'4CR;<GS>EVD;X3BF.)!@/<V-]2)7C$S?<*:$!)C%A,IAA+KD\1"]-SPAPN[
MZW$EV(K=BFE_>N1IO%(8 !2+M5'VPXDIDF4@;6E[!R1UV?$X;"\&KL'%S)(<
MQ'4=:L,;O+YBV[3;.$DB/,(7,JR.F4U: R GPDD!<A2" @_VO*6TI6M:=^]?
MTU[?I[4[]J=_.O:GC7QKX\5MI6G;MV\>_A6M/Y5IWI[:>5?9P*B4>Q]N[,^J
M!&820^[V.4J09TEG%1%".KUL+&[\MWEC'8;:1N9G]S"4J]K=S/8)F'@6+$:=
ME,JE[L\BY AL(4YBB)4[HNV.)7O8ZI-M"I;\>\"CJ68Y(WJLA1KCU+(5^KR&
M"44.29\4&XM0&_N&MN:'E37=%CD.Y0V]1,KAMRKHE=,N3'CE= DLOTI2E.U/
M+Z:_I\O9Y^';RIVI3PI3G'HV]^_;S[^'>O;Q\Z^CW]'O7Q[U[=ZTK6G?M7@5
M AK!L"A'TEV0SVZ*]':2IJ.NW/;A<)Z@*.0T#4K0STOE14/D,QFA+L\X.CD9
MW0!CW.C^#AU"$#0GBN4)56)S>I98,&\.JPW)@UTS^I*N&;MPX_6'^QN^IE"!
MRHBZ2BK:^Z+#=\PXXLE$0C^2EX3+AX\8 VY&[!252\,\GOK&THL#0Y83ZQ)=
M;8<]"WM6G:OCX]^]>]/HKW[V]N]>U*5I2G>O;MWKSGM3MV^3]-:U_GX^?C]/
MCY\"J'$+Y(*X/ 669![8YFT8:-NB?%-Q1#!)OH^ YNTN.I>!?$^8,:9*8&3=
MZ.801S?B]7E@03NAX"XMB\S%DJ=*&%S+QYD[R,!?J"8UD6'E!381!*!&'=.,
M<M)CYE,L!&[  G/W5F<@YCV(=VO%=G5N(]%95K$X;*MI&IR.K4XD;8JDS"G)
M'7)=FM/^A;V[>/M[^E=Z7_VW?TOT>?EWIY5[<Y[4_9^FO_S]/M^7@5C.F&/$
M3KN3JL8U8]UUA2'=,B91#=$@V:'MD?@NP;QF$L:F/Y\U(""<6^P7MD L<!N0
M%:])$"_-'+F%"8E<,8ZL+*R^Y]Z&NK]J=N1+)@M0[/#D25ZKLO&,\Y6P:V<E
M$:>HUF#IQMZ>%2C(/M#:;4,0-VG-N7,*5U#&M[81<X:P\;(LC$H90I @LK4M
MI3OV[^/Z:UI]%*5K6E*4^2E.U*?)3G%;:5[]^_CVK_M74[=O9VKX?II3M2OR
M]^!4HMC'=^7M:220R_)OXPRN):7:C%40,EQ9/@2:#4WE&^VW6>4%V88:')+E
M=IE8("^Y<QFK>]XG]6P1NJ8$CD@M85;=FR;$G<?E42S&2QO,MFXR3IRL.ZLX
M*E> /)=I3-VO3D.D6J99"J*I> O3YL*Y05FGUXV>5-E Y[7AJ#8+$,#KID1*
M\+"U8[)_:E*=J>7EYU^3_P"?_N<5I2OGW]OA6M*_JK2M*T_33RK\O JQ_<OW
M3-88+)/V"/=_ &0(RZ5NN*4+R 2>6BM\89FDB5]MQ633XDA.-S8'23#L<+:W
MW1)@F)G9'A5*(CC=W(B"$K=,-@:Y8)/ND:\FSA"\NMI.*%3&Q,4Z.:0$?E9C
ML$4Q>8L"R.H[<W%U@AOVN%!78(*CEO)U3VSNH@7Y"\=;I-2'N>/S=U%E2=K8
MY7NU.W;MX>RGAV[>7;MY5I[:>/[.*4I3R[_KK6M?UUK6M:_MX'/''' <<<<!
MQQQP-*^H1.)UKOJJ;23'#L,"Y9>7PK'B,\-6O*]"$6MTQS?'40D,NDK58K0X
M%S/% \<.D@*4SFL2L.6\?PVD:C P5<LE(MVK9O<<[VJ>-)0_:MKJQ1Y)^VHB
M\;/MD/Q.^269-46:XZCS$,#=S;D',<(H9'BR2MAWD DYQ88[HP/(RRI6G.*B
M!]G5/378&?F-D)F1W'"5H;" >?FU:S/K$]-R1W9WEH<T^1&XM3JU+L"E$Y-K
M@DS94JY L3YTJM-ERX%&')BOOLKX0.B^&8T8!YL (\C0 %Q7 \(Q1M$! 4%!
M\;2E2Q,H?4H\D9&UO;6=,1K\"3,[86VQ-B>5N)/>MHJ48\5;0KC#?4=W%E"-
MA?8?)L!%4/\ P)5=)$&>M;?N5#"W)/*G>]LUQ?I3E)$]ESBL-&)&XYID,Q?7
MM"".F9A;%4.2!<;IS9=[K>'^4E3?/8$A@T/*CL^C284&U<4["R02ZWN,?,6!
MLU65Z_[7PN#BS1<J84[.=N;<UU*5$12K]UY[6NBR>$C.Z!RD61)G, RRBSSI
MAJ,:;'H#HUDN0LKD W:E9WC6P.& 4\9A]GQ2S:QZ^Y6UO20X9SM",-E4I@B)
M?(+)$Y]&\-D-\8NA1)3>E8T4DNCU(@V03 [60GI(SP[$[<520I3*Y.?VV.PU
M&0'RQ*LM=4*D\=$K+C<2I2G76VN*+*0YU^3&II:M3UIEI;FH%?R<.H'NW HB
M8;"62,&'3"_3YU98.$887Q.SHP:/Q?4$BG]'#,IOA$.762B_/ 9CA3.13=FN
M([Q@BC"YZL9A(3)V6I>OW]TEF*<'*>=VM=99V8#=L6C7\!U8+ Z362/@$"??
M6IV Y6*B=C,D,9J*"*NM:B[ _!]&] VYTD?/XSB<<K^Z95I:_P"Z$Z"L#/D=
MJHZ.B5MC!)++Z416)%8@_(H\/&V3YH0$K:XY8Q+FS#C<&&6"'(Z$:S$O;?2=
MG5PRN5SQA<\*MR2J]*(B$]4>F>;/<;8':;Y4FR?Q#!(#@E!=:<I<[Y8IA#,V
M@K=B0QKIGK\'Q6"B0R02;ER7780=K>RHOD%[=%RUZRJ,6)L"-R$]R=L4\!B$
MC!<A@T>1AK["/1,SML&C<4"ZD9-J;G-<3,<SCQ"1OV9W+F(39F4ZL418F"7H
M>?!I_;L2A^?2Y@[C>;W/61()R3;$,(J#S^1A8D_ZO +RSQIG1(G(%K);-U0-
M#0ULD)U9$[@PNQ(M9TAU8H5),+RUJ:LB)P&$[TV,Q:_6*9CH0GC36>;6P9A5
MP "Q,2P_&$QI6MKC_.U-N>,TYH3QS&ZARP.@NUHF]U#SJ,"423 KOC2&$=/X
MGG:UH\/JT6#%384HC6*3@F&GXS 8_+C$(P.64/>2<3&R E$4S[F07.^4:<79
MN6.K G><[*V4<<C5F28G'.U(**;LV5"F]Q" LVW"W8#I44:<XI7?C(BP[@SM
M%MFQP?&^KPU+K@"Q]ISK7M4+A#<*3681OK/G,E3W/I,A='/)BQ/[A#$4.ZAD
M#\I5\()#8<V27L"<R_T[]#MDI66!@TZNFVV@1?*Y8!DR!7%20?2;7A@Z\GF
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M$HG1BDF.6<(3C,BT=P1O!$K***#B3367<?8B4=W"O2E[S,MBW5(EGDTV)*K
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M 0A,;WJQL.1RVF.CAT>GVPA?RP-7L)*/,8RY2.W Z6* B3<^&6G;+)F5((D
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M]K[2SWVIX^%/'OW\*>/?S[_3\OMYQ6VVOG;;7M6E:=Z4\*T\J^7G3Y*_)\G
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MQU3*D^7('9<<^?2M\?\ %;_AKVN\:?X:^ROCX5^GBEUM:]J74KX=_"O?P_\
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MAL]+KX=L\/0#+:][%98B4%2167!,82#+P+#*]$54<9-CHXD&7!$G>89=<N?
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MT[.J :,A%^.6[ F$7@H<;QX;96)VSYLHVRI')V6N+@\E0.$#;$UM[J]D<BG
M8(,;<L>'Q);0(''/<"<;W5&_V;?R\02Z+)>G#@TGB5ZC%LA+/OD!3<_BB2:9
M9.-?'-@;WPO4R#1PD$:-LH_C'6_6]HCA')K2AC],[J,SGTD;D&UFL$7#ISK_
M "9-)R\2DP]<I>-Z_D V/%L7MYK"$M;#R=K9\!0=I"6@FQ$CJ9X<=F98M*')
MVDM(4*61S4.*'&*)AZP?KEL]&VS5AI1@&)# ) B9^0#,@QA,X&NCR5 -42L2
M,G&U+H/N&9=2K&9#2I,[L+XRNCDT.V'$M;\BK&\,SPV-_P!FNX$ !V%)<E/F
M$^4UGJ)];7YKC0A&#9V")4F4X;P 493QO;"#U@3JG?'+%E>L+K;B=F]OPJ5.
M!J69<%R>H0"VSM,YN]-<):L;_3K+\+2)(?348BW:5II'IL<A1Y/[O/\ AV?C
M<)-7$!<QD?=WR+0N,CY:%J1]SIK23&2"Y WL*)\9@]'YV8#LIU]EC=<&8=S2
M$>>'#J)Q9@* J9-F;->G,TC-5TUXR)@ID9=HK(9.QW7ET*SY$Z.X\[R$C%AW
M8#'"3A$HX9I2A(4XR"Q2&[.P6YL<7*'DP$HE))DQ,:@)BZ23&.Q62'9Z+:K,
M[0/I1="7NN-Z)W>J-9E3(1I>_7.ER=1>B4+;L.:MGZJ[!POC;5;C([X-10G<
M)7*H69L<P$<?B=QV7AI(O'4R45];*5B8@QD2E'E<A)JKFQDREOSXLJX=:%]<
MZ'"&'="-EQR>H!AQ.K-3$DES'KW"TH'C?)[$-C4K9!Z3Z%K,%GIHS@^#"!V?
M=#6QV7.34Z!=<8Z^H4/PA9V]N:'5M3W5J-A^I?LP(K)WD*'MCBQC]_H#ZI%6
MP8/I+CDND,6ER $^5XUY3J=:&F*\H7J\1!R@=*!P* GV1BZ2YT%4F4AD8*=7
MM"0.K1:Z6RIKB(2/):=.:1IFG!JC]*02$%LY8*KIBK'\?M[N]LMSB'4>:%.!
M@:<1$[*V:U2A1M.)81JE=F3'F>,RG/@&;YJTOEW3Z/G_ &"(TX9 &]C-#X8-
M)BE:K#7\L5[)MP^HC\96*AU9G6LQ O3N[;A=7+ YW(QK!@6+7%[2LJ'.X6!
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M1&IU]+M";IKZ/Y!+[YJR&-@WK&QZWC\O3"@=X\GMOL="H*+#T20YXE+MF3G
M]X&QTUYR1^V'L>QZ/"%V4HWI Y&(8;Z875]F;6)QRB4? !AU!I.T8?AA S+@
M9N&1*)$#VWDL*MF%,N%7*,%.R+5*[X"X6E&K$GK"IS9V%.J8%Z*F7>J&.HQ$
MLK4UWR8H,GV,8WVU<W5C@:4#T4B_#')\2V"Q4=H1U1;'\KG10'NYD(A9B_CO
MP^$!A"\8F%8VJER9]5-K4OR!'\T:@=2Z$]E(RBXT9YK@[ Z&FJTK/@$\9\8D
M^*7R,QMR,&$*-6!5CL<D:(8D1O:<I"-*[,#>^8W% @554-5^7@0*Y-W)!"TA
M:)@6YDU;)0<: NC3T53R12/#$:XHIVGG0OE5;*,"%&Q:J,V4?UKCDSC4,'W<
MT:L Z^2/KP_O R' +4)$,I"S2EP#GGZ6#J/%$HG.R+P9R@$Z5_\ E D)QZ-*
M"84D@)D9X@F2(<?(,%'MA,(C%/N\E*J"GM(9J'(FCIG=I?#H_&I+SB=XQG>U
M)':QIL; (V..ZB22H.A-D;STQCK%BF@PCH)P$J\+,*@E[TTW.)<I1NK.3/>-
M'1@S+,R=\757MV!X9VIXST;<>:30L HW&W8[D(F$P01'K*.+Z9&;VS# ZQX\
M]V%NHX.Q&^JD+:UV9+LV!%16L6X*7URX4MN2ZM^+%4*\0EL]MBX]056P.$VC
MK&N2;O&FO_Q5W63%F1<LU('X]<7M@-VO61AUN<B!KR.8QB:IS:MMG*>$H!F=
M'&V/2)S;&!6W1RW:2SB7;3+]$QAREO:O88DLV#Z5\5;@3@2D"D7&$8)+ +LI
MJI>Y.@C:U [:W1.-)8YE,Q1G8^BQIFQW:PQK+B##:^MI&^NMLE7-L#M[_'+:
MOEJ)D1/,*"S+$K>L/@Q,^RBV9,>%=9DCI)F>+' W;[L2I.MMJ,8W5+6Q3@4V
M]_=L=]W3E&S>M BXD@^9[ 0<,NPHRN;Z7LA/+,?,S@-CC6YXV%X>R1M=B),I
M:&1N><V)F<G%UP)T21SS6-RO+C59*8;@A0UQVI/W3J=+HQ<=F'N9Q8NF#8P&
M9A^.Y2'7IG%@D$CC*1! S.&IQK%83(4*- FC&D+Z+;?Q>62 "[$D)^*K;W]6
M$S &(!K$L];=3:Q;M[F,XCMO)6.9(+W9T+A_4?1]!4!1@$UQI.\?:N.L_-3L
M-J@!47R.BN:S*725].4IACR:\8AM,89'809U2ZC]-^-;J:L/4VD$(8I)!Q^1
MT-T5-@O:0DX0Q8)>NEH&42*&-\-*LQ%[X296T535<E:,>1*/5<63!G18E:3)
M:JIU0-(.JD5.4I2<_$@O!I%.T[D2XHLFF1@L9<RV0P?WAU7;GD62.QHO0)&<
MS:83%T0HU,JE*K>L5B7,[L;86+WAH3!7G&-TM[LP)L6?I-B&I7,B[3WJ,R')
M4*X3?-)1?KC*,&M9#@@Q>V0 AUF%4FL"^/C%&RQ_B&9,EHO;=AVMPSD#-=(A
M4CO*:3#;7O<U:HZ-Q<U-$Z2@1J7&:X""=C-MC;,&J9+C&%)>F5IQ3M-=N3&)
M8  3P!#"0K&5@<JA606B(24HB%2BN0!F5SQR).LOPH,2$GC5ZD^,&"5']GSD
M*0!<S83:I!>1]K1K%2M^3"JMU3DKBS-:! O4*'7&WYD3>B1+,U^?"F2J+\>&
M(JW=USG5@P&T;F2,DAI;&93)N2;LZMA98I2,0:;N0"6-KRZD#VVO;.YL;DTN
M"]TN=QQ(/X&#%1PS/E**,"?*$"4M;8/[+@E%N8NHW-N.%(NU\V:D'2^9L0^Q
M-#ILKM!'\HJ!QI@UK.W4;4MN[#5"U$X8'!K",HEN;8I%*#PI=LQX0@]Q<WY2
M'<VQXK/<M[(I9(E^-2LFZG'3MCJ2-?&),,7PP[ML[Z<:'!<_IREE<0YW)7U<
MVKBAU9V@DJ9TLC]R!6Q4PYV]10LN()W7'8G6-HCL<E)UG*"FR)W1*J=!.1E\
MGQZACQP0M*S$T*W(=+U+]B&U:1M7J\#9G6-3CDQ(5:K$AR9,.;/;BNR]G)1M
M-B8,RE^94^$J6IFX9RYW9!AQD3@L;5;ND0L5^13;8[JU32WKG-.D;JJ<V=O1
MJUN+'>E3Y\M@5+:[E;6Y('RO\3;?RD9;(R'I1(<D;<"ZX7$R)-I#M<DV3UVC
MX"%V2.W 7RX8?=6K*>3K%2:$2.BVD@C$462&X-ZEQ8B$S?Y+(X< +3GJ*[)Y
M)JVQE5]'F3I_Z4*$:J>SMD?%9+A7[';'1H^GJEK'PM@N<%C2:O4>,SJ^#[6D
M8QQXE>U"Z)D+8^#21GE4)9OC 5968C:')J,K3 B&FMO3@KZ%N+@YI7J11B+'
M8Q]T6DK0B7BP ]DK?D/'A.X+%+"VIE*5.C<7KU!C6ZFW]0?I\S4H%Q)VE>,B
M(!D >/2EI.C9S&1^)7-9!FP01$#R'+2 T=F7'G*KY>=AJHT-96]0B,$"7"\M
M^5P;%;3[Z!)!2M*^-*]_&M/UTK6E:?JK2M.<\=J4\J=O.OZZU[UK^NOC7]/'
M <<<<"NOQQQS0\\XXXX#CCC@.... XXXX&=M9?Q[1Q_FSA_IUZY-C;Y4^BG\
MN0G:R_CVCC_-G#_3KUR;&WRI]%/Y<JKVQY?>6K ^"?FGTASQQY>?.A0E0RYJ
M"%*VD+&X*A%=1L*DZ)W;E><;<JMJ5YHWO^%.IR9&9=5H7(G2B1RM2J/>Y8E7
M>Y>JJ,.:^"YWW'/+#QP&%MF"\6+1@DL5#[(5IKV @:'FU0+DF1RPCQ'@N;%B
MJF5A?<K.[8F9XQUN;73(V.-B!4HN0JJ8?3^E;X?XK?\ %_L^-/'S\O'Q\J^7
MLKP/KCGSZ=G:MWIV^C2O:MWI4[4K[*U[]N_Z./2MIV[W6T]+_9\:?XN_EV\?
M'O\ HX'UQSY].RE*UK=;2E*]JUK6E*4_77M3S\/I[T\Z<\\M+Q1N=+61P)AY
M"\WY6/!8TK'MK2N=V8FS.Z<<PVH,ZO&KNRO^=@?,++CIAK>[969UQ-]%.1N6
MVX ]'QSK&=Z9R%I;7YA=6UZ8WEO2.K0\M*Y*Y-3HV+\%BE$XMKDBRYT2]"K3
MY,>=,L29\R91AR69<.6_'?;=7^CFZM;(UN+V\.*!I9FA L='5V<EB9 V-K8W
MI\BM>X."]7EPI$2%$EPY5*M6IS8DZ9/BR9LV2S%9==0/W\<_@G5)E>' H2J,
M"G IPXU"?.GS8\V'/@S8[<N+-ARX[KK,N++BOLR8\F.ZZR_'=;?;=6VZE:_U
M].RO>M+[:]J]J]JTKVKXU[5[>7:E*UK[*4K6OA2O ^N.=<ZN[4Q-KB\/3FWM
M#2T(5+FZNCHM3-[<V-R+#>H6+W!<LRX4J)$E3V7YU*M5EQ)\&&R[+ER666UN
MI_%R(&%GHVW.STTM='ET1,C15Q<D2&CJ\N5N2YO:6VJK/BHN<UUN'+<C0)?=
M5:JW%DK@PY*675H';\<\TP&8@5>ZU&2D<(O<4#(Z9O>)\:WCW%L)6ZCN.N.7
MWM5JO<T+\U5HY,RR_LF=6^M%J#*H35IEYZ3O3P\:>-.]/'SI[:?H\:>/Z>!S
MQQQP'''' <<<<!SBOE]/:G[:]N<\XKY?KM_G3@:W L?8#:F>5G9\*&=W.+?7
M?>D1(5XJSHVC#DS)F3"NPLEZ3*^O6)MLP^OO;MF4J,F:ZJ=+8E0IDJ?'EME!
M4;(XX7'"_FR_)ALS642O)F0/#??3-CKCK=E0+UF9-EOLI7TL-]]E;L.2E,F.
MM+J=^=5#?XK@;_BZ@_E?S)G TGZAD'&VQ.J1Q&<?,8\8$5Y;"IY6.RQVHQ#4
ML,,13A'4LE<.O;UDPJ$;8WRT+A3O'V56[8,P]9>08K27%D'KW.WFB,3Z634^
M[9!^TA?#0A$8JLWWF#9+#$C@1A1 51B$/?3]1:N-Y$[90Y:1@]TF2O+HVWR2
M8LL>$;TU,N!4SNK@3/Q*F>%>.4':C8\4U+@POGDU&#DT8!%P!6B\4C5I;'PY
M(':0Y#$XR&FL;:7E['6Q<N5$IDT8ZX5;TWV>K5SWVYKLMF/%DCR/NJJV@2Q8
M[GD92M&:F%B#:9BG^%\@E&TC%RBS7_7B+]DUCL*R&.3,@%$S>BA^5!N2$UK8
MA+%Y-9[\@ZE&,O[/9F<0\UN)HU(\Z;03([ML+A!=&$U@O3!QOAF1. #[U*+M
M0-_'V9)JCXQ&'FN0H>OA=#1,UN##DL9W<6(?@5D%'U<W+L8\E5:_2ETZ-@1V
M=R&7P:-<I)&UFR6ZQLTQ1#+YJ\UE"IBV6@+4@1&3=*,[1QV7013'>30G+8/(
M*!:G9SU -RNX%0VY/F%P*!,DD4-^I.#(Y:>X$AJ()4V#E]&=8 ,<80-9&K&,
MFBYL@X0V'D9V9I .3H?%D#!%\=R7$B4G<B%2TVK3F6P(.',3NISDBX:Q+#'5
M,$I0GIM8<+8\K(>FQGTL;8 R)A? U&C(<;%A&XQJ9)):QN1+;8W)A>NKRX66
MH&A*O7L15@6(K;7I L]\D(?B.=,)C;^GCII!;2.M\EF.K1II_(9M"CS(N%_:
M)2'X +&,B?X?;9'+FH(82"Y@QI$:N.70Z'Q<4?WL $D9&D%&M=D<6?#D&=/*
M6%NPP%/,N1)'(T'YY<ZETR((;<7H<+\\&_&O'-> 8 8Z8D%[V&KS Q01Y+!Q
M*&4$7N FP$4JDC&@=R/"M5OCILE)O5BC<)9W5T$X'GF4+Q@$W0E@Q3#6",6B
MP8B[0F?L^OD_$ZI:5R*SI5KAF)$N=YC,7;KE+R<,M*69K1]SQJT:3M&_J<M:
M]GE;W76><6,QC53"#GC%B9VAQF:UD;;%C9>4Q?+)9(ETDJ &*PG$A BQ >7G
MSXWNP>0-Z ?P-Y"YD@WA= K_ #C&:77G P:9R3'$2RGMB[E'0LRC#Q>3#*>5
M(Y0:^YM9Q$FC&-A@O3(3J3Q01RQ7,,@B)_ ;8216B:3^:*3*51H[AI$@(=WW
M_IQ;7E81GAE%$(2)NT6 /5M1N.QZL_%\F7;)[WF'97:8P:4[>T.SF<L]I"_2
M&,R+.2N86UN;A8TC >;PO,<MUZ$A:LNM76JO,9-3EL9:NS%-4*X].'K8HC;8
M]2PEDDB(<<.[2S[KULH0$122S>Q!AT-L"J(D]@"+PZYG!%*5$+F^A^)U;%2>
MJ:2>;MQPD!%-6);'"G,[17.3J7DZ):Q!:<FN/8X']-Y\VD1T:W)T,@ZX'O=!
MV+$[ZUD>1L+;UJE.D#5@ZUIB=48BH1ZO/3EEZQO,B!M:0\4D)]ZCD1;*XI-8
M[D#P;,$41_I;'\ 4)FNY(BH\NI0&$387W#0,D46*G1"H48D63%:2*[<VLO1]
M<(^-MIH#71#$<1"+-!/23:H E<XAPE%BI$_R';.<9*AW$96#B7&4 RPEL#Y%
M.1T,GO (;#I71UDG%)L9B3LTYG$DF:U/WI9MHR-:+9X7EB$WE?!4,;. 3?*=
M0/*O-(,G:\H1!1/E3 )D9XP\E1O(:^-92 E2E"0L=]6Q1V68UBFUOT(/^J<1
M FO&W9$B8E])NB+;Z984#,B36Z=G.(U0T([4LL/BZPLDMG&,T7Y'J\(=4WPB
M?%<BM:1(2Y,5KEA;%&.]IM#8H"Z;X>7R+N"4;(-Y>4BTR[B738)QHDG.5<$,
MF 6RQ9KZT"UTEPB/&#3&!/FL.8S=E;L/F(L])GY.W-%2/$[-_JB3!KNNZ=,O
M,E^$[!8S@G),&+J!]2'9C,_%EC3D1$X1L7K]M_'4-(I =FIMQ$K^S/+])$,L
M)\*XUURU"'(%*?W3)C'$>/%NS'VTT\D/4.E35$[AP4 (A%=>T<P1:>X#7&7F
M4K7996^ #B]+FEMQ($$=L;=2S(B3##GB?7YS5T]^;WAO24HT<Q!O1MOM/K6<
M)W@2Q:\-$?7O$/!<,1 <IB RV#WLE@\*[&\[B^#L(?) ]FB=0 #BYH4XB9\C
M26T^=7F>RDM:Q"-AE<1YPC!:M MSJE#P=D,#2^\XU$.=/IC';FN9M"HLEB)Y
M!TXF*1B[$X0R"1Q%U=7<[;&F*4,2J#([FA#( J>@(T^-TGR "%B$ 'LO8%73
MEW0>A-F<RV+:FMQAJSM#KGEC".W;2B,50HOE?:&0)78"J<$15%!S#(\MFH,,
M1IXV;/=-VM"4L,GA%ZP%$CQ(M8E@](I$V\NQIA*<-%;X+Q4KUPVAV9W$U<B,
M496XA:Y:"7S6)//2D'D(Q.UAD\B1@US39K-)5RX6:P$2OCFTH ;?A(2VH"/.
MKQ\BZC^SE=>YO.93BJ(=<)*!^H>%Z8JE!(2KY6B;7J/S)OA!?]V2:3!D=P%O
M,<;2ADI;FOHUNT:"E25]#!)T?FM"D>"A>&_<X0.;&/3_ );UK9%F(EDDDT_/
MX18W0B?U"RU[.7J#GB.V]Q>2IW2X5>:CJ^++,SD0N"/ JS8U2AP6IL>3)GP4
MP!)D5;9L@E(!I$@,$D4PQYJ_#$"ZX,AB_CZP5QD[P0L+_/4BK4KDM0MN3*QW
ML8$I&6%^7-*<I?8C0I%"UN:2#&YX,O:![6*]K(ZEE<Z$4<';Y!NQ,HZ\/4GP
M_A<D462EG L0V^-9V$-3L^EBMF1.8V9LB!\:,9B9-;>8-1'@8"Q_'_>MQS;V
M<"-35'7DS%(<V,87 :F2*YPFEQ('(JV,F:6(VF6;)*-7D H'#<D.;M$N=J$Q
M1#&K>D968)C(-: @(#6]HM1A0ZUIU2U:LT BG1K8O,":B@+AJ+$<*OFJ:7IY
MA1W,2>2 US+)PLUIV8%I-E)U$$H1<HP*(G4H!E^EAC5RFE&9=?Y-D-T;<@:R
M6_")[?;%7' K2B/2EGI!K%+ ._A,8JY>?M+>FU P.\YG]E7*&LKU@F>39-DU
MO2$61ONRLC0C5OXL_,KBEKBQO3X@2J,-N-6S),V'TCOHALP!2M-DBN>M<?;?
M!TR#_48C4:A<KD$!9 \&4[1;;OLT"YX9*#50EK@C^7HV=V(-G'+'Z5\E0821
M\.M[0'FUJS#</V-N.!6KP:/[M..Q$.%I)$Z)&.Q7LKMJ4NJ4")]91&",(5/N
MK\X:_A4C1ZUIAJNTTB&[A\,X^7[ O4_2>F=<2YA6+00&/*T:<C#NK(NI4NUZ
M?73\AY+';+(DIZHFO38+38(2/PABR+,.M95$WW7<080&2UD%%3HC'V$GSM%5
M[RQ)R)*EO;L"_#F<<&#++_QP*XF'ID; QSJ_ H9%<6P.KE4#C7J<*Y*8R;(/
M. +)4N;5"1@S@2H_P*D6)/(*$P]]6]E+<K[?<G1,]$C,[W_!Y%<EP]3%&@.W
M.?9(@E4K#C%$,OVQG3;F5,^S&=:OT/;QC5<>GD&D)E?@_5L5#XM%7UC:3 'L
M#A\2;B]O>!!(ESN,E*2+&I%6"RCQP()NH7HU/$^33/+_ !7'#(YL\LZ=:T ]
MII\+8[&%+D6:S[L6; &4)D%A8RE*JU-/44KJA@\_O ,=1=C7,U[/+#/:+W)D
MKAK*4Z#;/U5$<J#\'SLF+#:8Y\)VA2U3)T_G"9@]OD'6N-H5='*1X'*X92:$
MD09L14%SCTOCH2Y+)&&&!F##-I+R G-I19F^SGQP*[@!H#M*V3>'D9%%<4C6
M' <])F734HC%Z%F.,_?75>#I BB=  +%+\^ X0(0U^<&=TC=&Y,5S$YA#BD1
MH'U.\M2QHMUGG+I^O^L&GFJI$;!,+,,>:O:*:UQ3LH*KUV%.$2<6@NZ^GTUG
M46&3PQCCG@PQS)-X7*'PDE0N2VQF,+G]:1RNM9XY>3I\36N^?-]EF2R_'DMI
M?9?;6R^RZE+K;K;J=KK;K:]Z76W4K6EUM:5I=2M:5I6E:TX$-_2>5,ATU]12
M4(_CP4CJ-YIWJ+RZ.6\(? PF#WY*GU?UJ!B@D0%,<J7.-R%W6R.+ER,\<(](
M# .22"@*V5M-"E4T.3GDQ9$73%,87C+I'O TUD+G,^J!G#U=@VHIV)DJ0(W;
M1;/K+)$0RXX@8')A471DD=F K)V%Q"U<?"0F0LS6E<4 4ZL;.XNC6OG?P)\"
M7#C3IL.)/@Q6TLQ8<..S%BQ66T[6V8\=E+;,=EM/*RRVVVGR4IS^W BBT$Z<
M E \):DJ9K0&)3/&OH/7WM;B.=I7DV+8XD9Y9GL<(22,8\(#%?%HP\81I_>!
M9B?AH0;%0\-/;XRCE[6A>G;&LVBUPA@OBZ6=XBTA2-:5AGC9@:E&/?>Y;A4Y
M<PHV:HZVQ(LRN:3#CQ^]2ZAE&15AL0Y*Y,F1!B1./I^YKK+;=N^.! 5][7EA
M[.YV(S )C<A2%L/=8T/CZ]Y<V5XR("/>39D1D&+,EJ=:@S6-5I!&S2Z-Y>X4
MMK>RV9\["MJHPKU%N78V8]99ONAWIH+6X+33$YZ82)$!S,T"8"421991L'-;
M36&JN F^'[BR #N91'))<QR^&)C%]&6EV7!_K: G827 PJJRT<<"L01]/':9
MU%M@ QCU'A0 6[C@6NC(#O 3)X\H#^G]GC&?Y'DU];U%7-8S%SRM8\IMBGL8
MOUY87 ===B7,L'/<!L0;AZ0'+;V..G27,TZ0Q)!9',7."$5ZE'45VM,W!3\'
MG9S4@VQX',HC%+W2U2V9%#B39$Q!'C:[-WNE%;&A:4UF7/EQ,:>VR;KC@5#T
M?28VQ88WD>&E6KL0&Y1.VG&@VL@)L;?(D8VJ=-S+7%O+$!M(J5*]MUI[1I%,
MA&S%<=7PVG=G]\,@QF:U;4-M5B(K;=TW?IA3(1X-I%!*&1N2O$A:<]5:$XN<
M2!V8W)4F.-Q=Y]@I[CRY1<I0*,;"G(P$TC]<7NF+TK&=XPJ6C/51<W7Y,EAW
MC@5PI@TKW3+I]!WS%&:IQ#([W8T.V QJ LBU5$04WC6!H^AH)-2DW=7P9S[.
M2/LH/5;Y'&<+,Z2!'4-9XE;AW$Q.1 \I_@>_XI$>F'M6T12"LJZ%P599"X0&
MC*V(W(]!\(_.R6%>JK9MXH$VM:V9US"UBTZPZ@3JF"\]3LV!"7WHA>4!]E;[
MG)?CM)\<"!>'NG_*I%M6V;)2O"$=!(.]S-U 9?9X?>7P2,'F(OC#0KJ/" =<
MZ)&3,1 N8\D_)#4QR/)E %]?!E@7RJY-%SZ1+W-Z=U^29!TMV-^],:OP;&6$
M,1;LZA1=JH60UG>W[!>#-6P.N[ ,-"MN4D%$N3%D&W]AL-@=0X8L:? I9B'+
M9DNQ(<^:SDS_ !P*RVOW1XFZ \Y:"8LPB6Q7#<MZ(LFH61:1TO>6R!&+=J&=
MZ-W%!1B<K<]J<B(I9%W[&/-U:6Y'UE%V%#;E]%PQUQ>MC'I@RDJ92Q@D2"(O
M3)1?67JTP* XB%9'!&V.9=M?MG@E:'3@32M]KQ\'1\MBM=>QOBMY1CI0.Y6I
M8./C%8VY&Y0OL><<##>NP:11W 4(@)?[C\*PB(8R$";U=91QP5(!D'86-Z]Q
M<*4I1=B]\T"KW-92E/6K/1S]J>Z<S)QQP'''' KK\<<<T//<75[6UK3Y*5K^
MRG*X4O=4>>@Q^WG5)]JM&XR<M7ITEZ/(NUIE6*BYUEZ:AR.TS.N'J-#\/2,W
M*+UYHI<5@FVK4P[6WW]:U.;-G0I*Y<Z"Q[6G>E:>VE:?MIVY&NY=.<=>(7Z@
M,3.IB/.2[>*6YDE= 9.<8-3FNB%7*3$*MC6W)$ZQYO7$V0.<A?$])7)&\BF1
M8H55]53M2C#ZUEY-_#[_ &MWX2E3-,7O%]F[?%]L3X</YWZ>S'U#]AFG8MDB
M=;-.H^CC2LT=A_9EQ0;8"R@E6V2F>>[4(8>0ON&00G*I<FF^M:X4Z-L=G?$F
M:'"M&I8LK=@L]"0=2#;;/H1JWMB.:[Q^RY9C=XN9Y1+2,RS)&D(4%\ZIHN3*
M0>'G%)D*C!GDH?QU)QE[4F*1('(GM-F56$=R)-E5[<QMT_!H5V$8IU/2$3EK
M&R:7PMJ9C$#&+F=ZPWND1K&U1FE/$YD[D28DRPDPM]Z;WCQM/KK98L44R$CC
MCOOQ79QVZUNIM+"=L.X"W" X\<CPV>XWJT?H_P"'$GB606(XM8\+1A=6*S%8
M\8&6C,G58UEN%GMS8U5J%9B3T1Y$7SO_ %_$>.?&)_M*)H]V],;8O.>SQRC.
M?YW>-VTZK%;@5J\%G?T,"M5@L]*O>[T,*C)BL]*OAWN]&RGI5[4[U[U[4Y_#
MG]E&7W=0I4>CZ/K"E0H]'OW]#W?-?E]#OVIZ7H^GZ/I=J=^W?M3OVI_'G59Q
MQQP,[:R_CVCC_-G#_3KUR;&WRI]%/Y<A.UE_'M''^;.'^G7KDV-OE3Z*?RY5
M7MCR^\M6!\$_-/I#YR?^;O\ ^!=_*O*G)AEF&/=O=]@&/K2Y&W]43<-?ISE>
MT3(L7)(]/ V*M3U"Z4$*S);3$P)\NG<A;..-CTF[)%)=" <@[U=5N'+9;(NN
MI;;==7RMI6ZO;S[4IWKS4\ W3U^D@KE"/1\R;L,G14;RN#N<6O+X)M,D$JN&
ML+3E-'\*#%)-[]/P>GR/3:F3DER9$WV*E%ECE5MMNLR7P7*W4#2Q*<+POIE&
M[63.T!:\O>K'2EC&<IS0M(\+EL#0V4&?4G3NRM5*K^.J7,71DY9'4%PTK*"=
MQ5-L3IY(<B<:N"2TNJ7W9W?YRVO?DTO'NM&X,_3Z":S]/V7)M@J[[DXTUX-A
M94^,-MK%((3':'&#(WJ=V",8Y#&.\+S!:@=&MG% J#RQF0O*<@QV/U@!NV1@
MYR3Q8SEA\$Q^:36!L1V&1#))L!,4G.[ 0)FN[)AQ!M2AQRON1J6O*1B?,PUG
M(F3$\W^H)G5?;D39<_1:\[;0%LFE6(XO.&+(5,RD[2O,7.3X,I)0'6R.Y4+X
M;<R%[C]O?7-]9A9Q,0AXP#;XK2X$+FAJAOQWIU.:Y#@"O5(VU1FP)CP*@O?]
MYE[6)ODW4"C+/<LS?;%+=)LAGT1[&%4V:P,6^XK$!X(PVXN-H? 4Q8,I4SL3
M6QDI4[ZXLQD#*I"%!IEPYL?U')Z0Z[Q^>QEL#,HQ)<::;Q!.;4JG*1X8BW[H
M#JKG24QEZ+V2*XVBXV4[S*"T0C/.SEBEIQ@L #$<9Q*94SZ)NL@O+L,6RG.0
M(B9S)DAUX-8[:Y +FQ>^#D7.1*,(C H9T>13E='AC!U:[$]O;8DRIE65P<&]
MJ5),&7#GR*,UN3#FNLZ!KG+7LGR&5K++T.D&>+5F$?D&QKD,'=<T=N#JMJU8
M&,QHD>L]XBL<EV'WMQMCY[W95JG'1#;@RYL?N-H5@3&8Y6CG8;9F,!3:9U 8
MLDWJ.SJ_R_()GL>-0.DCYI^)MKC*>MH>W3JX0I,#?#@C+WOQ(A"&9G011MTM
M-,&MP:SFM<-2EK-?:BA',DKS#JE)LO9<19(!9BZ([V5FH^*E0^RE]6Z:^J_C
M2&^-G)0B/G=ER$0GE$BM[2*0H21)EI'5:U,#.-NK&EY8WS;"ZR98VK+F>;H+
MR1"N>;1JLFY9,CV^-E;^A<,K38P7&F1\J+*'=&[)LS98TW.>1:G<D^5':GL4
MX;[+/:KY=BAH-A.,W23(_;)&.VE8^@X X&HVC-C%C;;+LK@\BHHI=,;^1M2#
M';=D7.+.WK4B:RE;\^>RVVM:!4- YJGR*Q987CDU/84=S3I#T(L\EIWDA#HH
M%H3A:4*20&SU*P.S-$1%#3!PF(O*1HCU;)+;%92)P?FDYT>G)E;LJ!@<!F6:
M)I@FXHZ4V_Q01R,.S6X1N&[G#D$R*A77SDD+@P+AE:L&T;R?D\*Q@#['YA<\
MRE()D/&&.'<*D%L'4K8].!B1)2YP<9D!21(MD=<2H0@Y SES$\J-F+T8J4#A
M.O&\SLCHYH&LCP,Z]>I9LCH@K1P2(72U-<N1U];Q8<N"ONE?>X<&%/AQIT^+
M'@P8K+<6+#ALMQ8L6.RE+;,>+'92VS'99;2EMEEE+;;*4I2VE*4I3@5T6R3]
MI&F1<$OW3E,=C,,]26&]7&&&6T5:%$1(-=S#2N)2PU3*8U%PU,^FSI62R5W+
MV-ZP.=Q(R.K:@"096UMRET97J/UCV'.YDUT*&B2]RI&)V\"D7I0S>?[ QIL<
M"2/!-F$LW? @>2)#7%SM#,9R'J8^NR!<L."?4"6@MJ:(5;8^:WK#GR6,AX@=
M[FG;Z?;YU^CV_P#1Y?+Y\_':W(+,:G%8B2VXEF2[*KQVI\-,:K+?2E+\BFRE
MGHY\E]+;:7Y,U+[[Z4I2ZZM*4[!3)W@W0F4R4;3B8S,9&Z@LM19UBH))8?/9
M1#28SS/42:ZS\J@D6QZN!<:V)-=<C<=QL@:8G<B"45$T[*C3QB>2(-?;WI?\
M%MD(=V"D1XFR(X^BS; UWC@95*_3H,3^49+;(CD-5$6Q,ND&PB"9(.$WP6BD
M81@7J,>#848.8'@Q8SO79RJC04=@^IW8TJK5%$"*F6_/1(GIFR9;,^3+3#CI
MER9\6+W'%FR9*6^G?FQ8?]RQ9;JUR8L7?'9=;97T>?UQ)\&#TZ8<5F*F3)?F
MR4QVTLI?ER5[Y,M]+:4]/)DKXY,EW>_)7M6^ZZM*5X%,R-'$MMA?1]M+STCA
M0&C8Y_\ )_TZPN84HK&RA(E.]0')A?D1P;N(IZT]H$YHXLK2SHC)R7)!]Z<D
M0XWV(DRW T9)BNEM/>UVP\B2TS3J2O\ 5NTC'JZ3RKZR.,32RS;M^)2$2/,C
MS.E4H$>#)<W88/;X$>6#$S4;A^]SF@XPU;+JM37>GFHSIL"K#>G48K,V')2E
M+\>6GIV7>C6EUM:TN[^-MU+;[;O]JV^VV^VM+[;;J87@#7N-=:012 1BB?;&
MYT+2X_)GTN*R(\-C,Z.WI0_EA@:&Y:X.I*4D+POSVVY7%W<%&1.WI&YI1T3-
MC:B28 S?QQQP'''' <<<<!SBOE^NW^=.<\XKY?KM_G3@8TAO\5P-_P 74'\K
M^9,YC.&_Q7 W_%U!_*_F3.!A78."A/9",%T4&[@_M@\X%L7F.98,JD"-WM<H
MGE,+EL>P8\[FVNR2B)81 S2C>,=R*_-G9U"].DSHEF7 N38&7]/^#WB;7V<7
MU47OKP323*TEOXDZK6%2#NRZ8]8HAU/,1Y:V4'K'/,,98TAH=5)$-SOZY:1N
MI"J5."MJ5(6ANWCXX$5 -TH(SA6+8##=?)MG&*Y)UV?);= ^?U:X%D:3"=#.
MB5,UR4Q28B. QQ SEO6LS& HAS.N$T[@*715&U6U5>A9'-M?.NQ](>&1(?"4
MT-RY-D5F<78]9,\;'V)>!G3JPOVL#1/3$Q$CRV' 0Z-!BZ2.W[*RWEE&C_@R
M)G9T?$CH-8150VX+;I:..!&.']*^%A:.WB/U\FSB992;7C<O74I,BLA#%1<0
ML6]$TJIZFLR7*6X$;&FPWP':Y9\#<Z1H3CK*R9K6U<.N]V'"IL_+-G2OAZ7W
MG"6V'1HQ%B!SUG=6S([C<3R8&6J-7@6;XX"['N.9' '\5)\+L,S^;*G>QZ3*
M+FTL;0TN$KQUV&[+EDH7' A);^BD)#.(A^ >X^U(0L-(YF.##IS:$6N:A<6P
M3/,YR-L-(P2HHX07G0#Q)GD*6#JX8D8,;QI]#V-T3M#&CP8V])DLWXE'2:&)
M/CJ$8INM(PD$U\;2ADC9B"E[>EP-C"3:ORUJ51D47O;4^9,[>Q1?,+_G8Z67
M85&(D:1]<NSKV].X-;EM]QP-7(GU,CN'S]BD8;>"]:]C^K\.:G(TKRO:%#;D
MCR$GPP?Q9X484;(A4WEZY8:.F-]78U>)H4I\"&Q"RM^3'GRJ/$/VA\2$,"3=
MKPL(9 QAD\S-(<XESDF=&"PD;RN29G3SD^(!]7D&\C:E84I6FL0-:9>UN2["
MPUO3*7%6OK1QINUQP,&6P 'V[&UV<HXD7P[K"U\%^]553?\ !;X)WR%=)-7#
MU+WL]]/?_P!^[JI:*O??U#WL_P!Q][O6?]]\P(7:0YWO9\IVN%-CYCCZ0RD*
M"(YJC;Q37DV:A8$"\[@NS"<?KY5A4[+ 5B-GEU7$,@-XX2(<)6_T;7-?2N5B
M9+4&]W' COC;ITQ_&\X#DHI),DEZ 8TE">)OA"!'3$$8(YA^7]F:E=9A,A]T
M:1-O.GO&X5D&2_@@/$Y,YL@3;)IGB;4ZI/<+81;W)/I,-. 7L$-A4KRW&K[L
M%/Z+9%[,1AV'<JQD.D([&(OD&;!]T'50H91(0L<6-#.;QE(C05,IBS/A.V.F
M>F):VY&G=?C@:_:WZ[B^MP,ZBS&\/180&!H229))Z28V=*^GDAEMR*QX(%K6
M--K(+,"%(UM3$+# P,,K4P"P>-CP\VI:X6VJA1L#QQP'''' <<<<!QQQP'''
M' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' KK
M\<<<T//.... XXXX#CCC@....!G;67\>T<?YLX?Z=>N38V^5/HI_+D)VLOX]
MHX_S9P_TZ]<FQM\J?13^7*J]L>7WEJP/@GYI](?.2VMV.^VGG=9=;3Z:VUI3
MD%Z[IRR+4J>SQO HR3G;UU2Y[VG7&F)0P8"Q?",@:JS!"@SZZ16-M'=2YW.9
M:,LJH6SK,E4;!9DI?=<B1>KUG3XY!<IEE4>-T%.:+3\_CB)9&VJ)##H2J!5\
MH4#V.5HV2:^IM6PDN (W%C%*VGTGC0NXQ/-,GBQU #8216@;I#FO',!;&[J&
MOZ,CF)UXZ?AY$DGZ>R'4&C9B>8RF'J?&LT% [F9,)"^M.ULJ');%ZI0Z(VU,
MZEJES:E8;E?\"U1?E:,S2WX%=<M[,E]QFCO2)LBC$JO3X;U."W)9A478[+L^
M+'E]'W7'BRUMKDQV9?1M]TLLNMMR>C3TZ7=J<_1P(5'W5N>F7:/89TLUIBN?
MFZ>MOM<]F8ZV0D\V8&EG@ 0AJ(0002ASBP-ZO'->4YBLTC\H((8; %N<@!_^
M[6^JBLG"K+C1K((U+.E]NA*5PZV2?#"-,P.FH$.Z['(L2$>I ]$PTZQ[O%J]
ML6;@$6QC  FP>JZX+PP'EA'%*Z17V2Y5>\BNQCD1L /6J+B*VMQP($#G2*=(
M^W%+MH!J!AB?XDNV"V),6K6YF)XP&E#I6<-)=/H68)J2(Y+5C\<IR(=,H*EN
M-RM [.:,FQQW,#X4L'PFJL>!)ZP:Q=-?99HE!K1ND4I687,9(Z<DC-E\(2K"
M3=".M(]JD'1"T$\9-CY+42$.W]$\/NT8E.:!4D./[4'2@CD?*T'6"(VQP.\K
MQ9AXX&AW3>U>SZE:LBL8OH:&B,@+"N4SB2,@?C:\V,C+#R5SDQ]_WE[;DV#(
M_NRAE?6I/D6++\^5$G3X6=/?C1-R?!CWQXXX#CCC@.... XXXX#CCC@....
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M.]>!T\4H%S9&X2B<DF9 NPCC9ZRB4V>YJ4F7)@IFJF4XJ^.)3AIDIC48KO\
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M+R1!$"M]4FT;!DEZWB4:S)&,G&$C8Y*E>-89CV.9D:V/,C2:SS 0%\R1LZJ
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M[D_2.(Y=F5RFLH>Y#L='T:UV'B 19R1O0 K\JU4V$R;*0<4+F^]@4O>,C#Y
M7/J._,V$:!G?18D>&5]9E^>C8XMGECWI]P^9RLHF]D,I?BZ6%DF'$F*SB."Q
ME0NF97)4'1)KV?#B2PJ$"UN8V,ECJ$(ZP^^0VD:#H<?67.0!AF..#DX79@Q/
MHAN^0;F2#(QDQIEK9#I%J1H=L1$8,1-[(@)A=7L>R[ NQ6UDKTSV*[ER[+F
MQI!DI5:Y-K;<WYE352W$O58\NFPEUKRMBB*/E\QPW%C?.I5\;0^> FNPX;$H
M<GA?6S8LF@M/8'EDE(LZ<ZG(R=FFX?"HK;*I$)<[C9$3/AA&C YLB"DINJ6D
MT-:=-F9NBU:=N5+XTB>(+5YZ3V$;CACZ$5\CJXP8J*<;4TT4Y1I)*! S7O:[
M&K(']"F:E),YO#[@7/#A@O%TLX;9DU_P$F+9B,'F_+L6U8BR/)#&&0J3Q;M!
M)*F7I*A3&[*(Y<JW@:*1W!V*XZ?U2?/,<7N;R[W@TILUJ[-9P,:B75@;)7G%
M3#</Q0P/RAS%VE]!&H[G8*B6=2Y 4ZU-6Q0I*"'7$Y9$!BXZXJ+GUMBM^EL2
M?B]_'Y)3$*3-&2L>&GI^2:_0/U9)8?8XBHVD2(G<OE^<HXZ9>-GA('?@-AC9
M@.]XVF;UK65CYVZHE1<D%EZ:/TQ*>LY>H*%H"Q(TS>(5)WC \6/<@R/IUQ"E
ME4&D/+(<]/(A&4D"\PQU Y1)=A?$(1)X?%^:)F$L%LQ4/O,NLF# .9\KDL"$
M$M88U=C#*H,78+6ORM8K4>;B;I;ZVQ&UQJW-[K*Y:HB91K34->34V1KW9(V:
MB72DG@$?67,@X/MZYH!F*6R$7_W=O]\W]C;QZI$Y.;NWJ79>&NCUU;3BT:?[
M ?3<ID.4H8$MGS_:@!9IF#FMDB,-U8EDQA@ES@YZ]C*/#+9+)I>!EBN&!E0-
MQS>1#0T0.1FY #BB1,SIE;=#;$V8M:]/Y:B@H.HP1;'S]JH-$#J!1VT3!)K1
M&LUMBY_>VT0"EX%)2=])_4_4$EN9  D:Q-AQKEJ)LK3'6_'@3<3IB2B4/!3F
MU(5B@LBFR.-O8_F=\?)I/HG-E"K;20<LCOE75V8(LE]#(L2,120%I,U1VQ-\
M,2L)OF>]* 3^P#QJ:->23+XJ<>N<7:UQD6*GA_2ZPOL,%X.[(U%!_,M,(1&_
M@X,.[JB1TSX,B%3CR*E2YCMO]5NOSV8;<WH8++K@A (-^MBV!7LL%-L]38H#
MXZV?Z8,8-$ER)JR*B&U0VT;5FF5JG9C:]??N#LZ@I&\8OC'5,/G"G7]U7$!.
M\R&/L=Y=4"HJ39N)MINH*"ZU=1648?3V3:+P,))CC7R9=T(V(=42%W0,4&&!
MS/.'& "T%C+E)K?%1(Q"EL;9W"(XK8)#="DC#W*3<Z0,4D]\FAII+"![*Q),
M1 G*\I:4D6J)4Z8DI.H2LE'[34\,I#AAP2-5J:ZQ+EP/QR\X2JW'FK84-6)L
M;UEN&QMP9.9YE2-A29XLDN'S.Q6H#)3 S*,R_"V+[D#CD&S@<<15_P ")QQ4
MR9$"Z]I=55B97;9=E29[L>>VRMUE*5#5[9*?GF+=(E\]7/Y PO2<-B)Z4/@@
MQ"#J]IUAJ3Q\T+,C<Q&>%:*Y+55Y+G3J,"_'FL2(%"G*@NHX)T62W%,5=1)Y
MD.>Q*,';7@@#HUDC83<;6"-Y76R&-.SL02EIH^2(B,W)QC= T8<S%&1BUQ4=
MY HJJ7N915^8;V8B F5K<&@H<=Q91UVC>7X.5:]&29XS1TL:!!DS)F]WS-[O
M5"#NPZ],5MKMCQ7YK<F-<,-5RK+3'6JG%;GQ7TMIGNK3Q3%I_"HJ^QJ4($A!
MA<8DG+9'8D2RJ2+/D3)Y%VG72LX2RJ<<=^&W&M9U:B9C2K$T9KL>%CLSMUF#
M+FHVXZWABI_W;(\FPTBP]%VOA9+(9 1["T:;'2.P%X^VNT=%4X,(^9->04CA
M:ASN4D#T:1\9!DBS0[X" 85#0@14O!VB22%C(Q]KU0<NL14:BNR:R[58_;(]
MDW7TPV<U8N:S\3=2R;(P"Y-B^/E: M85S:QM<.2&1-4UQA(P<,K24V8G,+(5
M>-Z,1PI'WD>3;G'.A$2&\U/\S5,)A$K3XQAV1)BBX(.\0_%DW'L!V(4\6%$E
MM5K&J*U*AD;V(392!F%#,3%I*'@H2')28#1B9<+?DPZW=)/6-.T*A=Y?YI+P
MMKC5XA>) HHD7 I'=?8?(95#YA?HXAVQM&VIT0LKJ4QW'S;D=CET/#!$#A Q
M'S22MX<UXFBH8O=^IA+S<6E<=EFKV&/5(MLC;IX5R U3>.'[6-3*?Z^VSW#9
M$+#N2/AQQ. )6Q/H6VR,L>;0IZ#"5^JB'QF2F-J=7O#JO&'5XF8@U)BLAGF'
MSN##N8-+8IVEA2:10CA&1%$X"[:3:TA,T$JB-<J&P?B(CRO\_"9 T COB)V_
M/'Q0K<$3RPE8\I%VZ7XHTC@LN?"TB=T)+<Y&FR 9M2]WIR11@PWRR!Q(,PH/
MK$V&B>^S Q8@<3:,"IB_QIE;GCSN.3)3(HOQTU>!.CQK %B6,$<C+821@\>A
M,?UQB4>DB6KG]'!,'L1K'L@J([BG,@&V5<C;B,GBB.,Y$]&*HS+%3.%CHF@(
M&P2:D;)B#^;!U.'EPDGX/N^L1@VQH_2_O+ D<'2:3 !45G4HZ+YI/4&>.T!=
M;1MD&0*0VN'SM/'QB_25A7XB=HM:S87%!Q:@-%>N2[K%FYV-'#? T1PJ=RA&
MDY=.L1*;1'9H3F.'LT<;SSM]R'&C2RD$C[,CP3('/#&1!1F)IFYX' 1_<V R
M1$\C#252TN,@1_T[=:I(!<T>%K25JA7*7;C&ZI)@,%Z#-F=MYVF:&6?:95R?
M%8HL0N;?/,@6#>#%?BN%[U#7E19\MS5AKDQGEZ747.5APX/4^[1$!;((UK(P
MN)VXG<=VOC.IT\EZR;-="4,9FN)6X #W:/BZY;;5N'0Q"&EJ)V=EAJ+$1*XY
MR*H:]LG50)&*.B]\8H9D6?TL%1M.NR&RQ>\/\=QL] L%@VU6P\+-"$!'1Q@7
M,,J2-B:-?95=1P+OSQ[A= 6-DJ\E/*'Y<W-+IF_%U*E*B<KP9- +YFA5+MZ'
M:5+)P^Z(/V+UDKR1"@S-(.^C477,='%VCFY 7CXV8/KH6#Q //CHERL8H8MB
M5]5,O9EG2=UJ)V9Q&D)+-H4-&0.?13,S"%2/B:T4]Q!(\W'FP!#%<IJ%PX[.
M?P6L/I4D^QJ<(_7@)JVB4BF@3B+;A@A7M^38')I-!61<J76MC_@R*]K!7<B[
M E?\R=)@F0,!A:.V#*D2XD]N)*)(Q@/9$=!;%2B*N3!DRVY;/=?0M#6?<?JI
MQKI68FH;)$:FCNO'&W6(E'?@XX-"K.<!L^2!*06;%#0W^AD5HD&OC7$12;R=
M:NMI2P6R-:U)GP8EEZC!J9._5CDMKS&)?KN$7E-S(K0C L!R YAZ&.#8<:.I
MDPZ+D4R-9<QH\AOB7%ZVY_P +,I<L0IA&LS4>K\+FIPT9W63*>M&]8MKY' 9
M=E$<S%)9%T;[!PBQ+&DF5(6ZHAL *5CB5&-^1-N2Y.Z.*9GQN2!D4+*VKP]P
M<WS,@]75KU5O,.KNDYJG?$(M#@[;)(*R VNL8ZTA1"(FF!.6#(=$$MB\Z I.
MB7O+"]M*^0FZ4Q!E+5Y*^LCLF?UMBS$^,Z](X*\&4,4:G]0";RR6!R(YVA97
M@')7VLZ@L#1).36;@F>U>]ZM3#-ZIG$WJ,61K;W%K%&V)(T<!9JDC.[YR(I-
M Q>H( 9G;2%G*'28OFJ III#0>Z1.]MN$H4.T-S1L)/HFN<"*]1DRR3L]EE)
M1+3H]8L*-,F<43LJF$V5-C59A2(F3*L16H;+<+<GQ<VOX%=?CCCFAYYQQQP'
M''' <<<<!QQQP,[:R_CVCC_-G#_3KUR;&WRI]%/Y<A.UE_'M''^;.'^G7KDV
M-OE3Z*?RY57MCR^\M6!\$_-/I!=7M2M?"GZ:^5/TU\:>%/.OC3P^6GGRO@X;
M[G3"^; S!)VXS!#*Z--B=[X5;]-\\,#$J+,<5:NQ))A,&2*T# [D8)L42.Y,
M(*Q;2/!2620SPR2Q66HXS1MPA>1!DB5L(<\36-8\J6N9]4%#OAR],5!=X,O@
MNQ?"MU&K:VUM'W(D][_?I>QVULLK:T*UV9NMK99V34]&WM!<J]"N^&[1D;&^
MNHOLLZ##^0S'TS!<<D$Y1:5S!,0 -;9NNSC3-JZUFU[PE$(-EBADB0)+XI%"
M7.<OP XDJ7,5/Y:)O#2RW^QEW<>57K6+; RD3:D)RGEPYU384NT"DV(8R.K5
M MJ3'$MM060OR9A&&\J;C5Z80 6GF8".4KLD&'0I,6 %%H]#43[&.7+9$&(?
MB<)M;+ Z,H]%+&1%<VL]@T$B[#:U-][ME?[T#;:TM*.B!'>^9LSQ<E24PX+G
M7+D<:XZK<E^>O[[8SCJTH(#:T##+3(L9<(V4%EHJPT)B0>3V8\:=B?W^C?[[
M/+-@LPX;,#4YK%3?BMQ8K<::VW'92T(1&G9K:MLG:ALHF1Q)(_OZJ<SZ/L6N
MJ4"C-L"E$,BNKTAR*-TR$2,2K)RJ6,$E@B'W@*\)JG8;1YTN&WD(?U'9XYJ
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ML10G:%+8A4O-HJL68AE\P-V%SHB=*)*4Q) >N.MNK@.$0J M(G@S6!+8 HG
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MQ:#$<F5C.5FB[HQU>P^*Y5F9XA95&\I((TA)RS;7!I/>T.64M*1NQ2R!^56
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MAVIXU\Z_KYSWI[:?MIP.>.<=Z>VG[:<=Z>VG[:<#GCG'>GMI^VG'>GMI^VG
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MJ#_X*X^*5N?\ZW/'[K.H/_@KDBG'%O/^Y[\/7?)I3^WEI_'#UWRCK^*5N?\
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MOGQ]B_W+]!/[,<E_=GMG845[D^.K<S-V-0A2WKW5:F;45JES7)FQN3W*UN7
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MHT99Y,0 7KRN#QZ4E*B+2=]S&"*]O6$.!/>CEQG38D8A(5BHPR-N<S:)8G"
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M6A38RPY[RMQ"EE%\<$>92U,8"ZL[LVK&$K=5R-F(_74Z=@5N:O)1/SK6/>:
M#A+$A+&TBQT81W)1;)PD\FJB1AH,J!.$41@3R<6)'P4-,C*5Y7QC:QSW4H%K
MVQN?P\?5W&Q$B2"R)2NJ%8-I-]IW7-(+MB<]UH<')JTZF%#(Z4:!=\9^/P&;
MV'8G6@@2XIF<B-OAMO?YE'(E<IU&SYNTZ8HX>1N$[RO)$*\M<V**$E,H7NFQ
MKY&$,-!0CFR.-66B9-M<!:0,9%U(3F,2XK;QC7I\@=UC9S!&F+-Y0B%;5SCL
M"UQ@(G.<A!DLYC"QK'R0N95\,)$]@43ZFW3_ #@*(I"%]LX7<Q(4>@@=('3X
M76HLC8]R@H?TL6-N5L<L"-XR*94RC#U=%5B9OS6R1A26JP6Y]3+$&95L;'4^
MPM*\38YR Y(%GR)?425Q6'ESG1I9&7 %K'-N-;"90^VM:D46!CBR/+<8MI-@
M:'$47M#FA($C<I;U6+$&KT50DZ;$].B+H;W:9G^6GTX@8$2S&TR./K(]+B]]
M0MC<])[Y"%!DN=E(\7YER!I5&(\F*5UMA%C<T"[)DMR*D5N"XR'-H(TZ&\<"
M4$BKV,[<@W34#1V- U^9<K85CLTCVO;:VL;#E'GW!@]2,&<B2VHVYE?TMB;$
M2ID2%X353T4X:[3(.HGI(Y0\9STAV3C#/%,>OK0+EQ1:\*+*M)&2Y$6,/8?>
M#(AL*5[L>4<FS-';>U,2Y3(:1T;%P/C($3@D49O;Q[N=JC+(_D*8VV#B4W'L
M(C(!TH=APS:7-&E$8H7,;5)SZMOQ9JW(T,>NQ*Q-!K<JMQ91EW<D[6\XDB^N
M1-8$$)$-8BFT!=--V7J'E@T!')F3KB.<VR;'9H'Y:<>E3U#1K(0Q4NF1/6>6
M>0EDCE,8L<U+UV)%'%)O(8]906[%*;@>(;O5@\0[697M@G4B7;@JI2%=V>EN
M'##8[F$T?!5BUZ(-4M*&';7)AC3(NQA[B&OI@43??-I$_,#KA;CEB?'1Q<68
MG%,ZM%-A'>UT1G\@%T>)C,!2O3:KRKP;"DDD2?W"0P)!$D)RR]':-I:UMZ\<
M0,K3.X3>L9WZF)VL'WL8.?<;18R'EJCH6;?;3@B,X] !_8J,'PEE1*'J '$T
MD%'!H),\A#E#&/6=(4)L&05P$T@!UV(O!!%P>T14:"N=,1C+,ZLRM,MS! A$
M:R>,><41[G9.HRD+L,70#;ILE@K%-V(_6RRY;/SMAGI:5U<K<</*C!"V70\E
M+4^S:K$%H-6LEZIFPX!MP-UZC7>;'?::32[8_ Q@6RR!'-VO/5\AF0XE4-.X
M<K/+Q(*R.C1RUF&Y.>2T,'==6LA5.(\OLUJ$(!#[4+3'+NW#V&1#!N6(7 OL
M4QSU,M3RB,-:3Z19.#X4?=H0M@-0*/3TJ;J$*5K)'7W@:L[^J067M;*T+B2]
M.+M9.0Y64;=RI6E&6IR4ORC$WW^U(NH=I>-%)\#JM@H^7&L9MLKK3 8:'>]R
M<FMRA%G6$$I!E5&##[S7R(&L*%0^O,<6NM#5&PV4(\K%8P4N=; U9ZD8#<YD
M73CD*]DE==GC'9<OP^N1JJF'N,O!II7LR+1\XD[/%*NR[ @7S7EB\4H3DS=<
MSM%Y!F'7AW;!<M)T;K'0N#-HM>M;H)453[QR)G+.F@PF.QZQ\EK8]09W;0RM
ML#HVW240'9DWCLJR "N(("J)2=R4+C(.QGPQ#0U*#/%;*-/.9<^([&.O\X@.
MS,(Q7L!%JU8OCV8 8=D 24.":B!SM9R-OPN"=([(L>=3C1NS?=ER-[LCQJE>
M!.XI5.'"J58;+%&7,%:4K3M7O^VM*_MI7OW_ $^? K#:*L$]/<]0:B+V:5R
M0ASJ,["$X>Y.@%LHVQ\ Z_2ITN[<8GG 7C8_&XR';##K.SE)+(%NQ.]7)5)*
MXJ&UD0,+.Y"[';M5,4:;#RWMR0@#^MV:;]>2'J/0O5\H$%$IA F\:\MO2ED1
MP*F'(3"BQKN20L^;*I!QJ-\+2Z-[$YR=F2,Z]982K:8LLY]+:4\N_P"VM?T=
M_&OG7Y:^=:^->]?'G/ @>,(XG\HZ&FP,1OP_,Q1,E([VMC0.82AM+2Z8G,9'
MY^E 6A?#:F(DSH7&#A2*FL)SCKH]8GIR*67$U/2]2]VN&18KS.2:GGC_ +SQ
M8W33(DQ;.0D::/;N1:;+) #8S%1<7H<RSIHH3AV4H@J,(I]6=)#8F(@S)D;X
MY*7-:@#G54-T18D;Y7)+UQP(R.F=%E( Z>HS%;Y')6",D>%&VS6UQU8PDC62
MML=X-FIX7!;>PLUWN!-DL<X_4,:H/R)<E5[PW.#,N;%>:JY*KR0TO<3/NQFM
M$@F0U")O'CQ&VI\=Q/!G3^#=8=B8VS1QIXP[+ZZS1-D72/,DIQ\Q)-@MCSV/
MXF:193'('G3,3(MPEH8'HI4<R4IDQ^MF\X[4\:5\:5\*TK6M?YUX%9_8?7 >
MW?UUZU4D(8..#R+Y20CTCZG#[R"RJ&DDE;$0MICC!%<KAT4O;0(&3DNN,5#-
M'C!D=!Q4C-2"/;UB)O=\2!I79.WZG\;RXZF^R$<PJB*\TD;H:5PG"[4B+=7B
M^6V)^*P(SEZP.;H/FL;+403#Y2&O)_F*Y?LG1E:F6.FY2%SH!N9"O8REE262
M:4I2G:G?]=:UK7Z:UK6M?V^%.U*>%*<XK;;=YT[_ *.]>U?T5IW[74I\E*TK
MV\>WGP,51G+(E(SM*@F/J'G,_P '2 EBF0['<?>F/%B,,D>@LD67,RIX2)L1
M(S+1:0AMQ3D+/D6-6=2K5MU%57!M7X<.5^?@0M;8V56W-S>A07.2[.Z.%R)(
MG257.2FS%8I<%E4^/'54N468,-F=7GKD49;<.*W)DNMQV4M_?P'''' KK\<<
M<T//...8_4RS$Z)XRCJV58M1$6!=[UYQY9)0,C?\#I[K3![V9V-208G7"Y>[
M76X:M^5'8LIFNIBK@]TK2VH9 XYXHBDN-@]QHT%\CQV(N]<&)51H+#T/%W:J
M7/=DLP*:-;^]-R^J;/?AS685%$_N.:_#FLQ7WW8LE+>W=2H68L+4H?2@88T[
M\J3(&)0]D;&SIWU<LQV9D:)C4.:]+A>EBO#DQYDB1KR*U"K#DQY4^/)CR677
M!WW'.:TK2M:74K;=2M:76W4K;=;6E>U:74K2E:5I6E:5I6E*TK2M*T[\XX#C
MCC@9VUE_'M''^;.'^G7KDV-OE3Z*?RY"=K+^/:./\V</].O7)L;?*GT4_ERJ
MO;'E]Y:L#X)^:?2'/''/GW2RE>U;[._?MV]*G?O[.W?SY!<^N..]._;OX^?;
MY>U>_:OZ^U?V5X[T[]N_CXU[?+VIV[U_5WIW^FG <<<<!QQQP'''>G>E.].]
M?*GRU[>?;Z.. XX[TIYU[?)^OV<<!QQQP'''' <<<<!QQQWI[?9_T^%/VU\*
M<!QQY^7' <<<<!QQQP-6=T8PE^8]<#R/8))604DMY< !:TN;^NHR)5+0-R0(
ME!B/H2SX&R)F 2$K#69^&1>24(*5.T<$CJU&[*T97=B0Y\$(UG2MW 9?NCN;
M.TQ4I=S+821YM%RENWNW%$=BX]R2;K5K_#*K#CVD4QP9NTA)[GN!4M)=!I1C
M(SCZ7&%Z%EXZUQG?%;8+E-EZM:6T[UK2E/;6M*4_;7G%+K;O]FZV[MY]JTKV
M_97@0.A'3WW/&-B(D/U9O#[>B9B#75^G"4H[D.41-BG)OC&!0V+)(2GFC#R#
M%6O%LN/SF(T9(UV$BLNAH@!HXS""6@Q8Z1LE;RO$+#TJMR"X#A>-96?-9F ;
MUSU%@34H1S"A9)1HJDNR'MO=59X?9/)TKU%@HD#$IC'VN5H^WQREN,\K$6N-
M;UQF[L;A7,S60N.!$D2]/B1WHE+WM*8@F#"1]2,NW2PX\OP@IGQ@Y#H\Z:N)
M1E3=8SWV5,,!4MP/F:ME^1FH,XJVX7.]RMQM]<1Q!TLY0CJ&7F/',YCC.1.T
MG])4RRO[)4E3UHR]/D-U)&C]%1<H'<:^QQ(UL"&B^-[[D^9(BN(V52^5:,^1
MVQIIR>.!6@Z<8[*SCLGI/&N2+LK( Z#:M;BP>0&[I$\SQ@=9\YC(\$#D>7RT
MCD.,!..6*1S]!&#Z5/HC#LH3VQ%3B@=I<2'N$0?Q:CMO63Z)3*2[G$\TY72,
M<$5*=SM8]NF/-F?"92;J:11IL>ZN&H.X"WP-HQ-BS \+! T$25,7N&%W0KGU
MM<VP<7,#<J?Y<Z6TIXT_G6O:GLI2M:TMIX4\*=J>%/9Q6ZVW_:NI;W\N]:4[
M_MX%>&0.DY/>)X+B(2=8ZD%5)P!NA$K^-N^PNRFO@R+,>Q>ZD\;/ A.ZY(0;
M:.4S#287G-<)S%"I+\&$9&YB[->'R$U)UKDXTD*FS522$K!HP_039'I<9:-F
MC<\LH%)SX3A@3(PXIUW.]<GM/C,4[/+9,#%C*R'%Q8'D"]I.\EREL5C+VHSV
MD"@E12*4K2OE6E>].].U:>-/;]'Z?+G/ JV,6A.Z().TJQJ$,, EQ)*_3%F6
M,I-,R_')0-"P;(NZF]VUDYDB2+7-FCLNR'@Y"E)#7MRZ+WA. $$A#&,*?5)"
M!YE>5%GV)BWI&R?$LD"PBD)6:085'ME(:V/3RF9["[*M1JFS0_$L5B2)A4:P
M""]H@U^DO(9Q.V9AR:7,OO2L@0]9$1%'ABZCB1.]V"NWCW_5YU[?L\OU^?'
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M#'\! JK)(:YV=) 9JB0]5H.W-^384;ZXFK95M]0+%[VC3ITCPM($[BJ=$J?
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M7(18UB0.JT[VRG/879F<QLM'8H:(39M9-(9KC.T%DI+)3TB>MC!F3GPC2*#
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MD.1\>(@=O@.N2V),0[@:&I@M9V)IS,;=EP^(=.EIILXVC2%,"%["-,C*+C)
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ME2Q*/8%G'J([02#JG*6QD&Q:S@^OCF^F8M$L\M,CM;G*0\X1+LZ-PJH()&B
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M,Z8[\5RZW7QTN3^A@ORYJ7T0*O2KBIC]SIZ?IV2F4VOZSW:G_P!4=KKY4_\
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M93C@0U_&OZS_ ,T=KK_%'8OLE\?&OZS_ ,T=KK_%'8OLE\F4XX$-?QK^L_\
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MC>V6:P?<266R;;&=9@N';FYUMQVQW0I^!E2.Y[JBHP4Q4(_]X515<Z.5+/\
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MF?&D5VXW%15+<CJCL \<Y,1,6EVFJ:=G#Z3>$)ZCIG.4\;7,4M;8CEQ  )M
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M/1AD.<4AC"".49>\K,[:EVEV^@5[V;U[.X4'I#5QBY%^8/S_  EPH7IT;5J
M6.1HP=@HM:1HM 2-XCZ26I@6Q[([(PFXHZO0*3O[6D?4-RNMUT.:GH;$6(?D
M 89)9U50"IU+!C+K5']=&$K8%0Z9&,,0[$J4S@=S"I\#I;BZ1 .^($[N/%S'
M*EF$S0EA$CEAD,R7"P&3*&]RCJ0:>1V_S,H1CLB,P6'*I%)I0G 8@,KOBIUD
MJ-X.99ED(:>BYA9[G)7*#1#B!J4*,I2RMZ=W6,-(W:B-R.&&X22Y7E_?S7Z'
MC7[ESM]T(OE)0_1<*#T<1[&Q*7$Q.53* 37)D=L+%ZNG3,E%#R'Z^2FY*W)V
M>6A@&[6#%:3/#/8YH,N:/8\Z+A%(Y3("PEVB151'\:R!&!'+++!C<*[826&'
M&N3I!"<#V*EP0D,=C;8D*'WQTQRC@62'!RB3W)W'A)B62/9A9LSVOV(C;IT2
M2GV+8]I)SV/8I$DAHDZ&#VUC (4R1F!)FJ$M;=I-=&,7:$+S*<C$:?W_ ,.S
M[]() ].A [YK21GO:6EO0#SDD2L0,75AU]D(72N43K7]F="!BAXU!WJ:HFE8
M0#3<+.]F(YUE-K6'*UL"\GRD@%)1XCCA]:W!G;,+.;NC Z*\J^.<RTLQ=^W=
M733I4V$I*XN4K#00U!\K&(J=$D+2"V#<N)X1DQBAR4AZ'>S2H?)!,1J42L2!
MT(NVLF%S.WPE:Z1OC,47KRM%C%'TB!U&,0R,TG%[R60^ X01,LJ!MU+WW#AW
MPA'>*UQSX?A/6U!DJZ0NFCOU7%D564;G_.24S>M-V)G5XZV4Z8+RTZPQ$@C$
MA.91DO4,7FAZB0?$F\&%RDOD21-C8:V,%B9NN.BA(#Y7*,"6(V_.B "=Z:AR
M6DE50B[&L<W/& I9PWLCG?6)I:BC8J10X*F5,1ZM87!'+\,G<3E@'+HT9)(P
M:);1A'P2>4.2]W>74-(1YQ;EXRH?V%;A>$V1O=5UEF7T=+H$ZS4?R:5(L4AP
MY*D=A9:):*$C 4MT:R"8,D?*]VPA.N$&^<#1$/I1D.29I+<V*/!EUQV>ZNF)
M\9R]U:F</<*/Z;*^B\*3^_8=[I+V72.PT[[=2NS+QQ&Z@PU&I&C!AK6>,X/H
MY71H/RK."8);E#P-/V<88R>4BTT4-2=.\EN9M4.^!D;O+Q%TI%0)!!%$A;/&
M F?BECZ>C$YE8]%MPLT8D_3V=X^S"&=(,.,AE*NW-([)&[*A)[<I-?8RN:YT
M<V>F=)<C:4P;70[OYKQ.<JUB8-6&Z=<\I3]?%AB5QX3"L9SRWQ(^I1B55\&'
M;RCP,LBI8_?EJ9*[W-]R7(YMF6A:)8R4)I>2V^%-^I_JI'AV?B1:XGK8.QF_
M2&!/\P6QR_K88R2_%45O4U'T),I\BLSIW25!^-QQ_>,C#@06-CB\,KJ"M#ZX
M2 W*Q;#BS4'I;#FJ$L#9DTOT0N0E&(_+PU&=1O6P(#9O>6^5RU*])5,Y3M>\
MD;S(+M'PPGR!# N"1^*[2Y(N6$,EX"IYL;;$&$-O>E_)YO$NS8L$2UE+8I>C
M+:?;^+M?4@(E;9+?-HY=A23&5L!7&:UAZF'E,072X?/LBL0[DCIG)TY"Z,S"
M\2)G#&'(A< V>&NK-J>3BCZ0XDTVLKQ8EBMVCJ,RV!I'%):GP;G=P=6:$RV"
MHX?FA$0R"-R4\L+ZV-SC9@:[Q:YE<5\D)PAEP4=+^O(>KMJ0P,R9PM2S>]N*
M*.Y2E21!(?@>07,NA,!@<ZNCB>'J:&#WNP9P-1#Q9;ZF6C*K(K*W-%D2O (Q
M&32N0K5&J2OH[&\TM</R'LC.8)(TT05$>L\:PDB)-<V]7%[,/P\I5D!VU[ 1
MPNE@@PS203"L>,K"</ V3QBRCF,?8GZ-1X:>L2U0MSJ%])YG'0J7AY7)PJTN
M<UZD[):PD>"*X'$8JC\:R['R.5GZXK"@0??\EJ=L!$I$A$1YD)7HB+"!I'D3
MH;2.^/RM4LM#T9-U&->8^E T3EPRNDV4V0DG$.CA-K["9_(LA8H6AN/-9YAE
M[,3/R]@:T#<C8<,UQ^7NJ5A(\HF7)U@<WA]I1(R7*.XO;X^JSJ&NDD& 6-UE
M F9I$,H2C(<F$<A6276#?NO;#C P=1-$SO)^-AQLS&?D$?F0H:+FUUQ)6\8:
M2%E;B=V:"AR1CV;KP?IM,83+AM*^.5G5RSF8ILD+Y63((HDV%%CV*C/2R-UJ
MNQ?:_9LJB\7P:<-KJFQ7I<5';*>+TF;(AQCZ;.ZQF"NBNV$2R;%.H\;#YSGU
MJC_=#2_9Q]DM\$8P4A)LT0#&L289*+$4G_=MH<A& R-HL39L.OE=?R,Q:9+R
MVNC+,ZJ$7M4C' F)V$Z@&O>M9]D 9#RG"I2-A@S)DM% B!O)4$Z_QF;ERT&#
M)$FXE;Z43A J2DS018$:K#A>7!&S"A:8O3:U!8R\$27PVM&\*J4XUW(FR6!5
M?'T=ZW[+[$1&Q-;;'4D.!DL M>G*@DZ$BANQ)WESD4I*R-I('!N98U%_]XV+
M6L&3HW\D;UKHX^;VEZ>Y9/QG.BP-GJD51WM[!T>Z\;5BU\<XS(J?X]CMZ/,B
M5PADTS&3"BBXV) F43V.R-V(A.2F.C<O8B1F'&XB8,N5X]XZZ-+_ (KVTNNX
M=.!:!O.Q\F;%R@AE :;%#0]@#G/LDNLC965,G8R=G=75F9*N5XHZ*&LH$GXB
M&\SC1 [BCHLP." /(W=4W79*K4"*D*V#2379,::!;==ON)$.>9U$GN4,.&P0
MXS6L2!4K&,301PNSN9VVF:PP2A:1J;5Z(@(&1W;EK<G]Q)N\(BFTS%-Q(/1I
MSP3-BG7YF&DI.WOXBIHW3#L-'$(/V-Y9UR-&0,)"(7&+WZXQN"3!G2D3%>V+
M[*8:9KJZM:N])3#KQL&V3I9(,3-#8URFPR^WQ)!NN]D-@361M^JLDZKNK6A]
M8E(Z=%C>[,IRA-E! 0YWLS6D;4M0NSTL9EC,F&]CV[0%H;])!#3"V3'+*V"9
MS'YMC/JBR.U>MR@6S[%LMA;KQZCW5+@QN2UDL$LBBUURW)4BBYXLPYL^*C?>
M&J+/U:'M4,;5(B:*&$6E:!MML,5QN/.#ZOSC\U:X.>_Z;1Q+.(VNMQ8G#&]#
M!:W&3!(8MALSX14V9QJ]2HH.'8[?G].OWQV;#@@TVB+0"#WO5@!W#E[7,U'1
ME=(K7.0I'<?;=%&I.&8D2YQO? 8U7M3TSMAT5@.%J$LBD26/EH\2Y7MC0M!!
MZ^7>E !2Q'\=C6:4R09-8SW0E/;!AD5E8$UJQ>+35MXMVNDW7HC8ZO>-,\QV
M4.%!AB5*[U^!7A)8_!))P-^-T8+&//VEW3G-7]E>H9D'89F)-42/:V2MIB:'
MV2$,(T>F"PXV4)MK6F+2Z85\I%*11'C++#VUYGV@M&(B3F(X-HAS,_LC>Z/]
MKD&?MD][8)U:(D@L?X) ?WU)'9',YJAC*/'Z0\\504'.J=D+)KDC&PXKLPY'
MC&Z*+TURA/B<R1VM;W]4.C+RC&"50T^GB/<6'YTFF7X.B[$=E#M!ES8@D<[P
M1\2I8=;"1]'0@S8@YGE1<E3B)@4NX)(0N<IFL16O=F$3<<#HXJD%%*'"KP=M
MGHX>SJ>&Q[$4])86<YHU@(=/YKM>HRMDSWPB=X)" D:"B,:V&X/8#2X(Y3J1
MD+,_D.(]#%V M2J'P&<% RW449WU<U:'=6D4O,XL0+7IDDZ5D$C-J!>AL39A
M%L9X5AF$V<4M7T7+,S]1&QPTUN.=]56(5*U6ZJ,61#CM2V9LX1]Q)UA@!4,2
M82S6!R,/*QR7=K,Z40CV$Y+?7Z+=3]7I><(.?=@9MR*\F6MH_0Q&R)6]N@FV
MVY$BC$_APZ'DBV+3PCILT6=3[5@5/9:CJU9)I2[0U2-V@H<PB)#@L%'B0IL:
MXQ>X.AV/BAJ;,K/),LS"Q2V(OX0%A.=Y45&[G4E)50V/-2ATKK^4=+ T0IY*
MLA?9K%'BV>0/:F'9K<B*'\)ME51=LQL_,NS"-9&2=-(@M@"Y7BE?/<F!HX7D
M-3@0(FUX;GDCCJ]>PHDM_KY$Z5  61A)T>-!D@LQ$>QNM.Q\=(9 CQMDD&%G
M?6"#(#@01 Y#"G-^;<<M Q0(0==B,,6=V$7C)\,5N=E7M;NQ-3O>'IW'J@Z^
M-V%O.'TDRA<>,47[$DTK!AS',GMNP(3(<$2'KI'JV.<L=(!YQQ4*J/NP(DQI
MPVJA862$ZGT7KXA3&8R_*WFW]+7U4]:G,=N6WBFPK5(>*?6'5O)!3YK^=M4V
M)]A"F%W780>C7.(*4M$*?.ZQ.TJ"[&:92"R-$C=EP*G,V0I*YU2?3"8>D^\!
M,'OIK'E[68S@%H94/!&/-;XDB;7T:RR@43_IM-T>.,<"Y 2U&U>&';=.0Y"A
M$I?/'IUF^KD_,9?,0(G=&!P$\H:C:GSU)LL&6U&R2EZ!"7)O8.[- XT[QN-1
M^\% T%:!.>EEC>XQZQ3#,_W,6!<ZF1,5"Z=[E Z.5+:/(5!1A:[B?"A8@D"9
M=T=>W35B[<I24.8["2=@=GEY<R,1)FLL8W >)UH(_!;F!VMBDMRR"UR$VKH^
M^!;6UNCVZFF&QA'\#PI6M]5>"5G5'UY1#B/)E#]ALDOK).K$=FK26"#-5M%B
M+L8-CE15FS1%@QY%M!!'%62R1,T@8G;*#9&*[&WI2!269<(UD_N0].H5)]##
MS1EVD%P4LY>42,;HCO*),JVYJ)R[90@V>&+W((=5CBQ%# *FCFU-#P-N:W$A
M-QQJ6('#(UVO66B/6MAZ3A>#&XAL+$LMZ]0KL\$R@3$8ZXQCILSCNN*2,#F)
MVN)3&,W.&&:8&.12I>Y6M**1D,@$<_+'IB.$UK4QH&Z.5+D'+PVG#.J!IO(<
M.',]BI^_KHVCF$VC8(G>5T:'[*Y-\8/LD3+$S<[U&WI@0$GOE><0+)C4K&+V
MS"1MUK+@4.+8EQ.B'W7D:ZA$+-S_ + C\I&XXQ9X2IM*<K'!D&9%Q,Z2(-47
M$$;)95NSH0#Z-,['<?7'XLK+F40N=4"AM)1Y>,Y75+G57X(KX.Z0&R;UJBZ1
M(5;%8X@63##QAK3L7@*(49#^02D/ MW]LYT 9+ GX?E8:# 1ZEH<GYVN-&9T
M&3=O0CC\@PC6(4(VVY3AW:EGI#@$NW^F]RV3-]KGN?*6S!GB;!EMQXSN'IS3
MBZ69]3".F9VRW9(YDK $"&(D)$MV!XRV,*2W UXJUONX&:5/4EA-42M8.W"T
MOM#V<M$E)8G?Y!AXT" "0Y*BB('F:C2+6M\>DB5RP%(P$,#XYNF5Q96T:6WC
M94SC1,^/PVZMB;QL/]4N#S0<U\M-6LT:"J48WU:>)1)1..#8D@Z#)3VM!0(J
MB:*Y%E:QNN:A=].EY^.(!3$Y7*,23"1A64S7C%YL)U>L*K>D@0+]GD6QR^<
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%W->'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g846377.jpg
<DESCRIPTION>G846377.JPG
<TEXT>
begin 644 g846377.jpg
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MD2#&'<>I",5:D0\Q!0N%)\*0 Z4RZ/Y]LD<=Q*V\3*MT9:-6&WNVY[7L,=E
M]6+<[!CM3H<$2+752R1X.27*NOCD@#*3Y!N/XP[8-SN;5TMTYU-UQ-MLK0;E
M;Z;H"QM=*=3@UVOR.L<L_+QB!)(6PW"=F5U79(QG&?SC.,X_GC/GG/-:Z&[M
M=_\ I';H2J]KZ=/WBFR+Z@@EW+$(09--#YRZ6]0=QU=#D)/3+0^?DN0%N^5*
M+&PRHD6"96LU.?O2NZ-?]@-<P&T=:2_W>L3[3J4X>:^+*1$F(OV)2!G8Y2EN
MQLW$%X4,>&M2T85A! KQ01 I3W.WGIJ_LT4-MY*M[;K)XU]RV^86:<C^3VS(
M ICDP"0KJ W%Q&S\'X]_H_\ $?8^L+-O:XZ^Y[)U#MZ"2_T[O]0[?NT$644S
MI"7=)Z_.1 9(I&>,/$;$</>B#W6XXXY'M>@:<<<<::<<<<::<<<<::<<<<::
M<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::
M<<<<::<<<<::<<<<::<A/W]"U>?U]('VZ7LX.H?KNA.J<U-%LS%G5*LSK;D6
MEX(MMP%46E]*GGWBE-N#F-1[T5EZ=1%BD38Y&?MG,VF"U(Z?3]VTO04OBTU9
MC-\O809T+D1Z2P@B"0T:AYM!LK_=^RM [RU,#%,*4&R\])!98"1-$02"'7!!
M(QY_55<C^81C^@)U9( 4<'R.)_0_\"5!_D2!J1P/M_"$]I9+C7QA_;<,P_@M
M;?LH]"RL%)03@A2?"G_D(2_[N5^ZE+GJ3CM<ZP>5J$&4X2T8YD=G*RF$8;9)
M7EI&5$,MI<=2AI]7EUM&'7<)0M.,.+QC"L]GF+5^G'''&FG'''&FG&<XQCSG
M.,8_GG\8Y:S<^Y=?Z#UU8-H;+FD0M8K[",N9;;R5)RLB4OV8N!@HY"DO2DY,
M%Y0)' ,Y3EQQ2GB'1PV"BF, L[W>[\]V;?-5+J93)^CU !U I;E11!MR,.P3
M_>B$7_<%F2BO5N7?93DEJ J:QY+ WN_$;L#*4F9D.R]-7]YCEM(]:EMU9@MG
M<MPF%:G$QXGMB0AF>3#*2J*0O).XR<TY0#K#\1MCZ/L4]LF@W+>NH-Q0R;?T
MYL-0[AN]B(%E$[0AD2"N61PLDTBM((YC!'-V)0FR9YQ^/SC\_M^<?G_+G/-;
M<S1?UGJ*.FUA[#N=J?B\8.5!P6^82Z2+^&L>I;?Z7NT-#P$SX3C*E -F.K(\
M>T..2ZI#:I#=0?JHS<U=Q-'=N8)JC77,OBKCWPF%,I2!;/E;8PU=V=391MAV
MG2YY2TL#S@B!:\Z2^.V7&PHQ Y;O1L]&6OI9K>U;GM6_)60R6H=LLF6U#&/)
MD-=E#.@'^ EV\\8V 8B/;?\ C#MO[2I[7U3TWU/T/+N4JP;;;ZCH"#:[D[X"
MP"_'(R0S$L,]Y$A4%3).A95.<+CC'YXY#=>P:<<<<::<<<<::<<<<::<<<<:
M:<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<::<<<<:
M:<<<<::<@?\ 4BW5+Z0ZI7F7K1:P+7=RHO6-;D&G$MOQI=R6^-*R@JOPXDN-
MK(TZ6$ZTIMT<U Y+3B7&4^9X<Q/_ %CJK(3O5*)G0FR'!J-MNFS\S[*'%H8B
MI,&?J"C'_1C.$,BR%CCE+=<\(;POU*4GSCSWNEX*]GJ+9H+05H)-QK!T8 K)
MB0,D3 ^"LKA8V!SD,1@YU!OQ-NW]O_#[K"YMC2)=@V'<&BEB)66!6A9)K,;#
MRDE:!I9T<>5:,,"" =4/](+J[4JAIR.[*3<,.7L7:3<NU49$O'O.U'5HDDY%
M1,=#-/,(S&F6YV+=L%@-9<<)D0WH2-<(^#'-L*EYV6[TZVZTVJ H\Q4=BW*R
MS!%14<W5:VZU7JS$W6P.UF E)ZX3:HVMLJD99@H<&(!.-ERE!E8P*UEG&%^7
M]-"^1-\Z4Z,5'.#X-IE85K:Q@L95E<;8J$:1 '#$84E/I=)&'!ET>,*2L:4'
M=2I27,9Y]/J%:GV#N/2-9J^M*R1:K %N[3EH+CA3(L%QFOUJVM2,W(J>ECH\
M93<>'A;ZV4/+)=Q_9&8><_L\MZIM7+>_;O+<9S.E^S"$<ENU%#.\<4* GPD<
M:@+CP?+>2Q)O_#+;-HVOH;I2MM"0K1FV7;;C2Q!4^JLW:D-BS<F(\M-/-(SR
M<CR4D1Y"H%$HMMZFH.\=>V766RH :PU"T@N!203V,((8=3GUART46E.7XR<B
M"T-2,++"*;,C9 =@D=U"T9\X#_IFSUXZW=T]N=0K-)+DXJ2,N,.2M:<#CG6K
M7([$O5KJ",MI/QW+CKHG+DBR,@=MU2(YK*7$10F$;&_YPG/\_*O&/Q^<J5GT
MX_E^?./W_G^>:X6C;$#O;ZR-TV!5%X(K,!9=@OMRD=GY(1\;K?6@&I')1)#7
MEK(4Q94*0P_E7@A*FU->M*L<[W2;R3[5U;0G!?;5V.>^P?)CAW"LR&FZ9\)+
M(0V>.&D[*9Y",#4'_%2*O2ZH_"G?*7&+J%NMZ&R(\6$GM;%N22Q[O!*1YDKQ
M(R*.?)8/JY2G!IF)V.2G%,C$O(\>MIAYQ/G'G'J;;4I/G'G'G'G&/././Q_'
MD _IT]FMD=I=17&[[-8K#$U!;*E:F"BJQ1<2#F*#@:_),Y?8-E)5QPOY$F2E
M;R7VT*:PTGV4J2I2I\'X_P!@,QC_ .:$8_\ [*^:X?TW^[>E>L>I;;0MFL;!
MQ8[#M.0L4:Q6J%-6 5V//AJY#"I68*E#31;I\>^U\96/4A&6G,YREW'IY^S;
M3)N>Q[\:M%[E^"QL_P!/V8C+/'%(U[ZG@%!8(RQQ]P@8PJYUV^L>JH>F^M^A
M5W/>H]HV*[0ZO_:'U5E*]*Q9KQ;%^SQ.7(5Y(Y+$P@&>0:1^.<G4T;=VD[3]
MANR>T= =/']9T> T=AP2\;)V;$'S:I6QB'D0YD9'A#(-'$CG9T21A@,MQA9I
M&(63FR#A '(\(K[:8^H].BZM[,+[&4R.B]P]5,X'M$%3''1P+NX5..T^(3&L
M&NGIABWKBD.%E",E%QB1I>-GPF6QR'HH...JMH5WZ?7<SM4+V)9G:AKS=\D]
M==>; S7IJ7B)4=RR6&T  8?CA2GG35!6HR'/&89=>C)^#>'D&Q0CHPLBSM"T
M-L_M)3?J*]@J;2;''QV[W@R-/0,R*J+/O3$+M2-V6<F(P4EA)JU1%7C8D1_"
M4QIU@EG0!#2,A/OMS,[-LYA,=RE5J[$D'34FW[V%,4UVQ=L44W-7N\U[[-')
M=^HA.5H+ '58>/(^.IUCU<MP3[5O6Z;EUO+=_$2'?NC7D^JI;10VC;]WEZ=D
MBV7M.M)8YZ^S_17 $DWJ2VU=YK9DX)./0^S/J:;KC=>[ZC,]<0]3;!L,6ZUK
M*2"G Y>.UT9)8&-MH\^TEZ0():CVBB(P-^26;).I&+<AA1R<QS/D]^N_NY]
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M"D8=2,,200<8\Z&[6 5NX.+\>+ ,<EG= O$ N&YQNI!4892I(;QJ<O'(*O\
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M[2%7JW4;!;)O75?/F&9>\(K#EO'B9&/CV!B,2$5*I]YMM44J4\P7M%-R%AD
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MVY*L'%O-B"2N"0B'A YHPP>"/57ZK4SIJ+$TAV]J5\+-HV<5QG8H$(\7=H@
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MHZX$S.P%P!&Q&I.UAVAJ=DX78$A68:6N-?,-=AIF9#:EG0FSTH>15$)UKU+
MVARW"PLN7)8M>Q;D ',6RT3<!"S&VA<L;&1!UR4E2H2)B+8^X7)R4$&"W#XE
MY"0DQ@V"C'EJOSQRIGF.<RR'((/S;TV>0]^FR<C[Y.?9S:*M9<8KPCB5*XC4
M8*<>!]>UX)Q/L<%(\J,1!.Z*=:3:34M>(I,M'5*FUF[TJ.C8B^WV*?DJ;L:4
M$GKC5K/+ 6-B8M4),3\;$SS@<^>?@>6AXHH53/PTH5<,?K3J0>WG77$/,O2Q
M]_C=INA$VZTOUQK84=2IK7SUK$JSDMFOB2DY5)XZ/M"F(]#%E=P)(3+)<@&,
M2W?OC@SS$8,TA!Y9R['/-@SY\^>3 ,WZGR?.@J55(*UX%(*$8B08[2=N/&!X
MX)\4_P *^!@:C)5>H.B*<.V-$5F9=:#F-9RD-B8O%VGE5L'35C?MNK:A6')F
M?-<K] H]@+-D8.C1:AZRTX82T1'DL.8;3>ZD4:LZZ@/TQ40%QD+]\M=C^(LT
MT]7W>[6J:NED)^1($$D^D^QV"5.0/[OQPTDX$#:8#888;JWCEK2R/X>1W!()
M#,S D#B"02?(7P#[QXU='7@A(,4,49"E08XU0\2W(KE0/!;Y$>L^?>G'''+-
M9M....--....--.0W[UQE*E=#O#7VA;6V-!8N](=Q7].O$,6U!R)E*19!;C&
M5)^TC86ZT8E]E["GR0\"Y#D?A204R.11[ES;4!IAT]WL$]UJQFW5-A.QF(EV
M:=<R[(+RJNI"&0X9Z95I#CSKPV,)99 <5(YS#?<DJRP'$T1&0>:^N>??V[89
M\_Y5)_0:LD_(V<8P<YQC_7D0O]2!J4<>EI((:662&&DBCI:8*RXHIEM+*,(:
M)4\XZ[DAM&,(>RZZXYEU*_6XM7E6>WSJ@JPL(1>#$R&%C#JP<G#.$FX4RC."
M\8'2EC&"<9]_&&$I9QASPUC"/3SM<Q:OTXXXXTTXXXXTTXXXXTTXXXXTTY1.
MP==U#:=:<I]ZB$3U9(EJ[,FPSY!3 4B35K!&6B(8DFA7F?N$8F9AX]\^(,R]
M&2X[*H^5%,CR"!G:VXY4$J0RDA@0002""#D$$>00?((\@ZHRJZLKJ&5@596
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M[,Q"@ '/D@$X&1G.L<LHCCDD +E$9@B@EF(&0 !YR? _K^AU#G=7U<=5:=V
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MF6O:YTHZ.CXD(:-B@1(V.":2.&  *R$$(PWCPA@44=MIAAE&/PAMEM#:<?\
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MVK*BM6G'QD!79>/@(R/L=C3,.D$+E0PR9*3,B0AA@(D8@O"IN2:00B,AQ#I
MA3V1L-*R\7WM1-=U->SG1[<%W U]VIU 5,QF@;M*D,C@;,8'!6 U5W9M;K<=
M]VL\"D-V )?):^>7\;"77%.87C(A]-[^BZ:+H^OJ#O'L;OS<EFWS9(^,MY$=
MI6Y15*U]2ER;6"R:CB0>K<U8KF8$I:09^8(,@@W#FS@@X9IEA!C^OM'46V]
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M\LN..2Q0$'(/ ><DA0N1YQD 8)(;]-_66TZ]M2)+DX2*NL&L @<<Z'OU$ME
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M*>[7M?CQ1+($@,"ZUA9+$F:4MZ4)%R^SDD,<<9Q"7/=;8?92IS%H_P!1]O\
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M*AE09TE@BPBOL+<;<06/AO.$N8SR3.JM ;@T'L^SW#0%S;I;.T8I,1L>H34
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MU*('V\AB9:^5[61A_;^=\CYGM^RCT?+^9X+^3Z?'R/E?[1[WK]_^]]7.USJ
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M%81@)H!Q;S\$WZT"DD"$&2=@&[855*ALNSGD\A&,#RP\C&-3BC$(@LC@ (/
M/+ERXJ!Q& ,G&<C/C!\#(&Q3185ZMTNIU]]QQUZ$KD+%.K<_ZV7 8X<=:<8\
M8\(0IO+;:?SZ4(2GSG.,YS4A"'7&'D,.X8>6TXEI[+:7<-.*0I+;N6EY2ESV
MUY2OVU*2E?I]"E8QG.<?$"0 DQ6S8TT20#=RO#90)+!8SBFUJ;<PA\9;C*\H
M<2I"\)7G*5I4E6,*QG&/N^\T,RZ0\M+3+#;CSKB\^E#;;2%..+6K_P!%"$)4
MI6?X8QG/YY'0.(QZQX\^_'CSK)G/GW]]:X_8KZCW?+K1MNSZDN\'IC)D(_\
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M>+*==()=]3SSBW%J5GU>;&N=K2R^O]V7^H5!=A]S=0>JFXGZU2-VZ3T$0MN
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M8*M@A)G2-G$;#CW#B*U%]13MGM?3]TJ8=2U=UDM0]NSMK9=3HI-A>J;%LF+
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MR^Z0<[A=1A!Y$W+2BW4MC2TF8VMQEIA"L>LH)6<I:3ZLI3E659_/,HW/:_\
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M/V  UE4^EO\ 1'ZK=>=7UU\RBPFVME.10Z[!LO9,6+:BB3W4Y=+;I]=L"9*
MH=90XOVHR(A0$'_%9'(EI4^3601GSOJ@?3;ZGV6E%R,[I/7(<[%-^[&6JKU>
M$I=OBW&\^O"@[)508F1=:RI*?6')+D(Y]OU-/!K;<7C,H>M_?^D0=)":(EPA
MGV0DMK;<<Q_9RE'C.,8SG^>/./XI_EYY OO;W>'VPIND4XAN4E9TQJ.!':?S
MA1)9*E);1ZOSAMI&,J>(>RGTLL-N/*QA*,XY*(:5T;A*LR0?LL(5CAPC*P8
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M)OFR=04:<5%MX->PRF.+P/+!&0TCF+./^TS(I$1*?#D&E#\D=Z<?S5_ZZ_\
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M76SM?T1_+[[-.13YD;-:N$/5VXR701B/LSV?E6",E\[^O57L+UDI6J.LG76
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MI5AE]TPAA]E PP+CQV"XM)T>7+/D;.UV+YG49.==QFGI6>Q:*?[HN\,@II&
M%3PK;COF34B.^]-EK"^U8)6EWW%._;,.3'VYIS+#_:QYQ^=?94#W]RZN@_\
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MX+.==DPQ#P6=2/LUUUU-+2$A)LH@I1$X[+0T1,Q++L(Y@8%T63DYBQ'2D-*
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M(98,]Z+&<\UQCGGW]NW\_P#R^?TU8_Y&_P I_P /_N^/]?&I:1Z$-@AMM"N
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M8">?D"WHLQ8@<F*>^8UDI>KY<BJ/DV)66AI,3Y>,/.#0I#KS)XD>P2A\10Q
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M4.Z<,6*Z Z$:0F6$<145YSY$;8 R21@8X&3WZ_(.7CSZ'L@&TW:H\&>/.0,
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M[)RVY/X\)F3,'RPX[T><8YKG/''O_P ;(O\ YF _4ZM?\C?Y3^OZ?^$$_P!
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M*1SX",GTLX_[L^%5O'G 9N(\^LY]@$\1GE@A@-<7ZA\]Y0.3*"?&>"<V./S
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M_8>_OZ.BW*K+R6Q$5^7D.,?  O\ ?^Z".7Z??R#B67'(>G=X='1<15IB2?N
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MQK_:<+L74*X*H21&V-DVP7K32M>P=4C[3\E(#&F2K?,N_K=C $DVM-=LC!+
MR4KD@K&-:.[.U."INGX/6$RF2T1NB7[$ZH*B+"[9=?S\D#IPBTA4Q_8,M!T@
M".>O^Z\;)K\JS+1@ E:CMF1S:GBQ6L%N=..-BB<;JIA4<ABJ\"8P6&2^3Q!C
M7P,8+9P8\'AS3*)9!)MCOEW0.H=NZ!.1&<!"H+L)G 9@00N"5D++DML75RAF
MR\E:8FZ7VCVR4OTU=D6JO3T(W( RMHU/5M+3\. /-0,K$9BI6HTZ!)0,9'F2
M$=:@F+%%FB%--,IKO4>@]?Z47*)HB)D463K>L:FF.DI9<F+'0>I*6+1*@* H
MAG!N'&X 0=,D0:680>8G)3CB%+4C.+.K=9MW,NTJC35&BY\EOM%O*\6J3VI6
M)2\:W=%W-U;C+3;)F39CSPTS4.-MRYV^E5TQF1'#(F8C,<T0.OT.HNC V&X]
M1+X$!=K/OC:>E=7:P!K$S;#:WL*+CJH#3-?TZOPN5PK]?.U]MY^]W%:4UR2H
MUASM@:SV$N&GVK#6*^01&4>)V7M1VNZ3&2(P/SHK_!00S G(5E1CDEL("QPU
M8[$:.)I:/TZK* TS/_92/$H=RI521Q=EDD08"(&D(1<I(JO="]/US-@:'G;^
M2'/P!574(5,PF%B0Q6VD[J].))BMLS$Q*-W99JUS]DD)N:,B3G8\\PI;(Q;5
M7'=9M71%BA9QNXV>MRTIL'<\TPVY/UW";1([_81*[ IC TQ"$^\$8W7&)2&'
MAL,V2(&A271918OW#*_"[!Q.]9O:E+;U9,W>,@H#2V\KB@&">%CZ?:MS5X[7
M:-.5:]R[[.%IB3BI"RE/0+<A'#V ( X:7==AQCA2(=4.,[)RM>TG8KDK85W-
M@>P&NK$+"6W7FTDV2@6L_K-N&J6R4LLQ<ZO72RJ7)[7LU8^<16PB=?Z\=E9D
M.+L+-.0.B&I&LTB=QK2@%6)7D2V6#(%(Q@%@OLG!!\$O\3=(:T$@@2@<!D4.
M% 0*ABDY @\BL9<8 R0R^5"987.?Z-RX6SHQFOQM05JC%5I>I[',VBXE6.PV
M/2->TTK4LY5_T@[K08VLW^=B'B87-[INVX$!42\J6(@,ED2D%*2@H/4[75 C
M==QH,A,EYUE?1-A5TI,?1J\05, :WL>K0V;%BF4VM-61E-:M$H22?+-D3Q\V
MM$D3+J:2H',":5*]K\Z5<9NLGN:5F+A):KCYW#=:W_!V_4UT30+E*;1G'9"(
MI45:;16[-=P:M78FKZL07JRFSY/RTVQG7QZA$^ZBT=Q1RM?2T4SN"Y[+L/7*
M$!,JLU5;10JKK';;/7>RRTA8[.^_6V](;%CYK;@\8'-0\E-PE]KMR.B8RN.&
MT9B1CG<DB6'RAL1_!2I/D!^*C)+-G'@D,25&%'$-R0'!!)4A"NM.;]XX<+Q1
MC'W)/"K&F PR%,8 =R68.4*2E90372^M"5[7[%*OMP@IS1NO3*KHZ7/74'7Z
M/-MZUGM<Q5D+L@M-9N$N&P+..6&;J)LX[2K#8(^.D)2NO("8'1=ZPZDA-I1^
MK[2)LZX,2]+@IC%8V)1I6IJ+G!;I4V*Y+362"Z[8H AR5 2B4 D8D-C 1ZD%
MQKR6?2C./2M$=FG:7KYJWVG?Y>MIW9J\WI-7HNW6-T5)IG09)4;"R4C;J9'7
M:8IEFWBAN0FCJS7G:M5Y)X6E*G<ZV7(C!3_ZB5V<J/5KKO5[/#2->L5>TOK>
M%G8*8#1'RL/+QM4C!)"-DP6\):$/#*:<8+'92EEE]"T,I2UA&,8)Q)&H9IED
M96*KA?/&3N=P,64'/('FN"IY\B6Y@ZVJCPS.8TJM#&T8=N3G!:/L=HJ$8@*5
M*A'RK'M%.*F-@* C.B'7F&=#D(JOR@5CA)35,C4;AB3;*ME(%TZ+!#56"JDV
M<$40#"'+BI<ZU#E).*LLC>KZ9(&*=L;GQO1K'2;1=/)J,C7XVP@3517I93,[
MBPD/2,TG0T=98JB-SC3S"XQ?JC[5)BV-^+CXHNQ-,Q29$A>(>-P/+CCFN;$Y
MSF:0Y !^;>0,8!\^0, @'QD9QGSK=%*H.)%>(%<\?@/B2221X\$Y()'G!QG'
MC4<XOK+0ZUI&%T/4B#(&I0\/$P3Q+L%0;,=9HV)#4#[-S MU-G*Q:%2#*DKD
M79&OJ>>):9):<9<;SA?I:)T_,Z8C[#5<W>;LE! 73('4U9F2\2CU#HE,UU5:
MDB+?FR F):8E9ZP14[:)8J0+.::=E!PX[(H8^!6[]<<M,LA#AFY!SR;D 26R
M#RR1D-XQD'(4LH^+$&\5X5>-U0*T2\$XDJ F".& 0"OG/$@@L%8@LBD....8
M]9M.0V[UR=4B=#OEW*Y[AHD-^MJ0UF=T@,X5<OEN3"<"@NMI<8;3#%+PK!:G
MB6/);<>V(DZ2<"BSID\C/VSF[+ :C>/JF[Z9U_EOU356,7Z\@ 2,+D5Z33@J
M"0Q(MOLI-E6D_P!RM(S[F61B6<J!:==E <L']M%_G7]?U_@CG^B,?X:LD_(W
M\C_UY91_ZA_/4C0,HR"'EMPIU&11\H=-0ZV8XC+*,I<+;>;9>02M/A1"'6FG
M$O97AQMM>,HQV^=<-2EBC+42T8I0[*E%L(2VP2I32,Y(90EQY*&G\YRZVE+S
MJ4H6G"7',8PO/8YBU?IQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQI
MIQQQQIIQQQQIIQQQQIIRSVU-(TG;\GK"7MBIAD[4VPX;9-9=AI%$?\J7A,Y<
M8BIO"Q2<R-<*,;CY"0BT9%44;#Q;F2D-CN-/7AY"GMG';HF9G7L5J^4V9#PF
M:EON6LY>MW%B//V*$UPT;JR.E))D,DD?!=T]#D6$,Z*J:.&S$EJ+BB9"-,RP
M*S2 +((SASS)( "HS$>/NP!4#[D@9&<ZU[;(D#,\)G7E$.T%Y%BTJ*I(.1A&
M(=C@X52?MKUXSI)I..J\=3GEW&7KD=*;M/\ @3%E^1@L/?->F:E;Z^84."*5
MF!BJO,N5^HBCOC%04:!%LY-,6'[CE,3W3'3ZX>)$O%_MLU,XN&LCJQ9KY(T*
M5)38Z'2[!K2G1 \#,U#]'6#,M4+).Q$K$RU>ER+(:8[->E,ZR.:/&2==[?QM
M4*@RI/<+T 3MJCF6"U%QU^?N84#8^J<%99?,$]JFJ3MU15!.RA4@',1M6KKT
M?6C&6ZBMB+H;<H"Q_<[ ]@;7M#4 FQ\[CN<C5=J=.IZ"-B*%-06I92H1.OV)
M#<.PK1'-PR(BL6EC:S]D(D(FS'1USK0C-1C8R.;@')-)F\$FR";:D<2^5;D<
M$JQ7R H8LX,B,1A1R;D!@<KO5L<5V]U8.L0#J% 90T08A3R*A8RL$BJ>1^*E
M"?E(RW=7=<;CI\3;=?7P*TY@M6WRIZ:/C7=<MT88ZU:KMFI2256?7M+%G2ZE
M(YGY*3GZE%S#M+_4Z<SHM81(1$8(%6M#ZBU"O$TRU6JS7"U;"K,QJ^R/3YTS
M&I'<D=6:RMVM:U7V0XVN083E5C0-@W.1;0J-&FY26E\2<O*$K:0.F$]=LO;0
M-_JM&G5/=L-)PS6C7-C2+<%;GH6U05XV=<X7<$=8:O6X-N@5LJ@4YF&DIF6M
MCK%M2B6A)6AQX#<;(2\C04-7>V5&HVOM<5"8W531(28[-8FK7/5C;]YD([<F
M=S!G:L?DF*M5;$9>M;'Z[.D+#$->O^IZT'2L^Q9;*%/"1(T?=VIL<!:0 DHH
MR&/;P[$$J,E25!P$RSM\@& !L$U;EW#1D=@J2,2"H[V8$7"R$JLBAV +282*
M(%2T;<A.USI7H>$ LM'&F7J^'LNQ%3<##)"UBU-"3(6R ]Z&A0\K(TIZU7:$
M%M$,B1)J%TD[C7F:J@F")B\P3;*1/7D^DFNI& =KZ;KLF-3(U7=%#L,G&2E5
M$E)ZB[WMZ+]>:P3G%/5'1P;=L0J1KAT'&Q<M7Q"#(8,[,26Z-BP$#";AL7<2
MASUYBMQ'DTO>W89>5R%;-9TE5]0F:>E(#4$S4IIJ.Q7,G6)J0:%DWPYLVTOV
MF2M,;:QV1@:XR'5-RL^YH2Z=HI>2A.P5DMD4B2CM'4>E!VJ,T[+:G-H='8;L
M(-DK]9EHY>QHFUR5WGI-"Y%S:3AD'B!I<*6 [ !2./$X90MD%B@F)R/SNYB\
M,??QPS2,0.)Y$_?68-4X.[4^*+*:P]@B*.,6!E1Y!#ED2) S<\1J/:B5FVNO
M%!W-B+Q;2;$SB)H6UM<B?9)5B/QF W#4A:9;''?< +PN29B0VEPQ2?0V ;E;
M[HY:%89QX#_536+\R5-N%VOYI=P&N[J4S0V&4S G7&7ZO-H0UF,RI(&=;S1A
M3@V5Y4JU)8F?>P.UF-7CY]ON-/4&5C1)SL(!BI5SO3)4R1CH>Q04Y:)&K9UC
M,]6!I4BYQI5YF&S2I&S(J8%G)5-VX./D("Y*F!F)6.>NC?)OLFYGLS(1CV_!
MMN!5(;^HN"@:M+*U&_0G]7:Z.FI6,6)7S:D9MX:YD;-R-'V*4S<TV "+A8"%
M+@%1 DD$,R<46T@'S4!6/Q4RJAY#'Q4ENXWOBH+'.-&LUI"TC4)2V89.3(N7
M=87D4J2?DZ!.V@\%G*J,#SJ3T/T\U-"'U.2#.N2B*<O0JHCWY\5QMQ?72NVB
MKT+YJ<1*,D?)C;=*9LOH4SF5*0&ZQ]O2.IMWP:ITAU;51XT--FV++"P,?IJ#
MK0LI.PN6X"L:&VR5N/7=?#P!6P72QA+24X),R4LY(SL]"):".E,/L-%HMAJ2
M W[89[3(5GV)M-6O ;5O"WEJ$@K_ %(]<'7IO61&IM=[)L&U*]";(L,>R63=
M\#R4K'P\A?*X.B/E290,60*D^UM*2W\UM3L.NNN[C1;(G5K[G4R&K\$85HZP
M2S^H;(5)/WN3'BRJ@Y<VMIL.",!;)F8=0[ M!;K+/P9F?<D+<3%F3ZD$@!B2
M6_[N01H#D9!7P[?9(P6)(&-7YJB-)/HB 9&0*H5LF>$SRL.+%6#@E$SYDF94
M 4MD5K8^HO7Z-LU:M<K.XA)T21VL<R19W=>3C4]&WK8\OOVY0V +_59P$8:O
M6 F>EHJ8KPT=9*W5R9D5Z;6 IPIB8<.- )8S+0+$1@:>2Q)YDHAH'#,P@I&2
M!C\F IPW(I(;(]Y@O+KV'D/>ZAQ>'<J5AND*5O2Y4O7I$^)LK8OJM^_(J 8L
M-"V@Q9Z0-=NDMMJXT5:939E;K=C/CK'M*0D$"64R'%J=?E[)^A0YUZ*CXML2
M4$^[L4+1?3.,C1=O56DJSK^+WCC755M VV:[!Q6F)S$#&OUX."-M\)#?UK1U
M3C+JJ-A\20@'MC'J'K!D\0E-$Q$:M8[C'ED'/QRTC%<?F+'@.*D8+L IP0QI
M6LH#.RT^RJF/A@@]P&.NHD##X+&#*0S@DA$+2!7#(L^HN6BYR/"EH:2 EHN1
M'05'R488-( '"NX\MDAFB.O#%,.8QY0\PZXVO'Y2K..=_P!2?W\X\8_?/G]O
MX_G^7C&/.?/[<PN:+@NU%3(ZI4I2]A:WJ55TWUF;;B3J-?Y&*//3.6Y'8*I7
MR+J5:-IL3;I&!:K<6Q(;+FZI%T=TF,LE)4^XBRCOFF=\7VM7TN]1_9J K0=W
MZJ;4!KL*/M\VU5<X;<=H&W35X62DZZ-9+FY4:DFG34M"46*=HSI8 \UKV..$
M8DWBJ/3"NP$R,H90&'DD/($4@9 8X.2%8@%6!(P"U\>YEXT8UI%=D9BK'B 4
MC[C9."57/A2R@E6C8 \F"9E(^7BI;!:HJ2CY)($@9$G9 -&-P%*1SOLGQQ>1
MG7<#'A/9PT6&]Z"1G,X0^TVO\<]#F-S1E-VY3MY2,ZT+LB.I&P]Z=KY*T0DJ
M$^/2AJV8379S6ME'AR Q\Q)L_*,2)(4\]G[K+*D96**=6"R #&Y(^:TL8C8
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MU^Y+,M.+6ZPVO*!@B$EY9C5G$,RDY&SM;&7*6U*^)1M7:PV[-?JBINJJ6VS
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4QQQQIIQQQQIIQQQQIIQQQQIK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g139148.jpg
<DESCRIPTION>G139148.JPG
<TEXT>
begin 644 g139148.jpg
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M[^/B/#P.WGD;?CY><;>O4>S'CG&3[AT\S6$.)_.G:$JYWO2W>KN;+7+GRWR
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M3M;F:8U)%YB\L#<NV,@.DIWLBSTCY6N+.>.75G6I5VUG;E4%6A J=0/%3V9
MI2WN<_G4I:X_IA)?$3Z>RD+8PTK7&;2I(>J"L:(='GMZ/3A2HS#0T>RSFF?W
MG)VBTX_QO:E=<U7OYSN);A9*!GU1K6AW;JJK&D7"!W;T#95.)4CBAK&!V;/4
M1#XM')T[:>N3)4C],4#8M=RBCO?[\Y"LU<P>9 =8<T31W8Y%TIXL;TB#!!*I
M<UQEG(JBE4(>KJ?JP86IG$&?25HC#$M1OZ>*$+710(G38M]33A@&SN-NO4^
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M6*5SC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4JD/R=P<%F=0\;0O\
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MW(DYVJ5,I,0I5[D,Q0G9T>]Z);&P(]IV].'1!'H7K0=6.9!#FS_K<>0+\O\
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M[J^ON<OXK9%*6P]4Q:M.2EIEY+B@13).GU'-5PUED"W+UB ]42L? ZU\NI+
M:R-8QNX#?@7#;_+?I^S>:V?1K*UV)W%.4,FEUQ*;=GS^KB'CH?F-^0H8Y!'N
M%$Q"!]#N)>R4)RU WP";.JF5IPC)7"7((S,%)8DQ:'9HMCTTFTB5,?O4-<V$
MQ;I)0PW(5&6J:]P,Q"E:02HH6M3B@3AMMMR24O".6'=RT3:(-WN4MJX-\V.Q
M;I#_  <3B<$*;2X_EK?@AQE2)TA1(#$2+(ED+$8I.R$C6%+T25<GT;HA8F3J
MB='D')3]$J2@'E_&3*2RE"<W19@?B$'E%G$F:$4:6$81!U^9]T5VWY6[?\^*
MSD^>$SN0P/795>0Q7RJF9-_Q;/%&,4^C[JSK7?Z:@3*7:)KX<@3S=RE:AW"W
M.A!0U2A0%I]R(/Z4344&&0QN)D<D/=01>-)"GR7/QA"=4X@8VDL#I)'@P&BT
MQ"A:%(H=G$8= (*--/V'VEAUFOO2ODDYG@=(7SU,>K2R'IF^YM8-IQF!*(X8
M*>MK(JVBKRBJT4.2I*%>G2-L$BL4=W1C+<-I0O#Z_A:BA[<2 FZ=<+S LC*9
M$V<S#YSHCQ&G'$!^:^05IBQ&U%+DJ0L(X41F4J6\M;:0@DI%:%)A1KG<H5H,
M1-Q<EO+9AM'B)<>?=;BQ6V$*X )DIUU*8JR&WT)1(+2V\.Y^GY%:B,ZTZUK6
MC*9B+HY"HRN%ZRZIC$$#8YD05KF[P!PB40 @6N[,B425T^GJGD*$:TLT"=5M
M6L_0#O8[%_&MSW(^:J%D=?RAK=6Y>KMR:25(<])FQ$Y.K.Y(8\D:G10A:G5Y
M(0C.3MPB3$HEPS"SR#Q:!HDPD8_!S#!D?%O*#E8MRN)KO9DR4*;HOF2"+][R
M[V#.3DJDR/DGK#-JEI,4(5HHDRDFF@+$6WGJBDR+:T\D-@3:XHW=N0.K<>!2
MWN:-*X(5)0@C*4HUI!:E,>6,.]A& TDT PB#O>MAWK>M[U]\P-MMEC9U#.GR
MFHBM=OV]A^[.(GRWI$:V2G5QH<9#'>>YKB-&U=R1,3&"I3T%V0"V7B@>TZA[
M2NTN3V:V'LO1J65)[&+!<GV;%:6['9&;7*U%!4[=+C-8O M+=^64OZC?D18;
MMR;;:MLR A^*74*57NXQC-LKR&F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F,8Q
M2J$?-+-FNLE-96U$4O2ZRYJ4J&^K76*.=KPAW/R>-<],"VMD5M2"Q);)X).U
M4Q2#>W&$-\,K-K9' 3Y)!B=5(6@MH^MII8\(/BR/79USSU++%ZCG4ZJ!94$@
M(5]$V;![.9G^J[09I8KKJPJT6Q")Q!7'"Y*NBTQ9)G$I(@4NC*\Q9&82N6(%
MZ50.#_E:<FN[K.34;<_#O;#C3,:KBQ$BOJBA;4I&GT[BBG*N ,CO7*2:3.^X
MG%7"MK$2JBFV60>V&EM>':4Q=E612-KMM6WPB5GC K.50>2=,/[O0%\5LU39
MUK(\=Q==W%#;AZLO*9L+=+F^4(IXM@5@V'&8U7=3-Y\;C-51QM51]&A(=Y*6
MECB( 3!F<>W'G.XVZD^ \ <#J=\ >8VS5]PG&-CXXZ;^?KCIOYYZ"K<<8QG)
M5*X]-:^VM:UK]GIC>M:UOTUZ?;?]F<YP+\M_NW_9BE01YL_ZW'D"_P#/6A/7
M\_\ 4ZD_F_H]/Y?V[G?D$.; [UUOY =[UO7NFE";UZZWKUU_$ZE^^O7\];WZ
M^GI]OS]/UY._*-_8'M5_4:Y'/M#_ +;7_P!2/;\^72F,8R]<=,8QBE,8QBE,
M8QBE,8QBE,8QBE/SRN'JWQN4+T,98-BJ(\X$W&_L@?IL@!(WE.@,=6E(6!M(
M4M1*CY+2=:2F"UJAA)V(LI1M2 .SR@;U8]G O7VB]/S]-^G[_3.C<;7;;O',
M.ZP(EQBE868\V.U):XTA20X$/(6E+B4K6E+B0%I"E<)&36TZ0UQK'L_NWT[H
MC4UZTI>2P8JKC8[A)M\EV*IYB0N)(7&<;[Q#<?C1W'HCW''>+* ZVH "OS*>
M^_%K_A#=YRCI.)W5$HF@-65M(Y- 93]8T\II!$DC)'G!D*>V?9B=G&H?64MF
M=SO@B<6IQ^IR@:0\E:5\79$M+R;>/YLLNM*3LZ\911'1PY'%#;)Y'D[*[KVA
M1,3$33'GUJ4VJUL:AE;$=EQ4M*O:U*)_2-<_2&-*AU3-BMQ4DEUJ>2JO).V]
M?]H1-A?DS UV%/REB7X209A[$C=X=%]KC6<Q,J()2*G0P;@6K&<7L0 '_%WK
M9V@CRAGOWGGY'R..DZNN<*'NQ:_L6F$5FMD98B5D2>$$+::[1,OX?<'ES3N)
MQ!4-3->Y%M]3:.<'$AS F'H"@@P3LRM]\U5<M:-V34DC5<K1EU;M=QL;< +D
MP[!'B,EK4 DQ[%;5-PXCK4JT71<N;?)KLV(B>V\PW);,OT>_VKM%[#'M :HU
M9HO3N@M+=I$"'<] :D;UFW<I.NK?<6+1<9UDN\&ZW:[*@7]F'?K>U!EPXUF=
M#K5PF1 IWNY8_63:%[>Z-3<Y-1Q*AK7HDJMN/3[#L@U$H) :E&5L'J'X8B!
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MW$(K'/!5S[U7V=0=OVDXLS8\29L<MPF56O8>P F<DIAOBQ2Y@J]$M>A*R&F
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M@C&$0@##L01"#O>]"WK?9<8S&,1HT5)1&CL1T*45J0PTVRE2R "HI;2D%1
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M8\H#J+AM(/3>O1FFRA;94PE\2=MNA!I9+<!$7%(/)RG))I!\3XBAP5$'D&A
M002(G>QAQ"ZR[OAI:W-U.K/DTPEL;ESB847<-M>\T*%(<J$4$0JAT$(C-$[
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M_P!%^+_S_P!.+NU]OV_]!]_O_/\ +[?GF*:JNCO^UP6&-J@O'C;NNK8G53.
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MOU@@GQ&/9^(((]?PZ;YD''_OV'R/D.F*J$X>=VNYO(GY&>H:F>$LNYTFU?\
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M1M_8XQ6J-,9ZKB7+_EIY.OX13=V_UK=;;-JEHQ&U*7.568Y]$4'S=$X&OJ)
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M"'L(=_?6M;],%I$Q1YRDM.26H4>S2@\!18#C]%Z]I>CC0AT8;\,/Z(/B"%[
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M]N,^ZK7<^%)Y/&X5'7R7S&0,L4BD8:E[[))-(W1$RL# R-:8Q8Y.[R[N1R9
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M?8</0@>T7KK>_3627)R0LZ!4YN:HE$@1$C/4J3QZ 644#7KO>][^^Q;WZ!
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M966J=)6>M4/)Y)#XH*2A/.< A5#++)T$!&QZWK1>M!!OTUD^,_@LHLD&BR@
M+ 'U]H"P! '7KOUWZ!!H(=??]FM9_>;!;8BH%O@P5OKE+AQ(\9<ES/,D*8:2
MVIY?$M:N-PI*U96LY)RI1W/C&M]11]7:QU1JF+:8UAC:BOUUO,>R0U(7%M+-
MQFO2F[?'6U'B-J9B(=##:D18Z"E *66QA 8QC.[6K4QC&*4QC&*4QC&*4QC&
M*4QC&*4QGB+,V,.]B*,+WH9@?:+6O7>@&" $?Z.]Z]I@0Z,!]_7VBU[M:%ZZ
MTRH4" 1G!&1]50Z^A&1[ZDC!(/4'!\>GJ-C[JB)W3(;KAG.LAG=!.$.0SZOY
M57,\.(L6QF.HJ\>X9$9XP/L_C4[LY_;G='"(E(8>B=VE\?R6Y6N2(U0])"A#
M,WF!>4>\[/Z3FE=-2JE:%8X%9$.E\Y89_6_<58W>M>8M#7,<7=)/$H-&X2R.
M\MB:>=;30]TDK6MTV,CFL("N,^,,"4SM/DT2Q"1\[-\*?)[4,5D[S='/CO7\
M6O)2H%5EL32*W;!I#'*FL5M;DCHY*(+8[LVIH@_.>F=R;(_IU3OKNF/0-QY!
MM8?%,8MAKZ#XTB?0S'R52.ZMG?:4FJ%'4E]I;UL^Y97>YEA6 [UK'D\7KN+-
ML J:OH*]KI/+SWQT&*726+PO:9C:S41.AP<\6Q(&1TP0>F1TRG;X_"I !2?X
MAG;?IC).WD0.O09/@:V3<]1>@0NJ%8V.:-*XMKBE4(7!O7)R5:)<B5E#(5(U
MB10 PA2E4D&#)4)SRQDG%#&68 0!"#OV]?EK]?VQEZK6!JUY;YLIJ*RZ#5-0
M=.5M#)\8L-G$5@];1*,1Z8C<$IB%;^*&=I:DJ%^"J1G')#BW,E24-*:8GV#X
M0QA%V&GZ(I7GV-'PVBZEKBGHFJ<3G=5&ZSAD?A#(I=%(0@/<5+;'D"!*>N-
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M0H3C%LHHTA:D5)CB@[*"(ST5Y+CS8D\/U0 VYCA 2I 2 4H&,(4"G=(X0YQ
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MI?=YH6T0I3:4@MGC4\T$DY5PV+8QC-BK,4QC&*4QC&*4QC&*4QC&*4QG\A,
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M%9:N-0YW=%[7!33%(I"XA3I"6MY.]C0MK(\94/XLJ[H]O0\R]\<@6+(9ZS2
M,AIVA^0.8Z1EMCH6YF7.I(W"75@RM\P+11,SWR(QK)-+0C$E,)5)  V+0*G&
M?'((/AYCV$YQCQ^.*N#A)&?/ W\CY=-SGU(QMOG8XU^6OU8Q_7C+U2F/[_\
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M0V2Q:DLN_'<5=L88A+-(FJ5L*T"]Z)7+DS !,G6JR%.IB^2V>0TBK!0)T5=
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MW=P1(%&X^XRE'#F21LK'(!IE:12E5[VU!4D;  6<84?:1MC;)V2<XP,'<XW
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M:I@9T^EQ2"OZOD*?3;_&$_.#A^+;C7&:1JUK-!PZ9G;!OD7EW(],>//HF#\
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M_J#HA)'9H@J]CM/JNS>@'2)HG)HT=/GBOHY.W5>VQY[<8RW#;WQ_;TX'4V.
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M4EYIQIOT35VOO_C32L"P3;@;0_:C%EWR<X&%M0Y<UYYQNV*"8SSSI:1)A-O
MN<IF2VZV@.I6%([7Y#J-CT5\8U@<=4HTC.?)["F*C*+@I[@8X/4LE3B_-:TA
M 6H7&&&J#"TB)VDLA<CO8@9VI$Y.9^DK>D]@*%_&GXW^S_&]<\ZZ)OJ+0RM8
M,;6"ZO3K%:9/&YFMA1DOE\6+5R-.SID^Q'"1-2-<$@9NMI=+#D@5)1Y0]DBN
MJI'H$5X<Z.'E!D2LN*+YNTJ8G2L5?PDR-KYXK,^=%Q&1.[:A+"#4GL>4%-XY
M-+%C>4 UQ3MS7%F\K;*C5Z6YCJMO?9K=,%1R^9RBRJX<V>1S>/P"P7ILDKTT
M#;4*5.QVI,T[2E*:&U%*#EZ@B(5\N)4_AWXH'4:@+EH:%#G(VL]1Z-T[JG0!
M1">8NLV>=5NS6GI$X75+<9F="A2$24L9BF*EIZ0ZB2W(D]X6WS(W(4]J.DNR
MNT:SNEF[;;_)>>MFF)$J; BY61J1FU16K[/BCO$"5",J9$N3+C7?EEEM#@,R
M,XM3<.;\>$63'*^L5UN:^[0(1U5!JAE=A$/MO2MF)WSY&CW=C;T+K/I$E^1C
M;?*+-;U"]Q);%@1.3$WI0LS(:H+/<=#[2W]XPSL).WP3QS6C7-RN+\F4'3J_
MXVX%2^L.?8S\SIO$Z.X4H?@R*V'4P2@=<UBJ&A+<OD%DBDBM#&T&@N<4O.5R
M2P]8</JN":1,8(#=W1MBP]SJJ,1YM11]C>%U</">62R0V+IG0_&;JV8&!.<H
ME$@"@7*25QK$WH4BYP7)4IF(?X.;X=;O\2E-W\AZ!L.&RJP+[FD.>=Q6NUCL
MZ1*',D";'YM;SMO+J@:3'202(;^I.<MIFM.F1(D#8FTI5G?&^#X]*?$ES*04
M)0E* .FP^L< ?523Q8P"3_J)*B5'*ZRU(SJ:ZLSH\(08L6 Q;XD<!IM 98=?
M<"^[L)##*E*?672CB<E/!<R<_+N$F9+D61U+XG.!J>MV.=$L//,/>NC8^G7F
M'7Q+M+9'8\AD;T8:ID$XD*Y>J&U+9J]K%*M4ID)32G5HM*1(FC;>@)3)B962
M_GZH98[3F5R*%M#B_P YAQ<0D;JJ0%."@]G0%*MHAITQQ1P .*'9XC$JQ.7I
M;[RDX F;^"5H.;O77[?Y?YOVY%B7]:U]%[)?ZA2L<RE5A-C:2<R1Z,-"=>=,
M'O:0#BNC+$H,7)TR9Q9&Q0@<WYP?36EA:T;@E$:Z#4"VFUU3;FK@II*X34PQ
M'$RF@ZRV\&'&TJ:$A/,2I*%(0\M!<VX$+7DA!57G]SEVV.VRN[.,!IQ\-L"2
MD+XY"VW>%ME)2LEYQOFH0E"2M?$6DA2EA*M&SE#FNOZ^[L=''GM=;UGRVGK
M>GZC8;(JV8W;<\3Q<+JD?V>T6 D]&J8$RE#M>6!7[T 4Q6P#/VF= IDQV?\
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M^6?(;!D"@ *RD+N\3.ZYNSRMDV!>SO,2K=P6KHFX!B^RM*C$:F,@8R4.QIG
M1:,S1>\G$.FK'>-/SK;>I-SFL-MSI3+4-Y<:!*4J1'0EU:.ZB88LB/(=6RQ(
M4"TTR\XR]&EQ5N;] M%BTI=K/W5Q.HKO<&GD!$-R#?F;:E44(D2$1[3*.7V
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M /XB?2&O3_\ 39SGOU_];;8^W[/MZ:_5^O\ ID'TQ.9E6G/]P3VO&L3S.(K
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MQ#%-!MZ7AUK0@^QI//;(.WF[]HO;M7(S#G;18]A^,2Q"V#WAT/68&-]5YM>
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M;Q')G9L?T]-LBBS(O6MD>CS,YQ!&J6&%1L*A8F,1K4:SU,5%:$I":$ =6?\
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MD9M<."R)3+CL;@E">@ ,ET()8<0E>Z6T*(<13_8_GK3Q&)\_V155$MD,?)A
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%QC%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g904926.jpg
<DESCRIPTION>G904926.JPG
<TEXT>
begin 644 g904926.jpg
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M'X6Z-@\45VZS/XF.T54DXVX.&*-:E7BR4?'2CI\H1N:-G<K\(BUFUXV@Z?\
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MNAFS"ZAH'*D:=PX*F=!/X4[<RR1#D*H<BB7V/$/(ED+F:V8[)7MNK8G%?YA
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M?Y[\=@_7^\?[._;_ #WYSQQIIQQQQIIQQQQIIQQQQIK@1[!W'O\ +] "(_N
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MFG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FOPI^:'\]/\
MO"\@ZZ"?\7+;;^DVWM_Q41Y.*I^:'\]/^\+RJ;T8.H+B?%4]L%J'.8VV-F,@
M7GJ:;AGC+K4<(VBR89CPM^2!?1Y9_)[(P04.=DDW.29(X 31:QT4W  *I!&)
M(!R>!@_Z?]O[R-2 )! ^H_HK5K7G'</TA^_E<SK=; ;^X0RIHXMA.U5S%NJU
MIW-U!QODJS1#Q9;*.2K)DK+BD5+8Z*W, ,X?'Z-4C55YU=1-5S-.9!NV05;
MU-ZFCO50V?W4QUU+[Z\L^5]Y]:^G?ARJZ[ME,IZ]5%BKCMW:[C)1KRX2]N>S
M4$^2G:\U>.4:S-%BGK=Q&E4<*+'*44"J,\$X\>V>3C'@8)]QCZYT2GN(2#SC
MGC@?Q^PY/T\<DC5Q;D5?4(WDV%USR5@3 >JNKZVR6;<[,+Y8HR/E[>UH=-A*
MSCIO&KV!=[/N^Q5Y;QE6RC>.1$5?1[K"02B A)Y7I%E+P,++1LA\6CI.)C9!
MA*=P$)%D\9(.&K\!+V*(/$5"..X  =U![!VY +UQ]?FN:Y37:05TJVCVS?5
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MCC33CCCC33GHK)9J_4(AU/V>8CX*&9 474C)N2-6J0G-XD**AQ^THH;[*:1
M,HH80*0IC#VY[T>_W?Y_7^SZ\TQQM!9\R)FW+<UL#282O8JQW?RI:PM(R?CY
M56UUWX-&D>7N\P[5591A8FTW\71KC-T($:19T'ATO>' Q8J)& D94?&? &1D
MDCZ YQ[GCCR)  Y)( ')&>3SC"?J?Z#GP-9D)L7A)3T?#(D$;USHIH@ /NYS
MN!$$2@ L_JH(" =^WS#L/;D0'7)V2Q?!:^6O7RS5)Q;I&?QL^S:Z7?,VRE4B
MZ[3'JS>).\6<JE57EY"QJ,/A[-J@H)6Z2ZSHZ29BE//1V#] ?N_K'](_KY2V
M_"4=I\?8WO%XQ7>99-I9K/@2!@<=1AT@(ZD&%EE'KF8.S.!0460++-DBN2=Q
M!-0I1$"B/SPM\)ZH"6((6M^5-KHBRRVHN-Q7YK+<YU*@ZDMEN(7E)=!):4 O
M"L8UG-O?EXL"[8)!9CPI[[25O);0J<U$=57A?<TL.(,ST>]C +R<M]Z<DZH;
MZ0V:$?;M8R>7%A'RE8N5[>PUAC7S5$\>O'6DKZ/]$[<X F1-$[U$4>P *)TR
M&)XB4!#[$&E6TN.<HZUM++[-[0F>&W2&);I'SB*96\--51K&QB*C%S'F=(/8
MB1;.HYQ'.$?X0$G)$G"22I% #XJ&))0:MEZG3QU3)DK-L83*YTQ.!A1B7Y'2
MH%[  B)BHB  /8!_3W[<^KIT!=F*=L3 ;%/,82Z4S064GC:8=';$ S9C>YJM
M&0L385RAV%ZLUCXYT])W\O4.50P 8_?B5\>WN"O<:0XJODUTZ/+/:I;3,J.^
MP]"427 &RZAZ6VHA*BYV-@J'8,UCJKW=NV*'T_\ B4:Q@OP7 XELJBR4/-3F
MNSTEJD84U%6G+B QE:P%^J0)NW>RN"6!"*/<F5UHFHZ19%5<'>)) Z<.TF"2
M9U3M 32 SM9) 5%#%3(8X&4.4@"8,V-G+=XW1=M%TG+5RDFNW<(*$51715*!
MTU4E2"8BB:A# 8ARB)3%$! 1 >%VZ#E%5NX127073416163(HDLBJ42*I*IG
M 2*)J$,)3D. E,41 P"'-+*7'[+8[VE2QS#4>!>Z2NL;3TQ&79Q9V#B[5#*Z
MLQ#KL*8A7U%BR0T$(GXZ:-="DJ=F]519**BV30.;,Y6" K"@3C*01V_3()/!
M\9SG/MSQ@L)(.."!GD@Y_3@<_;G(SR,<[L\<<<GJ.G'''&FG'''&FG'''&FG
M'''&FG'''&FG'''&FG'''&FG'''&F@_(!']'(U-E^J?K7JMD6P8KR:C>D[G"
M1+.8281==.Y:R[61:&<QXQS\RR:)BNU$U&@*G$I$ETU /\B_.2OD!.>==&_4
MIWOBY6)BH6/P;J#.LL?Y2N+A-8LCE.V).T[),TJ"7;)&0>,*BX0;1#QRH[ S
M)Q*29!2*84RJ[-M6%42YTA=_\0BHB07Y,EZ.\EE;;B2@14 J;<]14EXIBMLH
M2%E3H<R$-+(V+;<.ME2I*[=+@KHL-Q]YY#I9])P+0E@$@$N*?6?0;93A:U+"
MD\(.MF-1L&2NQ]@F]WMHZXREI_*D*>*PMBFPLTY.&Q)AUPX]:/1,P?)G;C:K
M41)"1F'A$2F*B8A2*+%51%O*]R+_ '7WS>:XV_'6MV :)!9-V/OK%*3@J98)
MQ"I4RK4:,**:\Q8)UP)024=$;#&U^-:$56=O13(<I4PYLCIOM=5=OL0IY#A(
MB0JEGK\]+4'*-"ERA\4H&3*NJ#.UU1TL3NDZ+'O0$6KI,W=9HHB*Y$7)5T4]
M9G[EC6]N]##H;<C(].-!0'/AHD9E#?;#C+(#2W([*V%20E1>4IP//Y<6M6L]
M?[4W<=OP=[3:M47;4Y:&*M(?9*HD%:WH\!Y5>'3+C5\QR')CQ+!YA#$^3%?[
M'5K*"O:Q3\T/YZ?]X7D'703_ (N6VW])MO;_ (J(\G%4_-#^>G_>%Y!UT$_X
MN6VW])MO;_BHCRGN/T/]1K0/8_J/Z*U.1QSCN'T^\?V_V?0/UC\N!$ 'M\_W
M#V_?V[?U\KJFN>0(]9QU3,=7G5+8RL[A8;U,VFPP^R".(SYU:2#O&^4ZG;6$
M7'WBFV;X4@ZDF;8J31HX:/F35=9%PH?N4/(ARSW<K(_A"&T$[KK9M6C&CM56
M5,<QF4;O.3>RF.JWD96ZKT)2JN%<,TM"<;KN*Q+W*(DGZ[:=:%$BCAH1%0Q#
M(D\H+SC &23@>?OGQ]N-7&L=XSDCW&0,CW!)XP=>OTCR-E+=7;'7G8W:;=?4
M#(U9PA/Y J>!\-:M_C1(LK#FV\4"2:R$M;)RTQD.[![!TEA/24*P:H+HB!51
M5$H&/Y.;.]'+8+"FVQMB)*@85UWB:CAK*E)E\5Y$PG0HJ KT@AD+&J,PJQ!1
M*'9@6]4,LC+52Q2;)4RBJ+SVYCD34,4[E&^[MRK'/('N![ _7'M]M5=P%=H&
M,#[8Y^;CM &,'@\DC'.II\GM;^^QW=F6*I*OPV27=8F6M&E[4V=O*W%VA=DJ
ME#2$VT8"#QS&LWITG#I!L(*JIIB0@@)N4T)G.VZ6 .G5U-*G==H,BY#SE'=5
MJDZN63/R$M)QDM5:OD1;$,;=93&J)7/;'\*P0F9%A7&,29FC%-URN0(D\66.
M-V@0[AV'[^:-V'ITZJVW&NU>);10E)RD;EY+F,N9OC7DH\]>6ODNUKS4T]"O
MDSE<P#R.&K0CJ)6CCI*,73,BR1@$QP-50/<",D=I&., Y!!YY\9!P<'@$8Y$
M4J //CCZ_4?TY(_R(SJ&O0_-68=5\O=7[7. 2V!W4QOJ)*8!L^%,:VB^.,B9
MAEE,MU!%S<*1%7C(D@X4?-TUO*=2:2[[T6C47*2)"E.F'/<],#/5;S?U =BZ
MG;M7[UJW:<90]2EJIB/+3^#?W*N.+I3H"U.)Q7\7UW,2FTFB2TB>NHMEE%4(
M@A?7$JPG LQ^EFA&O.AE-M52P3"6 KJ_6$EJO]UN]GE[M?KM.(,TXYD[L=KG
MG#J5?DC8Y%)C&ME' H,VQ/!(H=Q$82ZXX7K'7<ZC^3D15,E08OISM9(H&$$B
M0E[Q/*5F165^8@"1%PCA.(_(# 4WU#N/-^I514NU5;NJQKHLR5LB[I;Z-(?8
M2Z]$B)N*]BZ<0L]W:A-6Y)F*00M ?B1WAAQAI;?4>E][;QK&]VI6V,R'$WYM
MRZV[,CQI#C3,V6NLDR*-IU"2E/<NX9C0DN?(HQYTF,HJ9DO-.6A>.<%,!RE,
M40$I@ Q1 >X" AW 0$/D(" ]P$.<\Z6#D9'@\C7*]....--15[&B\TFSI%;8
MU1 R&#\HR,33-FJC'!XMVLV]7.WK>6X^-()$SS#;R*PF%DB@HY:)&%PIV,4!
MWBQ]LM@;*DRA7L?93J%JG7+(TBWB8J516?K,TR%4463:CXJF!(ABG5)X^:0#
M]LH=A[:V=3VAW#(VG]_K5&K\C9Y]21K;Q*(BD#.G[ANTDO)R9NV( G7,D0X&
M%,@"82]Q[=@'E>S4*L9VT^S3'[ 777#*,M4*5 6 +&1C!@P=LXV6:%:*29%W
M9 1%-D< 47)]3)F$W</'N'*;G<MGM/=L2KC4LF7MNW]&PL+%#$UUBD=?>D-6
M#C9C,/(#*PRW.>964AMUV1(SVOD)]_=/.C&TOQ!]!9N\[?><*JZO;&:N-G[;
MHQ:;?A3=_P :IK:R7LV%:MW$V*^[/97.<VU!LF7$EZLC5<!06NN0I=QCCD-&
M+NLYB')^0Z3CMAB3(T6^NMEB:RSD7DA7EFK-S+NTV;=PX2;K"N=$JJA!.5,/
M/Q$1#Z<E4<Y;Q<S=KL'>1:.V>M7)V;AHO:H5)TBZ(IZ1VZB!W@*$7*I]@R0E
M X'^R( /RYOM1N&DOF')5/9Q+".R]\.Z['<[D(>[$.>F20GY^Q:%8^BAKRAO
MSHQU2Z96$&JWSLJYH+&RA+L845U#$QQ^$V^8RY _+7YB4-I?26CZBD$J' ((
M)R'SH>4W2['&61'K544'+2CVMRW6  $4ET()\JDH #\NY#E*8._R[ASO*:B:
MR9%4CD425(51-0A@.10AP Q#D,41*8IBB E, B @(" ]N>GLR*CBN3Z"46C.
M*KPLHBG"N% 20ESJ,ER$C%E3?932?&,#50X_(A%1-]W,G);4['D-)/:IQEUM
M*N?E4M"D@_+SP2#QS].=<VC_ "R&"0/E>;RE12@<.)R%*60E(]B5D)3Y40 =
M?-047DE)!>=0?KHRBZ[B2.]:K';NA?N%U%W"R:K<Q%4CJ'.H<!2,42"8"AV#
MN(V$^@'F.PCF/,.+[%9U'K>RU*-LT8RG'ZSN3</H)8S9Q\+7?+*.%"(M' J.
MFB(B4J8"X\  IS! CGPUFI&6+ ^F*BRJUEE[K8X)_KRS;/T@QE-1TVLBE5 C
MW1/C4U'/X55E+0<U&%4;R"CI9)(R@H=S2[=.76''6ST#D ,3Y'L^(=U<%/(V
MW5.WP2BGY/I6#=*^I 2*3(!^+1["1553A[1!2QPD63P!\T56QCIAS[IQU/WS
M9MQNF&^9QG439K&JO<#$A,>RI$T\91B0IK2XC<FZK)7H,_F4>2I%E'0A;S:G
M7FDQ%?H'U8Z9O5NQK"^GM1!7RX,5#]I79G1X*Y<J*EJ;+;0A*EQV)J6&E64)
M3K#C4GUFB]&<]9NY?QR*W5_J*,9FV26M^W,:RP7LU1B)L)E";<IQ]*R W;H&
M%.W5*9>&1:IM9=)--V#15;TC.'!T6*ARI&(3?-CL#@N4>M(V-S'BY_(/W"31
MDR9WNM.7;MTL<"(MVS=*1,JNNJ<0(FDF4QSF$"E 1YT>Q4S4SG:Z?)BQY32D
M80Y(:2'FW4A;$B.5*3Z\:2VI+L=]KN;>;4%(4>0/!LZAMJ]XLOPGU#L#S3[#
M:WXTB.K/9)CR&DJ:=86 2EQ*B 0I*NU:5)&7^...-8C3CCCC33CCCC33CCCC
M33CCCC37AR#3W[%XR!PX:"\:.6ONFB@HNF_N$%$?7;*A\TUT?/U45 ^9%2$.
M'TY6MN'X-#KSG6_4?(FV6P&;=EYS'ETLSZ)/DB55EE9[&TW)/9!CCJTR+V07
MDG*$2H],5G)1R[,S8&[46Z("GRR]S@?I_+\OW_+EIQEMU3:U]_<THK04..-X
M44E)SZ:T]P[5$=J^Y/.2,@$76WW&DN(04=KJ.QP+;;<RG(5@>HA7:<I![D]J
MLCSJCGKU^#3].J0ZFF[>&9MCDNPXTQ+BS%MKQ94)VS \C:Y-YF@YM1TYEW:!
M&\A:4*B[027K3"47236!-,TJ=P*10/,IH=T%,:=.W*.-+5K[LCF^*Q]5I*R6
M?(6,U)3V,+F"VRL4I#PSJZI1KI./?PM?9N%CL8E=BJ9)PDU.FX I/L9RZ9*"
MN3,\=1W:.94.I,7[:22PS!-U#@*L50<!13>KP4>N3L!DEA>N9%<Y!!,?$Q#"
M7[0#R8?D VEX-K65GTW"XV XXE.1E()0E02OY<C"TJ^IYYU><<+*UMMAL!3+
M;;O[)M9*BA"G.U:TJ4CY\\H4G'@8'&@?0/OXXXY]&ODTXXXXTTXXXXTTXXXX
MTTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXYP(@ "(B   "(B(]@  ^8B(C\@
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M[!V[!#QU;<86V]RV&)"I3W32A7,6WLK9R/4'J]<M/KIN3-3$#'+:Q^2+8Q3
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M>01_YK:/8_IJ8?!5R+?\0X^MG82JRE9C@=D$WD9-\S2]B^(<>P#Y@Z;*^0"
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M  DD@  9))X  '))/  \Z_J8Q2%,<X@4I0$QC"(    "(B(CV    $1$1
M!$1  Y@+#VT>!,^V/(=3Q'DRL7BP8LFC05UC8201<KQ3PIA2%4I2G$7;#W)5
M&?Q!L"C3WB*K7U?6()>1\]1[;S&=KU7G<3:^Y3=WG-NRL<ZH.$XG!DLTG[3+
MR2[Y)I*O_=1BJYH>MLVY7+:;F5"E!! ZA" /<QRPX:-=,'=F^9Q=35_MV3=-
MH?"L"OC9Y.4!ZQ8/9QJY(BY:5O%1_;&2=U\B1U9&PV6>-/).Y=TJFQ,BH40Y
MJ5CN*6S;0J^KK5VS;@29;T=8+;2G0I2&S(R(\=;;*?B5>NO]HVMM* "L+UZ
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M=3-Z 8WRK7@F71?D8M8MBWXM3*9C=P[)>$@FH;O]D!* F_2&W11 Q0, ]P,
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M&WKU4KMO@!CY65EY)Z67>SM!B7(^[J%#8IG^&QHN%'+R<23*Y!845/LV?P
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M[ZJ;*J]U-]07Z&FV5 3 8_Q?M*:XC>,&7-D*OZ^.JH^(4U'<[ZV2X^^P&5J
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M4('B/*D@#)X \GZ??40"H@ $DG&!C/\ #) S^I'ZZW VTR]9\;:F[+98PO\
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MB<EOQT4O%<)7&L](R1XLTVN]3*R3E45U!*=@90XE=@9,P"D4X]NX<NPW[9#
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M5*7\X4P<JIB<"_\ .$O< ^_MSV13%.4IR&*<AB@8IBB!BF*8.Y3%,'<!*("
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M _T<]MOE_P#J;;V_XJ(\G%4_-#^>G_>%Y!UT$_XN6VW])MO;_BHCRGN/T/\
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MGI';W=Y0RHI2H@ S785QC!X4P_BW#]91*A7L78^I] A4B$!,H1M2@&$&U-X
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M$/D';OS%U_2MV'NN-N1>XI:FF(D:(JO8;E1"L,5#-:%IF-6 <1ZBVQ(4GTE
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MF9>VD'KRENH^Y=P16Z=,I*JI<V?819YE!8<+DB78]\=#J/30^R&)#;OPS+@
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M8L94BJ8DT]H5R1>0.&<'V=])@E>L@.T/<VVS^[@J^20>*GBF[<C9N4RUXO\
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M-KB]PE:N"[KX*6QR35==LFHX57<$(*RH]Q[C.J/C\N_?Y_>(F[!V_2/T*/\
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3XXTTXXXXTTXXXXTTXXXXTU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g163379.jpg
<DESCRIPTION>G163379.JPG
<TEXT>
begin 644 g163379.jpg
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MPC2K37UO%N$77HP$U*.&('!*12:K 9,)'"8I0$3"!0 !$1-]T   $1$1'L
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M[1*XU3C)EL2C2MC1<+(SLG62QC^62,!'SA8J:8$D'*@/49'O^'?V'Q=#O4*
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MHDIXF'Q.00$/E\A$.5?:IZWPN"]KLBUV0?O7SZ+IQ+#CYU[A1)%[69N0+'R
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M)VPC^K&K<@=5?/\ 85)Z#^_NKM_,?6I&\CCMC5'-KP1>"QQ%335::M;O ^@
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MJIK0EF_7;J*9\49FRT%63T&L5Y@U:T+DN/1F/RFI4N;B#O?KCT([['^^*Y%
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MC&Y'ZHG/]0_V#ORIZI_U'_M5^^/EU[5D;ZG_ $J_2KSR_(/T!_5SGG!?D'Z
M_JYSRU8Z<K_WFT^SCM<3&Z>'-Z\^Z7I4L+>6S(X1AJ+,HY+)9"U\D8G;$;JP
M?I@G5PB) (M-F0$U@L$D#LI_!N)+ .4@]4C=+=;".UG3QU%TDAL$O,A[J'VA
M*ZF,](6-2LPOY :+3K\CZ2U;73>(#(14E/MC!Z#@5GI8U, 3(*AA@]#MGVJ0
M,D#('N=@/RSCYU[7IJZR]0K679O;ZI[3[/Y:VKUO6K6$S:O9%R<_HS)R9[Z%
MH=9/BS4FIL62M<E(A\YB(Q=\8@1,Y'MV#B.3343<%!R+D1N=U>=?M[.G]KKN
MA%:62.-]TLC9;I!)'!3:_+6B&)BO%#Z_/5U%[&X29-_=O'$(W;F(FY,*9'R:
MB2?F@KQP.G?Z@#^@J5#!QD'8?A.1T]<#YG^];)G''')JM4W?2 0[](G='^+'
MD4/]%O@.6":>?N2M7OY.V$?U8U;E??T@$>W2(W1_U>10?/M_G? ?V[<L$T]_
M<EZO?R=L(_JQJW('57S_ &%6.>4>G[Y/\_+WJ1O''')JM....*4XXXXI3CCC
MBE>IG8&&L\1(0%@C6DQ#2K95G(1KY$J[5VV6*)%$E4S?,!*(]C%$#D'L8ABF
M !")6M:2>++SE370Z96D76Y0;SCE  ,"9J1:%?6.R044'R7&'DS*-51#N)/(
M/(PCR9?(>;+(*8^MV*]A8],P)TN<3J=[%(@G.XH=K6(S<JJE 0 21+Y1-Z4Y
MQ[)^0F[AV[\UQKYENTKLNO&6D)D:5FH3>'TMI\9[2-S4(=]9=< YU1[:'8^H
M0V5<J7+22D N*SL;0;[MV:O6@GGG%1M50RNT1U.*+#6K[6#+L+[315X:95Q\
M.3ISQ0GF\.\GF)2V )A\<_-%5-=))=$Y5$5DR*I*$$#$434*!R'*8!$#%,40
M,40$0$! 0'MS].;&!! ((((!!!R"#N"#W!['O6NB""0000<$'8@CJ".Q%...
M.344XXXXI3CCCBE....*4XXXXI3CGI[#/1=6@)NS3CI-C#5V(DIV7>JF J32
M,B62S]^Z4,80*5-!JW54,(B  !?B(<AWA?*\7O-3*UF_%-_LT+KO8(Q)]0I6
MIOCUZQWYP<2^[EY555LNZBH2/5*HP:17B1P_<D6=KG!L5$JE5*P0 "I1Z =.
M^Y/0#;Y^@)J0DD$] ,9/;?M\_;V/I4W.:9_TLW#>'K9C"B9M=69K&Y+Q!5+@
MPEXR+>-W,A,PDN=@>KP\VP37%5F5*=6]Y'JN4DS+-U7GI@L %,GML0F*4X.8
M8S 9"RG*"R.<WU9-71>0AW?JF[^+Y@9DF5P0G[5,HJ% I?A\?GSY^_TBN8AW
M='VHGX.16,XR+L&LLY1>.BN)([2G,HRMBS34\A5+%-WD.Y<,F@ 5%NFL(%+Y
M&,8>#O%P?B.V6,RVGQ;E>8T0K)"BU';;=F27$(4VL*4IF,I@9Y"V7O%"LH 5
MSUE@19;5ZD27G$IMMG>ELLMMDB5)6^Q$:86Z'6RRA'F%2>;E=\13 8+82Z7$
M4"=$O"N-\_;;5NN9.FR0E:JMFI>0)M-RHDC&3%:B+5'A98A^NJ< ;-U8Y03B
MX-]TA2&$XD !,'V2XGZM^JXX(8S0\0#%J$6=@HDJQ-'%0(5D+-5$QT5&HM@2
M]NHD<R9T? Q#"40'GQ9>CM94H+=:E1;Y5NE#7.&L-0F!=^ M%6DU'*M2HKE4
M#TSD,J<AP(?OW,0O8._Q#ZN?3K(SREI1AVOHVF\0:V*'=BQX]D*[9%8UW+.:
MN^>,T =.@2='<QH1LBP4:-#"!6JJ"0)F]-$A>73/D#44JVN(2IE=IBSXSFR5
M)6)+\60QLV.9.4M/\RG"4EPI"<'(.08JM-Q;DA]293=VD0)$8-E39;,5F0S)
M+I=RAWJP6@QA2$H<\3(*39OQR/<M@R6]!%Y6\RY@CI^+$740I*7(TO!.'R3=
M=)!&PPR\>5*6BUC*]WC45$3F$J:R*A%4B#SK6#-L,=YCR5EG :$BBVSMKZRJ
M)\RTY$#J-H-:Y?7(03R+?F J<I'2:4&Y>$60+W9IN6S9UX.!,4.8"CD)4GE)
MR0<Y!QC;.V#OW&#V).U<%R[$@\P'7 .PVP3[9VVZ=\9%2IXXXY>JTXXXXI3C
MCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3E%VZ_[]1T>
M?S_9C<G]4;G^;EZ/*+]V/WZ?H\A^/V9W('^;\D;GE3U3OCXC_P!JMOS_ +]J
MR-'"B?\ H5^A]*O/+\@_0']7.><%^0?H#^KG/+5CIR@GKH5['T_$:PO)'#6^
MMAS11[A>K_@O8;I^TAI;<HZ\ST1&5Z(L!YP\@<L:6OW^+GT69X24(+";& 65
M653-%D(K?MS6?^D&TO8R[7O0%'#-,WJRO0ZU:\_6O+F*]'5YZK6M^HQHU<CL
M7W^;R/'.FT/".\=W^5C7D-49\%T+U$2ML;M4R&B5EDH5T.^/]_WZ;[>M61CF
M&1D9]2.O?(WVZU@'IDXW@\B;=4S9C8^,ZMNQ.;L4/X+%>$;GOGB>GX_I6(6N
M7H3*#VR7>EUZENE8M16/9T5W7+5;77^.1!KO78XI%R3!/9N33Z.61NI'FK/V
MW.8-SL'YRUVQ?:L:ZFPF/\99I29,"$S-1,?OZKG.VT&(36<.X^KW!RQ@)=0?
M)NV</5#'6:IRA7YSN0!MDG.=\C;T]#@XQU_:H5C.P(&!U.>WJ0#CTS6>^HOU
MB<4Z&9CUTUY;4>=RQF'/.3\;U%Y"QBCV&K^.Z;?[&G76]QLUG-%O8\'KAP<_
MU!7"&*ZESH+ =5JF7U>8PVZZUJ&LNS%_Q9!ZX6G*6#]<9O!M<VUSS#65LQ;X
MBF]A)@D52&,/6#1[@UJ4BBKM9"W^K)10Q#%P59/UR_$<J=8O4C+FUF.M6(?"
M55CYZ?Q[O'K=EZ[**KLX]=KC['EG/(V"1,Z6 JKD(UH/J)-"J"8XF$$R=QY6
M+OGTWMXKQL?NOB?!F-J?;=>>IAD'4[(5TS;-VI6+=8*7P=)L4LDQLU7R,UEY
M(LW"1;<:<>.46%5ZN?WH-REY52E;@#<*QD],$ CL,=2-R<J'OBLJ0@@9ZD'.
M3C< 9/4;C<X. 1[U8QU^K+7G'21W'9IST+[Q[C6"=,V9Y1BD\=MW=JKZ[55N
MT57*Y5*Y1,51 ")"90H@*8&[#VL@T]_<EZO?R=L(_JQJW*"OI"G3AU?G-'=F
M=MIFNV=UF_'V**+$UR?1M\JTB4D:I-P$3%'=5T@GC7(^U[^X(<@"L8W?R*8H
M"-^VGHB.I>KXC\QUVPD(_I'&-6Y9.=\C!SN.W0=/:J*Y>4<I)Z9R ,'?8>HS
MG?)^G>1G'''+52G'''%*<<<<4IQQQQ2G,'[)+"C@W)0!4WUV!>L2+8U>C^_N
M795D1(*P&*4YR$9]_=G.F4QR@CW*'?XAG#G!B@8HE, &*8!*8HAW 0$.P@(#
M\! 0^ @/S#G&7JW&[V>ZVH/^6-RMTV!YCP&I/@><CN1_%,=\*9?#?B<Q9=!;
M<QR+'*37)6:X"TWBU74L>:%LN,*X&-X[T;S'DY+4CP?,QU(D1_$\/D\9A:76
ML\[:@M(-4HZG]0-I2ZDG1,XKRCH(0\?'UN?1;^N\^KQ6(S.RDR"!3BE$D*90
M[PYS*@B041()DP[W-0<Y$V2)CYV"D&LI$2C5)XP?LU2+MW+=<@'3434()BCW
M*8.X=^Y1[E, " AR%VQ.BV.,V%AGL$+?'L[&NSE=/X6-0%O(1SQRHY?$<,BF
M03,]]995P@Y$W<5#"F?L0XF#V&M%G5Q8JWU=OS%I!VFH-5?L3,MD_;Q&1JR5
M4YT9:/,?Q )HA1_Y58]S* J!CD$P /-$<.'N(W#^ZL:(XB3(5TTL6(]MT?J]
M/,ER9<<A;-FG+4ZXZRZN.IUB&;@AGQ7(346-(DN/-I/H3BFGA9Q%M3VO>&5O
MN-BU<N7+N>MM#*Y'(EOMI 0Y>K24,,MO1TR4HDSVX1=\NB>Y(>C18\9:Q-;C
MCCGHJO--....*4XXXXI3CCCBE....*5X<A'L99B[C)-FUD(Z0;+,WS%Z@DZ:
M/&CA,R3ALZ;K%.BNW73,9-5%4ADU"&$ARF*(ASQ(*OP57BVD'6H6)KT*P3!%
MC$0<:RB(MFD4 *5)K'QR#9HW3*4 *4B*)"@   !V .>WXXI4>MK,L9%P;K]D
M[+&)\/R^>K[1Z\I.0&)X&1)%R]P6;.$?<L6+PS=V)%D68KNP33:KJK@@**21
MCG .?.CVSZ0?6%ZA6S&;,CUK"LQ1<49%B+!G+%].ODXZAJSZ]H09R+NA,Y*5
M:L_JRVK+N'2T>2PMXYBJL<R"+@ .0>?3AYZV8DV<'$R<U(*%081$>\E'RYA
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M[-OVLM:7V\ZR8M;T'1.@;*Y9;CI?5UQ\VM-P=NUUND6XV"!;X,D/VXKAF.\
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MF-6S=GG+#,VX:LFZ*+V^8W,I9H1<Q"E(:0?L0227CBJ@ J*IE,KX&$WB !W
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M-LJCK2EM"U92Z00-B20#+SCD6\4;>X>S#?K#CZIS7J2D0I_R2Z<!Z3*TMB$
MSAS!J' IERH#W\B&*4YB!YE#M\ E)SL%BU%8M3PE7'3]UA7>"B3(AKE07T/L
MIDQ7"V^R5()PI*@%#.SC:VWFRIIQM:NOZ@TU?]*STVS4EGN%DN"HL6:F'<HS
ML608LQI+T9X-NI2KD<;4.V4+"VEA+C:T)<<<<YJN$IQQQQ2G'''%*<<]-8K#
M#52$D['8'Z$7"P[19](OW)P(BV;(%$ZBAS#_ !!V*'S,80*'Q$.8 P%M1C78
M1:PL:FZ59R\ ^<IC$2/9)Z^B"* 1M--$Q["HU7_],  3(B) ./WN<',U+8;?
M>+7I^;=H4:]7I$ARU6UUY*94U$4!3RF6^_*">7F*2Z4N!KG+:PGG86F-0W*R
MW;44"SW"78[$Y%:N]T8C..0[>N:HHC)DO)!2V7%#&3LC*"X4A:"J3'*+MU_W
MZCH\_P"C&Y'^_$;G\/Z/C_8+T>47;KC_ ,]1T>0^'_1C<C\W?_)&Y_MW[?S\
MYH]4?ZC_ -BZX9OJ?9*NOR]@?TJ] OR#] ?U<YYP7Y!^@/ZN<\M6.G*]=\M9
M]P]CFN/&.JV\#C3QC!(W-MDEB3!U#S2SRBTL"4 C M9!K>3@A$-ZX1A.D.BU
M362F$[ HF]()&:(#85RDG8S8#K#3F0[E6]<L#Z8ZW8QKUGG86D94W+S>O.V/
M,4;7I(T:K9:[C'%ROE4Z],D]*5A1L=B&>&,<ME)>&BUUTD#P3CU^@R>H[8/3
M/\[2GKU QOOTKQ^F%COJ>89V9W!P_N_FF9V%P13:UA135W+2&)<?XHI5B"7)
M:WN0&49#5%LR?-;'7CFA(6?C54G%?13:LGL$^7]ZY*5SMNI>PG52_*[4\:;6
MX*U)RWCBP^X0L6Q&G.<2*(8O?#%R3^+4O>'<@J)VAW 2;J,&%2F:O)RB[>3?
M-/6CA9%<.47">@Z[;;C!_(_G177MT'3IL,?P5<CQQRC_ &@ZN.1<3[XKZ(X!
MU(F]C;Q6J/BN_P"1)EGD^@4%*KP64["6)CC,(^YS,2YLSV/CBN9AU&097LE[
M9$IBM?34*?@G&_;Y@8_,@8^OH!DFI2DJ.!C/N0/U_0;^@KM_T@$>W2)W1_U>
M10?_ -O@.6":>_N2]7OY.V$?U8U;E<WT@&;B"=)/<V/<2L8UDU,=0HA'+R#-
M-Z)E;= "0A6YUBJG,<0,4@$*;S$IO#R#ORQG3W]R7J]_)VPC^K&K<@$'.-]_
MV%"/A!W_ *XZJ^G<=\_O(WCCCEJK3CCCBE....*4XXXXI5<_4U<C*X-HN*BI
MF.7.6?<08P<&( '.BS=6,MF<+^'S$B85L@*"'P #!Y" #V',>VNKJ6SF G>#
MVML)1B+OJT[1GBP99LJ)*XJF=- 8TK^,\@7(D"8'*Z)Z/S IP#Q'#6S!5+ON
MKH_CA+Q?QM9=93S!:HWMYD;)0< TAZA*+%#N >E-/'::1C%[>8]BCW,/:PB8
MEH^!B9.;E7*3.,B&#J2?NECE32;LV2!W#A50YQ*4I2))F,(F$ ^'SYU418=S
ME:L3<$)<@N,Q;%)2M2FD.06;;YZ0%.H4A:4E5ZD(6M*D%'(<$*236^+CJ>\<
M.M)<!)NG9PME]M;NJ.+,*9X4>2(-XN&K/\.6Z4]$FLOQ7'&X7#FW2THDL.QW
MHKT=2FUH4KFUZF_08,50WN=ES'1$H]@;XN%);S[@(")SW50O@ >0>/AW'N ^
M0#W[W$:@ZVM]4L*0^'VUJ6N1(N7G)8TZM%%AC+J3;X[TZ0,"/7Y4B(";P*;W
M)Q. >0@'?MRLK)_6)@C4R#7QE6WB-W#(KA*?CI)JFZC QQ$2BW9R@].<HA+V
M6+%J5!,B!RQR_O3'5[)MC+=.N_6,R;:,M4S7#7K7Q>Z9MR9",YZ%KK"6;6*1
MH]3E2@"%^OIVJK:KUR$CB&]ZO'3,\VGG#8I#-X9<5T2GZ1H97#EN\3(_#ZPW
M2X79%L,B2JS6^]712;:?#D2G9#KJWV8,6&MN.)<F>N)'8=6TUXW.I2:Z=Q+^
MVSQ(XUV5O2>N^(<G6%GA3[?>(]L@:6LD8*N8CRXL-QM>G[#"DKD(9ER&EL.N
MA 4[\:"IO+<M.KMU%<=]/#4?(=YD;,R;YGN%:G:I@BFMWR:=CF[W*,%&+.>:
MM2D761B*:+LMCDI%=$C(#,6\?ZY7#Y'FG_T4NL)M]K54LTZ\%P\PV'0A8N^;
M/F;9,RN_QA,U>N,V2$]D$D [?U&S?6AK ]??:!FS<))'<.Y _LC*)' I;WLD
M=&W.-T7RSL/G^Z5/:7/]^AF<4G6K94(B_P #"QYI,RQ*YC,MZ39,\6P+(KQP
MZ7"O-C+*JMT@ 3AXF)X&"]!JA@^JY\RSN=BMQCNJU'&"DJCDN,692)8>+B$U
M&J[1[!09W#^;%@B+56,9F!5$A4_3%("@!B[MB<:+388B="6KA#J/5TK403*G
MW34JS8+:JYL% L[,&19EW:3"@Q2+FVXJ<[ GRGY#"BW&B2EMM^6[C.UO<]46
MIJUV6?!;=0ZU"+R4E(+YY0B8MEFX1T/RU-)0AIQ(\%?@I_$ ^J#O2AZKFQ\A
MOM;<@[B2=F@, []J/G&,H2>G):6I^O-LKSYP7'E83%XDRCZ["6VM&4C#RJC9
MA]:2"<*99H+M=RJ39CR-,:.RN<1+D-[1WEWD,;N9MR]D%XMS67$(5\=F=5X[
M2542^TB14_-N502KBP,FJEY&$!#74UQO72)R[FC'V,(O9W(=]D<BR;BG1E2>
M8MFZVG+O;)&/XQFDTL$<LN^K[YLJY(\CI=H0%HYTV0<E50\!53H^A.J#@_ >
M:4(:OXZR#E+'6+,BOX=B^R*^C;%-VZLUNP/(XX6%&5>'&5=.VS=1+R?N"J+'
M!%=82J!VYU#4]HXQ<4HK+[O!:QS+E N<9+EB;AQ[C"CVN.N3]T7!25RS";=B
MPBS8D+\QYZ8("ISC"ENR%'DH^I^,/")B*NXQ7[+-O,R9&\Y'NLB+--JD.-/3
MFW%0UM^-'4XLX2V]S)6V IK"F*W,)/8FGXBLHM-1<@7[,S8ZY =8CC*G+V>!
M;%,J(BC"3RJT62+2,;LBF5LTD"$ WEYJ=NPTC=1^WS&U^VL5=C15HPQ;\1X_
M/CS*N+6DLUG5Y6TKKFG:::SN3,$/L^YCV#@2G@RMUW#UHX!RJ\:&("8S!V3^
MDC:]:]Z_/*]0-9LXX1V;O-5:)X#Q9EW%32I5=V]M#0B$-D=Y*5MY/M%\=5M=
MRE*2:[=LM)N46Q6R<4<3G*6#.5]IM%M%M),;4B@9/H>WNU&:[.[V#V5V386
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M*6)ZJRJM=GL>0L"O!7T&RJI$9.13>33%Y")JB;UC*MF<@9=#NJ"!3? :\']
MZT9T];=0JU%,FZ*O:[E;[6]!D,>*Q)MEU<CNR[U&FLS/N%FX++DI3[CS2UKD
M-*>E$K2I7=_MM\1>%6F+M"T#9>#.B9'$71LJT/W2?>+4R;=)AR])VV:6K:QI
MJ]VF;>W(+,JW,&+J"WNQ41T%Z-"/P+JUCJ':E[F3E>K&5\F.:=?E()C:)&U_
MD]@D8&(H<'%,D)!W+STP_=(GD&JK9-P(+*IIF1]J?[QC* 4/.Z961:MIN\E)
M#96J26/ZQG.%AI[%N8Y6)&1J$K',VON%(U"<8%>$*C(-G#=^U6;>L"GF8KD$
M$S)'4UK>K=])<S9MGK$;#&/ZUC?%=)S,Y>Q-\IL/(WJ4RNTK%?D&,DBQM<G8
M*A68*(96!XFU "U&0G%7!(]VR>.&[58X.8-:9]32$?ZM(8WV9VVRA"-\+7J
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MWW..=)QQ98ZWT6J6&+GDK,UDH*-6&=223;_63DK1)-XY5:IF,5FX4=%5.NS
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M^F:E1)2DDYZ >V,C&.F,8QZ8VZU(WCCCEJI3CCCBE....*4X^7'.!$"@)C"
M  "(B/P   .XB(_@ !\1XI5<]!\+_P!2O.5H1$2M\&X!Q]BA9,QA,4\I?YI[
M?!<IE[]BJ R:E0.8H /@!2F'Y"./^M+L$;7#I]9>N+-G,2-@LCNK8ZJD?%(+
M';O;'=9UI$L$)YVB &CJ^('6-)N@43.=,I6B(F6<D(;OV@OG;K)N%F5\F*DA
M>MF;35V+\H@*+ZIXSCHZOUQ9!0!$%$B&6D$0, B4#)F OXARLKKM9VF;_;<#
M:#XW42<NIJ:@MBMB7A$$WB-:Q+0[$V)48*2$!,=BZR#="HQS/N4C@R;0AB *
M#@QPX?346#,LMZN-WC-R[*W#U?JF]-ONNQF'[#;T7*>4OO-+2\E$BUQHL1M+
M;C;DAQUF,RI"WF\=Z^TK*;M$^=8E?@TCP]T9HY# *E?^;Q-&6I%Z92IK_,*'
M-53+P[S <[3+A*@/"56D?LONYG@^0[ECND/?LM#5"XNF3-]!Q2Y)]T2%*I%N
MT';QT+ENXCW3\%W@%28I>8 V+ZIB)B4V_;]'PBL%63I\XTSCCK'25>RSD<)2
M.V#O4M$')<+[E*K2;B-LTB[G7A#OGU?,_(=:"9(+DBF""@I-&B)@. V<X_U3
MP#7JI3F[["6)7UAB:? 03^=>8\J3J9>F81K5!<7DHM$G>.CJKI&56.LLH954
M14.8QA[\D# 5ROU2+0A*Q!Q%=AFHG%M$P<:SB8UN*IQ.H*#%BB@V2%0XB<XD
M2+Y&$3&[B(CSOS,[0,'0ECT]I/A]%TG>68EK%YO<9Z,J==U-04)GLW)YN$W,
MEHDW!#<XM/2U1FY#27$1TK2E0\^:+T$C2[Z)JGXLAQ4 1R!"+;[;B_ 6XL2#
M(<ZEM2%#P\D'\8&0?UF)N&KK!:5GY:-A(MN) 7D99\VCF*(J& B8*NG:J*!!
M.<0*0#' 3&$ #N/();L[E:S8@P%<OMG-US++V_QKS'50PO3Y*,M=QRQ9[<U7
MAXVG0=?C5W;I87ZS@ >2!TB-(MN4SE9=-0$"GZ#UC==PV2Z>FP57;6=Y3YRB
MU5YF.M3;:5?139.8Q@P?V,[*3.P60.\8RL,E+QB;)P<6II)W'N52"+4@AK)_
M1U=,86_Q^9-\]DI!XTQMCNMV"B8RGK7*OBMX67?Q1SWR_1$D^4[,GM79*I1$
M9*L%4W[*8*\!JH50Y -CM5NA.PUW&1)?YHLE#9B,- N/*44>"AMSGYN9U:N7
M"$<PQL4G"AZ T]9;0_;';]/G2@JW36T*MT9I*7)"R6C%;:D>+XH7(<5R?Y3)
M6D)44J20%CW73B^CX[".<^73(>RYKIK!7:>S86+$#W&=OA'%G<3UM]V[&/83
M,=(/).%-1HEP$1*+J@W<N'SH4F:YTT%1'$^WW09JFIVR%PS=7,QXDK&M6)<:
MKY_=V;.4M7YU^6_5=9*3-0+11"F5G;%'72:3,=F\:P;]%1&0;-3&<2!Q3Y-;
M1RD;ZVG.MGR[@>2MV5J!BR:EEZ7^7&^7. IMTCYT))G6'PQ[Z=C59A-6*6]^
M'=4[-,%&[M8_GZ:B>LQ-;;L\RR3\+/:KIE[-,KF#\EZ4/-1:MSM=HOR5O]>/
MBV-<<(/H^:A$'I&Z+=(C->)2:%1(J4JG?ON*+:KFS=+A':U_9;4EBW,R7F@E
M#7(HA3BD2(CEUC26O*MEMUU]]UUIH/J;+. 0>ZW=3SUS>%RNFF9"(\%3K$*;
M:8DM$1T\CCN&9<IR9'=6A+3J%NN.,N!:D%GD;2#LEZ#;&0=MV*=;O]9/#,KA
MR[9LQW4Z1I.G<Z O,ZLXPP*X11*9O6% :3+:AW6_OVQ9N:?WQ"(>H0?LVZ2[
M% ZK8U=W5,TIR1U",R0F7>GAJ?@;'NKT0%JIU4N4!-X+P&YS79(:;]K9L@N(
MVR6"DOIR",^[Q\!*(,U6BS4BS@[I0ZA5.7)9+N&_742KM@T<)C#"AH+%<?0?
MR^R-;.F2$]VE&MU Q:ZL$B]?PT5-K(@HC8(VG"SG($Q#MT7<84I2FJ0W;UGN
MFK>1(;'MEID-C.OK5TD_3L952^V>\TZDQ;U<4G[:MK6F>L,G%-Y203,^?L2N
MP;>Y[JII)AW >BZ/NK^F]26>XV[5.DK6TN8Y;7!/U!&N=CN]TN")5N895!A7
MFU23)8EJ2EB(B:\X[-=;<0E+<-R/)RO<(]-WVR/V"^+%NU?=[?&F(8@OQ9TZ
MTV=AR!=6)T"&^VWX4W4D<L^&V#(8CV<2>5"7;G$+& =?GUINZM(Q<>$CZQ=$
M%U*'()2UDB(>.C+14R+1CU,L](NT80&QW<:;ZND22BC%\HHW.R=."+)&-X<S
M+WVG9JRX\O\ 0ZP\=;$Y'FY6_P!D5=N&4A+V*0K;6JLV;M@JD$4FR9DCFD:[
M8-UB'$D@I+HI&;N#+GZ>WCVY6Y#F  /V%0J?W2)D 1 "B %']L4![B;\X_,!
M >3KV%QA$T#)4Y1B'DY^$B4*J_9.[,4)1ZJM+5.#D5EUG"R9BKK$.Z.@@X*(
MG%JBBD8P@D'/%_&6^\'C(O;G"VSS[8W N;-HU/ CF9_AZ^S%.761&U!:9$B[
M39@;@3(DEN.U(1'3)B28DDK6XRI(]]6KAE(^V?I%W@CQNU*+U>=,Z;E:CT%K
M1NW-VF[6"Y1&;5IZ4S+CV5R#"ND%YZ;:;JY ="FS-MRDI>>;6P[%N\Z%D]1\
M<:UZYU^AG^KZ#E2K6ZNOZ^K*NY8]&S?CZT2K:ST]RLZ6669K'9@0[-DL9/\
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M9S'_ *ALM_5_[$>ZDFQ97Q)C[W(9[&/BI,#E9^2'Y-@5%#Q,YNOAZG<WA?\
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M^4SC_!&[)F+X^(''@=8WQ,M%VNKC*E1V(CPBP@ M7EF&U^7BA.,+=?/_ *F
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M!K%M$6+8 *5/L7LDW(( 7L!1^7X<\OM<#%7*3($W4CR9?AQYEP<3 #C?WA<
MX](CH"I8!4SRAQ3QW<3(;RA 3A7H&;Q6;LVEK#=8UA9*[I<;U MD=<Q:"+!8
M46V-$FKPPHYE3GYL9+?*E+:K<\0XX5X;ZGA:.?1.(L8QDFU68R+"A51F^9N"
M@5=J[;PK1-=NL4!-XJI* 8AP[CV, AW'F3>..>EHS(C1V(Z5%089:9"B "H-
M(2@*(&P)"<D#;)VKRX\Z7GGGB DO.N.E()(!<65D G<@$X!._K7 _+] @/\
M, @(\T'>H-6+.CN_M"8]4M9R.<PSSQLLA5IYZW<-G+2+.W=-W+.-<-G"2Q2B
M*9T%3@8 $/(! 0YOQ\]>K$QBZIEEH]BJL80,991FV45$P=NQA4.D8XF#L'81
M$1#L'Q^'.F:ZT/&US!A0I,Z1 3"EJEH<CMMN%:E,K:*%!S   5D$'((Z&NXZ
M'UH]HF=-FLP&IYF1!$4VZ\M@( ?;>YTJ0A>2>3E(*>^<[8.J-@/5W(6W73"K
M<C1MB8*RT^B,K7)L,0M*H1X^JUMJKR1&3JCV8,_)(QLZB4IW'M5HM%8BQTD_
M1$IA.6G3:&K7JTXFUDV7+4;?E.,Q/,7_ %TRC!4&JK.[1A^,<UQN[J=GM+QH
M"KNX1#51-=5U'';)GKYG"ZB2ZZQ12'93VIQ7?>E]L%/=0S6*JR=BU=R:^;#O
M]KC5&JCE%D@)RMR[+8ZK+<HI)6* 24$]X812*:LI& HY.BZ)YII^ITLM^/,7
M;Y6>MX\L$):M:=W<>IYDP786+XCBK22RYAF5H^';B"K=Q*%77D(J5*X!-TB^
M1,P41*HW$H?/?N'C?#6[<-M;Z/O%T<LTE^#IV5>7ILTR8%U#3"HMONC+<SP8
MRV;BRE#<=*DVV7#F0I;<<@.L,["L'$>YZITY>E2(4#_%'"R^3];6BV"-&+-Q
MT#K";;+=K:"T!%"[@U$O430^I'5.H5(AVZUZO>7):RM]VL'H$T>[3G4!O&0H
MBJ3<=CJDZ[,(&T6YTHZ0C9^UVN4E9!A$)0[M!LZCEX9L9!0QW2(+N2N"G$B8
M!V'=5Y1/E5^MHSU/*1DE!7ZJP7NFV956^$,]EBPT+DJ)3/',YM9FBT/')*O#
M+1GMT_4,!4BJ"1-(3&-R]@![_P!OQ_'FWM1-..W)Z^*><?:U,HWI"G%K<5'>
M>"6)UO#CBUN%J!.CR(\1"E89@IB--!+"&DCHG$%XW*YV^_M-H;@WNS6YV(EH
M("&50HS<"5$5X:$)4_%?8*7W"GQ'U+$EY2WGUK4XXXYP5="IQQQQ2G.DY,C7
MTQCB_P 1%B<)*4I5ICH\4_V_O7L&^;-0)\2_>%=1,"_>#XC\P^?.[<B+O3L,
MVU@U?REE4BJ86%E!*P=):F31<"\NMB$(>MI"T562,Y;I23M%R^(B"BB;)%=7
MTQ*0PAE8B/7!]F#'25OS74164@9*G9"@T@;[8YEC). !DD@9-?;;H;]PGPH,
M5'/(ERF([*3G!<=<2A/,1DA()RM7_"D$]J^;<A5<E!B>*PK!X.RA/9NDJ^[P
MRGCNJMW\Q)1EO:KOJC(7&8M31F$='031-H>T.E%'(NR*.V3$6XD6]R%ZNK^M
M&P>YNT#Z$)GP7MPP;2(V.+G:8HPRS1"8KJ,=$1$@E5G4J5$RR4?',8I%D61\
MRMIEV^]8QO53Y>QB2F(Z =+2Q7BS(@RRQ*46<R+:9MT@1682REE<&[&#*[6>
ME%9!:"4D:_%R)2&!(#1;IR =SG.-9F",HY"U0UMI&#=9H-K<^I1U!7;NT42$
M<))OVV%L6O%%6H9MR<HLB=*%JE,C%'#V.3DTBISL@U9MFK)\5(S=7K6LX%WX
MB\2]$:'A3Q<K79(4.9*>G%:XS%DTDT]%3=[K)E.2$)A7-]^>_<'7D^)X*DE]
MV1Y:.EGT+KGB$+;PGU<(S##"-8ZKM_#NWRHT:*'+KI_2LFVZUUXM#2([86Y=
MKPUPTL:H3*A!EVN[2F5PV2I7BZ\77BQUGN1W#B<3S^9)7=')&)\8P3;(%OHF
M*I*/5H;F?DY20A*!/)PKNR%4>,&*@S:(*N4 ;!8E&H)@X*Y3)N!_1N2NX_I>
M8RK$KBNTXML%4N-^AY]*TP;J#7MTA]H'#LMI9)/R(R"[9RT<-V*IG;9$473%
M=NW!1LFBH:PW1W1W'&EV&6U!C5!ON1[3).;QG#,EH0))77,&59T2N;-<[)+/
MBN'RX+O#'0AV"BQD(F+2;,VY"^!Q--E%!%NF"2"22*11$0313(D0!$>XB!$R
ME* B/Q'L =Q^(_'F^M7Z^M=TTO"T5;;2%1[/,:?8U IUN*N>ZVTZU*DBTLQ&
MT169CCJELLJDK4RPED.)+J?@\K,L7>5?)^H[G<09-VC,L2+;'C,,1([$?P1"
MCME@-M<L1MD AF.RVMY;KH&5$J_7CCCFI:Y>G'''%*<<<<4IQQQQ2H-=2K%*
M^:=%-G:"R5,A)OL4666B'!" =5O*UEH:P,542]A'UBK1P>EV[#YB4 $._?GS
M]<+8/OSO3VHXO3NH-\K22S:?8WA9A-EKM?DW]S9OGC*0LZ<:#-..CH]TZ;3R
MX.B+B0Z[<Q!\.QOIO3$6SFXJ2AI%$CB/EF#R,?-S@!B+LW[=1HY2. ]P$JB*
MQRB @/P'E%O2PQ=7;=K9MMIUD:%078XOS[E/',NW5;(G<,6UO67LK(S13P]4
MJK%LYCG"!3& @JMR$$#)F.4VN]8P[G-NU@AVZXN6PS7'Y(=;;"DOW*PQI4NU
MQY:N8*\FXS-NB7TI"EJ;4H)!!6E789MNNEZT B99M17"PWKASKJU:MLIB>'X
M:IEVB^5:F/*)\=M-ON-AM0*F,$^<P3S<E0LH^2)_&V=>G'><@2#9&ZZ^Y=N6
MCN8I%L\.Z:2%,S# DG\86)-V8"&>0\@](U0C5!,HBFBJW33*501#FUH7]J'Y
MP^ _I#X#_O#FBMOI!Y7UTG[OC*XO"2]IHK>GS]2LBI7"*UF;X>GFUQQM;Q%-
M$#/)EG$-E8MS(J 990# S !1;I@&ZWA/(;#+6(,8Y.C7+=VRO]"J=O27;" H
MF-/0;*1<$+V   47:ZZ)R@'W3IF#YASL^D;NF[Z5M[#G.BX:9E3=,W".^HJE
M,)B+3*MQD$G*UJBR5L+? #;\B))<;*ADUM/C&N'J>!HGBO:8[<2W<2+;<;G.
MM[0 ;L.L(]P=3KG392"0S]UZM<O*X#.R389=FD->(U(2ZK*''''.=K1=.<"'
M<! ?D("']/.>.*52-CX2:V];[-5.5080U,Z@&LU/R[!+K./\<L6:M>GJM+N+
M-FD'@F HX_EX-XL00.NH"/F ^FF/:[GE'_6235PM+Z,;YQ9&K);53:>I0N0Y
MLR"CAXGA//(EQI=8\A$P,;VRLO(UQXX,!/%,K7U#C]T#!=PT<MWK5N\:*D7:
MND$G+99,WDFLW73*JBJ0WXD42.0Y1_$I@'G<-2I\Y:]*WU.5&9:39IB\' N&
MFUI@(05'.5?<CED<(*B07"<)04)'%6\AJ1<H1/\ Z,KS;2?ASY>X R"K .0G
MS@FH!(&>3N02?(Y1=NN'_/4='D?Q^S&Y ?(?E^2-S^/?M\?S?S\O1Y1=NN _
MLU'1Y'\/LQN0'\_Y(W/]A_FYTT]4?ZC_ -BZYEO\1Z?@5UZ=#_/UVJ] OR#]
M ?U<YYP7Y!^@/ZN<\M6.G'''%*<<<<4I\N4@;7]:VDZP;+W+#']SUE')6+L&
MRF$X+:'8&J2%=2I^#YO8.4+$XZCG\0]>)S=@5*JH@[L8Q390L,R<)+.#ID[J
M<N^$.X"'YP$/Z0YJ/[\]/_>BU['[WX9PC@1'(F"^IGD/4*_R^P:]X@(2,P,&
M%I"/0RC'6FMO3C-RAGD)%(JU,T,(^N^<""I#%(8A:*)&,=_V_?T'<C%70$D_
M%CY$D;=^F^W]S@XJ5?7HVIJUEUKSEH?6*U-SF2\QXKK4G#69%U&MZC#-96P,
MI)@O*K*J'?'(NUC%3I@V0[*>HGXJAV-R8G3?W^P?D_!]6QC-R;+$]FP-C/#=
M"F4,DVBJ0"=F=LJ.VA'4K6!<RJ)GT:B_KSDBI^WJ)E<LQ4(0RW@6OGJ.]-?9
M;(.T#K+& \<#D2 L.*\;U*6<O;Y%0AFDI0X]6$3*WCYD3^W27CRH+'!J)6QU
MO(?3*<QC#$'6'H_;!77=^GL-R<*2D5K6YPE='TB,-<8IZT3R#'3$6WK[1],0
M)2/D7;EJ[<K-V9E!141064[? >:I9U%K]6O)5H^XVCI=#LA,>XO1)44.\D1+
MC8,X*D-@>.2A"Q&PZ $Y"CFO;4K0/V4V_LU675:];3&>-,B-;#=K';+LW=YD
M9YR_*9F*1IJ4_:X^UK^)Q/GT%AM7F4AQ2 E=QF4.MS@;'V2+50(7&U]R&QJL
MZZKZUVJDI5UZM).V/B1TXC'7O5CNV22XG;^X1!0#JI' I1  $?44SKGX%LMT
M@:K-XKR12H^>G&4"G;9Z0JY(!FYD .#9R^6!XD=NQ.J0$3.%?3\#J$\B]C!R
MIW)'2$VVQ_DJ\5?"V'6UGP\E;IIS09D]^KK-TA59!T9Y'LW+"0!-ZHX8 L=H
M=1=4RRY4BJJ*&,;X>DKG2)W1OMRJU9R+AAG6L=+VJ'6MTX;(%9=JGKC)4SIX
MFBQ:E5=%7<&310)Z1A4)Y"<AR]AYT]S6?&!.H%PT:7;5:DW-49+_ -T32%0D
MS0T'Q*#X226-_%\'D*3XH:Y<5N^)P?\ L#KX21;[(XE*3K9>B69[\,ZO0BY)
MU0K3B93D,V$*6RAX73FS $E3*9.('GBD@FU%#KZ8/6%%P; ^8D8E5!N[^M%'
M55!--FX*D<%SH>]]0OI)J>:I1$ *4AOOCV$0MYA=FM?IN&B)I'-.*&R,Q%QT
MJBW=9(I:3I%&29H/4DG"1IL#)K$37*54@AW*<#!^'-.=+IA=0A>02QRYUY6)
M(&K#59W:BW:KC602$48YR8C\R/M?K$515<%BR)"J5$0/X F'W;Y*ST)-"R5F
MN)V+'5@/8DJ_"I3JJ-TFBI+3:44U2EER%3<>D4B\@5RL!$@!$@'\$BE3 @!W
M'0>HN(5W-S&I;!&A>!Y7R7B-RK6'4N%[Q59<1-\8I"6\I!:+>1E)*MM(_:.T
M!]DK2HT?_P#2/7UXNAGMW9>H/N9Z+K'RRVONXP6Y F72R>0SXLOP_#,H2>5?
M,I/@@J[;L;UC<#8$R9*8UB*?:,R+PS&,<R-DQO.U.1K:3J30,Y+&IR!I%1)9
MXU1]([LI#]D?63#L)O( QF?KM:[?9%.:;8TR.[M83*L:\QXF\K1;(Q8D8I/$
MYQ43O00-&+F63:)J%* BY$Q!$ +W&MS9?H[YWQOF:W,M1</$M>$9=*'EZZ1]
MD"&CG\/)J1Q&TY&N#393/G9!=MB.4G"JAP[.!3()2)]N0?:=*7J1MM@Y:2_(
M"HM"O,7IKBE]M*BC#)RA)B/;I,T[ +< 7EC)@[648BKXE;$!40^!._6[EJ_B
MPS=[[&B::85 A^;-L>-MF/"26GF4,MB0EYM,@+0M:@I++'BA',E20#6SM*<*
MOL,3-#\,+C?.(\IO4EXE6AK6L:1J)%OE0([]NN;LYZ;:VUR6[.E,MJ"E[P)<
MXQE.(93S^(I:;_(SKP:[N8>8=S6+\F5R<;)-CU^K2#JM*2ML.JY*@[1B#(O?
M1]2.2.1V\]03 1 1,'Q#XU84;,V,=L>LEA#9C,#<U*Q-!&DGF.:Y;G\*D6,R
MO'U1&$H[^U/5U4XY%G%I-I.7C#M' ';V)2/.H*@$.)L<GZ.>]=J.A=)+%D;7
M)V@F47KU:4OE6?'MIIE5%G((A(IH')&"P8I&<)G.8ON#'(G\#%\@RK@[H_;.
MY#S%C>*V0PVC4<+QMG3F[L^:9$@Y)\\CF+!X"<8V1B2E>IJ/G2J*/N$3D.@G
MY*%,!BAWQ6G6G%]-]TG*<T\(R ])\^ZBT2$B(FZLWC3DK*W'W SR6FX.OM.C
MF7'?6W*"^5"$CG[]H;[%&G.'_P!H:/HWB&U,ODW3C]HT;'=U>X7+RW;[-HS6
ML"+#+;*S,;EZXM'E99=9:\RVS+M!9,<%;EWFZG5GUWT]F,=5%5O(YGM64&%D
M=PT/B:?J4VO'-X!Q$,EUY8XR_@W]PO-("U3+Y**@@X$"#X@'*RM7.MCJYKI@
MVWT*Z5^].<E4*Y+KS4"DXK24G=IF_P!OE4$'-:3=22!UDDE4#%<"[*13P2%0
MOF!@ (9;*=&C8FO]0"WV'5O$,U8M<*!BVE+T:'F;; Q[:7O=N-*HVI1E8;&@
MX?F-7B1+15PR(L0@JR+5;M]PH<B]G?Z/?O;EZK9BS73*G&X^SRLOCQ[C:@2U
MWJTE&NY*"DC&LKQ:79MR-6HOF":1T2NC& KPZRI )ZG;FV8ESLZM:VL:AL&I
M&H]KMS\4WNT-&X0G)%TO%HESHIC+;BJ0@6*W^73<6W741YCCX\-YSECI_*ZW
M2H+^MX4.X:;EJM\73,]#5W^\E-0G[K+E1II#RUH82RH183=O;;;<2@NN**E%
M2@ZF[.4^D;X?&">KPFL>;QL)DW:$5'RKNH$9D?>V5&.=RRK66%1.',]] KX[
M4RCQ-J*IT4C*%* ]JZ&$MA62Q)F79*QY&J\GG7+F:;ZRR?+6*PP+67CWD/..
M%#Q28NW:+L$73EP9\X.J4#+JF('[5(H!K%I=(3KIDM[RQJZOTX]><48E<:55
M/,E$ 6ET*R*M]M#N#G,8[#ZT.LD,<53U3,?3*8?4(*@S2Z0'T=;)M9RIG2H=
M2>DWEQ65*;2[G2Y:E97GH>KN,AVY=T_NK!HZK#]J,@]A0%)F[6="H!C#]T3=
M@,&[=9731]MM(M>A"^])NTTHNCDKSG(J%:_B;9#[C:@TS*E2&I*/P^.(F%()
M0DIV1)E:98MTV#:U2X[,Q;29TD*2[(6B(X#'0TPZ\V7692G''7N1:0SX+86G
M+B4G:BW^ZG^L73QU\D-A\KV5"V5UI8X>J-*[C^8@)VSRDU.(R"S%NS8)R(]R
M"6.6]98_9-$HE.H8I.XAJ]=*7J<:Q=23KN9^VHLY)K'RB>NL%2M9ZID-]%(I
MU>K46,;K9'L<V_.X^JHQW*.UU))-)HZ\6H*N3JG, ^?),=7#Z,UB[)NIRT-H
M%5K6GG^-OU;G&C/(.8[1,5^6K#-E-H34;Z=HDG4:T?*J.F!VCSTRKIF3,4JA
M4CJE-49TB?HMVW]8V75N.]]1_)CB6/I%OC&2E%R9&NK2XM,HR1;0;U,:^Y63
M5C6:@KKN8Z0]5E(>!$'K<Z)A(.FI9DO,24O!:GT28"V(C;*EQE+:>8?91XYB
M*4MIY]&)3WQIB(!40@()7PUM3:47& A4AQBUR$R&+C<E!HW"/%>2IF8^U 3.
M2A;T:,M2XD8NH5.<RT%GG ;V8Z]N/@S>+JSX2K-1LS5?'VK%&RQ/TV=D7B48
MRR)F&=3C:PH:I>[%()AE&UQW)E:D3]5R^,@X>L4S-B**$V#@<-P  ]9+L
M??+\>WP_/S2SU ^CCR:6Z.>4MC;%DI+!F/BL&V/;%5;-*5A3*#6S)+KE2K4Q
M'.DI*JIPR!"FLKA@9.13DU$V40Z:LQ<^K<1_>\W3Q_A=I?A_^K?.?Z/^M?\
MOYATV+H6)SUTCAF3*GN/J4$!OF_R6& V&RXM0;C)93';=*SYA+7C)2$K2I??
MN-#FC$W/2]LT/=57"S6/2[%J;0E\3FV?_,KC<1*5.2U%0Y+O"[B[=IL1$='W
M8]*\DZ4OMO1HMXON4/X9/_;+_P ><>Y;_P .E_ME_P"/*.3?1YNGGV'Q6VF
M>P]O_.VSD/Q[?#YVK\_\?(-ZQ] _$TWLAO9"9[:[4-L(5;*V.F>H[DVT6862
M;S'DAC=L_NITG[.T%>2I4;N9= 590RKAKX @DIZ??OV/F.P(P3T! WQ\EG^"
MM-  @G)&,;8ZYZ]QT_M6U5[EO_#I?[9?^/'N6_\ #)?G_;E^7Y_GRCO^]YNG
ME_";2?+M^ZVSE_XJ_P!_SX'Z//T\NP_X3:0?Q[?W6V<OCV_#_I5\A^0@'&5>
MA_(?_P!_S!]LQMMN1Z[9QT]Q[_TZYVNY?HQ4JR>1LBDQ?L'[5=D^8O$T731X
MS=HG0<M7;98#I+MG*"ATED52F352.8ABB41#FGYNAJUD;IG[-8DOF!'C1YJ3
M-Y5F,M8QJ1W22\UK_E9NHA-Y!H571='%13&&08M=_*QL0508^'LBI3JMO$I%
M!R_J;T"\63F:]W(_8Q':EMBJNYU:1>J2I]I<P,BN\1C663APX3<,+*DY?_\
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M@K8$Y'[:W/4+JUK7G78VP1ZLK#83Q7=<F2$:W,5-:00J4&[E?9$4, @F+E1
MB0J"4W@4QC>(B !R0/,%;/8(KVT&N^;-=[8[<,*YFK&-QQK,/FH>3ADRML*Z
MB3O$B=R^H9J9P1?TO(@J@04P.03>07/\_AVJHZCIU[]/KCM6L'TJNO)N1LON
M%K/@/;W%&%:[2-W=?K-G77V9Q,2PMYFOM8"RW2&)#6_Z[E9%%Z*Z%!G1$6Z+
M90!48.@/Z:QVZ>W@';\ #X_Q=N:D?2AZ"NUNK^X&%,_[>YCQ9<:?I-A6Q:^Z
MKP6,6,FE)6*LSEDO$X%OO9I!) L5(I$O<TD,81245,F:-;>_*FP,*^V[\N5
MQGJ1MC.21MONK?'3VR#\S*L;=,XWQL.GL3WSW.V.^:];,RC2$B)29D%DV["(
MCGLF]<*B()H-&#95VX64[ (^":21CF[ (]@'L CS6$Z//6(VCZC&RUCK5ZN>
MEU<Q;%OLJ@QQ!6?MI'[(J0=6EWL359QLVF9YS#R+-044'5@.VC^Z+43JIE0
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M?1B)(")QY%"NCG6 B9";,%7K[.J5NOUB.$PQ]<A(F!8^8 !O9P\<VC6OD ?
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M$I"AT7;#I%;8;(Y8G,:N<Y8D-IED#,>ON9K),2V/R&V8IA\!FK;M&E5"ZM@
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M&Q3OOOGYGWZY-27%'J<G(/-_Q#&^Q^>_KD#>IQ:QZ38?U7FL@V^ER61[G?\
M*):\VNN1<MWR7R)=I:*J;51E6H()N7[*M82%;JJ@QCD"E2(HJJL83**&'DO^
M..6  & ,"JDE1R22?4^U....344XXXXI3CCCBE....*4XXXXI3CCCBE....*
#5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g251911.jpg
<DESCRIPTION>G251911.JPG
<TEXT>
begin 644 g251911.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!#1$E32S$Q-#I;,3A:0D,Q+C$X6D)#
M-S8W,#$N3U544%5473DV-C=?,5]&24=54D5?-4%?1E!/7S1#7U!(5"Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" $? F@# 2(  A$! Q$!_\0 'P !  (" @,! 0            @)
M!PH%!@$""P0#_\0 5Q    8" 0(#! ,+" <% PT  0(#! 4&  <("1$2$Q0*
M%2$Q%B)Y%Q@C-CE1<H&1LK@D,D%A<:&U\!DE)EB8L=8:,Y6VP2@W@C0X0T1%
M2&)V=Y:ET?'_Q  = 0$  @(# 0$              0(&!P,%" 0)_\0 1A$
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M,4IC&,4IC,,FY$:-+M4-'#M:C!N R .@UH-@9?346PE\P'(5_P ?K_3BD K
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M*8QC%*8QC%*9ZF^0?I$_?+GMGJ;Y!^D3]\N*51[T,?Q$ZDGVPG/#O_X_1_\
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MB]);RKU^>VUM>[,RUIN/;AH>4CD8QO4*0PK>DTEIJMRMI>R2\M]+[84*N$7
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M*@MJ\QH#GURJ@3&\)+SIOCELI%,1$/./%J[ UV[6*'R$4R0#)(Y@ 1^L0#"
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MCA5K8%8R,K\B]D$X-R@Y9K-Y@[1!8L6NB[:JHOA;JIN$#D*J3%-7Y=<;+IR
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M8EQG8X)?0^V6D@$E:RL (P.2',["D?$%$>M?;;I4B%/B2HI"7V'VUMY^$G<
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MK383*/07=/W='MS5DV:I&7<N';BNR2+9!NB0#'5767.FFBF0HF44,4A0$3
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MNCL;%()Q<9(2-:L$<S*8PM44[A7'P*%-X7,:>5*V(#I%'Q_3)4 #$,40 0,
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M#^UD[*!=02]/V ,U"Z-R)A]\T0'(T'RB^I<'+]ROR1MQ5_&*+4#^XS(^$#O
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MG7B99V\3+N*\K^@EFB@EBHGQ%U& .R2Y/"H9^EY:,>'C(NFJ8"^+(\9[+1S
ME(:(M%EV/I2,V,SK$Y'FKT;L>[/**$C+$4%K[Q.&NFJ[X8\3IHJN$V1P4!)0
MR E!8HH]SK*P_AKM=CL,326L.HI>C7NQ0)1L]I]IRC8VW'&)ZY:=0V*WQD1D
MQ4!3DN(MZ>AQ,8L1)"7'15],:BZP:FU7JN^Z_P!+=+F?:\&_7QI,Z_7>U0_T
MDG2X<QEB(G3ERODE14^],2F'+3&@".J6HW%#K$!I_NCCVJ7E1.WBE2U(TAQB
M6TW)1J3B<6F5]O\ TK<GDO)!-XQ=H/46<<G"^4X,JT&)D_>Q7!/"Z8F;F!5?
M?:H^5<H:IOM,:(XWC#^]5SVU._I[>3E'+!DHNV4BXQ!C)QZ48H\.9-RA-*&E
M?+3;"F:+.5T0Y.I:R]E\YK2%IIQ;3=N+.FM71)6K&8JT7-;-VY9/0QI5^ZK1
MZC&4"/<'FEBI *'G,@C6RPG.H[<)JI*9NLWLH&QHI.M1>G.4FGZK7VCY\K8F
MMFU+L:<?.$Y%TH\</(]RWV4@11RDJ8"),5TVB1R+*'._("**0]39G.@2;OT[
M]I0^JBHC.DYK>L%2)5I%M_2 1VPS[;9AJ-RES5R%2U1Y&EGFK4VH6X/)=9\X
M&?NO".H(M'446Z3T<3<7=4Q7-%"/'UPN<G3OG+?XPM+LM;EHCQTQDN)<8U4S
M(NCB3?BVI+ITXMRM3D;UM>3O- W'^/Y#:HXZLXS1^\J]N!)C0TMD,X&Z&A9I
M)VUKUQ9SDO-OVT.VCD4F;E>"65?2 ^I= BV,=)H&0^E][2+1K#U>=_;6YDZ_
MJ>JX;F/!Z9T+&[-K5P=)Z_T>ST<6V,ZNI8"6]%NY5IMYG+$^D+#9%'[!:M/G
MK1RO'.(PCD[.8\#[*GR=0EZ\XGN8G'MU%(OGBUB9L]([0\U=DBN!XMM'J*;,
M;@H9\@ %DS*G9&8&,)6:C[L!QR%P+]D"UAQZY45_D9RBY#5_DC5Z19G=RK6C
MHC3!:K1YNQ&<NG42%_7M5ON@S]6AG#A-R%40BVZ,LY:,R2DFM'%=1[RW52X=
M+)";!!Z7LWQF'$]KR[FBX)>3 5+GO0FT/->?6Y<%SE,P4-.K*O*H@,V]IK+K
M;B4=1I :\-M?7U E::DSF50[?:!:!*]H,6EA,J>\Q(+3;5G$(W6ZSI#(:2JY
M+N+]S6\LVTVS.R6'5/Z;!C>$O/3B&8P"(>$O(/61C=R_,  MB'OV_P#P]P$
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M&#9JH_ I'8S+;N+?,@+^RF<J1!^#?F?Q[_F101IU=&;/*)E#>#WV+LA=FG!
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MMHWJ :[M&Q](LME03*G6QO4[!6=N4"6UK=F*LK5X"\56>^C<P=1PM5;O2K/
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MM>:F)#RD6J;]N9--Q^%!*7F5H]1CIEZVZCC/3;38.Q;Q0 T_.VQ^P/48VH3
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,&*4QC&*4QC&*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g741581.jpg
<DESCRIPTION>G741581.JPG
<TEXT>
begin 644 g741581.jpg
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MD? (H;$6(R0RP=$S0E+A%T-R\3138A@E1%1S@I*RDZ+2_]H # ,!  (1 Q$
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MCCCCC&....,8XXXXQCCCCC&....,8XXXXQCCCCC&....,8Y7)Y8<^G1RP?\
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M7<>WS6*KDRI(U?PAKEG[ I+$C5WD2+=/7=NVD'L&VR211--UK*__ &_I^_(
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MT5)4-]CFU1N*OKB/R)\Z'2OL]91!MB[$EOMI;"DNLM+0%*;<65-(7T]/F-N
MG[IS;RSG&/KG.,8_7G/IQC.,_7&<9Q^O&?7E*7=]#R[E^M5@:UK,.I]*S<0V
M92$%+ZTL6>?C$NY KY(*08'I:4 :P[YA-TD=@3+)0@PT^,<H:ZNT?:SOB(_6
M+RW(]$>LE9QCRP2WL(\[&SPG,I8G(G-9#;"C[^/N7;1R$C$9FU0Y>PPB]C(I
M=HRD$:<O<36.R-<B-.C&K?48HX\TUBW&_P"XDQ),CJ ^#CO)=D]!!V[T#_RP
M1I2O0$@;V0,EOA]E(K38PG(U@1+$018"UR7RKR_,*PI"/**4I[K2%E204D@=
M0S9FXY#X1WXZCEI-%8-M=<7#SZ8)Q# J!R'0F#ER#^<B1AF.A"X=^P3W#G'+
M,PPU<"R"B#EDZ6^$=ZHN-=M,=8[K=WJ_ZIU:=.L)%!9#:V%&#2(5L1D">2!A
MXX>M\/%"# 0X4+#QS$7ET]5?+)H-_;311PKMNOIIMJ4KD5%#B64YZV@&/4!W
M[24U*9?5$<8"BXP\VRM;B9.T*0F,4^>MP>6A!60,]>-<!YCR[DE'Q.BX_9R[
MWD4N+#JHBHCS ?5+?;81)6\\A#3$!I3B7)4]U:8D5@+D/O-M(4L3HXY17UM\
MZG6.6DI#!>U$S@_76R181>="-"CHLV@LA@6CUN)]Z+DI/"^7<L8DL/ER<<32
MU<)!$T"[?"S?#O+>:_0/R1=;_(]$K2E_7DR3=LZHL\[7!UA(&B8PN\9L]\K1
M:>,!WO=W.L/GPK&Y.,N7J;5_Z-G[ BS:$&#E#78*F+-N^-1N85U?8/<:ELL/
ML7"H4EF&MN2\Y&9/F/--]U2&G&"G6T.IZ%A*E)!QW-^-6GAWS6[\/>5B)!Y9
MQZ:Y M*MJ=$FJ9DM,LR5);>B.O,O(\B0RZEQI:DJ0L$$Z.I^\<<<\<P&.,X]
M?OQQQC''''&,<<<_DHNBEMKHHJGIMOG&--=U$]-M\YSZ8QKKMMC.V<Y^F,8Q
MGUS]/OP2!ZG7XY(!/8 D_(#>?USG&/OG&/Y>.4P^4_NI+Z2BU?:==+@C+.6)
M323B+"$QU>+3$\.:"P.SI)L5 [:%B(W9J[2<96S\&DHFJGE%?.-M<)YL*Z>6
M.9MSK%2-D2,ZVDT@ET #%3IQIHT21(%]]5$2*GN6.B;1!;1TBHBX;HIIX073
MW3V3TVUSKC6X7*:NPY!9<;C%Y<ZKAQYLAX)95#<:D*2D)8>0^M;CC2U!#Z5-
M(#:P4]1(UG4[KPAY+1>%7%?%Z9,IU<>Y=>V/'X-:S(F&^AS*U4X*>LH;D%N+
M'BRDU\AR$XW.?<?; 5Y20%]$E...0;[Z>1GJ9XUZJ#7!VSL1Q!XQ)Y.C#8DQ
M#QH],)-*Y(HS6)+#08"/,WCM;#$8W<$2+]WLS&,6R>NKAYHX<M$'&R9RO)R<
M<@O4?DSZ!W;5\(N"#=N:"UA=@ 6LA ;RVT(= I"FS<;;I*-CD1FA@')XZ59.
M4EFC\4:%,GK1RCOHHE[.=-]Z:KF_*U_%13]J6)5R3R\+,VKV2Z1;><5G A!N
M!2I^S+.!4D=Q$X_E(M0N%![ME%4#6K1,?)$\:JQY9ZUW1=*QL?\ MW_IDZ/R
MU^/;^N;/O',64?<]>]BJ>K*]ZF-YD=:6]!HU8D&.;-'0]0E&)6+;EQ#EPP>I
MHO&#K+5SIH[8NDDW#-SHJW6TQNGGF4^3D8XXXXQCCCCC&>F1_N!Y_P 4<_\
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ME /25@J Z KOTE6] Z[;WGM$0')49M31>#DAE!92HH4Z%.)26DK )07 >@*
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M9R:)M(VRMN.3(O=,PJ]K 1V[LK'*_P UY'XX*T97.^ #0ORP.U*28/&LRW1
M$KNX>2_;W.@<W<X9*53U//)EK XJ9J;7D4RE:4_91Z^+N' 8B-)_XLVWOYU5
M50V.ZE^?)D(2H1%I/T]_"]8\WXGR;E'/N"UM3:7M!Q*QKJFOO$QA6V-K>NQ8
MJ6G79:VV&$5-6BSY/*=6H),*B?C**4RNH?!+RIY#;7)O-7ST]9)6^2=0DCHE
M!XX0EEC)3 G'3"8R0D!X\8Y%FS IVJRDRJS0,:1V0=(/U<O$<JW%=9>VEY=-
M)7 H1&ZSDYR'%3^X:_>JDITVC]GQ6525=8D-LJA,R)5BU4?R)#?&[FN2KO "
M=%E$VD=.B#A,0HZUQKDVG-:3X%6@FZRE00..GWS:,T]<]2BX/-9B+ED5>%W.
MDQ"RU-G*FI60 9"K*!HS1KNWCQ-7?:)Z99-F&Z5CL<NKM+V/ZRU)*'-!]II7
M$8&#7:U"/;=)>P$TO>25X'&DA8MNX[;"XEK 91#LR4?H?BL8=17#K<8B(1>3
MT<^&JZ.=6C>!?+_"Z?&\0:955<0Y2WYM8TNR3/;Y)QN43(:H+9EB/!M(5VY5
MN,.F17LV$:JLY"51;)UDO2COWB!XARN=-L1N8S>+TK2:N+X?W7$./UO]DZ2S
MHZ5V3=5//^/(E6UC05G-ZZ_O[2P;=GN<2J;^$!5WU94UTQ#\&\&Q//AUPNFN
M.QM==,)%+F_:JM*QE4M8 ;OK.4TV$C_X//@Q4UP;-S\/@<$DH$4_++"Q1P?M
MHH>8(,W[;*7O--J#)1*JG\T$/F$X[8=@),$ZW=2;1 1>E1?8VQP=1 +PM.>1
MPF2ESL:JM%1,F;;!XJ&15%Z2"7/M7PU5[J/#1ULXV7>QJZ_UA!*WN!SV((1A
MU;AFP'3@_94#OI1U-0\UCIGWLAFD)ECE\AH?C960/<HM"$J-OI-D4X8X#F!!
M)J2?>S<[TO\ '5T=[Z]>KSZR(=>L]?I' 'L9E44NX)99RT+!U+S$T:(Y)O\
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M5,EK'F)S4+LQK<#-H"_?3$EMMHZ6>F<^Y!B'.6 M;1T[>+Y8[_#>3(B19"'
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MF;)KL[7T01U6<;);+*:)):[[YU3TUU[CY.V/7 A3L42OBXB]#25K+7Y*C+0
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M"-N=MMUX^B"$I UM]U=5]]U0Z;/4:IMNOIHMOMNUVVW5TT4VSG?37;$9 3H
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M&2?QNHNO$S5/9"O)U!^O@ @.[!]I#=O:@98];U7;M?C)Y9YC2%:@DL=9X=K
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M[&GM<J$V\/#MZK91Q2&M0DB>A,@I<)EFKO770PJKH62:NFOZ&12,1LVO\48
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M[)R.I7<;/?>^_P _7]?WZG'''')R,<<<<8QQQQQC'*X_+%_@.6#_ ,JG4_\
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MAO<7IA*KSZ$^3PW*JVAG="HFE<]+43MC:6-3I*[*ADAF78CD(+#Y 5!5Y-5
M*:4HB\6=,(X]G,9:EM!F%7XE85MSWEE$W=4*HL-IEFTK5ILJ5\,-)#%C!?:G
MPAU#H(;=DM.-20=A3#ZDD$'0ZEQJ\1QRXX_=HA_%_84F8F17LI98-IQ^TBOU
MG(: /DI^'3?4-G?4SLDH6J,U9EUL%;:"C:.Z%B%.L=S]@NF/O]5:F?EG':?J
M(^3=*N1N].VZ8<.9[78)53.$E&M9V(HJ1;-F7OL(A)VP6S[#?":BMKW-,.]8
M[W+NVGJQL*$"YND_Z/U'/J&NXG%INC'ST.DT D;WYL43%M"XR1.&9>$HQU=^
MNP2<INV #*[S3.C#7W>VYUZ7(NJ#I%R8(_-RR]15LN3+?,,%OF;]:&AE79#Y
MKKMOJ3^,7WW<Y(:J*:O,JY<84W]Y[>V(XCRZ5R"3+@/4\Z''@08+L*RE=26Y
MT9U):;80E32-O5X;^"D.^:ZMUZ.XX\$.J6#LG/>(P^/+8FQ+J)9IL)4C^[82
M$.EA3;4R!;+;\U:V6KZODQ;B.RM#?EM3D);ZF@@YF#CCCF^9SG''^WZ_ZN.1
M([Y.Y&/Z;]DW\2.*QJ1,*BE[X6<;G,1QP.<,V'Q&R[8UE9#+%U[A-5-JHFLF
MLHNHFW0VPLMIC-I/E*A0)LU+*Y*HD23*3';(#CY896Z&4$@@+=*.A)T=%0.C
MZ9=08PF38<,NI8$N5'C%Y8VAD/NH:\U8!!*6^KK4-C8![C*S_-1:!VPX4CTM
MKXP0#-9'%=[C[.2\3HKLI#*/ E4Q\0A.CM#;;#*87_96HRO8@U6PBOLA\V,)
M;9;C%\X\^IU(T97="/[LNJ%1&2U)U)K3 :"C3P(1)A;695^FK.;AGL69%6[A
MH_-.[&UTC%=$DMUGV%0378-\,_<X4<5(5W3W;N%E0M+6F"D;&5=R)-2<F"/I
M3+&<LDQ&+5B],%Q:II/YJ7D8AFQ*28<ZRQ-?#)MM!Q%NFDT=-'&Z<JNX/0>6
M]^.PM!5KU%GUA@NN?5LA%J-[>3M*TC4<JF7.(Y*6\ND(>LXJ)?JCYW;L->M3
M#6RS&K%D,#R:41@9L_=&(X42#<TX3,>\1.2-R+6OD4==QDBSM8T]I0?1<2%J
M%/"*W$,>;&16-P[,1U]1BW$>#81V4*G.'/JRPHZ[@'A97TR;]@N^(D^;9O6L
M)3;D7^R/'>NF5+ZD/A<2PLK^3R_C<9:%K^.J'ID-U#Z61JW[J]U"@\_J)Q:?
M;FDJRL.\^Q4M4OBRV=E5]&9B\B"YA=)Y5M9I_BD,]78I4M7Z$6A:#-#";=L>
M%G2"7O'!)VX<=O=I$.DDE6*,]5G/3:4DU%BXANDLNIU=E)=[[]W)F.WKME#K
M\;>+.G4F994PA59=UH4%MT8@[?HB)Y,6B;!FU8H[N-TF;9!JENZ<N'KK=)NE
MHBGLY>.U5G3MQMHGKE=RY65775SNJLINIOMMD^8LR;)V-(M&K\>0;+LGS%ZW
M2=LGK-TEL@Y:/&J^NZ#EJY1WW1<-UM-TEDM]TU-=M-LXSVANQ4'G_/1YT.4H
M!^)U=* A/W651R>L,/QD:3&= 44)!:6'([CS3GR^NU<>E279"?.BRU=+L3J*
M4(802(Z8W5UB.N&V0B(M(5Y2 6E)<8<=:<K0['=?Z!J]W$^S<7I^IM(8B:7$
M]CVPV$1I</.Z2LYNU$FY249MF&[$V[B!O\,RS4IA+=;:.('L_%Y:*[8S&7R!
MBR?2IS3UN=)(>+JR23IW(8#/EZ^K]H6AAF*M1'XECZY^*,1CF/K$VYC*^0IG
M9%H141=NT$WBZ&GNM?7-]7+7JZU.T5!16P)D0KF^>MTT']-Z]-SLGM7\7*:.
MV"MD5U\,94<(CB@!N0;.HA[>S]FA!7Q/5%1!4<JFCFWQ91V\J_0["U%V#DQ4
MK,*YE4 &#(Z:E*\IR CKR&Y=C'0-9SG=/$:*(;)(CG37?9!9P->M=M$EV*FN
M>:<PH(\:^8XY6(DLP>2P8EO7\KK8+<=%/9Q$*?=82OJ0MF8_$@B&\U'> ;?8
MG:4ZEQ:\[+?<)@<Z\%;'E\CG52[RCPW<;KX-7,6Z]RJPXGR"QK6ZF[@1U2%+
M XCR7D5JR_+DK>ANF2S3OI,:$F+,\NI_9GOU8E&0N5R7K9'K'+$%"Z3J;/[$
M"TVXD230PY:MWND!(1ERL(2RBG[A!QIONW()I:OT=,:*^F:)^VG9WMU<K2\Z
MMN@=% \0F;V5Q67QIS10)N6'1^'G"*\7'_G)WCZ9E9>!.L*N0LPT>)*C<K+'
M1V[;+]3.=T/&,:XQC&,8QC'IC&,>F,8Q]/3&,?3&/XL8QCG69?$PTVB\EB)U
MHD[$2H"8CA9'=)/?WPTZ/<#'Z>?7&-OW;9RIC/IMC.?3'UQG&,XM;7AMU+K(
ML6)S?D;,B%&*/,#K+/QKB6VP@2'8:8<I25N-!2E2Y4Y:>I2B5N%2U_/#:;]F
M2U*@<NL*J49C,EZ:Q1\6D+:*$NI68495*RU#*7'OB6$1E-I8>8C*;Z5QV7&]
M/6%>4@PP[\>.N"RWI5%)#5S -#.O9CM2^IAI/IJ2GMFM& VL2=4V_B%+$(HU
MA#Y+=A)82 //799,C(WNVVFP5NAC;?L*D*9MUS&'UJU-6EEOH23P9ASR?P6+
MS)U$S&NR>?FD:<2,615"/_;12V^+&[-EL[)([[;9V23SKJ@T_1/8P;0US4P#
M)[QZM:&LZ>U[+Y0ZD6SM2J+9A]@+&Z%[&A(RX;KO1:E4$@T).2HH#WQJ6CJ<
MFT)L"**CG;?9PZ:]AV?:/KG7-O803'20FQ(1JQX_K[O7:*VQ RSV%VC&,IIJ
MJYP@(G ,TB,6WSK\>&W&DTM,(/4N;3P?D%1R;P[XQ]G4CM-9<,B1N&<A+SKC
MB[MZM0]#@<I'6G0%U*J[QEU"5N")(K7(94E#3 .4Y&]8Q_$3GE9;+!DJO)%O
M$+4.1"KY%?;]-A'E4K4M")*J:1'EQG8:W0Y_Q'4-RIS:$SI&3]:/IC6SM[KU
MJ6M,7'N+R$WM?$%C&+*W#90RVR)VG.!>)-L.RVVRVRSR3RCLWSEOG7*']KYS
M6](TU3GXC_-'4]:U=^,"VQZ6?FZ@T8A/XG-[8VQL8D'X:%C?G!/.-]\?&D/B
M'&,;[XUWQ[>WKE#CF:SPV?F<KY\H?6F(=G^D/8&'&X3')=,(W6LJL*HW1J+B
MI,3C=J5\/S.802C/S)JX7&DW4BC(P:NJ/404?,72XYUARS<+-E)/=<;>"=@>
MOM(7K&TTD -QU+7=GBFJ*B2NK%E.8D)DB0[;9#.R6%1WS'+!=+7/]I7;J(YU
MURGG7&8G*"+E!9NX3T606241724U]K11%739-9/?7_TM=TMM]-L?IQMG'*O_
M !):/H9UOL'K>13RCOT][2=D>LX-'*.4-4JXB5COY=2J;;3?^WJ,D:8G,";-
M'"^NJBZ3?V_W>/W>T:[[^G[WV_U_+UR=[3KY'?Y'0(_71_,Y9R1_N![Z??X1
MU_U=7E<'AV_@R>FO_(Z.^_WQ_OV<^F?X\?;/\?+'R/\ <#W_ (HZ_P"KJ\K@
M\.W\&3TU^_TIT=CZ_?Z&SF/K_'^O^/DY4/\ A*__ %$=_P#]J_K_ *=O8]SE
MEG'''&>><8V]<[8]-L>SG&/7./3&?77&WKKG].,>OIG./_2QG'Z.<\P7V3[&
M5?U/I2>W[<9$P.K^NPCDT:VCL<-RZ0O?=:;9;# 4<CS)^5*E2*VNK9H@BWU0
M3WVRX?N63!%R[1C #\F_7F4=E*8ZKQ@78Y^S+IHV"]AQ[AD$CB,:AE;V,+-%
MXL[G#XE+&!1F6=LP+U1R) !I"X8I;M'3OW3)?#G6"H ZWW_?]?8>^Q\\D))]
M!\_Y:W^FQG7NNW\)MY'?^27H=^C[?_)N]/T^O\7V]/X_Y;"YO"8I9$1D<#G(
M(?)HA+1+P%(P!1+*K J*?I91=-'&NFVBFN%-,^NBJ*B:Z"NNBZ"B:R>F^M G
M0SN"_MOR9]C';81$EAUZQZ-1-\X &MBV@-MUE9S@='"#%ZW<.&K_ &E*$I>+
MEM-\:)M]D6F6*FR?M^WL2<Q''^0UU]'=L*:2ZXU%L)$-3I9?BN-3(:D%P(#R
M&W-ME2%(=0.D[!2K8.NB>)'ACS/PCOJZBYG#CUMM/HJODL%,*SA62366*GT0
MI E5S[[33WFPWTJ9+@>94V"4@%!.D;Y+6ED=>.TT-AXR5&V4PI./1![3]G-3
M[]H]V@S4J0UKDD^09[-MGTYC$/12K.1%S>CYN89Q(&06;D4%G[9?:[ZN=J(S
M? C,8-#3==7?%  $A/ZEG.XM"7L618>W<#)H'5%*;!Y=!90BHF2#RV,[+#,?
M%ZCBC<(827$H8$\B/0B*=L0L3L :#'.K3JATJ6;#]DLLE;3B#5%9X0JP@::K
M-7(UT4<)Z;Q$ZX4<M8Z<6RJNU58/7NF<45VJ$[BT1N.9NWXGM[UQC!1S2EEB
MW#6!V.R>:L7S"'NG3U<>X:LV9,J'3KB_X&4&$XCK+PA]H3":,7$<=8M)M0*:
M[D<CK)\B0URUUUZSI'8;#,&%?QFU//-PYK3Q=,N_8$VXC(<BHC!<:PA!6D,N
M1]VL.35/.N%\5I;=M49?&@[7_;;(9#E&Y9/,E,B7&#;:97'I<M*W)S(D-OU[
MKZ9]<5J185L^XGCFOSU8\C79ZDV%@//*3#)/7<#1?O!\+N=:K"((0]LX9G?!
MVH!P:+-26[IB[214<5Y)G[9J.E#IL29BY <;;-%V]RE5]DJ2N6LXA;L$L..O
M8--WZ 0$2)D6H%SM)U5E&N\.>CC"S-XPF#=XDJS<1EPEJ6U73SA-LJGNFIO=
MUM[7VB 6G%1Y'0IQR!,"8\]E"5]'6[&4HJ#:B4]#J2II84DI6=YHG,?#+E?"
MY+B9L5JUJA):AQ>3\>4];<8L93L<R?A8%PTPAAZ4TA+J7XBPU*86RZEUA/3L
MYRXYCFU;<KBD825L6U9:,A4,"_#Z/S97XC=/"[M?1LS9,V3-!T2*$7CA35)H
M,%LWA!UO[6$&RGL[>SVB+RB.3:.AI;$3@N2QB1#FQ8$>"O6Y$46&/$\*M7S!
M\UW40<MUT]L;:*)[Y^OKKMC7?7;7&4#K1<+(<;+R4!Q306GS VI12EPM[Z@A
M2DE(41TE0(!V#FDJ@S4PV[%4.4FO=D.1&IRH[HAN2VFT.NQFY11Y"Y#33K;C
MC*5EQ#;B%J2$K23][CCCGIEKCCCCC&....,8XXXXQD.;QZ=QR[^S_3CLZ4F)
MP&=Z=F+C+QR,#QHIT(F.]Q0'6!$D#KUY_N\<F'::X(,=Q?JHNZQ[IQG"/KZQ
M/NCQ'5W9%Y=O;C@]M36GQG>WJU(>NG9VLHR#!EH7/Y0Z%.@$2[ IMRCA)01;
M$1C[GY!LNV34#R,5JIJ7:_'O'K]>W;CC(*0=[&]^OY_OT^@^687ZZ4P,Z[4!
M1]!"#9*2BJ1J.NJE&2$NBW:DSH^NXD)B;,P29LL_ -GY%N*T>.D&F/AD%UMT
MV_HEIIS$-W=/(Y=G:WI3VJ)S(Z#/]+'_ &#?QF*#QXQR&FNW8&L&U9&$I ^=
M_P"^ W2/L6VI09D5C.SIYG*#S.&^/K,;CD[.]^^    !V&@!\M>GZ:QCZ8QC
M]7'''(R<<<<<8QQQQQC''''&,<<<<8QQQQQC''''&,<K2\KO^"[%O\K?HS_K
M=T]RRWE8_EK?L1?5 "2)O68T:/[7]'WC\B1=MV ]BT;]MZ@47=/GKM1%JT:H
MIZ[;JN'"R2*6N/:WWUUQZ\A7H?P.5(_SI_\ 4G^HRS;7[9_QM_\ G[<\N0V[
M/=[^N?4FLH/:]FRI\6BUF6)#JR@"M=B7,[VE$GG$K'14=EH]!?$!&(4>\)Z.
MC)XN5'"F;9NLW3=."ZS$8[^!27D&HWL'VBOWJC60^>%IMUK*DHY:4L<B0#.
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MC^ZOU'/;_P"RG8&VHG5%9QUV9/3 Z4BS<=$E'>4@HXZS9!X&^)E)'J\)(L0
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MY>-N,*ERP[48P$JD_P 0X/IKHLP/RI9?+\EOAEG""V-\:1T[+]5O$35$8?\
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MDRKB6-91%9+!;*>/F$CJ:4*,/GL"DA@<VDK4Y7\J.A4Q(T@ND83L%XY'2-:
MT/E@J).]]] ;T/8:^7R]_7*T>@/CKUZ//9H\?W46N;+N$5_2M6:$H.(A&:TH
M"J9!8DH@, ?;B"Y7$WDK$Q:$ER:GSO0,H:9-PC9./CE&3IP0\.RO0^T^Q7;.
MGKX>]GF8BEJEB1D&RZR'Z*!SV/[2^4C)1'I-<4=F)2;CL1JVE(I(]HC%Y6[A
M\DQ#8ZI(6(ECOM+2ZV;,>..D:U[?B?Z_O7MK0U'4=[WW[#?X:U_0975XZ>@3
M3H+![%B;>Q TUVL&4QPWH(@=4 J'JB)#H?!@4"#HQ*H(N<D,?"2>0L 29ZS9
M6/?-OQY+'*AC<,'T10::X4[0^+V=]L.Q-I6?9/:Q1S3$YZ^RVAH-1;BCPA<A
M1>9A%LCSEA5)9S^=8VC\RE$N;A9!/R6\(7?32+Q\76C@B.C.BF^]P'')Z1K7
MM_WWCJ.][[GMZ#(A],.L)[JW6TP 3>V'%WVA:=O6!>-L6;M"QM<#I-/K <#M
M'R@&!"BQ]I% 8X.$""F(O!XRKG+)9ZL^W4=Y21C]?WC2B]V3[M+824UC(EUV
M7I:CZL>Q*74Q$[,KX68HZU#%L#95+H@=*,1]E#Y88(M1DIC!3Y0LN-9;*,I&
MU(*MG;"SWCCI&@-=AV'[&.HC9WW(T?P&O]AD6.EO61+I]UJKCKRC.B5C?@1.
M3*K2M^)2CC9T\EDO/S-Z/C<4;D"S2&PH"[D"P.#PUF3(M8K%1PD(@^=Z,_B%
M(<6_XL&\WL&_;@K6\5:DM&S;WZY]BJL,(58#E,:IZQ* JLS46^7T1WD0)O8H
M:>1J4RM<RS</XLZ'E#";YN^=+LO;<6W<<$ ^HQL@[WW/^^\P!U6Z]QOJAUPI
M'K;$3!:0QZDJSB5<#I">PVT,R#2,BD6*YXHDSTT:(/C+S5R2<MVFN&S95UL@
MAZI)Z9S$J6>.$9*/(?"^^:=FL +B*M1Z[Z'@ZGC(VP9*4#UQ)ZS' "]^L2S2
M6/:=4%RA>0EJD+ "S!],1HHPU.CFS90<K9IQQH=OIK7Y>F 2-Z/J"#]0?7./
M3TQZ8_1CTQG[_P#QY23#_"Y$8EY-S?D)_/\ RLM%7MHSGL #ZWNH,#0%@+]L
M6H@%+R><_G/;%]3I,"I%0F[D?"W$>119E7GQ"AARBVPBM=OQP0#K?M^_W_MO
M )&]'USCV<>S[./MZ>S^OZ>GI^WE75;^,T)7?D#G'>EG:2:&TK3L)WK7D1J^
M,0$Q(#EG"(8&-[W3:$?)8)WA&HFWA35W5("41MD^@90H4>_B SC=LDA:-QQK
M>C\OW^_]MX!(V =;[']_OMV],ZY+XP,FD8.Q4PW:.AIX6]&.4GS%L2;8PZ0W
M22748N]=VSC9HMLFZ1T5U],+HI[8SKMKC;%)<6\(<=BCWJ:W8]DY:I$Z'K?J
M%7=OQW>O /Q/8%#HO:TGNOKL50-J'UEZI7&V!,#JTY;"6DGUF$?5:!T5P3II
M@JK>OQP0#W_?_O\ (^HV=>N 2/3^@_?L,P7V:HL)V7Z]770)]XV$LK@JRP:X
M3D:X-E(E8D^F\2,QAI+QPA^JW0=E8RL7^<#4\/&*NSIKIHD^9[;_ !&E=X'Q
M*@@7:[KYV7:7(DPS1L/J *_8QVH8M&+2L$M3--EJ6 ASM["S6LIS2,A#FG$E
ME])%1$B'%)8/"/VDE',QV62]PG'! /K_ *^^ 2/0_/\ GK_89!;R#=3K1[G4
M+BBZW[&J]<QYN4B7MDD]:Q:VFSLZO&+9]@M4,E"N)G!ET85,WBP_6::#C;=V
M?C[)Y%5U-!1LEA2-_7?Q2,J/[5,.R)6\EI>&!&;!M*,5*$JJ/5Y'H[V!NJF:
MIHVYY\-*"SY99& 2"&U,*S"*B2&I-*\>ERGNI7(&B;!LVMYXXU^_T_V&-D C
M?8^N5[>0/IK;7<^.5/#()V91HF$0RPVD[M""EJ;'7'"[^9!%1[Z+P:Q@CV<P
M7=S!A!IGN<)1G=\^#2I_J-2D#!V/&?!.NG=7/&^SZV]K[O[/IVD*,J6VVF2*
M<*A5/QBH$WKRP[ _.3)I-<QZ*&7.EZ302:QL'KR5G00 I#8H\+B%]SSHJX*8
MLZXXT-[]_P#V_P!A_/YX"B 1['Z#?ZZW_/Y_/( ]Q>E<Q[8SN@2R780M6M;U
M!9,'M&0UXPK>,R8M()?6TX#S2(2VN[&?$1L@IZ<HMV)N"&9*P:RIL6KV820$
MF#8/7>A;3IW0;QUZ](CMA&7MU%;AU,0V"TW5K1]!A,'TK"@ZPEUI3>"U\\4$
MF2V)Q(1IRWI5J3G;I$&H5&MPC/2/L=V*Z[RR_CCI&]Z[[W_(#_3&SK7ME='9
MSHC)NS'9"B+@+]A"L6K6D'1&1CZH&UE$B,DWFQ*%S^ORY.*W ]>Z&HA%YO$I
MYL$L^$.HW)Q\U&Q\4R2? D%R>COS\=70-MT'@]EQ5*Q0DU4L>:!I/\I@%3 J
M$JB'L8U" $#%,H;4,7/2, ".&F(!,[84E8/V_P"-)2[4*9$"$4&S).Q3CCI&
M]Z[_ )^^.HZUOMZ:_#_VRDCM+X0:?[.]F)KV9?W_ 'Q$S]F51=573Z)Z&!DG
MC#UO:-?1*!QIU&=2K1%]%05>YB;.0)0A-T3CT@,>Z<83!K8)+E9Y]*NJY?JG
M74]!S"U7%U6;<%UV/V MNR,PT?70J0V'93D9\SQ&X&-+R%O$XX-% PHH:(WD
M)QQC#-9VX)+*NMM$IB<<:&]]^_Z?O_?!42-$]O3^G^P_3**K)\&%92Z^.PE^
M@>P=G[%>Q-;3**2^N[IC\3[!U0]ELJMN$VNV-R6(3% 9O,Z^!*P0-%QE3%B2
M3 <!;LFX"2@DAC)MK9%TNZU#^E_66"T)M8;ZP&T Q,BI"8&&3>,CL+2Z8R*>
M%&$>C.A,HP@L C+@^Y"0F'MRS]C$8@,%ADW[E-ELXWECOG.,8]/_ %M,?LSO
MKC/].,YQRD_QU";OO/HK85XV5;$S[13SL&S[+QIE2U\G(L,H<?M%;MN.NXU#
MF*<4KY,\"AYL"$"@)4L14ESE44FY50:;KJ92V@Z![ DD:]?0#0'Y>@[;/T.3
MM2@ 5; T!OV]AK?R ]R!K+4V/8.AB8F&GQUUU(_!6+(%XG7YEE94*=B9S*6V
MZR;B-PXBW.*,Y.?04;N-%@P-9\22W06U4;:Y2WQKE_FHBGX2>W\PJ>%B95!>
MHD%M"5NK1CUMNX=-#+BOJOEECW!U]M9#MKULAPRF8N%KR;0Z*TEK1T1IR+CH
MQL,C&1,D?6V5)D),@\V[<8]/7^/.<_3^7_O^^?X\YY().]C6OT_TP0!K1WOU
M^GI_W]?T&<\<PEV*[$U!U2IV;WS>LN;PFLJ_%*%I";59D"CGV,8SJV'B@XAJ
M]*FC))Q[+,6)&M'#Q\[43123^N=M8]C?)%U8*7'4U(-93)?Q7<L?K@M%"RD)
MD.L*9';A@A^T*KKB4S#5KN'C-G6!742EDSC,-)*Z/GP..$G&ZJ*N6:+L2!ZD
M9&CK>CKYZ[9CSKM_";^1W_DEZ'>O_P"&[T_S^G^;TY9IZ>O_ ,<X_JY65UR=
M(N_()W0DS041UWG4!H :05^=1HH-%L*K9S(;%R:>1#QPM[$]:S$@0:(J**JM
M$PV=5TT=E=O2S7F'H[RNOXTJ76+?<9BV5C5O?$PID%Q$VLDKB2V_)FL1W5(0
M\VI*74H+3@&T+5WUF;ZALN/2XT.T1&0]+JZJW8^%G0I[:H-M 8GP7"]!D2&4
M..1GFU+96M+S1/2XA)UNBGR"P/N'7-XN[5ZBC)_&Z]/0(1)+J?UT_'HC"LFC
M1DO\S.%(PHZPL^D&D2T9:O2 L6L1*,FZ:2RCI9#&N+J8%*@TXA44F$>,LI"$
MDL?$&1AL<X3=,B;5^Q07T=H+)9SIMJKG?;.VOTV34QNDIKHIIOIKVS.NNV/3
M.,9_1]<8S_7_ %?;/VS].003PIT[M'">=T6W5BZI9G1#7.-DV="W+*7J>$F^
MGIC;1C6%K&'#A7.^^4QT/G+A)'75F*D'JAC&*T<>M+*S3,G2*V[D,KEQI$CK
MATD@=24R(,<)0B-"ENNK59* 6M,A34MU08$EQGKUCRY?BUPOB?"W*.@KN8>'
ME9*8H+2L@%FZ\1*LM1DOU-_8N./2++D5+"KXW]EF2IIB57,S:6&S]IKJ8D^=
M:Z"+I%9LY12<-W"2B*Z"R>BJ*R*NF4U4E4E,;:*)*:;;:*)[Z[:;Z;;:[:YU
MSG&<5VG150W7%,PJT:]BTRC>J&J#0>7%-5,B\));)-U0SM---X&<---\Y9.!
MB[91IOC3='.N=-?3+&,^OZ_Z/^_[9_9GG/-O;=<96AUIQ;3C:PXVXVI2%MK3
MW2M"DD*2H$=E)((]CG#&7WH[B'6'G676U=2'&EJ;6A0_YDJ004GZ@[S7/NJ_
MKO\ $.]:Q%C''-P5'."SUM7N\I.KC(VHBW9;D%'6"@\>_=Q2QQNFFHZ611B+
MUATV'X:6()V$21S*1Z\B?$#V/(=@'_;\X4BH^#;S&W8Q>XZ+CBZYMHU:VG$$
MXR5=-"+EF/7=(NY'5Y-VMOLS0U3>.UTL:?N?:VL@[0]:J^[74])J@L)O[IB;
M226$R-FR8.3\0-M5DEF<ACCA\BMHR)H83V;*;Z^SJZ8N'3%SA1LX43VUSY?<
M\@\.O:UW6X98)=<'D%.U\"#JFM7,<E,1KEI8<SD =F;3"-,#)">!+GIDD+=H
MX;;&&+IM\<JR40U1UQK?%_C;ZHFU-V(CTJ=,8>XE+<KX-0IQRME/N6--,D):
M6U(DN(<==HTR/AVUHDOP&4L.-1(?;*"PJ>5\3Y33(K$?VXL:N.1-1\5NR^SK
MVHG><II"%PVG_A&GV''5^6XHK<4%)0OH7M;\<BEU*[C5#W-A4@G%1[GT1\8D
MBD8,#)2/:BCK-[AHB^;.%V#1^1339$&RWO&*V7.=EL)+8SIK[O/K*WF3>9<C
MO/QWD]#\9]Z-(;)25,R([BF9##G22$NL/(6R\V3U-.H6VL)6E21Q:7$DP9#D
M68PY'D-=/F,NI*5HZT)<02#[*;6E:2.RDJ"@2"#CCCCGGEOCCCCC&...<9]?
M3Z??_;Z?;/W^WKZ?3]'&,^,5DD> [(:G#H8-LZPIEMJ5*,1VSC".,95RAAXN
MCE;">-L94RGC;&GKCV_9]>4=_E K^%2;QTS/#*\!%;3$4[?V77!)JT%RQ*4I
MP4 :%6 .0&J;K-U$FD.E97"$@:J(NXM*%HX0:/&I#5OC>V^JJB(Q./>MIRUM
M=%E/W9->1V27AX:-JE&:I8@XCX<=%QZQ /'!,:!.& %NT$J::%%6"L@*X7-E
M2+E75\_*)YMV#NM%GT[Z>=3+IOR2;!916,^S&*QD@.(0![: .,S0#(PDR>#&
M$5DC&21\24$;N&)A(,RD05V&(O<&L:,<XZQ5(^%*&$,%U]Z+'"7RV4!IZ2RW
M)60ZI+;BFHJGGD-*Z@XM"6RASJZ%9&L$<3$KDE[R66I+Y4P5I7YK49U<5/6A
M"EMMN2PRVZX E2&UJ4EQI0#B:+?R/0=%,=K);+Y?;^\3;1;#X-#:T<8U28S&
MR+$C"\> ;Y**^UJCLO&=)DCD(GAEK(3@>,+K+/W8@:U1_29VGD(T=:,=IC%M
M7N[W0:FSVD(C#O<BHX^%38:M\O??[/5'7^YM&N-,N-W']IU3RK^YY^4OX;*C
M\@O2^W!]R%.CW9)6GY3;$5C$VL9M6DL^(JU;KI9#226=)]XZ@/5-OE(8+92H
M&3;J#6Z+LKH\C0UZZ.:+CM?U3 8V"6-$ DEUB+7(B; 1DC1922)8"'4V4B8(
M%4$3@4LP:F II-!YIJ1'D4&Q480PL@Z30>(;XUF,J3\58H<2P&A(9=BJ04!;
MC+L2/UEY+9V'!*1(2E:TI*V@V?OD*44M,?X6L<;+Y>^'>:EASJ*$/-2WBV&%
M+0/N&*XPI20MP)=*P"A)"$Y']?7CF+:HA,S@8J2!Y?9+NR6KF:R$K!UB$='
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MZ#!=L[&!?+7)C6,AI-O4*API57+;C5CQ,GIFP#*;*X"Y3?D3&]>[Q)V$9K2
M2R3=?SSFPYQDPFXNCJ3*7  $:LF.AVZN@VS>JDI?JCW$H?!V2K]F3&%,/!1M
MTR<!,O&;O 0BZN@$>6;H>16$#"5V:Q:4$G#(<[ATGA4['22/'G;O0<M')$V3
MCCAH-,CB6V6!)'9YN@V<:;[97V1QA7,M+2ZZ4A<\290BR:UBLDCP?*:@!MN-
M3&O8LX1VQNW>Q(N&R/,11^WWUUW0>QY\.<)[::YQOG&/3FK'Y#/'Y8%3]J(]
M,@<W/R^IYIH$E;Z?260#)A:E71^ME JEC2"3!O<,Y18[2#QO",E!Y#B3<D*A
M1J[<XY)/QSMX]VCS9D&I@0;2^AP7(3?D)Y78U]E=F6$M.&-"N82+-FR7(DR
MS"A7#,Z>\'7D1YD!<=;+\#%]?AYXL<HL9;JI7#["RDAR!53+2N0VX77H\6/
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M]I93#YGV"/QAP)C@Z5EEY[(8+'W+9K*SQEI&&^I)H%223(J;:6.Z_;/^-O\
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M*/WU575W+Y\FTATXOY?)I%4^["L9"YM6TB');;86(B$)=2I7I97K]L_XV_\
MS]N>7(G=K.Z="],05?F;O-R9JXM:>Z5M7$9@T#F%ES69S%024D*HD!#X,)-'
MW^60,01*$'"++9NR9M=U7"FF,ZXS*4>]2),&1%%)TBB_:-GJ2+YHX8/4DW2"
M:Z:;MD[32=,W*>BF-'#5RDFNW6UW163T4TVUQNFQO7OGSKHZWKL?0_O]^ORR
M''>GK#).UE1BZ_B)VLHM(!LN;'FTELRMY#9#82R5 GHX9_#;.+6#6QD'(2 D
M^\&ZF49#NA\J=$ASH:\1>YRE_/QXU+:-%]2*PJBYH15< L2%N9T+-A:7T(ZU
M\0;?G!E#@%+QVYHP?/+%IX 6&3.5KR$T4/JRDX8V,OG#_P!\KM%CRUU>',5U
M#['>J6!("#&4@H6A"6@WN59%;[#RF3!!^;*4STXD("4E9)E1!JW;3*1X>AP[
M-' _.$5WK?"O:/#F@V.=,(9:J3"91AQ9QB:+/8&<FUTR6)QA2#S^7P-JZ@4;
MON1R6Q:Y&R5@#:FRL/-NA[X>37V0(A1K]LNAB@?YU?=.]:)WVU[?K\A]=_7T
M._+'?8!V!KT)['OOY#U(/N.VQNU;CCCGIGECCCCC&.5Q^7['KXM?(+C/V_L0
M[X_T ,?KY8YRN/R_?P6WD$_R0[X_T ,<9(]1[]QV^>8<F>R_2^T*C[C"=&C#
MKM?41J>IN[C;/L-F,,E.D=!QFB^U[UQNIJD@@ 55'TK;;[;&NFT&,0:2D=]6
M->+K:^[.Z$K[K1VU&]^0* MW2TT': +79#'3S BK)-+]= FG88,/$N]P10,4
MW3#1R=YU&K.1+0P2F^CS9LB1RCGSM'2=H]D?'?8U!TU(83%;$N#KX-KL+(+$
M&.BT1&M)5&Q J0JDV;)H_=>^4CC@L@+=),G>P\JJR?\ PZGPV,8UKO%7/O(G
MTA[517Q6]VJ\G\YZ23-U;'6.E[&,UF1"UV[E[ +*;)3>0>PI$*9%II!Y/'QL
ML$C!!(@KLR$K,GP5IHV&;L^=6X[#<N^.3K*-;0F[:I@R*ZVI7)!CSKWB<:(B
M07V%J2I+EA6MI5&B@%0<B1&&RE(B*;FXZ)?.\;MS'6Q+73WB!&E.,_\ ":=F
M.AEY@D:+27B4R6WBE09EK6IP.,OK0C=#25363351WU424TUW343VQNGOIOKC
M;3=/?7UUWTWUSC;3?7.==]<XVUSG7.,Y_IRJOHQ6DGZIVQ;'7FU9_/I@O*-]
M95UK,S"P#<HC96C8EMD5I#8Z*,K^[ SNO\OF6TV'-<.5" 0C'RC-3(YHOA*U
M3G.;2$W EJ88DIFQE-M/1IB&RTB2RZVE86E!4LIZ%E;+B2HJ0ZTXVH)6A21G
MK&&B#)++3XE,*;;>8E)1T(?:=0%!:$]2^R5=;2QU;2ZVXA02M"DAQQQS'Y8X
MXXXXQCCCCC&....,8XXXXQCCCCC&.1T[&=L^O/4H!'Y5V*LT15D<E)U.,@39
M]@<6&/SJJ*KK47AZ*%D$&[O+-!R]PDYW1WRR:/'>NNR#1QNG(OGYR/Y8[V.M
MHEV#J6A7R,WA\/K!FC*(&X$+EP\1F@>R(RPT-2A^0RG\O/2C$D!FX>-08N6N
M8<&BY?XM EO-%-V'B^IP)"6@?,<5T(7Y8=0V2"?,=076-MI ^\$N!9V @%1
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M/,P(ES&BT\EFQY*S%D74U$EQ=;.MK@VL&$PP9,%FJ5.D5[$1X_#M1GC(D/\
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M_P#S]N>7)"0#L#7M_0>GI[#(*B?4[[D]_79.SW]>Y[^OKE7/EJAQN;=;HT)
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M7%$(::1O0+CKBD-M@D K6D>^5\R3M-J&)WKY0]J_E=B14V_?]+.ECH2J&6$
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MA<0D:VI: GJ2!U#9( [CYC,@FNL%R'(B(,Q4IE)6]&3&?5(:0 DE;C(07$)
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M-]'+E5%/,5;S],XZNJ<=KB^ZP^^(KSS:'WHK+4>.X\T'"RXMMAIMHJ4V2XE
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M9$H<(YT:).$1C'<J8+%%F ]HJ4(/7RCE=3HH\7_$53P>5?@."1\9U?9-(/\
M$?"""%Z%>4D"+MOH(\OJ >" [I>6RN(<<#7EIA**#'$4H,R>0(_GB86O_B00
M/BAYFTD$]TG[NTYJ@=M?$[XF[XJZJC5<^1*L^OD!ZW:;4Y=TG#$GTX:VE<!0
M>%0B9TM&9+:.0\?(I,(M.2HS:+"GPUR)>R9Z-*: 8R36;6"0'\G'\?Z%#]<A
M<VF!*Q_S1L)$>E5TB"OX:'7E I&)D!,$V/X3DT@  8G&,F14G!%8<_8HN]0V
MCEXX<,2K[U^M+O"]V*ETQL2XWO:2G=+=D=G,Y>%9(=?"J=4/FBW6^X.JLFD4
MGB[JPR)UC+3%76RW=AHS%#S"L(A)H.B^"1O12=RYUM=M35()T5U@JOKC%C#:
M2(T]1$)I6/'I@*PY9GDX#7XZ#B2TF!M'/L*-"GRM!X8$-'>$\MUW#!LOKI[M
M3&NO<SY/+K&:B39N.0&)KMDTVIB+YJ)DA+J7G/B@S\44E+RTI8+Y8;2$!#2/
M*:Z-AKT)I[)5Q5NOP[%R-\"Y(:D/??B@)Z6RT5EG[I'4%EKS O:PH+VHZW]#
M=(?!_20X)92W:.O;0I-*)1[KV[9D[/F[)[-NQK<\?G[ZT""=?3$.@ZE,LKAV
M,&C6P6)(AG,( -9"*)O!"^SG,\K?\'OB])S*O^R$HAJ%?5_30&52VP6#R?RA
M""3J.H!4R0@Y9$JELF>G0X6N4VKN0L'0HZ%1TU4V^8K8:M==>1D->#OL)/JV
MV_./V!H1;LDO<$VL[?L9!:MN2 RD04FU5,JC 2J&M8A=<=1B!OK_ !(8. 4;
M Q>N:H915G^')#''.KXH0?; 4Y@DV*4)*:VC,GCQ6PGM5DX8"F=J19&8QE_+
ME(KN%'RB?PQJL/:R84Y+^[,R.-HKLFI=+=T-U4007]=<&FPG!QQWXE_K6%]1
M"U#J+@(7I)40 0?NZ2GI(!3TE*=9C[<MDR')2+.9Y[X>#RP^H$B0DH='3V;2
M2E1 *$@-GI+90I (UY:=Z/\ @NB]WR.^!]NTF?A?9LU'8#U\KI&TIC&_P--8
MTDD)M=F+,-)TSECEY.9*;B#HCO+-AJ(I^:%#-'#K\7A=7%J4E\8_CHB$?,2J
M654PC$9CPUV7.R*07;<H8(%%,$=EWI,J4(6DV8CV+-'399R[=KI(H)Z;;J*:
MXQZ\K.0\%]U2".1YM/NQM2.)K,8W9M;=HI]'JDF&9%<<6M.]:3[!R.SQ#P]8
M+W\*W<I)Z8'PP6LBEO (Q7KT*#C$=&-X4&9K[#MIUM$[?KF8UE.8]'97%)H
M( C,?EH-A)HX11=H;80U+ 2J+@>5;-GFK9[\*[1W3W6;)[XQKOKKMKX.O/25
M>9(477$H0VE2R5'I0D!(V1O0 '?U)V5;423:S)TN8ZAZ3+?D.!IID+<<*EI:
M90E#2-Z3W2D:).U+5MQ9*U*)HDK'J7XDXY9F$)-<44L_7NG(@=L]1*_Q<=U[
M*#:G7A\2AZ8N [C;-?*&H@:F8PS*4)$Z3&,%"<G7&I9W^$34VS+W!\0?CD*T
MN;D$N6VZV1N JHS$[;A"T)<]!QP ,]=3^AU.S9L5C2+!\*4<M='V<-'[%_NS
M=-5G.R61[OH,8\-<XATJ\?\ )HS?<=CTBZ?4915&R6S8]%I\#LV01:F9^=GA
MX!$-1MD-Z_Q#+H0-[0R<1JQH9,= H--4I'W6YA1KEC;MVCH**]H.O=O4-,!4
M7*C;,@$LBS+:81IA+P020%P1!C&I4K'R6FS5\[B1QRQD(S/]J<MB ULZ9.&K
MU%!RE92(C$V.[%E,-O,.I2E;:TE(4 0H':5%22E24J2I)2I*T@I(4D$7=/>6
MO';2#<T=@_7V<%Q3L:6T4J4RI;:V' 4.I6RZVZPXXR^RZAQE]EQQIU"VEJ2:
M9>OG07Q00F7_ )B9;:D1NRR+Q-%KKH>)%KGL\=+1=!S8 Q)5Q#0C$;9::) :
MRCP,Z;C;O+40\D8_!LF("88AWVS;K"O@& -R!M4OV868U\$T(E8*-:0%8<1C
M+ABB]4CJDJD+J=K(R$+'$E$MR+;=J.V.(,O:(.D\J+;[9Q@?B$ED,[$T?:*E
M[@2=?0%ETHE<^CN:_?-YU(;9Z/\ 7VQ>O\&6BLN_$VX\'7DV&V0^DTM!$PQ0
MPU?B=1PPCEJ>)K)W,63#=;"KJ>5_N^U&:3>%2F'[$MVF7^H_63 7X/9]LQU=
M,<O,-,/LN,M,/6F7&$\HX<M\[X6TPEMQ#C=XF&FTJ(LI-<5F$G^]CI9ZT-H4
M F.ZT%#H;0@!SJ"0-(Z=JS?N)^-_BOP1V\=XISN[K'.3-L-WCI<CSW9J6'W9
M+?4NRCS%L+0^^\XIR*65K4K:UK 0$T$^.;QV=-K0!SRRG78&+=T1^'^L+8&:
MO4L&L(5&-ASYP453TWC\^RYDA9\@JQU7([$7 I--MM@;IKJOOGG<NTGA@J4A
M)#5J5Y=[#KG5H^+IO[%%S4>>GX4./C Q]L7E3683&QVJ\>:?*=-%RFA5=V):
M99*/==4L*J:YF/XR>A\PZ$UQ/Z].VD,ED7D<DBSZ UI#6<[8UC4 2*P0)#'K
M2#M[*G5A2MHK8940XL.6C-3R4;$R8R\81@8U'(^^<R@[B]<QO;OJOV"ZPEY(
M0AP^^*EF]7.)4+;Z/'T=Q+@KD6D909*+-]'WR]=5)PJQV<-\/4-%6N7"/O?>
M:VRN!\1<IVJ)=##-6RYYK<8><E25AU;R29"7A*5IQ:E="I!1WZ0.D #)L_Q$
M^-<;G$OQ$8\1;Y/+YK!C2K8JAN-NLJA,UZTBJ<B*IVR8D=IOK:KD. I\T*\Y
M2W%:T7CL\05'W+4E82JK?(W"^WE.1"4N1D_E4!AY+4M+#0F58DY2+O)+O9;\
MW%';H,_'L%=WZ&YI 0[9E!"^C1P.7UM_[,^*_I\1I.>.H_E2@R$<%[S16VBT
MVLF7@X8+B&V9$<)GP$LL)4&\ ZAF#],ONZRCNS8;+/&SANZ026T]OQ,^.F=>
M/NOKO3MBUHA:MJ]@+3#6-,'M;PE_7M< $(G6T0JV-AXO&BADV_U67"1! N>)
M.'2/Q90@HV0:Z-F*"R\_.R%0I7_0%TT<N^'C4+=J^<5PN^+#71@2W0F,>?@E
M=BHEB3"O28O9-[LF18,S IV[9[KHMB+-;?1PG[,<+XNPS:M-TL0(O''WK0*\
MUQ4IV2' ^OS'75K84X'%[,=;.BK:>D@:LIWCQXOV,SADR5S^]4]X?1:R#Q!3
M+D>*U41*=<9RN9$:)&8C3TQE1(^C9,S5.I:"'BZ@J2K7!HOP\UUV*J0-<5(]
MXXQ9+HZ1W&.I_&JK+KUD3%B$T?4> CKZ=M2;=ZDY=JO%3BI5YJ]2<MD4],M4
MM<[S%EWB\\>E(43%*'LB>"(7?5Z-Y74%46X=L^Q(A*)=?ECLI$Z$&X#7@JSQ
MK!Z;!FR6IP='0:.$6[<6WT>.TME=G6\]O'=U*F73"@'5/3*S$K#V6L>93*+B
M1.DPQ":@ADAV&IQ^F*TWL&5S><*5_"41RNX/,GDI%^DJ5>MF^&8Q!@R0_MW'
MZ6@>U,NZC3Y)>(QR<=6>U-67\-F!:&M)!*'41A*AE>5UO&SWO&Q2+(3E9X(4
M*.FKK=@YV!LLDQS_ .':>XFCX;QGCC[DNEJ&($A^.W$><:<DK*XS:TJ0V4/O
MNH 24)4" % CNK1.Z.?^.?BOXHUT.GY[S2QY)65UK*NH4:7&K& Q9S$.MR9*
M'(,&*[MU#SJ?*4LL("_N-)Z4ZAKUDZ.>*VS8\XK&%EXIV&LNAQ$8K^Z9''+S
MN!X8<S@*-S'3DB/,1]IN$6R\ADL>D6SI5FN]'HGV1T)\<H3#D4$/E]KO&MX\
M2\7SUDB<M%]:>R_8^/RJ-]?#Z%R6X_L5*0 !#B3&I+"H:YMEH^/?AD$')/2*
MZ>R#%LAC=-P\T44T15R]X]O&W*>EU@2^4RBW8]8H8=6ZU'T^/CL$=0LBPK!:
M^K=[!;$;-=KR$VVEE@_B*VW4=^;BVXL?D2"P4RWR3D!--#/G8OI2#O+L]TX[
M-L743C$RZO2ZSR!4ZK#69&;3"$3^D+,J]I!&$OT4;$@X,-)Y^E.=Q;A5X(=O
M1RGHQ2?N-'R6R@=O\H]>VQW(&M$]CW^O;Y^F<J*SO0<7TZU_F)[?+V[?EV]"
M.V1?H3I]XC^S 8^9H4-&[>$PTQB+R0[#KHO4D+:GD4=O?-?F&+%T9O=MLHK;
M^_8+O&VVVBFN'&V^NV.8*[4]%_%X3*(]78Q;D2ZT=CWKVO;0;[J7?;:TG;5Q
M!9>QLB=B'K$C;0]@/8V#6,%G@%QN1(MG:475/R=HR?, ;O;277C$\?LJZ 1"
MR822LH#((=)7\*2@M:P,?8 NMX"TAX!R'+R8(-LJ?V,:#2>T7SG4_- 4>,#H
M*+?L6FL>#)J+/GCG''<OQP7+W"[&/Y-)+>J@5UG=T;9-9"JUQ6!W\XL5LNT:
MCGE3&;_2F0B5!Q<TGD9C\RV!5\.G(XJ A,<4D2<?9L#TE>&M(Z?NC[J=['_+
MKMOM[GOV&^Y^O89/6>HCS%].O^HG?8#WT"/IKT]<[!2O1_Q2=CX7FQZ+B\9M
M6#[&2@+:30N\+I*"T3(K=+9^*7W;V7KEH\;(NF;K5LLDCLL/>CR+;54>^9N%
MHS7MU&\6#6THW7D0NZ%]?;4ZU3N)]DKPCJMU6N\)%J-K(2YE=BP65I%[30'B
M@I>,&@I^2*;*/GX,%H.-/PVPYZW7VL'\?/3Z:=1J_L1A9=@1.Q+%M&<1V4R(
MG (8\K^"CF$%J&M:0B \)%GYL^[2>KQ.KQ)F3DUB.<D9"5?Z((),FC3.\1^S
M7C%NSM%V&[&3>P+6H@I1MG=>["H^GZU)U',?G=1N;-B<4#V-,"Y&-V#%Q=A2
M&TG<5' YI(RZ"$J%5LR9PF#F8\V5+*D:'66WF5M/,M.-O(4T\TXV%MN-N)*'
M&UH(Z5(6DZ4E?W5(VE6]YZ,OO,OH=9D/,N,+0ZR\VZM#C3K2TK;<;6DA25MJ
M 6A:2E25)"DD$ YA2#>,2#=GWC:Y*<[ZR.6=5YC.5C Z&Q*O&(]<I!6 (A%9
M#5R5HLCX&2*!2,A4W/NSF@EN24=LT&6F' _=3*T5(5X^^FM:WVA*[0\E$$/1
MCI'L8T[$5&T^)JIT8A,C [UY'A5C'XC80TLML+M A&'*;8$D]"N9ZU:1-0*E
M)G[=!/8 Z&=9YGU+Z\B:=F]CXL8DPET[D@WX+:6JQ>!1V625X; U;!G$_D\S
MG;F$P-@XT#@%Y=*#)G9#"FOOFK'1D.9UV=A/$O=E^WS=%ZD>PU7@RY=A4:-.
M"V=+EUQ^RU(=JH?VIKAM<S-U.G \JR!%XV5@A-2MVD-<35I(]IY*]'LK!"4=
M-=B<*X?7LUS%=Q'C5>U6!WX9%?25T !3\:/$>=D_"L,F?(=CQF$K?L/BGBMO
MS2YYZE.JON5WMWSNTAVW,K^[Y).K5.F ];V]C-;C>>7@Z&HSL@Q DHDOH2GR
M.AMMQ3;:4M_=&#H?X/Z.NT8QG<"[9.YGUQF+>;S2K%8.*1(D5T9^*E3(&Y7L
MY*7/'$H%QA[(=':FB[9%_)5 :028+O&RA1JO!.5^.;JGM)"][$/+C6H4!UB*
MN*OM<(P@@].%H3*;DU8E4Z,S"H3C=X_*-Y,SDXF'/1NKIJ\-:%AL/=,G(TRD
MIM)=)>M[OJ3U@J^@24N;3HQ"T9:1D$K8 ?PN++R:?3R4V/)E L=^/)[! #8]
M+B+$ ,4(/%F8=JR27<JK84VS4K;7AJMZYSG9B8V%=M)RD[<DJZ]F8Y&]JELB
M)PK5;KE(;3?P:;21:%V^'F4;G[0'9# :R:UA(X] QA^&(39.,KR*6'G.A?#.
M*J!/]G:Q169ZE?W&OO6B4(G=@M.@ZA(Z$I[1NG_"".H[.D'B?'UJ<ZH:OO&P
M/_QL\)5]JZ%@"$R=:E !2@!I"].-A"QU9)+J9XJNID9I<,].E3-^/)Z1)6:C
M9+.5637 @JPG.&A4<B B$2G T8-"-V7N,LO?H*E'7OE7)1PN[5WVY6K=WC_Z
M' +6LF32[R UK6G7H+?&\2FM=O2N[F<P6ZB,;8R+%5NK>>V"Y-,MA<<<IRDI
MH3:;RF/ E=\%CHZ.-ETT]BBFZ:F5:=7JZH217/,9U/(72P"KRM]OD&B<ZD4F
M#P]&-K6:HW);&FFLC7()?B!!,JJ9U^.T2P37)[9<*KZ^>/R=F>12*6I'8!W,
M3,K6#/KF)-'UL4L#-J(1+LQU;9]:+V/RG,/,152676620S/ <[64:#=CJ2FI
M8.HN:+$=[A?%N.K:B-*H:I2(2V'HR3#:'ENQDA#"B4A*W>A.P4OJ=2Y_YJ5D
MDY>+HJAYJ''=C M5[L9Z'IZ0AQMV(.F.XMY#@=>+:?\ YZW I7WG HC>9"U\
M"1,X#UCJG;46Y@)0*V#:/@E.--) XC*K9+5LN.*:3QP U?*MMM7#-^@)48Z+
MJ:/FK/7?.F>8=[(=)^BF]Q [F@7D0@U0PJ1(:=5856Y<@>N\"]NFK#Y5Q<>P
M%^6L,F3UG.$B<:$2\6$^&&"<A$\G\.,N?9;[%Q>AE%^L2W6R+67.:^SI2[2F
MPMKP]8<VL6,-V,.:PUI,8^[)-"(YK*VC5M@BR=KM'*;4CG5QIIG=/3;%!8K\
MGSG$(KB%5[ .V MB_KN^+ELRJ+*WK$S"I[0H*WS-;$B).JU*CGT$!OK#PS@+
M\0?S/1LBA,H0F)==T#:X0V;/K1'".),194)GCM:(TX@RFU,J<+A!!!#JW%/L
M@* [,.-^Y /?=E&XEQV/%F06H):C3W$N2VQ+G*4ZXGI)7YRY*GFE.!*4NEEQ
MLNH2EMWK; 2)H7%X>QTRZS=4.OU6WV5JXGU@KVXZ?2G9"OQ<XUFE;]D:R,55
M>K5>,/#HIL D9X&=?EH@78$EQ\0-ZMM-0Q(.GD;RW6NH.&K* 0>MXYEUF/5_
M#XQ"067RN%WOR:)@V  7\6OKIIA9UEB/0RX5QIIA17V]\::XSZ8[CKCV<8QG
M;.V<8^NVWIZYS^G.?9QKKZYS]<^FN,>N<^F,8],8YYM*$(;2E*$A"4I"$I2-
M)2E( 2E('8     =@-9L)4HC[RUN'>RMU:W75J/JMQUPJ<<6H[*EN+4M:B5*
M45$DN...5Y&....,8XXXXQG&<XQC.<_3&,9SG.?IC&,?7/KG/TQ^WE;WEW<(
M.?%EY!%6ZR2Z?]B+?.GO$54U=/;U@)C7;7VT]MM?:UV^FV/7UUS],XQR4O:R
M"R^S^L78BMJ_5?(SBP:0M2$1)46>:14KI(97"#8(5L*D[]@381PI\6_2P..O
M1[QH(>Y0?N6ZB+??7.MC9O4/M[0O@H[?UP5F#/K/'X)7?:*2;UN3@=06K9%G
M4HO6@IJ. V_,X:6;P4%9!<D)DCEY-Z[3>NW0,D%>F45),@_]8V0H#7;Y[T?R
M_#W/ML94 -;WH@]A_K\^WT!S:/JW_@TKW^8\1_T=&\[NNEHNBJBI[7NUD]TE
M/8442W]A37.F_LJI;:*)[>SMGV5$]]=]-O3;3;7;&,XZ35WI^;6OO3'IC\$1
M'TQZ^OIC\.C?3'K^GT_7SZ<V-:QR'2H_NIJCJ$CALKE3;;&N-,L!CISIG.<_
M3]^GIC&/UYQRWDOM1HC\E_7D1X[C[W5KI#339<<)WVT$)).^VAWSUC,.R9,>
M.P"IY]]IAD)WLNNN);; UWV5J&M=]^G?(7]9NL52X@QB3/19"2(3::3(XQ;'
M3QMZQ:A4I,5&ADO@</TF;QRLP9).'I1\@Y?D%5-5%U]M==-<9\)=7.O1;(K+
MVH()MD.30+L]D +-JIL[;_735ZHWTT4(L]]L:[+L'VSAFXSIIE=%3&N,9['0
MX96/TO5HIQI[ITV@D9W>I^GIG5^[%MWK[VL?HVR[<K;;8^_M9SZ\RSSGW$.!
M\29XAQV-)XIQ\N*I:UV6A^H@O*,M]AF7*ZUO1U.*/QBW'!UDE"M!.@D =!Y;
MSWE\CE_()S/+N0[^V+!N,^Q<SV#\*R\[#C='D2$)2/@D-M;2!UH)ZM]2M_'3
MCP%$@V+(A12)1D,V"LR23!JD^:!]E4U]A39VFEJN@.V6125RR2WT;>VGIM[O
MUUQZ>PS%#!JCY8>.8L5BCS+\DJT:H-E"#]1--#=Z]W13TV=.]D4DDMG*^5%M
MDT]--M\XUQC'T.<9^W]&/Z<^G.B(C1VR"AAE!2M3@*6D)(<4@-*<!"00M38#
M:E_YE( 224C6<]5(D+!2M]Y:2@-E*W5J!;2OS$H(*M% <)6$^@62H *[Y148
M[NVKVTO"T.AL?@\0K9G)"EDUT1M0B^D$K>C8O'?F#8L19Q35H$9*'BPYKMH*
MT=&41[-PO[Y39TFCC7?T8'X.(E%)G%9*;OPI+@L?D <P_BKZMV31E(6(UVDY
M<A7SM.6N-T6I%-/+999)'?;1/?;.$]_MRP/I:.8RIA=5]*C&.KBZ+[L [''V
MK9KLOK"H;LSJV-^X<ZHZJX1?)PY^5SMIMKAQDENOMC;99112</.=0N$UO(VX
MUQR\CDTQ$Z5-I)#Z7(34"I=DI?KHJ8L*0W%D#RVVY#CTEIQQ[S$M/=26D[^N
M^5_Q!<G\)[&SX%X$L_\ A)0II:NGYY60%P>1RK[G$:M^"Y/;+N>05DVUKELR
M'':F/#KIC$6(J"[.AICOS70FNKN%XUJ"[0=;IY147A534Q*)&'T'0NX1-)PF
M3RRKG^Y%BY>R"(^^P"),C[H<U<C$2S&0CG[/+WXU-PHJWT2WU]KA\*GE+ZD=
M:P=*>.SNU=-OD)M:[N763L9L.*4!&HA&0(T22CK8(/)/91*"D@D,T;:/#A<1
M/@[%<&*Q'#,<)CB2BR>W58=C0&I8:=L.SYE&J_@L9;)O)#+Y@98Q^.AFRSE%
MFBL2+$ED&;1-9VX0:I965U]ZX6213QLHIKKF,^GD1Z+*Q@?,T.VW7]U%R\D=
MPX29:6?&';0I+&(]H6=QH=\,^45?'D!CYD^W$MDU'OPSMLKA+V%T\[=UXWRF
MVXNPPFOAU<BK@/.RDQ+&FA3(32TM;5_?EA,N,RR0F4&8TR.RA]/GJ02X[YGR
M%;Q+3DC,^5/F<AE)ED&PFIL;1:7G&DI6IV8LO.1GI"66PE3\E#CR6$I 6E"$
M=.O_ &KV01BEPUH[\AG5&9POM/7%<0@O:\SZYSZO+2CTSD.66C*IS<6'"!3J
M7CIL9E@_=-_#W4?SL%0<#%Q+V4 %6+W?-EW=V'DNH:R=KJL?M95M6-HL<)RF
M-%N@?8]ZNQC+<<X^8C;/O):JHC'T!JF^=<$7 2-#!C7;9-!<R[;:*[J4W]D[
ME[4]_P#R7Q6?=0*6$S4"<M$ .J.<%HB<TA>CGKZ[U4/[3&;K:-X*]9HLQ^A"
M1I'$#3M$:NT#L]4L:-D%;H/)5<G? 3TFOM#NU2-&5GU8)4X>9WK8]!%3_92;
M!F9/W Y)D*K68':-1%?&E'@U%G)DSDK:QTC[A\_'.AR*OKRF'POA5Q9W7)KV
M@M>.UG-YHFKB</Y';\?9<@S&6(;TV77H^U+54R7Y+]A'2\J-4Q$RPVN,IX/2
M'M[^&\6;:FX<WR3Q,J+"LHH*)/#^,<A=BM67%./PW53JU#LAT5TZ6);(;D_9
M55,5+22FFDPEOUT=+,1?#<(ZIW%V7 6LG:&KX>)$IRJBH7)T70IK)Y8L[R#1
M<)8*Y8__ "PK]]J8T;159HJ467=#I ,SNV&JJ[;('8W"M=6SUROYKNBS#AYB
M[I2TG><X2U4KRY-&XV/NR+GV=O\ <,>M@;"'>OO,Z:(:$WRN5$]-E<[Z%?AJ
MN;JC;M2!-&5S:PSLQ1EKH*Q7JM(3HVNYWV!A6YES(FCBB; $FV[UQ9:PW8FU
M6CPP?L19G6**3=59D3:NU=LGJM8DF[A1SM7ULGUL1JR1DUKH78%=E&$Y:RB9
M0! VKN-C\?D&6P./[)GX.8#1@C(<9'M%!LCS[U;WBAK1?&,XAR*3Q*\K?#NX
M:G.T-?/MZ#A]I+D1)DU_A;TBR>KI5L8,>+$-DY'D.I<<999>,U(=DP83?D*>
MZQX[2:F\M_#[Q#XK-MN84?).)T''O$2QKJJ\^Q. \WJ^+0(%[2//77Q%LFLG
MM-JLJ"ZM),MJSE+FPHUA,>I9JVKU,9]<8_7^GT_7CZ9Q^S/TYSS!/6:RBELT
M77$UD:6K69.H^B(GX_&=,;"[$C"RT:G@U1'35/X?9K*A)371'*>GLH;([:XR
MGMIMMG;G1'V7(S[T=T .,.N,N '8ZVUE"M'W&P=$=B-$>N?-K[*X[[T=P .,
M.N,K [CK;44*T?<;!T?<=\<<<<\L\L<<<<8QSC.<8QZYSC'\N?3[<YY4!Y.+
MX-P>4T37E<]H5^O<K(ER<EL]\F0B2(QA2K?1!,T9>-Y&R?.'<W6=-U&=71X2
MEJ]DY'4TEMC#8?NLG<16F'G2)<Z)616VGGY-A/6IJ%$99;4XMV2ZE*RVW]T(
M"ND[<6A &U#,S045AR2UC4]7'D2ILH.EIF+$DS7E!EI;RRF/#:>D.?=01IMM
M1V1V[Y7]YG>X F735+JVSA(WV*BFD<F!2RB4KSN"=D"D4<-%(HY'#6S5Z T9
M*']-)*26(.'31HCC8<EHNMLHWJQZ-=C^O6;J>$)I#&E1R*0!"#T[!8Q=1F(]
MG*E3@\D2!R![75B-\PK\_H=LAAC94%CR TT<EE92/WPP:Y.Q(JEM_*KJ5U[=
M]N22,TFS" ==)]VN%U<O5MNNC9Z_Y2"5?@9W(3\XEIAV,^7L[C$.W$)@.$D7
M))8R_(F&V<LV0QGRVWOSX,Z4)P,P;IRG1-CQ=C'M6R-62'!B13&N"@M38@+G
MU-R50GF0O]Q[I+5K(*T>.%M3P5Z2UCS]@42'II</BSG+'EG)N13J&LG4]:Y
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MUBU8-G=;S.&%.N=K53 YM"[G/R6=!A[B3V/6UQUS^(JF7C5:3&$3QPX*.T)
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M!CQXN#0E:@M/5EF0H"TRN$,9UT=:YSMMF2%$#1]#OU(_ =NROS]?Y9'4G>]
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M,OKHINE&_F?I[E^AMOFU+*E%2NI2E$J)4=J4HG9))))))V2>Y[[[[SB@0
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M54UZR1CLX6M03,T2T/,]?[&<PJ.C)&PDD*(IA+3;,K*@F!K"9QP?)X]'K;D
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M8_5CZ?;Z?;U^_!&_TU_3^?\ KH^V2#KVW^_W_/YG,&]EX9,+#Z^7/!X#,)S
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M-;"HN?-+-(Z-G<;<RUO-H1K*7PV,DI!'6P@J7!:OT#@WS6C92L;ZT!24D*(
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M4SH\-1L&$6-'K8*CI6DK(X\N06)BC\>(9"LTR<><-P!9-TDXQEVSUT25SC]
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MA*EK4E"$)*EK60E*4I!*E*42 E*0"220  23K()"05*(2E()4HD   ;))/8
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M0CQVXU8!PS1D.9ZKNE57*V&[9/"KA1193VE-]MLTD'>P=#7I]?W_ $]?E4"
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MW:[!O8W;F=]'ZJ35SKJFENXQOIMMK11+Q]=@;QI*47!4@$PZL2.W>RI@E!A
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M<;/V@+?54<LU606NS\OWD;A70ZLJS!&*WC5H2*\+"AT9V"V*&?.ZGC]<;6-
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13DXXXXXQCCCCC&....,9_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
